Petros Pharmaceuticals (PTPI) S-1 6 Jan 22 IPO registration Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Sep. 30, 2021
Document and Entity Information [Abstract]
Document Type	S-1
Entity Registrant Name	PETROS PHARMACEUTICALS, INC.
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Central Index Key	0001815903
Amendment Flag	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS	Dec. 31, 2019USD ($)
Current assets:
Cash	$ 2,145,812
Accounts receivable, net	2,605,130
Inventories	2,204,428
Deposits with related party	2,325
Prepaid expenses and other current assets	5,129,820
Total current assets	12,087,515
Fixed assets, net	69,837
Intangible assets, net	38,811,137
API purchase commitment	6,721,574
Other assets	676,230
Total assets	58,366,293
Current liabilities:
Current portion of senior debt, net	6,681,936
Accounts payable	3,776,443
Accrued expenses	20,887,262
Accrued inventory purchases	9,305,594
Other current liabilities	453,092
Total current liabilities	41,104,327
Long-term portion of senior debt	7,061,034
Deferred tax liability	1,432,167
Other long-term liabilities	749,546
Total liabilities	50,347,074
Stockholders' Equity / Members' Capital:
Preferred stock (par value of $0.0001 per share, 50,000,000 shares authorized, 500 shares issued and outstanding as of December 31, 2020)
Preferred units (1,619,754 units issued and outstanding as of December 31, 2019)	20,018,205
Common units (3,434,551 units issued and outstanding as of December 31, 2019)	29,117,233
Accumulated deficit	(41,116,219)
Total Stockholders' Equity	8,019,219
Total Liabilities and Stockholders' Equity	$ 58,366,293

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical)	Dec. 31, 2019shares
CONDENSED CONSOLIDATED BALANCE SHEETS
Number of preferred units issued	1,619,754
Number of preferred units outstanding	1,619,754
Number of common units issued	3,434,551
Number of common units outstanding	3,434,551

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Net sales	$ 2,145,169	$ 3,464,695	$ 8,678,424	$ 6,630,180	$ 9,559,469	$ 15,577,166
Cost of goods sold	319,158	981,903	1,355,838	2,305,169	4,046,466	7,427,111
Gross profit	1,826,011	2,482,792	7,322,586	4,325,011	5,513,003	8,150,055
Operating expenses:
Selling, general and administrative	3,413,223	3,121,023	11,411,113	11,997,185	15,674,968	19,727,223
Research and development expense	280,576	36,828	799,803	307,796	459,636
Depreciation and amortization expense	1,728,829	1,661,362	5,186,486	4,984,084	6,660,438	5,291,107
Impairment loss						2,443,930
Total operating expenses	5,422,628	4,819,213	17,397,402	17,289,065	22,795,042	27,462,260
Loss from operations	(3,596,617)	(2,336,421)	(10,074,816)	(12,964,054)	(17,282,039)	(19,312,205)
Change in fair value of derivative liability	1,970,000		9,640,000		(1,680,000)
Interest expense, senior debt	(67,936)	(300,355)	(356,873)	(1,085,347)	(1,323,424)	(2,428,264)
Interest expense, subordinated related party term loans		(669,730)		(1,148,447)	(1,727,455)	(11,416,697)
Loss before income taxes	(1,694,553)	(3,306,506)	(791,689)	(15,197,848)	(22,012,918)	(33,157,166)
Income tax benefit	2,345	(6,143)	9,045	(49,895)	(1,426,993)	(645,866)
Net loss	$ (1,696,898)	$ (3,300,363)	$ (800,734)	$ (15,147,953)	$ (20,585,925)	$ (32,511,300)
Net loss per common share
Basic (in dollars per share)	$ (0.17)	$ (0.96)	$ (0.08)	$ (4.41)	$ (3.85)	$ (13.22)
Diluted (in dollars per share)	$ (0.17)	$ (0.96)	$ (0.08)	$ (4.41)	$ (3.85)	$ (13.22)
Weighted average common shares outstanding
Basic	9,826,599	3,434,551	9,794,267	3,434,551	5,340,682	2,460,026
Diluted	9,826,599	3,434,551	9,794,267	3,434,551	5,340,682	2,460,026

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY MEMBERS CAPITAL - USD ($)	Class A Units	Preferred Units	Common Units	Preferred Stock	Common Stock	Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2018	$ 1						$ (1,681,269)	$ (1,681,268)
Balance (in shares) at Dec. 31, 2018	100
Exchange of Class A Units for Common Units	$ (1)		$ 1
Exchange of Class A Units for Common Units (in shares)	(100)		1,000,000
Net proceeds from private placement offering		$ 2,904,005						2,904,005
Net proceeds from private placement offering (in shares)		245,933
Issuance of lead investor warrants		$ (250,000)				$ 250,000
Issuance of placement agent warrants		(135,800)				135,800
Conversion of related party debt/ subordinated related party term loans into Preferred and Common Units		$ 17,500,000	$ 29,117,232			(385,800)	(6,923,650)	39,307,782
Conversion of Preferred Stock to Common Stock (in shares)		1,373,821	2,434,551
Net income (loss)							(32,511,300)	(32,511,300)
Balance at Dec. 31, 2019		$ 20,018,205	$ 29,117,233				(41,116,219)	8,019,219
Balance (in shares) at Dec. 31, 2019		1,619,754	3,434,551
Net income (loss)							(15,147,953)	(15,147,953)
Balance at Sep. 30, 2020		$ 20,018,205	$ 29,117,233				(56,264,172)	(7,128,734)
Balance (in shares) at Sep. 30, 2020		1,619,754	3,434,551
Balance at Dec. 31, 2019		$ 20,018,205	$ 29,117,233				(41,116,219)	8,019,219
Balance (in shares) at Dec. 31, 2019		1,619,754	3,434,551
Conversion of related party debt/ subordinated related party term loans into Preferred and Common Units			$ 17,227,455					17,227,455
Conversion of Preferred Stock to Common Stock (in shares)			1,762,913
Proceeds from exercise of Metuchen warrants		$ 20,551						20,551
Proceeds from exercise of Metuchen warrants (in shares)		2,055,115
Net proceeds received from recapitalization for the Mergers		$ (20,038,756)	$ (46,344,688)		$ 971	87,380,223		20,997,750
Net proceeds received from recapitalization for the Mergers (in shares)		(3,674,869)	(5,197,464)	500	9,707,655
Bifurcation of derivative liability related to the Mergers contingent consideration						(8,209,998)		(8,209,998)
Net income (loss)							(20,585,925)	(20,585,925)
Balance at Dec. 31, 2020					$ 971	79,170,225	(61,702,144)	17,469,052
Balance (in shares) at Dec. 31, 2020				500	9,707,655
Balance at Jun. 30, 2020		$ 20,018,205	$ 29,117,233				(52,963,809)	(3,828,371)
Balance (in shares) at Jun. 30, 2020		1,619,754	3,434,551
Net income (loss)							(3,300,363)	(3,300,363)
Balance at Sep. 30, 2020		$ 20,018,205	$ 29,117,233				(56,264,172)	(7,128,734)
Balance (in shares) at Sep. 30, 2020		1,619,754	3,434,551
Balance at Dec. 31, 2020					$ 971	79,170,225	(61,702,144)	17,469,052
Balance (in shares) at Dec. 31, 2020				500	9,707,655
Conversion of related party debt/ subordinated related party term loans into Preferred and Common Units					$ 6	(6)
Conversion of Preferred Stock to Common Stock (in shares)				(500)	60,606
Non-employee stock-based compensation					$ 6	187,796		187,802
Non-employee stock-based compensation (in shares)					58,338
Stock-based Compensation Expense						990,876		990,876
Net income (loss)							(800,734)	(800,734)
Balance at Sep. 30, 2021					$ 983	80,348,891	(62,502,878)	17,846,996
Balance (in shares) at Sep. 30, 2021					9,826,599
Balance at Jun. 30, 2021					$ 983	80,295,724	(60,805,980)	19,490,727
Balance (in shares) at Jun. 30, 2021					9,826,599
Stock-based Compensation Expense						53,167		53,167
Net income (loss)							(1,696,898)	(1,696,898)
Balance at Sep. 30, 2021					$ 983	$ 80,348,891	$ (62,502,878)	$ 17,846,996
Balance (in shares) at Sep. 30, 2021					9,826,599

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (20,585,925)	$ (32,511,300)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,660,438	5,291,107
Bad debt expense	202,525	(25,943)
Inventory and sample inventory reserve	1,752,041	2,987,606
Non-cash paid-in-kind interest	1,771,904	6,959,236
Amortization of deferred financing costs and debt discount	37,500	4,669,384
Accretion for end of term fee	116,196	244,477
Deferred tax benefit	(1,432,166)	(645,866)
Lease expense	92,711	25,881
Derivative liability	1,680,000
Impairment loss		2,443,930
Changes in operating assets and liabilities:
Accounts receivable	(2,750,364)	932,887
Inventories	728,286	2,558,067
Deposits	1,734	1,404,758
Prepaid expenses and other current assets	1,031,108	(2,201,178)
Accounts payable	2,222,114	2,024,247
Accrued expenses	(6,203,476)	8,340,885
Due to related parties		(41,152)
Accrued inventory purchases	(250,000)
Other current liabilities	(231,325)	81,435
Long-term liabilities	(148,626)	(5,982)
Net cash used in operating activities	(15,305,325)	2,532,479
Cash flows from investing activities:
Acquisition of fixed assets	(4,633)	(71,540)
Net cash used in investing activities	(4,633)	(71,540)
Cash flows from financing activities:
Proceeds received related to the recapitalization from the Mergers	22,592,285
Payment of equity issuance costs	(1,042,910)
Payment of senior debt	(6,181,711)	(6,013,257)
Payment of portion of senior debt end of term fee	(534,375)
Payment of debt issuance costs	(50,000)
Proceeds from subordinated related party term loans	15,500,000	2,904,005
Proceeds from the exercise of warrants	20,551
Net cash (used in) provided by financing activities	30,303,840	(3,109,252)
Net decrease in cash	14,993,882	(648,313)
Cash, beginning of period	2,145,812	2,794,125
Cash, end of period	17,139,694	2,145,812
Supplemental cash flow information:
Cash paid for interest during the period	1,191,400	2,040,965
Noncash Items:
Issuance of lead investor warrants		250,000
Issuance of placement agent warrants		135,000
Increase in preferred and common stocks from conversion of subordinated related party term loans		(46,617,232)
Conversion of subordinated related party term loans into preferred and common stocks	17,227,455	39,307,782
Noncash increase in API Inventory (other assets)	5,148,311	$ 4,775,937
Deferred Merger costs reclassified to additional paid-in capital	$ 551,625

Nature of Operations, Basis of

Nature of Operations, Basis of Presentation, and Liquidity	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Nature of Operations, Basis of Presentation, and Liquidity
Nature of Operations, Basis of Presentation, and Liquidity	1) Nature of Operations, Basis of Presentation, and Liquidity Nature of Operations Petros Pharmaceuticals, Inc. (“Petros” or the “Company”) was incorporated in Delaware on May 14, 2020 for the purpose of effecting the transactions contemplated by that certain Agreement and Plan of Merger, dated as of May 17, 2020 (the “Original Merger Agreement”), by and between Petros, Neurotrope, Inc., a Nevada corporation (“Neurotrope”), PM Merger Sub 1, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Petros (“Merger Sub 1”), PN Merger Sub 2, Inc., a Delaware corporation and a wholly-owned subsidiary of Petros (“Merger Sub 2”), and Metuchen Pharmaceuticals LLC, a Delaware limited liability company (“Metuchen”). On July 23, 2020, the parties to the Merger Agreement entered into the First Amendment to the Agreement and Plan of Merger and Reorganization (the “First Merger Agreement Amendment”) and on September 30, 2020, the parties to the Original Merger Agreement entered into the Second Amendment to the Agreement and Plan of Merger and Reorganization (the “Second Merger Agreement Amendment” and, together with the Original Merger Agreement and the First Merger Agreement Amendment, the “Merger Agreement”). The Merger Agreement provided for (1) the merger of Merger Sub 1, with and into Metuchen, with Metuchen surviving as a wholly owned subsidiary of Petros (the “Metuchen Merger”) and (2) the merger of Merger Sub 2 with and into Neurotrope, with Neurotrope surviving as a wholly owned subsidiary of Petros (the “Neurotrope Merger” and together with the Metuchen Merger, the “Mergers”). As a result of the Mergers, Metuchen and Neurotrope became wholly owned subsidiaries of Petros, and Petros became a publicly traded corporation on December 1, 2020. On December 7, 2020, Neurotrope completed the spin-off of certain assets, whereby (i) any cash in excess of $20,000,000, subject to adjustment as provided in the Merger Agreement, and all of the operating assets and liabilities of Neurotrope not retained by Neurotrope in connection with the Mergers were contributed to Synaptogenix, Inc. (formerly known as Neurotrope Bioscience, Inc. and a wholly owned subsidiary of Neurotrope prior to the spin-off), a Delaware corporation (“Synaptogenix”). The Mergers were accounted for as a reverse recapitalization in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Metuchen was determined to be the accounting acquirer based on an analysis of the criteria outlined in the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) No. 805, Business Combinations Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, considered necessary to present fairly our financial position, results of operations and cash flows. However, actual results could differ from those estimates. The condensed consolidated balance sheet at December 31, 2020, has been derived from audited financial statements as of that date. The unaudited interim condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission. This Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes previously distributed in our Annual Report on Form 10-K for the year ended December 31, 2020. Certain prior year amounts have been reclassified for consistency with current year presentation. These reclassifications had no effect on the reported results of operations. Principles of Consolidation The unaudited interim condensed consolidated financial statements include the accounts of TIMM Medical Technologies, Inc. (“Timm Medical”), and Pos-T-Vac, LLC (“PTV”), subsidiaries of Metuchen, as well as the accounts of Metuchen and Neurotrope, subsidiaries of Petros. All intercompany accounts and transactions are eliminated in consolidation. Liquidity The Company has experienced net losses and negative cash flows from operations since its inception. As of September 30, 2021, the Company had cash of $8.1 million, negative working capital of approximately $20.1 million, including debt of $1.7 million that matures in 2021, and sustained cumulative losses attributable to common stockholders of $62.5 million. Our plans include, or may include, utilizing our cash and cash equivalents on hand, and our liability due to Vivus as well as exploring additional ways to raise capital in addition to increasing cash flows from operations. In October 2021, the Company issued 3,323,616 shares of its common stock and received $5.5 million in net proceeds. In November 2021, the Company repaid $1.2 million in full satisfaction of its senior debt (See Note 8 Debt). While we are optimistic that we will be successful in our efforts to achieve our plan, there can be no assurances that we will be successful in doing so. As such, we obtained a continued support letter from our largest shareholder, JCP III SM AIV, L.P., (“the JCP Investor”) through November 16, 2022.	1) Nature of Operations, Basis of Presentation, and Liquidity Nature of Operations and Basis of Presentation Petros Pharmaceuticals, Inc. (“Petros” or the “Company”) was organized as a Delaware corporation on May 14, 2020 for the purpose of effecting the transactions contemplated by that certain Agreement and Plan of Merger, dated as of May 17, 2020 (the “Original Merger Agreement”), by and between Petros, Neurotrope, Inc., a Nevada corporation (“Neurotrope”), PM Merger Sub 1, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Petros (“Merger Sub 1”), PN Merger Sub 2, Inc., a Delaware corporation and a wholly-owned subsidiary of Petros (“Merger Sub 2”), and Metuchen Pharmaceuticals LLC, a Delaware limited liability company (“Metuchen”). On July 23, 2020, the parties to the Merger Agreement entered into the First Amendment to the Agreement and Plan of Merger and Reorganization (the “First Merger Agreement Amendment”) and on September 30, 2020, the parties to the Original Merger Agreement entered into the Second Amendment to the Agreement and Plan of Merger and Reorganization (the “Second Merger Agreement Amendment” and, together with the Original Merger Agreement and the First Merger Agreement Amendment, the “Merger Agreement”). The Merger Agreement provided for (1) the merger of Merger Sub 1, with and into Metuchen, with Metuchen surviving as a wholly-owned subsidiary of Petros (the “Metuchen Merger”) and (2) the merger of Merger Sub 2 with and into Neurotrope, with Neurotrope surviving as a wholly-owned subsidiary of Petros (the “Neurotrope Merger” and together with the Metuchen Merger, the “Mergers”). As a result of the Mergers, Metuchen and Neurotrope became wholly-owned subsidiaries of Petros, and Petros became a publicly traded corporation on December 1, 2020. On December 7, 2020, Neurotrope completed the spin-off of certain assets, whereby (i) any cash in excess of $20,000,000, subject to adjustment as provided in the Merger Agreement, and all of the operating assets and liabilities of Neurotrope not retained by Neurotrope in connection with the Mergers were contributed to Synaptogenix, Inc. (formerly known as Neurotrope Bioscience, Inc.), a Delaware corporation (“Synaptogenix”), and a wholly-owned subsidiary of Neurotrope. The Mergers were accounted for as a reverse recapitalization in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Metuchen was determined to be the accounting acquirer based on an analysis of the criteria outlined in the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) No. 805, Business Combinations All transactions between the consolidated entities have been eliminated in consolidation. Liquidity The Company has experienced net losses and negative cash flows from operations since its inception. As of December 31, 2020, we had cash and cash equivalents of $17.1 million, negative working capital of approximately $16.0 million, including debt of $7.2 million maturing in 2021, and sustained cumulative losses attributable to common stockholders of $61.7 million. Our plans include, or may include, utilizing our cash and cash equivalents on hand, negotiating an extension of our debt arrangement and our liability due to Vivus as well as exploring additional ways to raise capital in addition to increasing cash flows from operations. While we are optimistic that we will be successful in our efforts to achieve our plan, there can be no assurances that we will be successful in doing so. As such, we obtained a continued support letter from our largest shareholder, JCP III SM AIV, L.P., through May 17, 2022.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2) Summary of Significant Accounting Policies Use of Estimates The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and reported amounts of revenue and expenses during the reporting periods. Such estimates include the adequacy of accounts receivable reserves, return reserves, inventory reserves, and assessment of long-lived assets, including intangible asset impairment and the determination of the fair value of the derivative liability, among others. Actual results could differ from these estimates and changes in these estimates are recorded when known. Risks and Uncertainties The Company is subject to risks common to companies in the pharmaceutical industry including, but not limited to, uncertainties related to commercialization of competitor products, regulatory approvals, dependence on key products, dependence on key customers and suppliers, and protection of intellectual property rights. In January 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China ( “COVID-19”) and the risks to the international community. The WHO declared COVID-19 a global pandemic on March 11, 2020, and since that time many of the previously imposed restrictions and other measures which were instituted in response have been subsequently reduced or lifted. However, the COVID-19 pandemic remains highly unpredictable and dynamic, and its duration and extent continue to be dependent on various developments, such as the emergence of variants to the virus that may cause additional strains of COVID-19, the administration and ultimate effectiveness of vaccines, and the eventual timeline to achieve a sufficient level of herd immunity among the general population. Accordingly, the COVID-19 pandemic may continue to have negative effects on the health of the U.S. economy for the foreseeable future. The Company cannot reasonably estimate the length or severity of the impact that the COVID-19 pandemic will have on its financial results, and the Company may experience a material adverse impact on its sales, results of operations, and cash flows in fiscal 2021 and thereafter. During 2020, government regulations and the voluntary business practices of the Company and prescribing physicians had prevented in-person visits by sales representatives to physicians’ offices. The Company had taken steps to mitigate the negative impact on its businesses of such restrictions. In March 2020, the Company reduced its sales representative head count to reflect the lack of in-person visits. The Company had maintained a core sales team which continued to contact physicians via telephone and videoconference as well as continuing to have webinars provided by the Company’s key opinion leaders to other physicians and pharmacists. In response to the spread of COVID-19, in March 2020, the Company closed its administrative offices and as of September 30, 2021, they remain closed, with the Company’s employees continuing their work outside of the Company’s offices. The Company has selectively resumed in-person interactions by its customer-facing personnel in compliance with local and state restrictions. The Company also continues to engage with customers virtually as the Company seeks to continue to support healthcare professionals and patient care. However, the Company’s ability to engage in personal interactions with physicians and customers remains limited, and it is unknown when the Company’s offices will reopen, and these interactions will be fully resumed. Revenue Recognition Prescription Medication Sales The Company’s prescription medication sales consist of sales of Stendra® in the U.S. for the treatment of male erectile dysfunction. Under ASC Topic 606, Revenue Recognition In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers Stendra® to when the customers pay for the product is typically less than one year. The Company records prescription medication sales net of any variable consideration, including but not limited to discounts, rebates, returns, chargebacks, and distribution fees. The Company uses the expected value method when estimating its variable consideration unless terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Stendra® are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes. As of September 30, 2021, and December 31, 2020, the reserves for sales deductions were $4.2 million and $8.6 million, respectively. The most significant sales deductions included in this reserve relate to returns, contract rebates, coupon redemptions and distribution service (“DSA”) fees. The Company’s estimates are based on factors such as its direct and indirect customers’ buying patterns and the estimated resulting contractual deduction rates, historical experience, specific known market events and estimated future trends, current contractual and statutory requirements, industry data, estimated customer inventory levels, current contract sales terms with its direct and indirect customers, and other competitive factors. Significant judgment and estimation are required in developing the foregoing and other relevant assumptions. The most significant sales deductions are further described below. Product Returns Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return Stendra® and receive credit for product within six months prior to expiration date and up to one year after expiration date. The provision for returns is based upon the Company’s estimates for future Stendra® returns and historical experience. The provision of returns is part of the variable consideration recorded at the time revenue is recognized. As of September 30, 2021, and December 31, 2020, the reserves for product returns were $3.2 million and $7.1 million, respectively, and are included as a component of accrued expenses. Contract Rebates, Coupon Redemptions and DSA Fees The Company establishes contracts with wholesalers, chain stores, and indirect customers that provide for rebates, sales incentives, DSA fees and other allowances. Some customers receive rebates upon attaining established sales volumes. Direct rebates are generally rebates paid to direct purchasing customers based on a percentage applied to a direct customer’s purchases from us, including fees paid to wholesalers under our DSAs, as described below. Indirect rebates are rebates paid to indirect customers that have purchased our products from a wholesaler under a contract with us. The Company has entered into DSAs with certain of our significant wholesaler customers that obligate the wholesalers, in exchange for fees paid by us, to: (i) manage the variability of their purchases and inventory levels within specified limits based on product demand and (ii) provide us with specific services, including the provision of periodic retail demand information and current inventory levels for our pharmaceutical products held at their warehouse locations. Medical Device Sales The Company’s medical device sales consist of domestic and international sales of men’s health products for the treatment of erectile dysfunction. The men’s health products do not require a prescription and include vacuum erection devices, VenoSeal, and other related accessories. Under Topic 606, the Company recognizes revenue from medical device sales when its performance obligations with its customers have been satisfied. In the contracts with its customers, the Company has identified a single performance obligation to provide medical devices upon receipt of a customer order. The performance obligation is satisfied at a point in time when the Company’s customers obtain control of the medical device, which is typically upon shipment. The Company invoices its customers after the medical devices have been shipped and invoice payments are generally due within 30 days of invoice date for domestic customers and 90 days for international customers. In determining the transaction price, a significant financing component Product Returns Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return medical devices and receive credit for products within 90 days of the sale. The provision for returns is based upon the Company’s estimates for future product returns and historical experience. The Company has not made significant changes to the judgments made in applying Topic 606. As of September 30, 2021, and December 31, 2020, the reserves for product returns for medical devices were not significant. Fair Value of Financial Instruments Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy: Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by an observable market. Level 3 — Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. Financial instruments recognized at historical amounts in the condensed consolidated balance sheets consist of cash, accounts receivable, other current assets, accounts payable, accrued expenses, other current liabilities, and senior debt. The Company believes that the carrying value of cash, accounts receivable, other current assets, accounts payable, accrued expenses, and other current liabilities approximates their fair values due to the short-term nature of these instruments. The carrying value of senior debt as of September 30, 2021, and December 31, 2020, approximated fair value. The fair value of the senior debt was estimated by discounting to present value the scheduled coupon payments and principal repayment, using an appropriate fair market yield and is considered Level 3 in the fair value hierarchy. In connection with the Mergers in December 2020, each security holder of Metuchen received an earnout consideration classified as a derivative liability to be paid in the form of Petros Common Stock. The Company estimated their fair value using a Monte Carlo Simulation approach. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative liability as of September 30, 2021, and December 31, 2020, was $0.3 million and $9.9 million, respectively. See Note 10 Stockholders’ Equity. Stock-Based Compensation The Company accounts for stock-based awards to employees and consultants in accordance with applicable accounting principles, which requires compensation expense related to stock-based transactions, including employee stock options and consultant warrants, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options or warrants. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. Employee stock option and consulting expenses are recognized over the employee’s or consultant’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the volatility and expected term. Any changes in these highly subjective assumptions can significantly impact stock-based compensation expense. See Note 11 Stock Options. Income Taxes Prior to the consummation of the Mergers, Metuchen was a limited liability company (“LLC”) for federal income tax purposes and had elected to be treated as a Partnership for federal and state income tax purposes. PTV is a disregarded entity for federal income tax purposes. As such, all income tax consequences resulting from the operations were reported on the member’s income tax return. In addition, Timm Medical was included in the Company’s structure where taxes were paid at the entity level. Subsequent to the Mergers, Metuchen’s activity is included in the Company’s consolidated group. The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period the rate change is enacted. The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions in accordance with FASB ASC No. 740 Income Taxes The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statement of operations. As of September 30, 2021, and December 31, 2020, no accrued interest or penalties are recorded in the condensed consolidated balance sheets. Basic and Diluted Net Loss per Common Share The Company computes basic net loss per common share by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period, excluding the dilutive effects of stock options and warrants to purchase common shares. The Company computes diluted net loss per common share by dividing the net loss applicable to common share by the sum of the weighted-average number of common shares outstanding during the period plus the potential dilutive effects of its convertible preferred stocks, stock options and warrants to purchase common shares, but such items are excluded if their effect is anti-dilutive. See Note 13 Basic and Diluted Net Loss per Common Share. Recent Accounting Pronouncements Pending Adoption as of September 30, 2021 In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Measurement of Credit Losses on Financial Instruments	2) Summary of Significant Accounting Policies Use of Estimates The preparation of Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the Consolidated Financial Statements, and reported amounts of revenue and expenses during the reporting periods. Such estimates include the adequacy of accounts receivable reserves, return reserves, inventory reserves, and assessment of long-lived assets, including intangible asset impairment, and the allocation of the purchase price in acquisitions. Actual results could differ from these estimates and changes in these estimates are recorded when known. Risks and Uncertainties The Company is subject to risks common to companies in the pharmaceutical industry including, but not limited to, uncertainties related to commercialization of competitor products, regulatory approvals, dependence on key products, dependence on key customers and suppliers, and protection of intellectual property rights. In January 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. As a result of the COVID-19 pandemic, which continues to rapidly evolve, “shelter in place” orders and other public health guidance measures were implemented across much of the United States, Europe and Asia, including in the locations of the Company’s offices, key vendors and partners. The pandemic has significantly impacted the economic conditions in the U.S. and globally as federal, state and local governments react to the public health crisis, creating significant uncertainties in the economy. At this time, the future trajectory of the COVID-19 outbreak remains uncertain, both in the United States and in other markets. While the Company anticipates that currently available vaccines will be widely distributed in the future, the timing and efficacy of such vaccines are uncertain. The Company cannot reasonably estimate the length or severity of the impact that the COVID-19 outbreak will have on its financial results, and the Company may experience a material adverse impact on its sales, results of operations, and cash flows in fiscal 2021. During 2020, government regulations and the voluntary business practices of the Company and prescribing physicians have prevented in-person visits by sales representatives to physicians’ offices. The Company has taken steps to mitigate the negative impact on its businesses of such restrictions. In March 2020, the Company reduced our sales representative head count to reflect the lack of in-person visits. The Company has maintained a core sales team which continues to contact physicians via telephone and videoconference as well as continuing to have webinars provided by the Company’s key opinion leaders to other physicians and pharmacists. The Company anticipates rehiring and/or assigning representatives to cover sales territories as states reopen and physician access resumes new normal levels. In response to the spread of SARS-CoV-2 and COVID-19, in March 2020, the Company closed its administrative offices and as of December 31, 2020, they remain closed, with the Company’s employees continuing their work outside of the Company’s offices. The Company has selectively resumed in-person interactions by its customer-facing personnel in compliance with local and state restrictions. The Company also continues to engage with customers virtually as the Company seeks to continue to support healthcare professionals and patient care. However, the Company’s ability to engage in personal interactions with physicians and customers remains limited, and it is unknown when the Company’s offices will reopen, and these interactions will be fully resumed. Concentration of Credit Risk Financial instruments that subject the Company to concentrations of credit risk includes cash. The Company maintains cash on deposit at U.S.-based banks in amounts which, at times, may be in excess of insured limits. Cash and Cash Equivalents The Company considers all highly-liquid investments that have maturities of three months or less when acquired to be cash equivalents. Segment Reporting Operating segments are components of a Company for which separate financial information is available and evaluated regularly by the chief operating decision maker in assessing performance and deciding how to allocate resources. The Company’s two segments, Prescription Medications and Medical Devices, focus on the treatment of male erectile dysfunction. The Prescription Medications segment consists primarily of operations related to Stendra®, which is sold generally in the United States, and H100™ for the treatment of Peyronie’s disease. The Medical Devices segment consists primarily of operations related to vacuum erection devices, which are sold domestically and internationally. See Note 18 Segment Reporting. Revenue Recognition Prescription Medication Sales The Company’s prescription medication sales consist of sales of Stendra® in the U.S. for the treatment of male erectile dysfunction. Under ASC Topic 606, Revenue Recognition In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers Stendra® to when the customers pay for the product is typically less than one year. The Company records prescription medication sales net of any variable consideration, including but not limited to discounts, rebates, returns, chargebacks, and distribution fees. The Company uses the expected value method when estimating its variable consideration, unless terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Stendra® are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes. As of December 31, 2020 and 2019, the reserves for sales deductions were $8.6 million and $12.0 million, respectively. The most significant sales deductions included in this reserve relate to returns, contract rebates, and distribution service (“DSA”) fees. Our estimates are based on factors such as our direct and indirect customers’ buying patterns and the estimated resulting contractual deduction rates, historical experience, specific known market events and estimated future trends, current contractual and statutory requirements, industry data, estimated customer inventory levels, current contract sales terms with our direct and indirect customers, and other competitive factors. Significant judgment and estimation is required in developing the foregoing and other relevant assumptions. The most significant sales deductions are further described below. Product Returns Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return Stendra® and receive credit for product within six months prior to expiration date and up to one year after expiration date. The provision for returns is based upon the Company’s estimates for future Stendra® returns and historical experience. The provision of returns is part of the variable consideration recorded at the time revenue is recognized. As of December 31, 2020 and 2019, the reserves for product returns were $7.1 million and $8.3 million, respectively, and are included as a component of accrued expenses. Contract Rebates, Coupon Redemptions and DSA Fees The Company establishes contracts with wholesalers, chain stores, and indirect customers that provide for rebates, sales incentives, DSA fees and other allowances. Some customers receive rebates upon attaining established sales volumes. Direct rebates are generally rebates paid to direct purchasing customers based on a percentage applied to a direct customer’s purchases from us, including fees paid to wholesalers under our DSAs, as described below. Indirect rebates are rebates paid to indirect customers that have purchased our products from a wholesaler under a contract with us. The Company has entered into DSAs with certain of our significant wholesaler customers that obligate the wholesalers, in exchange for fees paid by us, to: (i) manage the variability of their purchases and inventory levels within specified limits based on product demand and (ii) provide us with specific services, including the provision of periodic retail demand information and current inventory levels for our pharmaceutical products held at their warehouse locations. Medical Device Sales The Company’s medical device sales consist of domestic and international sales of men’s health products for the treatment of erectile dysfunction. The men’s health products do not require a prescription and include Vacuum Erection Devices, PreBoost, VenoSeal, penile injections (Rx), and urinary tract infection tests. Under Topic 606, the Company recognizes revenue from medical device sales when its performance obligations with its customers have been satisfied. In the contracts with its customers, the Company has identified a single performance obligation to provide medical devices upon receipt of a customer order. The performance obligation is satisfied at a point in time when the Company’s customers obtain control of the medical device, which is typically upon shipment. The Company invoices its customers after the medical devices have been shipped and invoice payments are generally due within 30 days of invoice date for domestic customers and 90 days for international customers. In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers the medical devices to when the customers pay for the product is typically less than one year. The Company records medical device sales net of any variable consideration, including but not limited to returns. The Company uses the expected value method when estimating its variable consideration. The identified variable consideration is recorded as a reduction of revenue at the time revenues from the medical device sales are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes. Product Returns Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return medical devices and receive credit for products within 90 days of the sale. The provision for returns is based upon the Company’s estimates for future product returns and historical experience. The Company has not made significant changes to the judgments made in applying Topic 606. As of December 31, 2020 and 2019, the reserves for product returns for medical devices were not significant. Contract Costs In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. As such, the Company did not have any contract assets at December 31, 2020 and 2019. Accounts Receivable, net The Company extends credit to its customers in the normal course of business. Accounts receivable are recorded at the invoiced amount, net of chargebacks, distribution service fees, and cash discounts. Management determines each allowance based on historical experience along with the present knowledge of potentially uncollectible accounts. See Note 3 Accounts, Receivable, net. Inventories Inventories consist of finished goods held for sale and raw materials. Inventories are stated at the lower of cost or net realizable value, with cost determined using the first-in, first-out method. Inventories are adjusted for excess and obsolescence. Evaluation of excess inventory includes such factors as expiry date, inventory turnover, and management’s assessment of current product demand. See Note 4 Inventories. Intangible Assets The Company accounts for recognized intangible assets at cost. Intangible assets with finite useful lives are amortized over the useful life that the assets are expected to contribute directly or indirectly to future cash flows. Intangible assets are amortized using an accelerated method based on the pattern in which the economic benefits of the assets are consumed. The Company review the carrying value and useful lives of its intangible assets with definite lives, or whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable or the period over which they should be amortized has changed. When indicators of impairment exist, the Company determines whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The Company evaluates the remaining useful life of each intangible asset that is being amortized during each reporting period to determine whether events and circumstances warrant a revision to the remaining period of amortization. If the estimate of the intangible asset’s remaining useful life has changed, the remaining carrying amount of the intangible asset is amortized prospectively over that revised remaining useful life. Given the impact of the COVID-19 outbreak on the global economy, as well as its potential impact to the Company’s business operations and cash flows, the Company constituted the COVID-19 outbreak as a triggering event requiring an impairment test for its long-lived assets with finite useful lives. The Company’s projections included the undiscounted cash flows of the remaining estimated useful lives for the Stendra product through December 2028 and December 2030 for the medical device products. Based on the impairment assessment as of December 31, 2020, the Company determined that no intangible asset impairment occurred as the undiscounted cash flows exceeded the respective carrying values of the assets. The Company did not record any impairments of intangible assets for the years ended December 31, 2020 and 2019. Goodwill Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. The Company evaluates the carrying value of goodwill annually in December of each year in connection with the annual budgeting and forecast process and also between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit to which goodwill was allocated to below its carrying amount. Such circumstances could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. When evaluating goodwill for impairment, we may first perform an assessment qualitatively whether it is more likely than not that a reporting unit’s carrying amount exceeds its fair value, referred to as a “step zero” approach. Subsequently (if necessary after step zero), an entity should perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. This quantitative impairment test uses a combination of the income method and guideline public company comparable companies. The income method is based on a discounted future cash flow approach that uses significant assumptions of projected revenue, projected operational profit, terminal growth rates and the cost of capital. Under Topic 350, goodwill impairment is measured as the excess of the carrying amount of the reporting unit over its fair value. The Company incurred a goodwill impairment loss of $2,443,930 during the year ended December 31, 2019, related to the prescription medications segment. ​ ​ ​ ​ ​ Balance, December 31, 2018 $ 2,443,930 Impairment loss ​ (2,443,930) Balance, December 31, 2019 ​ $ — ​ Fixed Assets Fixed assets consist of furniture and fixtures. Furniture and fixtures are recorded at cost, less accumulated depreciation, and are depreciated on a straight-line basis over its estimated useful life. The Company uses an estimated useful life of 7 years for furniture and fixtures. Depreciation expense for the years ended December 31, 2020 and 2019 was $10,220 and $1,703, respectively. Leases The Company accounts for leases in accordance with Accounting Standards Codification (“ASC”) Topic 842. Topic 842 requires organizations to recognize leased assets and liabilities on the balance sheet. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all leases. Operating lease right-of-use (“ROU”) assets are included in other assets whereas operating lease liabilities are included in other current liabilities and other long-term liabilities on the Company’s consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The operating lease payments are recognized as lease expense on a straight-line basis over the lease term. Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Company’s consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories. Topic 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The lease term for all of the Company’s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. See Note 2 and Note 15 Commitments and Contingencies for additional information. Fair Value of Financial Instruments Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy: Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market. Level 3 — Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. Financial instruments recognized at historical amounts in the consolidated balance sheets consist of cash, accounts receivable, other current assets, accounts payable, accrued expenses, other current liabilities and senior debt. The Company believes that the carrying value of cash, accounts receivable, other current assets, accounts payable, accrued expenses, other current liabilities approximates their fair values due to the short-term nature of these instruments. The carrying value of senior debt as of December 31, 2020 approximated fair value. The fair value of the senior debt was estimated by discounting to present value the scheduled coupon payments and principal repayment, using an appropriate fair market yield and is considered Level 3 in the fair value hierarchy. In connection with the Mergers in December 2020, each security holder of Metuchen received an earnout consideration classified as a derivative liability to be paid in the form of Petros Common Stock. The Company estimated their fair value using Monte Carlo Simulation approach. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative liability as of the closing of the Merger and December 31, 2020 was $8.2 million and $9.9 million, respectively. See Note 10 Stockholders’ Equity. Deferred Financing Costs Costs incurred to issue debt are deferred and presented in the consolidated balance sheets as a direct reduction from the carrying amount of the debt liability, consistent with debt discounts. Related amortization expense is recorded as a component of interest expense over the term of the related debt using the effective interest rate method. Stock-Based Compensation The Company accounts for stock-based awards to employees and consultants in accordance with applicable accounting principles, which requires compensation expense related to stock-based transactions, including employee stock options and consultant warrants, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options or warrants. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. Employee stock option and consulting expenses are recognized over the employee’s or consultant’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the volatility and expected term. Any changes in these highly subjective assumptions can significantly impact stock-based compensation expense. See Note 11 Stock Options. Costs of Equity Transactions Incremental direct costs incurred to issue stocks of the Company’s preferred and common stocks are recorded as a reduction of the related proceeds. Income Taxes Prior to the consummation of the Mergers, Metuchen was a limited liability company (“LLCs”) for federal income tax purposes and had elected to be treated as a Partnership for federal and state income tax purposes. PTV is a disregarded entity for federal income tax purposes. As such, all income tax consequences resulting from the operations were reported on the member’s income tax return. In addition, Timm was included in the Company’s structure where taxes were paid at the entity level. Following the consummation of the Mergers, Metuchen is treated as a disregarded entity (“SMLLC”) for federal income tax purposes. As such, all income tax consequences resulting from the operations of Metuchen are reported on the members’ income tax returns through the period in which the Merger was transacted. Subsequent to the Mergers, Metuchen’s activity is included in the Company’s consolidated group. The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period the rate change is enacted. The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) it determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. As of December 31, 2020 and 2019 no accrued interest or penalties are recorded in the consolidated balance sheets. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, was enacted and signed into law, and GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act, among other things, includes changes to the tax provisions that benefits business entities and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act, including, permitting net operating losses, or NOLs, carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The CARES Act provides other reliefs and stimulus measures. We have evaluated the impact of the CARES Act, and do not expect that any provision of the CARES Act would result in a material cash benefit to us or have a material impact on our financial statements or internal controls over financial reporting. Contingencies The Company may be subject to various patent challenges, product liability claims, government investigations and other legal proceedings in the ordinary course of business. Legal fees and other expenses related to litigation are expensed as incurred and included in general and administrative expenses in the consolidated statements of operations. Shipping Costs The Company records the costs of shipping related to prescription medication sales in general and administrative expense in its consolidated statements of operations. There were no shipping costs for the years ended December 31, 2020 and 2019. Shipping costs related to medical devices are recorded as revenue and subsequently deducted as a component of cost of goods sold in the consolidated statements of operations. Shipping costs for the years ended December 31, 2020 and 2019 were $108,870 and $130,242 respectively. Basic and Diluted Net Loss per Common Share The Company computes basic net loss per common share by dividing net loss applicable to common stockholders by the weighted average number of common stocks outstanding during the period, excluding the dilutive effects of stock options and warrants to purchase common stocks. The Company computes diluted net loss per common stock by dividing the net loss applicable to common stocks by the sum of the weighted-average number of common stocks outstanding during the period plus the potential dilutive effects of its convertible preferred stocks, stock options and warrants to purchase common stocks, but such items are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between the Company’s basic and diluted net loss per stock of common stock for the years ended December 31, 2020 and 2019. See Note 13 Basic and Diluted Net Loss per Common Share. Recent Accounting Pronouncements Recently Adopted In August 2018, the FASB issued ASU 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement fair value measurements. The guidance is effective for the Company for the annual periods and interim periods within annual periods beginning after December 15, 2019 for both private and public entities. The Company adopted this guidance as of January 1, 2020 and its impact was not material. Pending Adoption as of December 31, 2020 In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments

Accounts Receivable, net

Accounts Receivable, net	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Accounts Receivable, net
Accounts Receivable, net	3) Accounts Receivable, net Accounts receivable, net is comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, December 31, ​ ​ 2021 ​ 2020 Gross accounts receivables ​ $ 2,929,064 ​ $ 6,560,291 Distribution service fees ​ (537,363) ​ (972,652) Chargebacks accrual ​ — ​ (121,269) Cash discount allowances ​ (135,527) ​ (84,601) Allowance for doubtful accounts ​ (303,753) ​ (228,800) Total accounts receivable, net ​ $ 1,952,421 ​ $ 5,152,969 ​ For the nine months ended September 30, 2021 and 2020, gross sales from customers representing 10% or more of the Company’s total gross sales included four customers and one customer, respectively, which represented approximately 78% and 80% of total gross sales, respectively. Receivables from customers representing 10% or more of the Company’s gross accounts receivable included two customers at September 30, 2021 and December 31, 2020 equal to 70% and 93%, respectively, of the Company’s total gross accounts receivables.	3) Accounts Receivable, net Accounts receivable, net is comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, December 31, ​ ​ 2020 ​ 2019 Gross accounts receivables ​ $ 6,560,291 ​ $ 4,989,260 Distribution service fees ​ (972,652) ​ (2,061,481) Chargebacks accruals ​ (121,269) ​ (60,507) Cash discount allowances ​ (84,601) ​ (235,867) Allowance for doubtful accounts ​ (228,800) ​ (26,275) Total accounts receivable, net ​ $ 5,152,969 ​ $ 2,605,130 ​ For years ended December 31, 2020 and 2019, gross sales from customers representing 10% or more of the Company’s total gross sales included one customer which represented approximately 85% and 86% of total gross sales, respectively. Receivables from customers representing 10% or more of the Company’s gross accounts receivable included one customer at December 31, 2020 and 2019 equal to 93% and 88%, respectively, of the Company’s total gross accounts receivables.

Inventories

Inventories	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Inventories
Inventories	4) Inventories Inventory is comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 December 31, 2020 Raw materials ​ $ 328,558 ​ $ 325,932 Finished goods ​ 189,923 ​ 434,598 Total inventory ​ $ 518,481 ​ $ 760,530 ​ Finished goods are net of valuation reserves of $435,927 and $935,866 as of September 30, 2021, and December 31, 2020, respectively. Raw materials are net of valuation reserves of $2,872,977 as of both September 30, 2021, and December 31, 2020, respectively, which is related to bulk inventory that is fully reserved.	4) Inventories Inventory is comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 December 31, 2019 Raw materials ​ $ 325,932 ​ $ 798,161 Finished goods ​ 434,598 ​ 1,406,267 Total inventory ​ $ 760,530 ​ $ 2,204,428 ​ Finished goods are net of valuation reserves of $935,866 and $220,254 as of December 31, 2020 and 2019, respectively. Raw materials are net of valuation reserves of $2,872,977 as of December 31, 2020 and 2019, which is related to bulk inventory that is fully reserved.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Prepaid Expenses and Other Current Assets
Prepaid Expenses and Other Current Assets	5) Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets are comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 December 31, 2020 Prepaid samples ​ $ — ​ $ 58,483 Prepaid insurance ​ 172,205 ​ 149,452 Prepaid FDA fees ​ — ​ 756,972 Prepaid coupon fees ​ 71,500 ​ 71,500 API purchase commitment asset (see Note 14) ​ 1,304,541 ​ 1,304,541 Other prepaid expenses ​ 587,319 ​ 391,552 Other current assets ​ 612,673 ​ 114,784 Total prepaid expenses and other current assets ​ $ 2,748,238 ​ $ 2,847,284 ​ Prepaid samples, which are presented net of reserves, are expensed when distributed to the sales force. The prepaid samples reserve amount was $379,612 and $351,224 as of September 30, 2021, and December 31, 2020, respectively.	5) Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets are comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 December 31, 2019 Prepaid samples ​ $ 58,483 ​ $ 391,024 Prepaid insurance ​ 149,452 ​ 287,844 Prepaid FDA fees ​ 756,972 ​ 732,204 Prepaid coupon fees ​ 71,500 ​ 71,500 Rebates receivable ​ ​ — ​ ​ 1,243,120 API purchase commitment asset (see Note 14) ​ 1,304,541 ​ 1,409,592 Other prepaid expenses ​ 391,552 ​ 468,226 Other current assets ​ 114,784 ​ 526,310 Total prepaid expenses and other current assets ​ $ 2,847,284 ​ $ 5,129,820 ​ Prepaid samples, which are presented net of reserves, are expensed when distributed to the sales force. The prepaid samples reserve amount was $351,224 and $145,474 at December 31, 2020 and 2019, respectively. ​ In relation to a transition services agreement with a prior owner of the product rights to Stendra®, the prior owner had processed managed care rebates and remitted them back to the Company during the year ended December 31, 2020; therefore, the Company did not have a receivable related to rebates processed by the prior owner of the product rights to Stendra® as of December 31, 2020.

Intangible Assets

Intangible Assets	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Intangible Assets
Intangible Assets	6) Intangible Assets ​ ​ ​ ​ ​ Balance at December 31, 2019 $ 38,811,137 Amortization expense ​ (6,650,218) Balance at December 31, 2020 ​ ​ 32,160,919 Amortization expense ​ (5,178,821) Balance at September 30, 2021 ​ $ 26,982,098 ​ The future annual amortization related to the Company’s intangible assets is as follows as of September 30, 2021: ​ ​ ​ ​ ​ 2021 (remaining 3 months) ​ 1,688,951 2022 ​ 6,191,740 2023 ​ 5,445,729 2024 ​ 4,650,787 Thereafter ​ 9,004,891 Total ​ $ 26,982,098 ​ The intangible assets held by the Company are the Stendra® product, Timm Medical product, and PTV product and are being amortized over their estimated useful lives of 10 years , 12 years , and 12 years, respectively. The carrying value of the Stendra® product, Timm Medical product, and PTV product as of September 30, 2021, are $20.4 million, $5.1 million, and $1.4 million, respectively. The carrying value of the Stendra® product, Timm Medical product, and PTV product as of December 31, 2020, are $24.6 million, $5.9 million, and $1.6 million, respectively.	6) Intangible Assets ​ ​ ​ ​ ​ Balance at December 31, 2018 ​ $ 44,100,542 Amortization expense ​ ​ (5,289,405) Balance at December 31, 2019 $ 38,811,137 Amortization expense ​ (6,650,218) Balance at December 31, 2020 ​ $ 32,160,919 ​ The future annual amortization related to the Company’s intangible assets is as follows: ​ ​ ​ ​ ​ 2021 ​ 6,867,771 2022 ​ 6,191,740 2023 ​ 5,445,729 2024 ​ 4,650,787 Thereafter ​ 9,004,892 Total ​ $ 32,160,919 ​ The intangible assets held by the Company are the Stendra® product, Timm Medical product, and PTV product and are being amortized over their estimated useful lives of 10 years, 12 years, and 12 years, respectively. The carrying value of the Stendra® product, Timm Medical product, and PTV product as of December 31, 2020 are $24.6 million, $5.9 million and $1.6 million, respectively. The carrying value of the Stendra® product, Timm Medical product, and PTV product as of December 31, 2019 were $30.0 million, $6.9 million and $1.9 million, respectively.

Accrued Expenses

Accrued Expenses	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Accrued Expenses
Accrued Expenses	7) Accrued Expenses Accrued expenses are comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 December 31, 2020 Accrued price protection ​ $ 1,853,979 ​ $ 1,853,979 Accrued product returns ​ 5,590,248 ​ 9,452,248 Accrued contract rebates ​ 341,715 ​ 412,046 Due to Vivus (see Note 14) ​ 2,267,523 ​ 2,267,523 Accrued severance ​ 25,417 ​ 519,609 Accrued professional fees ​ 31,463 ​ — Accrued marketing ​ 1,258,255 ​ — Other accrued expenses ​ 225,514 ​ 178,381 Total accrued expenses ​ $ 11,594,114 ​ $ 14,683,786 ​ As part of its acquisition of Stendra®, the Company provides the previous owner with price protection for certain Stendra® product returns that are processed by the previous owner in accordance with the Company's returned goods policy. Some customer agreements require that product returns be credited at the current wholesale acquisition cost (“WAC”). If the Company subsequently raises the WAC, the Company will reimburse the previous owner for the difference between the current WAC and the original sale price for returns processed by the previous owner.	7) Accrued Expenses Accrued expenses are comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 December 31, 2019 Accrued price protection ​ $ 1,853,979 ​ $ 1,847,639 Accrued product returns ​ 9,452,248 ​ 10,707,807 Accrued contract rebates ​ 412,046 ​ 1,368,279 Due to Vivus (see Note 14) ​ 2,267,523 ​ 2,259,769 Due to third-party logistic provider ​ — ​ 4,388,600 Accrued severance ​ 519,609 ​ — Other accrued expenses ​ 178,381 ​ 315,168 Total accrued expenses ​ $ 14,683,786 ​ $ 20,887,262 ​ As part of its acquisition of Stendra®, the Company provides the previous owner with price protection for certain Stendra® product returns that are processed by the previous owner. Some customer agreements require that product returns be credited at the current wholesale acquisition cost (“WAC”). If the Company subsequently raises the WAC, the Company will reimburse the previous owner for the difference between the current WAC and the original sale price for returns processed by the previous owner.

Debt

Debt	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Debt
Debt	8) Debt Senior Debt The following is a summary of the Company’s senior indebtedness at September 30, 2021, and December 31, 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 December 31, 2020 Principal balance ​ $ 1,740,752 ​ $ 6,653,292 Plus: End of term fee ​ — ​ 534,237 Less: Debt issuance costs ​ — ​ (12,500) Total senior debt ​ $ 1,740,752 ​ $ 7,175,029 ​ On September 30, 2016, the Company entered into a loan and security agreement with Hercules Capital, Inc. (“Hercules”), a third party, for a $35 million term loan (the “Senior Debt”). The Senior Debt includes an additional Paid-In-Kind (“PIK”) interest that increases the outstanding principal on a monthly basis at an annual rate of 1.35% and a $787,500 end of term charge. The end of term charge is being recognized as interest expense and accreted over the term of the Senior Debt using the effective interest method. On November 22, 2017, the Company and Hercules entered into Amendment No. 1 to the Senior Debt (the “First Amendment”). A covenant was added, in which the Company may achieve a certain minimum EBITDA, as defined in the First Amendment, target for the trailing twelve-month period, ending June 30, 2018. The end of term charge was increased from $787,500 to $1,068,750. The minimum EBITDA for each of the trailing six months and the fixed charge coverage ratio were reduced from 1:1 to 0.9:1. The Company was also required to prepay $10 million in principle. On April 13, 2020, the Company and Hercules entered into Amendment No. 2 to the Senior Debt (the “Second Amendment”). The Second Amendment waived all financial covenant defaults for all periods since inception through the period ending March 31, 2020. The Second Amendment also included the following changes: ● Extended the maturity date from October 1, 2020, to April 2021, which can be further extendable to December 1, 2021, upon achieving the Financing Milestone, as defined in the agreement. ● Increased the cash interest rate from the greater of (a) 10.75% or (b) 10.75% plus the US WSJ Prime minus 4.50% to the greater of (a) 11.50% or (b) 11.50% plus the US WSJ Prime minus 4.25% . ● Removed the PIK interest rate. ● Removed the prepayment penalty. The end of term charge of $1,068,750 was partially extended with $534,375 paid on October 1, 2020, and $534,375 paid on February 1, 2021. Effective September 30, 2020, the Company and Hercules entered into the Third Amendment to the Senior Debt Loan and Security Agreement (the “Third Amendment”) to provide for interest only payments commencing on October 1, 2020, and continuing through December 22, 2020, unless the Company raised net cash proceeds of at least $25 million through an equity or debt financing or other transaction on or before December 21, 2020. The Third Amendment also amended the minimum cash, minimum net revenue, and minimum EBITDA financial covenants. On that same date, Juggernaut Capital Partners III, L.P, an affiliate of the JCP Investor., Hercules and Wells Fargo Bank, N.A. entered into an escrow agreement (the “Escrow Agreement”) to escrow funds amounting to approximately $1.5 million, an amount equal to the aggregate of certain principal payments due under the Loan Agreement, as amended. In connection with the consummation of the Mergers, the funds held in escrow were disbursed back to Juggernaut Capital Partners III, L.P. and the Escrow Agreement was terminated. The Company satisfied the maturity date extension requirement pursuant to funds retained upon the closing of the Mergers in December 2020. As a result, the Senior Debt now has a maturity date of December 1, 2021. As of September 30, 2021, the Company was in compliance with its covenants. On November 3, 2021, the Company repaid $1,179,651 towards the senior debt. This payment satisfied the remaining balance of the senior debt as of that date. Interest expense on the Senior Debt was as follows for the periods indicated: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended ​ For the Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 Interest expense for term loan ​ $ 67,936 ​ $ 287,855 ​ $ 344,373 ​ $ 1,015,898 Amortization of debt issuance costs ​ — ​ 12,500 ​ 12,500 ​ 25,000 PIK interest ​ — ​ — ​ — ​ 44,449 ​ ​ $ 67,936 ​ $ 300,355 ​ $ 356,873 ​ $ 1,085,347 ​ Included in accrued expenses in the accompanying condensed consolidated balance sheets as of September 30, 2021, and December 31, 2020, is $16,681 and $65,885, respectively, of accrued and unpaid interest. Subordinated Related Party Term Loans Subordinated Related Party Term Loans Entered into During 2020 During 2020, the Company entered into Subordinated Promissory Notes with the JCP Investor in the principal amount of $15.5 million. The maturity date of the Subordinated Promissory Notes was April 2, 2021, and they had PIK interest that increased the outstanding principal on a daily basis at an annual rate of 20%. In connection with the entry into the Merger Agreement on May 17, 2020, the JCP Investor, Neurotrope and Metuchen entered into a Note Conversion and Loan Repayment Agreement pursuant to which, the JCP Investor agreed to convert all of the above outstanding subordinated promissory notes and accrued PIK interest held by Juggernaut Capital Partners LLP and the JCP Investor, into Petros common stock in connection with the consummation of the Mergers on December 1, 2020, and the Subordinated Promissory Notes were terminated. Accordingly, the principal balance of the Subordinated Promissory Notes and accrued PIK interest was $0 as of both September 30, 2021, and December 31, 2020. Interest expense on this debt was $669,730, and $1,148,447, comprised entirely of PIK interest, for the three and nine months ended September 30, 2020, respectively.	8) Debt Senior Debt The following is a summary of the Company’s senior indebtedness at December 31, 2020 and 2019: ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 December 31, 2019 Principal balance ​ $ 6,653,292 ​ $ 11,688,979 Plus: Paid-In-Kind interest ​ ​ — ​ ​ 1,101,575 Plus: End of term fee ​ 534,237 ​ 952,416 Less: Debt issuance costs ​ (12,500) ​ — Total senior debt ​ $ 7,175,029 ​ $ 13,742,970 ​ On September 30, 2016, the Company entered into a loan agreement with Hercules, a third party, for a $35 million term loan (“Senior Debt”) with a stated interest rate of the greater of either (i) Prime plus 7.25% or (ii) 10.75%. The Senior Debt includes an additional Paid-In-Kind (“PIK”) interest that increases the outstanding principal on a monthly basis at an annual rate of 1.35% and a $787,500 end of term charge. On November 22, 2017, the Company amended its loan agreement with Hercules (“First Amendment”). A covenant was added, in which the Company must achieve a certain minimum EBITDA, as defined, target for the trailing twelve-month period, ending June 30, 2018. The end of term charge was increased from $787,500 to $1,068,750. The minimum EBITDA for each of the trailing six months and the fixed charge coverage ratio ( 1:1 0.9:1) Monthly principal payments, including interest, commenced November 1, 2018 with the outstanding balance of the Senior Debt due in full on November 1, 2020. The end of term charge is being recognized as interest expense and accreted over the term of the Senior Debt using the effective interest method. On April 13, 2020, the Company amended its loan agreement with Hercules. The amendment waived all financial covenant defaults for all periods since inception through the period ending March 31, 2020. The amendment also included the following changes: ● Removed the Adjusted EBITDA and Fixed Cost Coverage Ratio Covenants. ● Extended the maturity date from October 1, 2020 to April 2021, which can be further extendable to December 1, 2021 upon achieving the Financing Milestone, as defined in the agreement. ● Increased the cash interest rate from the greater of (a) 10.75% or (b) 10.75% plus the US WSJ Prime minus 4.50% to the greater of (a) 11.50% or (b) 11.50% plus the US WSJ Prime minus 4.25% . ● Removed the PIK interest rate. ● Removed the prepayment penalty. The end of term charge of $1,068,750 was partially extended with $534,375 paid on October 1, 2020 and $534,375 due on February 1, 2021. Effective September 30, 2020, the Company and Hercules entered into the Third Amendment to Loan and Security Agreement (“Third Amendment”) to provide for interest only payments commencing on October 1, 2020 and continuing through December 22, 2020 unless the Company raised net cash proceeds of at least $25 million through an equity or debt financing or other transaction on or before December 21, 2020. The Third Amendment also amended the minimum cash, minimum net revenue and minimum EBITDA financial covenants. On that same date, Juggernaut Capital Partners III, L.P., Hercules and Wells Fargo Bank, N.A. entered into an escrow agreement (the “Escrow Agreement”) to escrow funds amounting to approximately $1.5 million, an amount equal to the aggregate of certain principal payments due under the Loan Agreement, as amended. In connection with the consummation of the Mergers, the funds held in escrow were disbursed back to Juggernaut Capital Partners III, L.P. and the Escrow Agreement was terminated. The Company satisfied the maturity date extension requirement pursuant to funds retained upon the closing of the Mergers in December 2020. As a result, the Senior Debt now has a maturity date of December 1, 2021. As of December 31, 2020, the Company was in compliance with its covenants. Interest expense on the Senior Debt was as follows for the periods indicated: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended December 31, ​ 2020 2019 Interest expense for term loan ​ $ 1,241,475 ​ $ 2,216,341 Amortization of debt issuance costs ​ 37,500 ​ — PIK interest ​ 44,449 ​ 211,923 ​ ​ $ 1,323,424 ​ $ 2,428,264 ​ Included in accrued expenses in the accompanying consolidated balance sheets as of December 31, 2020 and 2019 is $65,885 and $132,006, respectively, of accrued and unpaid interest. Subordinated Related Party Term Loans Subordinated Related Party Term Loans Entered Into During 2020 On January 31, 2020, the Company entered into a Subordinated Promissory Note with JCP III SM AIV, L.P. (the “JCP Investor”) in the principal amount of $3.0 million (the “First Subordinated Promissory Note”). The maturity date of the First Subordinated Promissory Note was April 2, 2021 and has PIK interest that increases the outstanding principal on a daily basis at an annual rate of 20%. On April 1, 2020, the Company entered into a Subordinated Promissory Note with the JCP Investor in the principal amount of $3.0 million (the “Second Subordinated Promissory Note”). The maturity date of the Second Subordinated Promissory Note was April 2, 2021 and had PIK interest that increases the outstanding principal on a daily basis at an annual rate of 20%. On April 22, 2020, the Company entered into a Subordinated Promissory Note with the JCP Investor in the principal amount of $4.0 million (the “Third Subordinated Promissory Note”). The maturity date of the Third Subordinated Promissory Note was April 2, 2021 and had PIK interest that increases the outstanding principal on a daily basis at an annual rate of 20%. On July 31, 2020, the Company entered into a Subordinated Promissory Note with the JCP Investor in the principal amount of $2.5 million (the “Fourth Subordinated Promissory Note”). The maturity date of the Fourth Subordinated Promissory Note was April 2, 2021 and had PIK interest that increases the outstanding principal on a daily basis at an annual rate of 20%. On August 31, 2020, the Company entered into a Subordinated Promissory Note with the JCP Investor in the principal amount of $1.5 million (the “Fifth Subordinated Promissory Note”). The maturity date of the Fifth Subordinated Promissory Note was April 2, 2021 and had PIK interest that increases the outstanding principal on a daily basis at an annual rate of 20%. On October 1, 2020, the Company entered into a Subordinated Promissory Note with the JCP Investor in the principal amount of $1.5 million (the “Sixth Subordinated Promissory Note” and together with the First Subordinated Promissory Note, Second Subordinated Promissory Note, Third Subordinated Promissory Note, Fourth Subordinated Promissory Note, and Fifth Subordinated Promissory Note, the “Subordinated Promissory Notes”). The maturity date of the Sixth Subordinated Promissory Note was April 2, 2021 and had PIK interest that increases the outstanding principal on a daily basis at an annual rate of 20%. In connection with the entry into the Merger Agreement on May 17, 2020, Juggernaut Capital Partners LLP, Neurotrope and Metuchen entered into a Note Conversion and Loan Repayment Agreement pursuant to which, Juggernaut Capital Partners LLP agreed to convert all of the above outstanding subordinated promissory notes and accrued PIK interest held by Juggernaut Capital Partners LLP and the JCP Investor, into Petros common stock in connection with the consummation of the Mergers on December 1, 2020, and the Subordinated Promissory Notes were terminated. Accordingly, the principal balance of the subordinated promissory note and accrued PIK interest was $0 as of December 31, 2020. Interest expense on this debt was $1,727,455 comprised entirely of PIK interest, for the year ended December 31, 2020. ​ Subordinated Related Party Term Loans Entered Into Prior To 2020 ​ On December 10, 2018, JCP III CI AIV, L.P., an affiliate of the JCP Investor, acquired from Krivulka Family LLC (“Krivulka”) all of Krivulka’s ownership interest in Metuchen Therapeutics, LLC (“MT”), a holding company that owned 55% of Metuchen, giving the JCP Investor a controlling interest in Metuchen (such transaction, the “JCP Acquisition”). Concurrently with the JCP Acquisition, the Company executed a Subordination Agreement (“Sub Debt”) with several related parties, L. Mazur Associates, JV (“LMA”), KFE, an entity controlled by Krivulka and the JCP Investor (herein referred to collectively as “the Related Holders”). On November 22, 2107, the Company and the Related Holders entered into an Amended and Restated Subordination Agreement (“Amended Agreement”). Under the terms of the Amended Agreement, the principal balance of the Sub Debt was increased to $30,579,496. The amount due was divided 20.9%, 20.1%, and 59%, respectively, amongst LMA, KFE, and JCP. The cash interest rate of the amended sub debt was 12%. Additional PIK interest was 8% payable on the maturity date. On December 10, 2018, as part of the acquisition accounting for JCP Acquisition of a majority ownership interest in Metuchen, the outstanding Sub Debt was determined to have a fair value that was less than its carrying value. The fair value of the subordinated related party term loans was $22,250,746 at December 10, 2018. A debt discount of $15,506,463 was recognized and was being amortized to interest expense over the term of the debt using the effective interest method. On December 10, 2018, the Company signed a subordinated promissory note for an additional $4,750,000 of Sub Debt from JCP. The proceeds were used for the acquisition of the Medical Device Business. The principal, along with PIK interest at an annual rate of 25%, was due on April 2, 2021. On September 16, 2019, Metuchen entered into an Exchange Agreement (“Exchange Agreement”) with JCP and LMA to exchange Preferred Units and Common Units for the Sub Debt. Upon consummation of the exchange, the Preferred Units and Common Units issued were for the full satisfaction and termination of the subordinated related party term loan. As of each of December 31, 2020 and 2019, there was no outstanding principal balance or accrued interest for the subordinated related term loans. The following chart summarizes the instruments exchanged in the transaction as of September 16, 2019: ​ ​ ​ ​ ​ Common Units, at fair value (2,434,551.28 Units) $ 29,117,232 Preferred Units, at fair value (1,373,820.51 Units) ​ 17,500,000 Total fair value of Preferred and Common Units exchanged ​ 46,617,232 ​ ​ ​ ​ Sub Debt principal balance ​ 33,250,000 Add: PIK Interest ​ 16,544,318 Less: Debt Discount ​ 10,486,536 Total carrying value of Sub Debt exchanged ​ 39,307,782 ​ ​ ​ ​ Excess of fair value of Preferred and Common Units exchanged over the carrying value of Sub Debt ​ $ (7,309,450) ​ Based on ASC 470, the Company accounted for the exchange between related parties as a capital transaction. The carrying value of the subordinated related party term loans, including any accrued interest, on the date of the exchange was $39.3 million and the fair value of Preferred and Common Units was $46.6 million. As this is a capital transaction between related parties it is not appropriate to record an extinguishment loss; therefore, the company recorded the $7.3 million difference between the carrying value of the subordinated related party term loans and the fair value of the Preferred and Common Units to members’ capital. See Note 9 Members’ Capital for the determination of fair value of the Preferred and Common Units. The Company had subordinated related party term loans which was converted into common and preferred stocks on September 16, 2019. Interest expense on this debt was $11,416,697, including PIK interest of $6,747,313 for the year ended December 31, 2019.

Members' Capital

Members' Capital	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Members' Capital
Members' Capital	9) Members’ Capital (a) Capitalization Prior to September 16, 2019, the Company authorized 100 units of Class A Common Units (the “Class A Units”) to be issued and outstanding. In addition, there were Restricted Member Units (“RMU’s”) that were designated as a class of incentive units (also known as “Class B Units”). On September 16, 2019, the Company amended and restated its operating agreement creating the rights and preferences relating to the Preferred Units and Common Units mentioned in the Private Placement Offering below. The issued and outstanding Preferred Units and Common Units were exchanged for Common Stock of the Company in connection with the Mergers. (b) Preferred Units A holder of a Preferred Unit was entitled to vote on any matter requiring the approval of such units. In addition, the Preferred Unit holders were entitled to distributions, after adjustment for specific items, for each fiscal year. The following actions required the prior consent of the holders of a majority of the outstanding Preferred Units: (a) amend, alter, or repeal any provision of the amended and restated operating agreement (if such amendment would adversely affect any of the rights or preferences of the Preferred Units); (b) authorize or create membership interests that have a preference over the Preferred Units as to dividends or liquidation; (c) declare or pay any dividends or distributions; (d) dissolve or liquidate (in whole or in part), consolidate, merge, convey, lease, sell, or transfer all or substantially all of the assets of the Company; or purchase or otherwise acquire (directly or indirectly) all or substantially all of the assets or equity interest issued by another company; or file a petition for bankruptcy or receivership of the Company; (e) repurchase or redeem any Membership Interests; or (f) enter into any agreement, commitment or arrangement to do any of the foregoing. (c) Common Units (formerly known as Class A Units) A holder of a Common Unit was entitled to vote on any matter requiring the approval of such units. In addition, the Common Unit holders were entitled to distributions, after adjustment for specific items, for each fiscal year. Effective with the amended and restated operating agreement on August 26, 2019, each Class A Unit was exchanged for 10,000 Common Units. There was no change to the ownership percentages as a result of the exchange and the rights and privileges of Common Unit holders is consistent with that of the holders of Class A Units. (d) Class B Units As of September 16, 2019, none of the Class B Units had been issued. Effective with the amended and restated operating agreement on September 16, 2019, the Class B Units were no longer an authorized membership interest of the Company (e) Liquidation Upon liquidation of the Company or upon any Company sale, the Company was required to pay, hold, or distribute, or cause to be paid, held or distributed, the proceeds thereof as follows: (a) first, to the holders of Preferred Units, pro rata in proportion to the number of Preferred Units held by such holders, until the holders of such Preferred Units receive in respect of each Preferred Unit held by them, the preferred liquidation preference amount; (b) second, to the holders of Common Units, pro rata in proportion to the number of Common Units held by such holders, the remaining proceeds available for distribution.	9) Members’ Capital (a) Capitalization Prior to September 16, 2019, The Company authorized 100 units of Class A Common Units (the “Class A Units”) to be issued and outstanding. In addition, there were Restricted Member Units (“RMU’s”) that were designated as a class of incentive units (also known as “Class B Units”). On September 16, 2019, the Company amended and restated its operating agreement creating the rights and preferences relating to the Preferred Units and Common Units mentioned in the Private Placement Offering below. The issued and outstanding Preferred Units and Common Units were exchanged for Common Stock of the Company in connection with the Mergers. (b) Preferred Units A holder of a Preferred Unit was entitled to vote on any matter requiring the approval of such units. In addition, the Preferred Unit holders were entitled to distributions, after adjustment for specific items, for each fiscal year. The following actions required the prior consent of the holders of a majority of the outstanding Preferred Units: (a) amend, alter or repeal any provision of the amended and restated operating agreement (if such amendment would adversely affect any of the rights or preferences of the Preferred Units); (b) authorize or create membership interests that have a preference over the Preferred Units as to dividends or liquidation; (c) declare or pay any dividends or distributions; (d) dissolve or liquidate (in whole or in part), consolidate, merge, convey, lease, sell, or transfer all or substantially all of the assets of the Company; or purchase or otherwise acquire (directly or indirectly) all or substantially all of the assets or equity interest issued by another company; or file a petition for bankruptcy or receivership of the Company; (e) repurchase or redeem any Membership Interests; or (f) enter into any agreement, commitment or arrangement to do any of the foregoing. See also Note 12 Section (f) for further discussion of Preferred Units. (c) Common Units (formerly known as Class A Units) A holder of a Common Unit was entitled to vote on any matter requiring the approval of such units. In addition, the Common Unit holders were entitled to distributions, after adjustment for specific items, for each fiscal year. Effective with the amended and restated operating agreement on August 26, 2019, each Class A Unit was exchanged for 10,000 Common Units. There was no change to the ownership percentages as a result of the exchange and the rights and privileges of Common Unit holders is consistent with that of the Class A Unit. (d) Class B Units As of September 16, 2019, none of the Class B Units had been issued. Effective with the amended and restated operating agreement on September 16, 2019, the Class B Units were no longer an authorized membership interest of the Company. (e) Liquidation Upon liquidation of the Company or upon any Company sale, the Company was required to pay, hold, or distribute, or cause to be paid, held or distributed, the proceeds thereof as follows: (a) first, to the holders of Preferred Units, pro rata in proportion to the number of Preferred Units held by such holders, until the holders of such Preferred Units receive in respect of each Preferred Unit held by them, the preferred liquidation preference amount; (b) second, to the holders of Common Units, pro rata in proportion to the number of Common Units held by such holders, the remaining proceeds available for distribution. (f) Private Placement Offering On September 16, 2019, the Company executed a Private Placement offering (“Private Placement”) with V4 Capital Partners, LLC (“Lead Investor”) and other accredited investors (collectively “Investors”). None of the Investors had previously held an interest in the Company. Pursuant to the Private Placement, the Company agreed to issue and sell up to $3.5 million of the Company’s Preferred Units. Each Preferred Unit had an offering price of $12.7382 per unit. The Company issued 245,933 Preferred Units related to the Private Placement and received aggregate net proceeds from the Private Placement of $2.7 million. The Preferred Units maintained a 5% non-cumulative quarterly dividend, included one vote per unit on all matters to be voted upon by Common Unit holders and required a mandatory conversion upon the closing of a qualified public offering, with the conversion price being subject to adjustment if the price per share in the qualified public offering was less than $15.92275 per Preferred Unit. Subject to adjustment, each Preferred Unit could be converted into one Common Unit. The Preferred Units did not meet the criteria for liability classification and are classified within equity. In addition, the embedded conversion feature was considered clearly and closely related to the Preferred Units and did not require bifurcation. However, the embedded conversion feature represents a beneficial conversion feature with a relative fair value of $26,500 and has been recorded to additional paid-in capital, included within the $250,000 proceeds received related to the issuance of the lead investor warrants. In connection with the Private Placement, the Lead Investor received warrants (“Lead Investor Warrants”) to purchase an aggregate of 615,838.50 shares of the Company’s Preferred Units at an exercise price of $0.01 per Preferred Unit. The Lead Investor Warrants had an expiration date of September 16, 2020. The Lead Investor Warrants were only exercisable upon a qualified public offering being consummated within one year. As of the date of issuance, the fair value of the Lead Investor Warrants was estimated to be $2.1 million. To record the issuance of the Lead Investor Warrants, the Company allocated the proceeds of $250,000 received from the Lead Investor for the Preferred Units between the Lead Investor Warrants and the beneficial conversion feature for the embedded conversion option. Of the proceeds received, the relative fair value allocated to the Lead Investor Warrants was $223,500 and was included in additional paid-in capital. The Lead Investor Warrants did not meet the criteria for liability classification. In September 2020, the Company and the Lead Investor warrant holders amended the warrants to purchase an aggregate of 2,055,114.66 shares of the Company’s preferred units at an exercise price of $0.01 per preferred unit. The amendment also extended the expiration date to December 16, 2020. In November 2020, the Lead Investor warrant holders exercised their right to purchase 2,055,114.66 of the Company’s preferred units and the Company received $20,551 in proceeds. The Company estimated their fair value using Monte Carlo Simulation approach. Significant judgments used in the valuation model included the overall likelihood of a qualified public offering occurring and Management’s estimate for the aggregate equity value, including an estimate for the proceeds from a qualified public offering as well as giving consideration in the event the price per share in a qualified public offering is below 125% of the $12.7382 price per Preferred Unit. Also incorporated in the fair value of the Lead Investor Warrants was a risk-free rate, estimated volatility of equity and an incremental discount for lack of marketability. Also, in connection with the Private Placement, the placement agent received warrants (“Placement Agent Warrants”) to purchase an aggregate of 10,500 shares of the Company’s common stock at an exercise price of $12.7382 per share. The Placement Agent Warrants could be exercised any time on or after September 16, 2019. The Placement Agent Warrants contained an expiration date of September 16, 2024 and were converted into shares of common stock of the Company upon the consummation of the Mergers. As of the date of issuance, the fair value of the Placement Agent Warrants was estimated to be $135,800 and was included in additional paid-in capital. The Placement Agent Warrants did not meet the criteria for liability classification. The Company estimated their fair value using the Black-Scholes valuation model. The inputs used to value the Placement Agent Warrants included the Preferred Unit Price and the Placement Agent Warrant Strike Price (both of which are $12.7382), the expiration date of the Placement Agent Warrants of September 16, 2024, the risk-free rate to the expiration date of 1.73%, and the estimated volatility over the expected term of the Placement Agent Warrants of 90.0%. As there had been no public market for Metuchen’s Common Units, the estimated fair value of its Common Units was determined by the Board of Directors as of the Private Placement date, with input from management, considering the Company’s most recently available valuations of the aggregate equity value of the Company. In addition to considering the results of these valuations, the Company’s Board of Directors considered various objective and subjective factors to determine the fair value of its Common and Preferred Units as of the private placement date, including the progress of the Company’s products sales, external market conditions affecting and trends within the life sciences industry and the likelihood of achieving a liquidity event. The fair value of the Company’s Common Units as of the Private Placement Date was determined to be the difference between the fair value of the Company’s aggregate equity and the summation of the fair values of the Preferred Units, the Lead Investor Warrants and Placement Agent Warrants.

Stockholders' Equity

Stockholders' Equity	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Stockholders' Equity
Stockholders' Equity	10) Stockholders’ Equity Upon consummation of the Mergers, each outstanding Common Unit or Preferred Unit of Metuchen was exchanged for a number of shares of Petros common stock, par value $0.0001 per share (the “Petros Common Stock”), equal to 0.4968, which resulted in an aggregate of 4,949,610 shares of Petros Common Stock issued to the holders of Metuchen units in the Mergers. In addition, each holder of Neurotrope common stock, par value $0.0001 per share (the “Neurotrope Common Stock”) received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope Common Stock held, and each holder of Neurotrope preferred stock, par value $0.001 per share (the “Neurotrope Preferred Stock”) received one (1) share of Petros preferred stock (the “Petros Preferred Stock”) for every one (1) share of Neurotrope Preferred Stock held. In addition, each holder of outstanding options to purchase Neurotrope Common Stock or outstanding warrants to purchase Neurotrope Common Stock that were not previously exercised prior to the consummation of the Mergers was converted into equivalent options and warrants to purchase one (1) share of Petros Common Stock for every five (5) shares of Neurotrope Common Stock outstanding pursuant to such options or warrants. As a result of the Mergers, the former Neurotrope shareholders collectively owned approximately 4,758,045 shares of Petros Common Stock and 500 shares of Petros Preferred Stock and the former Metuchen unit holders collectively owned 4,949,610 shares of Petros Common Stock. Accordingly, the former Metuchen unit holders collectively owned approximately 51% of Petros and the former Neurotrope shareholders collectively owned approximately 49% of Petros. On January 26, 2021, 500 shares of the Company’s Preferred Stock were converted into 60,606 shares of the Company’s common stock. Effective January 1, 2021, the Company entered into a Marketing and Consulting Agreement (the “CorIRAgreement”) with CorProminence, LLC (the “Consultant”) for certain shareholder information and relation services. The term of the CorIRAgreement is for one year with automatic consecutive one-year renewal terms. As consideration for the shareholder information and relation services, the Company will pay the Consultant a monthly retainer of $7,500 and issued 30,000 restricted shares of the Company’s common stock to the Consultant on March 24, 2021 (the “CorIR Grant Date”). The restricted shares vested immediately on the CorIR Grant Date. Effective April 1, 2021, the Company entered into a Consulting and Advisory Agreement (the “King Agreement”) with Tania King, an employee of Juggernaut Capital Partners LLP, for certain services. The term of the King Agreement is indefinite but may be terminated by either party, with or without cause. As consideration for the consulting and advisory services, the Company will pay Ms. King a monthly fee of $4,000, an additional $12,000 payment included with the first monthly fee for services provided since January 1, 2021, and issue restricted stock units for shares of the Company’s common stock (“RSU’s”) with a cash value of $72,000 as of the date of the grant (the “King Grant Date”). The RSU’s shall vest and settle in full on the one-year anniversary of the King Grant Date. Effective June 4, 2021, the Company entered into a Service Agreement (the “IRTH Agreement”) with IRTH Communications, LLC (“ITRH”) for certain investor relations services. The term of the IRTH is for one year with an optional one-year renewal term. As consideration for the services, the Company will pay IRTH a fixed fee of $6,750 per month for the term of the IRTH Agreement and issued 28,338 restricted shares of the Company’s common stock with a value of $90,002 as of the date of the grant (the “IRTH Grand Date”). The restricted shares vest immediately on the IRTH Grant Date. Backstop Agreement In connection with the entry into the Merger Agreement, Neurotrope and an affiliated entity of the JCP Investor entered into a Backstop Agreement pursuant to which Juggernaut agreed to contribute to Metuchen at the closing of the Mergers an amount equal to the Working Capital Shortfall Amount (as defined in the Merger Agreement), if any, as determined in accordance with the Merger Agreement, up to an aggregate amount not to exceed $6,000,000 (the “Commitment Cap”). Following the closing of the Mergers and until the one-year anniversary of the closing of the Mergers (the “Anniversary Date”), Juggernaut agreed to contribute, or cause an affiliate to contribute, to Petros an amount equal to the Commitment Cap less the Working Capital Shortfall Amount (the “Post-Closing Commitment”) on the Anniversary Date; provided, however, that, (a) in the event that, at any time between the closing of the Mergers and the Anniversary Date, the closing price per share of Petros’s Common Stock on The Nasdaq Capital Market or any other securities exchanges on which the Petros Common Stock is then traded equals or exceeds $2.175 for a period of ten consecutive trading days, then the Post-Closing Commitment shall be reduced by fifty percent (50%) and (b) in the event that, at any time between the closing of the Mergers and the Anniversary Date, the closing price per share of Petros’s Common Stock on The Nasdaq Capital Market or any other securities exchanges on which the Petros Common Stock is then traded equals or exceeds $2.5375 for a period of ten (10) consecutive trading days, then the Post-Closing Commitment shall be $0. Pursuant to the Backstop Agreement and upon closing of the Mergers, Juggernaut paid the Company $2.6 million for the Working Capital Shortfall Amount, which was recorded in equity in relation to the net proceeds received from the reverse capitalization. Contingent Consideration Pursuant to the Merger Agreement, each security holder of Metuchen received a right to receive such security holder’s pro rata stock of an aggregate of 14,232,090 stocks of Petros Common Stock potentially issuable upon the achievement of certain milestones set forth in the Merger Agreement. The milestones are for the achievement of stock price and market capitalization, as defined over a two-year period. Milestone Earnout Payments In connection with the Mergers, each security holder of Metuchen received an equity classified earnout consideration to be paid in the form of Petros Common Stock if the Closing Price (as defined in the Merger Agreement) per share of stock of Petros’ Common Stock equals or exceeds certain milestones set forth in the Merger Agreement, as discussed below. Each milestone earnout payment is only achievable and payable one time and upon attainment of such milestone earnout payment. In no event will the sum of the milestone earnout payments be greater than 4,000,000 shares of Petros Common Stock. As of September 30, 2021, the milestones have not been achieved. If at any time following the Closing (as defined in the Merger Agreement) and prior to the one-year anniversary of the Closing, the Closing Price per share of Petros Common Stock is, for a period of twenty (20) trading days during any thirty (30) consecutive trading day period, greater than or equal to: ● $ 8.00 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 10.00 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 13.00 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 15.00 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. If at any time within the twelve (12) month period following the one-year anniversary of the Closing, the Closing Price per share of Petros Common Stock is, for a period of twenty (20) trading days during any thirty (30) consecutive trading day period, greater than or equal to: ● $ 10.00 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 12.50 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 16.25 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 18.75 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. Market Capitalization/Gross Proceeds Earnout Payments In connection with the Mergers, each security holder of Metuchen received the right to receive earnout consideration, which is liability classified, to be paid in the form of Petros Common Stock if either Petros’ Market Capitalization (as defined in the Merger Agreement) or Petros receives aggregate gross proceeds that equals or exceeds certain milestones set forth in the Merger Agreement, as discussed below. Each milestone earnout payment is only achievable and payable one time and upon attainment of such milestone. In no event will the sum of the milestone earnout payments be greater than 10,232,090 shares of Petros Common Stock. As of September 30, 2021, the milestones have not been achieved. The fair value of the derivative liability was $0.3 million and $9.9 million as of September 30, 2021, and December 31, 2020, respectively. Metuchen equity holders will have the opportunity to receive the following during the period ending on the second anniversary of the Closing: a. The Earnout Payment shall be equal to 2,000,000 shares of Petros Common Stock if: i. Petros’ Market Capitalization (as defined in the Merger Agreement) is greater than or equal to $250,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $17.50 on each such trading day; or ii. Petros receives aggregate gross proceeds of at least $25,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $17.50 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $250,000,000 . b. The Earnout Payment shall be equal to 2,000,000 shares of Petros Common Stock if: i. Petros’ Market Capitalization is greater than or equal to $300,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $18.75 on each such trading day; or ii. Petros receives aggregate gross proceeds of at least $30,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $18.75 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $300,000,000 . c. The Earnout Payment shall be equal to 3,000,000 shares of Petros Common Stock if: i. Petros’ Market Capitalization is greater than or equal to $400,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $22.50 on each such trading day; or ii. Petros receives aggregate gross proceeds of at least $40,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $22.50 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $400,000,000 . d. The Earnout Payment shall be equal to 3,232,090 shares of Petros Common Stock if: i. Petros’ Market Capitalization is greater than or equal to $500,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $23.75 on each such trading day; or ii. Petros receives aggregate gross proceeds of at least $50,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $23.75 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $500,000,000 . ​	10) Stockholders’ Equity Upon consummation of the Mergers, each outstanding Common Unit or Preferred Unit of Metuchen was exchanged for a number of shares of Petros common stock, par value $0.0001 per share (the “Petros Common Stock”), equal to 0.4968, which resulted in an aggregate of 4,949,610 shares of Petros Common Stock issued to the holders of Metuchen units in the Mergers. In addition, each holder of Neurotrope common stock, par value $0.0001 per share (the “Neurotrope Common Stock”) received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope Common Stock held, and each holder of Neurotrope preferred stock, par value $0.001 per share (the “Neurotrope Preferred Stock”) received one (1) share of Petros preferred stock (the “Petros Preferred Stock”) for every one (1) share of Neurotrope Preferred Stock held. In addition, each holder of outstanding options to purchase Neurotrope Common Stock or outstanding warrants to purchase Neurotrope Common Stock that were not previously exercised prior to the consummation of the Mergers was converted into equivalent options and warrants to purchase one (1) share of Petros Common Stock for every five (5) shares of Neurotrope Common Stock outstanding pursuant to such options or warrants. As a result of the Mergers, the former Neurotrope shareholders collectively own approximately 4,758,045 shares of Petros Common Stock and 500 shares of Petros Preferred Stock and the former Metuchen unit holders collectively own 4,949,610 shares of Petros Common Stock. Accordingly, the former Metuchen unit holders collectively own approximately 51% of Petros and the former Neurotrope shareholders collectively own approximately 49% of Petros. On January 26, 2021, 500 shares of the Company’s Preferred Stock were converted into 60,606 shares of the Company’s common stock. Backstop Agreement In connection with the entry into the Merger Agreement, Neurotrope and an affiliated entity of Juggernaut Capital Partners (“Juggernaut”) entered into a Backstop Agreement pursuant to which Juggernaut agreed to contribute to Metuchen at the closing of the Mergers an amount equal to the Working Capital Shortfall Amount (as defined in the Merger Agreement), if any, as determined in accordance with the Merger Agreement, up to an aggregate amount not to exceed $6,000,000 (the “Commitment Cap”). Following the closing of the Mergers and until the one-year anniversary of the closing of the Mergers (the “Anniversary Date”), Juggernaut agreed to contribute, or cause an affiliate to contribute, to Petros an amount equal to the Commitment Cap less the Working Capital Shortfall Amount (the “Post-Closing Commitment”) on the Anniversary Date; provided, however, that, (a) in the event that, at any time between the closing of the Mergers and the Anniversary Date, the closing price per share of Petros’s Common Stock on The Nasdaq Capital Market or any other securities exchanges on which the Petros Common Stock is then traded equals or exceeds $2.175 for a period of ten consecutive trading days, then the Post-Closing Commitment shall be reduced by fifty percent (50%) and (b) in the event that, at any time between the closing of the Mergers and the Anniversary Date, the closing price per share of Petros’s Common Stock on The Nasdaq Capital Market or any other securities exchanges on which the Petros Common Stock is then traded equals or exceeds $2.5375 for a period of ten (10) consecutive trading days, then the Post-Closing Commitment shall be $0. Pursuant to the Backstop Agreement and upon closing of the Mergers, Juggernaut paid the Company $2.6 million for the Working Capital Shortfall Amount, which was recorded in equity in relation to the net proceeds received from the reverse capitalization. Contingent Consideration Pursuant to the Merger Agreement, each security holder of Metuchen received a right to receive such security holder’s pro rata stock of an aggregate of 14,232,090 stocks of Petros Common Stock potentially issuable upon the achievement of certain milestones set forth in the Merger Agreement. The milestones are for the achievement of stock price and market capitalization, as defined over a two-year period. Milestone Earnout Payments In connection with the Mergers, each security holder of Metuchen received an equity classified earnout consideration to be paid in the form of Petros Common Stock if the Closing Price (as defined in the Merger Agreement) per share of stock of Petros’ Common Stock equals or exceeds certain milestones set forth in the Merger Agreement, as discussed below. Each milestone earnout payment is only achievable and payable one time and upon attainment of such milestone earnout payment. In no event will the sum of the milestone earnout payments be greater than 4,000,000 shares of Petros Common Stock. As of December 31, 2020, the milestones have not been achieved. If at any time following the Closing (as defined in the Merger Agreement) and prior to the one-year anniversary of the Closing, the Closing Price per share of Petros Common Stock is, for a period of twenty (20) trading days during any thirty (30) consecutive trading day period, greater than or equal to: ● $ 8.00 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 10.00 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 13.00 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 15.00 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. If at any time within the twelve (12) month period following the one-year anniversary of the Closing, the Closing Price per share of Petros Common Stock is, for a period of twenty (20) trading days during any thirty (30) consecutive trading day period, greater than or equal to: ● $ 10.00 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 12.50 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 16.25 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 18.75 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. Market Capitalization/Gross Proceeds Earnout Payments In connection with the Mergers, each security holder of Metuchen received the right to receive earnout consideration, which is liability classified, to be paid in the form of Petros Common Stock if either Petros’ Market Capitalization (as defined in the Merger Agreement) or Petros receives aggregate gross proceeds that equals or exceeds certain milestones set forth in the Merger Agreement, as discussed below. Each milestone earnout payment is only achievable and payable one time and upon attainment of such milestone. In no event will the sum of the milestone earnout payments be greater than 10,232,090 shares of Petros Common Stock. As of December 31, 2020, the milestones have not been achieved. The fair value of the derivative liability was $9.9 million as of December 31, 2020. Metuchen equity holders will have the opportunity to receive the following during the period ending on the second anniversary of the Closing: a. The Earnout Payment shall be equal to 2,000,000 shares of Petros Common Stock if: i. Petros’ Market Capitalization (as defined in the Merger Agreement) is greater than or equal to $250,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $17.50 on each such trading day; or ii. Petros receives aggregate gross proceeds of at least $25,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $17.50 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $250,000,000 . b. The Earnout Payment shall be equal to 2,000,000 shares of Petros Common Stock if: i. Petros’ Market Capitalization is greater than or equal to $300,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $18.75 on each such trading day; or ii. Petros receives aggregate gross proceeds of at least $30,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $18.75 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $300,000,000 . c. The Earnout Payment shall be equal to 3,000,000 shares of Petros Common Stock if: i. Petros’ Market Capitalization is greater than or equal to $400,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $22.50 on each such trading day; or ii. Petros receives aggregate gross proceeds of at least $40,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $22.50 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $400,000,000 . d. The Earnout Payment shall be equal to 3,232,090 shares of Petros Common Stock if: i. Petros’ Market Capitalization is greater than or equal to $500,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $23.75 on each such trading day; or ii. Petros receives aggregate gross proceeds of at least $50,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $23.75 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $500,000,000 .

Stock Options

Stock Options	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Stock Options
Stock Options	11) Stock Options and Restricted Stock Units (“RSU’s”) The Company established the 2020 Omnibus Incentive Compensation plan (the “2020 Plan”) which provides for the grants of awards to our directors, officers, employees, and consultants. The 2020 Plan authorizes the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, restricted stock units and other stock-based awards and cash-based awards. As of September 30, 2021, there were 1,213,301 shares authorized, and 0 shares available for issuance, under the 2020 Plan. Upon the consummation of the Mergers as disclosed in Note 1, Neurotrope options issued and outstanding as of December 1, 2020, were converted into equivalent options to purchase stocks of Petros common stock and restricted stock units were adjusted to give effect to the Exchange Ratio set forth in the Merger Agreement. The following is a summary of stock options for the nine months ended September 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ ​ Weighted- ​ Remaining ​ Aggregate Intrinsic ​ ​ Number of ​ Average ​ Contractual ​ Value ​ Shares Exercise Price Term (Years) ($ in thousands) Options outstanding and exercisable on December 31, 2020 574,331 ​ $ 51.43 0.9 ​ $ — Options granted 638,970 ​ 3.37 9.18 ​ — Less: options and RSU’s forfeited — ​ — — ​ — Less: options and RSU’s expired/cancelled — ​ — — ​ — Less: options and RSU’s exercised — ​ — — ​ — Options and RSU’s outstanding at September 30, 2021 1,213,301 ​ 26.57 5.08 ​ — Options and RSU’s exercisable at September 30, 2021 852,166 ​ 35.77 3.32 ​ — ​ Upon the consummation of the Mergers as disclosed in Note 1, the vesting of former Neurotrope stock options in accordance with their terms was accelerated due to a change in control pursuant to the terms of the Neurotrope, Inc. 2013 Equity Incentive Plan and the Neurotrope, Inc. 2017 Equity Incentive Plan. Pursuant to the change in control, Neurotrope extended the period to exercise the stock options to be one-year from the closing of the Mergers. Accordingly, the Company did not record any stock-based compensation expense in connection with these stock options during the period from December 1, 2020, through December 31, 2020. On February 19, 2021, Fady Boctor, the President and Chief Commercial Officer of the Company, was granted an option to purchase 215,669 shares of the Company’s common stock at an exercise price of $3.74 per share. The option vested 50% as of February 19, 2021, the date of grant, and the remainder shall vest in equal installments on the first and second anniversary thereof. On April 8, 2021, in connection with the Directors’ appointment to the Board upon the Company becoming an independent publicly traded company on December 1, 2020, the Company awarded each of the five Directors an initial grant of options (the “Initial Grant”) to purchase 50,000 shares of common stock of the Company at an exercise price of $3.18 per share. The shares of common stock underlying the options vested 25% on the date of grant, 25% shall vest upon the six-month anniversary of the date of grant and the remainder shall vest in equal installments over the following four On May 11, 2021, the Company granted to certain officers of the Company options to purchase 150,000 shares of common stock of the Company at an exercise price or $3.21 per share. The shares of common stock underlying the options vested 30% on the date of grant, 30% shall vest upon the one year anniversary of the date of the grant, and the remainder shall vest upon the two year anniversary of the date of the grant. As of September 30, 2021, the plan is short of shares to cover all the May 11, 2021, option grants by 134,955 shares, and the grantees have agreed to not exercise such options until the Company notifies them there are shares available to cover such option exercises.	11) Stock Options The Company established the 2020 Omnibus Incentive Compensation plan (the “2020 Plan”) which provides for the grants of awards to our directors, officers, employees, and consultants. The 2020 Plan authorizes the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, stock units and other stock-based awards and cash-based awards. As of December 31, 2020, there were 1,078,346 shares authorized and 504,015 shares available for issuance under the 2020 Plan. Upon the consummation of the Mergers as disclosed in Note 1, Neurotrope options issued and outstanding as of December 1, 2020 were converted into equivalent options to purchase stocks of Petros common stock and were adjusted to give effect to the Exchange Ratio set forth in the Merger Agreement. The following is a summary of stock options for the period from December 1, 2020 through December 31, 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ ​ Weighted- ​ Remaining ​ Aggregate Instrinsic ​ ​ Number of ​ Average ​ Contractual ​ Value ​ Shares Exercise Price Term (Years) ($ in thousands) Options outstanding at December 1, 2020 574,331 ​ $ 51.43 0.9 ​ $ — Options granted — ​ — — ​ — Less: options forfeited — ​ — — ​ — Less: options expired/cancelled — ​ — — ​ — Less: options exercised — ​ — — ​ — Options outstanding at December 31, 2020 574,331 ​ $ 51.43 0.9 ​ $ — Options exercisable at December 31, 2020 574,331 ​ $ 51.43 0.9 ​ $ — ​ Upon the consummation of the Mergers as disclosed in Note 1, the vesting of former Neurotrope stock options in accordance with their terms was accelerated due to a change in control pursuant to the terms of the Neurotrope, Inc. 2013 Equity Incentive Plan and the Neurotrope, Inc. 2017 Equity Incentive Plan. Pursuant to the change in control, Neurotrope extended the period to exercise the stock options to be one-year from the closing of the Mergers. Accordingly, the Company did not record any stock-based compensation expense in connection with these stock options. On February 19, 2021, Fady Boctor, the President and Chief Commercial Officer of the Company, was granted an option to purchase 215,669 shares of the Company’s common stock at an exercise price of $3.74 per share. The option vested 50% as of February 19, 2021, the date of grant, and the remainder shall vest in equal installments on the first and second anniversary thereof.

Common Stock Warrants

Common Stock Warrants	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Common Stock Warrants
Common Stock Warrants	12) Common Stock Warrants Upon the consummation of the Merger as disclosed in Note 1, Neurotrope warrants issued and outstanding as of December 1, 2020, were converted into equivalent warrants to purchase common stock of Petros and were adjusted to give effect to the Exchange Ratio set forth in the Merger Agreement. The following is a summary of warrants for the three months ended September 30, 2021: ​ ​ ​ ​ ​ Number of Shares Warrants outstanding at December 31, 2020 4,407,962 Warrants issued — Warrants exercised — Warrants outstanding at September 30, 2021 4,407,962 ​ As of September 30, 2021, the Company’s warrants by expiration date were as follows: ​ ​ ​ ​ ​ ​ ​ Number of Warrants Exercise Price Expiration Date 76,569 ​ $ 32.00 ​ November 17, 2021 131,344 ​ 64.00 ​ November 17, 2021 2,780 ​ 1.60 ​ August 23, 2023 18,000 ​ 35.65 ​ June 1, 2024 4,800 ​ 35.60 ​ June 5, 2024 74,864 ​ 21.85 ​ June 17, 2024 20,043 ​ 31.25 ​ June 19, 2024 22,800 ​ 26.55 ​ September 1, 2024 10,500 ​ 12.74 ​ September 16, 2024 22,800 ​ 4.30 ​ December 1, 2024 28,000 ​ 5.65 ​ March 2, 2025 28,000 ​ 7.30 ​ June 1, 2025 28,000 ​ 5.50 ​ September 1, 2025 28,000 ​ 4.71 ​ December 1, 2025 2,221,829 ​ 7.50 ​ December 1, 2025 908,498 ​ 17.50 ​ December 1, 2025 623,303 ​ 51.25 ​ December 1, 2025 157,832 ​ 125.00 ​ December 1, 2025 4,407,962 ​ ​ ​	12) Common Stock Warrants Upon the consummation of the Merger as disclosed in Note 1, Neurotrope warrants issued and outstanding as of December 1, 2020 were converted into equivalent warrants to purchase common stock of Petros and were adjusted to give effect to the Exchange Ratio set forth in the Merger Agreement. The following is a summary of warrants for the period from December 1, 2020 through December 31, 2020: ​ ​ ​ ​ ​ Number of Shares Warrants outstanding at December 1, 2020 4,407,962 Warrants issued — Warrants exercised — Warrants outstanding at December 31, 2020 4,407,962 ​ As of December 31, 2020, the Company’s warrants by expiration date were as follows: ​ ​ ​ ​ ​ ​ ​ Number of Warrants Exercise Price Expiration Date 76,569 ​ $ 32.00 ​ November 17, 2021 131,344 ​ 64.00 ​ November 17, 2021 2,780 ​ 1.60 ​ August 23, 2023 18,000 ​ 35.65 ​ June 1, 2024 4,800 ​ 35.60 ​ June 5, 2024 74,864 ​ 21.85 ​ June 17, 2024 20,043 ​ 31.25 ​ June 19, 2024 22,800 ​ 26.55 ​ September 1, 2024 10,500 ​ 12.7382 ​ September 16, 2024 22,800 ​ 4.30 ​ December 1, 2024 28,000 ​ 5.65 ​ March 2, 2025 28,000 ​ 7.30 ​ June 1, 2025 28,000 ​ 5.50 ​ September 1, 2025 28,000 ​ 4.71 ​ December 1, 2025 2,221,829 ​ 7.50 ​ December 1, 2025 908,498 ​ 17.50 ​ December 1, 2025 623,303 ​ 51.25 ​ December 1, 2025 157,832 ​ 125.00 ​ December 1, 2025 4,407,962 ​ ​ ​

Basic and Diluted Net Loss per

Basic and Diluted Net Loss per Common Share	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Basic and Diluted Net Loss per Common Share
Basic and Diluted Net Loss per Common Share	13) Basic and Diluted Net Loss per Common Share Upon the consummation of the Mergers on December 1, 2020, the basic weighted average number of common shares outstanding for the three and nine months ended September 30, 2020, has been calculated using the number of common units outstanding of Metuchen from January 1, 2020, through September 30, 2020, multiplied by the exchange ratio used in the transaction. The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended ​ For the Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 Numerator ​ ​ ​ ​ ​ Net loss ​ $ (1,696,898) ​ $ (3,300,363) ​ $ (800,734) ​ $ (15,147,953) Denominator ​ ​ ​ ​ Weighted-average common shares for basic net loss per share ​ 9,826,599 ​ 3,434,551 ​ 9,794,267 ​ 3,434,551 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic and diluted net loss per common share ​ $ (0.17) ​ $ (0.96) ​ $ (0.08) ​ $ (4.41) ​ The following table summarizes the potentially dilutive securities convertible into common shares that were excluded from the calculation of diluted net loss per share because their inclusion would have been antidilutive: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended ​ For the Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 Stock Options 1,213,301 — ​ 1,213,301 — Warrants 4,405,182 21,139 ​ 4,405,182 21,139 Total 5,621,263 21,139 ​ 5,621,263 21,139 ​	13) Basic and Diluted Net Loss per Common Share Upon the consummation of the Mergers on December 1, 2020, the basic weighted average number of common shares outstanding for the year ended December 31, 2019 have been calculated on a pro forma basis using Metuchen’s historical weighted average number of common units outstanding multiplied by the exchange ratio used in the reverse recapitalization. For the year ended December 31, 2020, the basic weighted average shares outstanding has been calculated using the number of common units outstanding of Metuchen from January 1, 2020 through the December 1, 2020 acquisition date multiplied by the exchange ratio used in the transaction and the number of common shares outstanding of the Company from December 1, 2020 through December 31, 2020. The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended ​ ​ December 31, ​ 2020 2019 Numerator ​ ​ Net (loss) income ​ $ (20,585,925) ​ $ (32,511,300) Denominator ​ ​ Weighted-average common shares for basic and diluted net loss per unit ​ 5,340,682 ​ 2,460,026 ​ ​ ​ ​ ​ ​ ​ Basic and diluted net loss per common share ​ $ (3.85) ​ $ (13.22) ​ The following table summarizes the potentially dilutive securities convertible into common shares that were excluded from the calculation of diluted net loss per share because their inclusion would have been antidilutive: ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended ​ ​ December 31, ​ 2020 2019 Stock Options 574,331 — Warrants 4,407,962 127,396 Total 4,982,293 127,396 ​

Marketing, Licensing and Distri

Marketing, Licensing and Distribution Agreements	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Marketing, Licensing and Distribution Agreements
Marketing, Licensing and Distribution Agreements	14) Marketing, Licensing and Distribution Agreements (a) Vivus On September 30, 2016, the Company entered into a License and Commercialization Agreement (the “License Agreement”) with Vivus, Inc (“Vivus”) to purchase and receive the license for the commercialization and exploitation of Stendra® for a one-time fee of $70 million, and for an additional $0.8 million, the Company also acquired the current Stendra® product and sample inventories as of September 30, 2016, that were owned by Vivus. The License Agreement gives the Company the right to sell Stendra® in the U.S and its territories, Canada, South America, and India. In December 2000, Vivus originally was granted the license from Mitsubishi Tanabe Pharma Corporation (“MTPC”) to develop, market, and manufacture Stendra®. Stendra® was approved by the Food and Drug Administration (“FDA”) in April 2012 to treat male erectile dysfunction. The Company will pay MTPC a royalty of 5% on the first $500 million of net sales and 6% of net sales thereafter. In consideration for the trademark assignment and the use of the trademarks associated with the product and the Vivus technology, the Company shall (a) during the first, second, and third years following the expiration of the Royalty Period in a particular country in the Company’s territory, pay to Vivus a royalty equal to 2% of the net sales of products in such territory; and (b) following the fourth and fifth years following the end of the Royalty Period in such territory, pay to Vivus a royalty equal to 1% of the net sales of products in such territory. Thereafter, no further royalties shall be owed with respect to net sales of Stendra® in such territory. In addition, the Company will be responsible for a pro-rata portion of a $6 million milestone payment to be paid once $250 million in sales has been reached on the separate revenue stream of Stendra®. Should the $250 million of sales threshold be reached, the Company will be responsible for $3.2 million of the milestone payment. In connection with the License Agreement, the Company and Vivus also entered into a Supply Agreement on the effective date of the License Agreement, which has since been terminated, effective as of September 30, 2021. The Supply Agreement stated that Vivus would initially manufacture, test, and supply the product to the Company or its designee, directly or through one or more third parties. In connection with the Supply Agreement , we and Vivus have been in negotiations to determine the amounts ultimately owed to Vivus, but we may be responsible for payments of approximately $20.7 million. The Company provided Vivus with notice of termination of the Supply Agreement on September 30, 2019, which became effective on September 30, 2021. The Company is currently negotiating with multiple contract manufacturers to manufacture and supply Stendra® and serve as potential replacements for Vivus. The Company intends to enter into a new supply agreement with one or more of these candidates in the near future and hopes to have an agreement in place by the end of the year. However, these negotiations are ongoing and there is no assurance that we will be able to enter into any new supply agreement with such potential vendors or that we will be able to do so at terms favorable to us in a timely manner. As of November 15, 2021, we believe that we have sufficient supplies of Stendra® to meet demand for the next 10 months. Stendra Stendra As of both September 30, 2021, and December 31, 2020, the Company had $14.2 million of accrued inventory purchases related to the Company’s minimum purchase obligations with Vivus for raw material or API inventory. As API inventory is not a finished good, the Company does not have title to the product and classifies API Inventory in either other current assets or other assets, depending on whether the Company expects to take title to the product within one year from the date of the financial statements. As of both September 30, 2021, and December 31, 2020, there was $1.3 million included in other current assets (see Note 5 Prepaid and Other Current Assets). As of both September 30, 2021, and December 31, 2020, $11.1 million is included in other assets on the accompanying condensed consolidated balance sheets. The Company reviews its inventory levels and purchase commitments for excess amounts that it is required to purchase but projects it will not be able to sell prior to product expiry. During the three and nine months ended September 30, 2021, and 2020, the Company has not recorded any additional reserve to reduce the cost of API inventory. During the nine months ended September 30, 2021 and 2020, the Company incurred royalties to MTPC for Stendra® of $302,346 and $206,435, respectively. During the three months ended September 30, 2021 and 2020, the Company incurred royalties to MTPC for Stendra® of $68,865 and $129,508, respectively. Royalties incurred were included in cost of goods sold in the condensed consolidated statements of operations. As of September 30, 2021, and December 31, 2020, the Company had a payable for royalties of $68,865 and $8,728, respectively, which is included in accrued expenses in the accompanying condensed consolidated balance sheets. The license agreement between MTPC and Vivus (“MTPC License”) contains certain termination rights that would allow MTPC to terminate the agreement if Vivus were to breach any of the terms of the MTPC License or become insolvent or bankrupt. In the event that MTPC terminates the MTPC License with Vivus because of any contractual breach the Company has step-in rights with MTPC, which would allow the Company to continue to sell Stendra (b) Hybrid In March 2020, the Company acquired the exclusive license to H100™ from Hybrid (the “Hybrid License”). H100™ is a topical candidate with at least one active ingredient and potentially a combination of ingredients responsible for the improvement of penile curvature during the acute phase of Peyronie’s disease. We paid an initial license fee of $100,000, with an additional $900,000 payment due upon obtainment of orphan indication for H100™ and termination of Hybrid’s existing agreement with a compounding pharmacy, and additional annual payments of $125,000, $150,000, and $200,000 due on each of the first, second and third anniversaries of the Hybrid License and $250,000 annual payments due thereafter. The Company is also required to make a $1,000,000 payment upon first commercial sale and a sliding scale of percentage payments on net sales in the low single digits. Annual anniversary payments will not be required after commercialization. The Company is also obligated to make royalty payments between 3-6% of any net sales. In addition, the Company may terminate at any time after first anniversary, without cause, upon ninety The initial license fee of $100,000 and an extension payment of $100,000 has been recorded in research and development during the year ended December 31, 2020. The Company has treated the acquisition as an asset acquisition and has concluded that the asset acquired, and the upfront payment should be expensed as it was considered an IPR&D asset with no alternative future uses. On September 24, 2020, the Company and Hybrid entered into a letter agreement, pursuant to which the term of the license agreement was extended for an additional six months six seven	14) Marketing, Licensing and Distribution Agreements (a) Vivus On September 30, 2016, the Company entered into a License and Commercialization Agreement (the “License Agreement”) with Vivus, Inc (“Vivus”) to purchase and receive the license for the commercialization and exploitation of Stendra® for a one-time fee of $70 million, and for an additional $0.8 million, the Company also acquired the current Stendra® product and sample inventories as of September 30, 2016 that were owned by Vivus. The License Agreement gives the Company the right to sell Stendra® in the U.S and its territories, Canada, South America, and India. In December 2000, Vivus originally was granted the license from Mitsubishi Tanabe Pharma Corporation (“MTPC”) to develop, market, and manufacture Stendra®. Stendra® was approved by the Food and Drug Administration (“FDA”) in April 2012 to treat male erectile dysfunction. The Company will pay MTPC a royalty of 5% on the first $500 million of net sales and 6% of net sales thereafter. In consideration for the trademark assignment and the use of the trademarks associated with the product and the Vivus technology, the Company shall (a) during the first, second, and third years following the expiration of the Royalty Period in a particular country in the Company’s territory, pay to Vivus a royalty equal to 2% of the net sales of products in such territory; and (b) following the fourth and fifth years following the end of the Royalty Period in such territory, pay to Vivus a royalty equal to 1% of the net sales of products in such territory. Thereafter, no further royalties shall be owed with respect to net sales of Stendra® in such territory. In addition, the Company will be responsible for a pro-rata portion of a $6 million milestone payment to be paid once $250 million in sales has been reached on the separate revenue stream of Stendra®. Should the $250 million of sales threshold be reached, the Company will be responsible for $3.2 million of the milestone payment. In connection with the License Agreement, the Company and Vivus also entered into a Supply Agreement on the effective date of the License Agreement. The Supply Agreement states that Vivus will initially manufacture, test, and supply the product to the Company or its designee, directly or through one or more third parties. The agreement is effective through December 31, 2021. The Company provided Vivus with notice of termination of the supply agreement on September 30, 2019, effective on September 30. 2021. The Company is required to make future minimum annual purchases of Stendra® under the Supply Agreement as follows (based on current prices, however, subject to annual price increases). As of December 31, 2020, the minimum purchase obligation is $4.1 million in 2021. Stendra® can be purchased by written purchase orders submitted to Vivus at least 125 days in advance of the desired shipment date. For each quarter, the Company is required to submit purchase orders for at least 90% of the quantities in the forecast above. Vivus will have no obligation to supply Stendra® in excess of 120% of the quantity specified above but will use reasonable efforts. As of December 31, 2020 and 2019, the Company has $14.2 million and $9.3 million, respectively, of accrued inventory purchases related to the Company’s minimum purchase obligations with Vivus for raw material or API inventory. As API inventory is not a finished good, the Company does not have title to the product and classifies API Inventory in either other current assets or other assets, depending on whether the Company expects to take title to the product within one year from the date of the financial statements. As of December 31, 2020 and 2019, there was $1.3 million and $1.4 million, respectively, included in other current assets (see Note 5 Prepaid and Other Current Assets). As of December 31, 2020 and 2019, there was $11.1 million and $6.7 million included on the accompanying consolidated balance sheets, respectively. The Company reviews its inventory levels and purchase commitments for excess amounts that it is required to purchase but projects it will not be able to sell prior to product expiry. During the years ended December 31, 2020 and 2019, the Company recorded a reserve of $0.8 million and $1.2 million, respectively, which is included in cost of goods sold, to reduce the cost of API inventory to its net realizable value. During the years ended December 31, 2020 and 2019, the Company incurred royalties to MTPC for Stendra of $317,875 and $550,533. Royalties incurred were included in cost of goods sold in the consolidated statements of operations. As of December 31, 2020, the Company had a payable for royalties of $8,728, which is included in accrued expenses in the accompanying consolidated balance sheet. As of December 31, 2019, the Company had a receivable for royalties of $309,147, which is included in other current assets in prepaid expenses and other current assets (see Note 5 Prepaid and Other Current Assets). On July 7, 2020, Vivus announced that it has completed the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma LLC will take 100% ownership of Vivus. Vivus is a specialty pharmaceutical company and the Company has a License Agreement with Vivus for commercialization and exploitation of Stendra® as well as the Company and Vivus are parties to a Supply Agreement for which Vivus will manufacture, test and supply Stendra® to the Company. The License Agreement is a sublicense under Vivus’ license agreement with the owner of the Stendra® patent, MTPC. The license agreement between MTPC and Vivus (“MTPC License”) contains certain termination rights that would allow MTPC to terminate the agreement if Vivus were to breach any of the terms of the MTPC License or become insolvent or bankrupt. In the event that MTPC terminates the MTPC License with Vivus because of any contractual breach the Company has step-in rights with MTPC, which would allow the Company to continue to sell Stendra®. (b) Hybrid In March 2020, the Company acquired the exclusive license to H100™ from Hybrid. H100™ is a topical candidate with at least one active ingredient and potentially a combination of ingredients responsible for the improvement of penile curvature during the acute phase of Peyronie’s disease. We paid an initial license fee of $100,000, with an additional $900,000 payment due upon obtainment of orphan indication for H100™ and termination of Hybrid’s existing agreement with a compounding pharmacy, and additional annual payments of $125,000, $150,000 and $200,000 due on each of the first, second and third anniversaries of the license agreement and $250,000 annual payments due thereafter. The Company is also required to make a $1,000,000 payment upon first commercial sale and a sliding scale of percentage payments on net sales in the low single digits. Annual anniversary payments will not be required after commercialization. The Company is also obligated to make royalty payments between 3-6% of any net sales. In addition, the Company may terminate at any time after first anniversary, without cause, upon ninety The initial license fee of $100,000 and an extension payment of $100,000 has been recorded in research and development during the year ended December 31, 2020. The Company has treated the acquisition as an asset acquisition and has concluded that the asset acquired and the upfront payment should be expensed as it was considered an IPR&D asset with no alternative future uses. On September 24, 2020, the Company and Hybrid amended the license agreement for H100™ to extend the term of the license agreement for an additional six months to March 24, 2021. In consideration for the amendment, the Company paid Hybrid $50,000 in October 2020 and an additional $100,000 in December 2020.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Commitments and Contingencies
Commitments and Contingencies	15) Commitments and Contingencies (a) Employment Agreements The Company has employment agreements with certain executive officers and key employees that provide for, among other things, salary, and performance bonuses. In connection with entry into the First Merger Agreement Amendment, Neurotrope, Neurotrope Bioscience, Inc. (a wholly owned subsidiary of Neurotrope) and Metuchen entered into an Employee Lease Agreement pursuant to which Neurotrope and Neurotrope Bioscience, Inc. agreed to lease the services of Dr. Charles Ryan to Metuchen prior to the Closing. Dr. Ryan was required to devote no more than 75% of his working time performing services to Metuchen under the Employee Lease Agreement and Metuchen paid 75% of the costs associated with Dr. Ryan’s employment from the period beginning on June 1, 2020, through the Closing, including but not limited to, the costs for all compensation and benefits paid to, for or on behalf of Dr. Ryan (the “Fees”). Upon consummation of the Mergers, Metuchen paid approximately $0.2 million for the Fees pursuant to the Employee Lease Agreement, which reduced the amount of cash that Petros retained following the Closing. In connection with the consummation of the Mergers, on December 24, 2020, the Company and Mr. Keith Lavan entered into a Separation Agreement (the “Separation Agreement”), pursuant to which Mr. Lavan resigned as Senior Vice President and Chief Financial Officer of the Company and agreed to serve as an advisor to the Company through December 31, 2020 (the “Separation Date”). Pursuant to the Separation Agreement, in addition to other benefits, Mr. Lavan received a stay-on bonus of $50,000 for continuing to remain employed by the Company through the Separation Date. For his services as an advisor, the Company agreed to pay Mr. Lavan an amount equal to 50% of his base salary as of immediately prior to the Separation Date. The Company paid 70% of such amount on January 15, 2021, and 30% of such amount in equal installments from the Separation Date through June 30, 2021. In addition, Mr. Lavan executed a general release of liabilities in favor of the Company. (b) Legal Proceedings On July 14, 2020, Greg Ford, the Chief Executive Officer of the Company, was terminated. On July 14, 2020, Mr. Ford, through his attorney, claimed that he was entitled to severance pay pursuant to an employment agreement following the termination of his employment on that same date. This claim is currently at an early stage where the Company is unable to determine the likelihood of any unfavorable outcome. The Company is not currently involved in any other significant claims or legal actions that, in the opinion of management, will have a material adverse impact on the Company’s operations, financial position or cash flows. (c) Operating Leases The Company has commitments under operating leases for office and warehouse space used in its operations. The Company’s leases have remaining lease terms ranging from 2.9, years to 5.3 years. The components of lease expense were consisted entirely of fixed lease costs related to operating leases. These costs were $44,812 for the three months ended September 30, 2021, and 2020, and $134,435, and $179,246, for the nine months ended September 30, 2021, and 2020, respectively. ​ Supplemental balance sheet information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, 2021 As of December 31, 2020 Operating lease ROU asset: ​ ​ Other assets ​ $ 502,697 ​ $ 579,535 ​ ​ ​ ​ ​ ​ ​ Operating lease liability: ​ ​ Other current liabilities ​ $ 121,589 ​ $ 108,971 Other long-term liabilities ​ 437,749 ​ 530,597 Total operating lease liability ​ $ 559,338 ​ $ 639,568 ​ Supplemental lease term and discount rate information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, 2021 ​ As of December 31, 2020 ​ Weighted-average remaining lease terms - operating leases 3.9 years 4.7 years ​ Weighted-average discount rate - operating leases 12.6 % 12.6 % ​ Supplemental cash flow information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months For the Nine Months ​ ​ Ended September 30, Ended September 30, ​ 2021 2020 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: ​ ​ ​ ​ ​ Operating cash flows from operating leases ​ $ 45,942 ​ $ 45,660 ​ $ 137,826 ​ $ 136,979 ​ Future minimum lease payments under non-cancelable leases as of September 30, 2021, were as follows: ​ ​ ​ ​ ​ Lease Liability Maturity Analysis Operating Leases 2021 (remaining 3 months) ​ 46,413 2022 ​ 187,739 2023 ​ 189,374 2024 ​ 155,242 2025 ​ ​ 81,107 Thereafter ​ 82,326 Total lease payments ​ 742,201 Less: Imputed Interest ​ (182,863) Total ​ $ 559,338 ​ As of September 30, 2021, the Company had no operating leases that had not yet commenced.	15) Commitments and Contingencies (a) Employment Agreements The Company has employment agreements with certain executive officers and key employees that provide for, among other things, salary and performance bonuses. In connection with entry into the Merger Agreement Amendment, Neurotrope, Neurotrope Bioscience, Inc. (a wholly-owned subsidiary of Neurotrope) and Metuchen entered into an Employee Lease Agreement pursuant to which Neurotrope and Neurotrope Bioscience, Inc. agreed to lease the services of Dr. Charles Ryan to Metuchen prior to the Closing. Dr. Ryan was required to devote no more than 75% of his working time performing services to Metuchen under the Employee Lease Agreement and Metuchen paid 75% of the costs associated with Dr. Ryan’s employment from the period beginning on June 1, 2020 through the Closing, including but not limited to, the costs for all compensation and benefits paid to, for or on behalf Dr. Ryan (the “Fees”). Upon consummation of the Mergers, Metuchen paid approximately $0.2 million for the Fees pursuant to the Employee Lease Agreement, which reduced the amount of cash that Petros retained following the Closing. In connection with the consummation of the Mergers, on December 24, 2020, the Company and Mr. Keith Lavan entered into a Separation Agreement (the “Separation Agreement”), pursuant to which Mr. Lavan resigned as Senior Vice President and Chief Financial Officer of the Company and agreed to serve as an advisor to the Company through December 31, 2020 (the “Separation Date”). Pursuant to the Separation Agreement, in addition to other benefits, Mr. Lavan received a stay-on bonus of $50,000 for continuing to remain employed by the Company through the Separation Date. For his services as an advisor, the Company agreed to pay Mr. Lavan an amount equal to 50% of his base salary as of immediately prior to the Separation Date. The Company paid 70% of such amount on January 15, 2021 and 30% of such amount in equal installments from the Separation Date through June 30, 2021. In addition, Mr. Lavan executed a general release of liabilities in favor of the Company. (b) Legal Proceedings On July 14, 2020, Greg Ford, the Chief Executive Officer of the Company, was terminated. On July 14, 2020, Mr. Ford, through his attorney, claimed that he was entitled to severance pay pursuant to an employment agreement following the termination of his employment on that same date. This claim is currently at an early stage where the Company is unable to determine the likelihood of any unfavorable outcome. The Company is not currently involved in any other significant claims or legal actions that, in the opinion of management, will have a material adverse impact on the Company’s operations, financial position or cash flows. (c) Operating Leases The Company has commitments under operating leases for office and warehouse space used in its operations. The Company’s leases have remaining lease terms ranging from 3.7 years to 6.0 years. The components of lease expense were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended ​ ​ December 31, ​ 2020 2019 Operating Lease Cost: ​ ​ Fixed lease cost ​ $ 179,246 ​ $ 88,002 ​ Supplemental balance sheet information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2020 As of December 31, 2019 Operating lease ROU asset: ​ ​ Other assets ​ $ 579,535 ​ $ 672,246 ​ ​ ​ ​ ​ ​ ​ Operating lease liability: ​ ​ ​ Other current liabilities ​ $ 108,971 ​ $ 96,104 Other long-term liabilities ​ 530,597 ​ 639,568 Total operating lease liability ​ $ 639,568 ​ $ 735,672 ​ Supplemental lease term and discount rate information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2020 ​ As of December 31, 2019 ​ Weighted-average remaining lease terms - operating leases 4.7 years 5.7 years ​ Weighted-average discount rate - operating leases 12.6 % 12.6 % ​ Supplemental cash flow information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended ​ ​ December 31, ​ 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: ​ ​ Operating cash flows from operating leases ​ $ 182,639 ​ $ 92,068 ​ ​ ​ ​ ​ ​ ​ Right-of-use assets obtained in exchange for lease obligations: ​ ​ ​ ​ ​ ​ Operating leases ​ $ — ​ $ 698,127 ​ Future minimum lease payments under non-cancelable leases as of December 31, 2020 were as follows: ​ ​ ​ ​ ​ Lease Liability Maturity Analysis Operating Leases 2021 ​ 184,239 2022 ​ 187,739 2023 ​ 189,374 2024 ​ 155,242 Thereafter ​ 163,432 Total lease payments ​ 880,026 Less: Imputed Interest ​ (240,458) Total ​ $ 639,568 ​ As of December 31, 2020, the Company had no operating leases that had not yet commenced.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Taxes
Income Taxes	16) Income Taxes The current and deferred income tax expense (benefit) for the years ended December 31, 2020 and 2019 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended December 31, ​ ​ 2020 ​ 2019 Current expense (benefit): ​ ​ Federal ​ $ 5,085 ​ $ — State ​ 88 ​ — Total current expense (benefit) ​ 5,173 ​ — Deferred expense (benefit): ​ ​ Federal ​ (1,378,731) ​ (165,483) State ​ (53,435) ​ (480,383) Total deferred expense (benefit) ​ (1,432,166) ​ (645,866) Total income tax expense (benefit) ​ $ (1,426,993) ​ $ (645,866) ​ A reconciliation of the Company’s statutory income tax rate to the Company’s effective income tax rate is as follows: ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended December 31, ​ ​ 2020 ​ 2019 Income at US statutory rate 21.00 % 21.00 % State taxes, net of federal benefit 1.56 % 1.59 % Permanent differences (2.68) % (0.02) % Recapitalization 36.49 % 0.00 % Pass through income to members (32.71) % (21.13) % Valuation allowance (17.22) % 0.00 % Other 0.00 % 0.51 % Effective income tax rate 6.44 % 1.95 % ​ Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2020 and December 31, 2019 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended December 31, ​ ​ 2020 ​ 2019 Accruals ​ $ 90,222 ​ $ 5,732 Intangible assets ​ (1,238,128) ​ (1,438,682) Depreciation and amortization ​ 5,661,235 ​ — Expenses no currently deductible ​ 148,708 ​ — Net operating loss carryforwards ​ 57,266 ​ 783 Interest expense limitation ​ 25,547 ​ — Stock-based compensation ​ 2,505,425 ​ — Valuation allowance ​ (7,250,275) ​ — Total deferred tax liability ​ $ — ​ $ (1,432,167) ​ The Company assesses the need for a valuation allowance related to its deferred income tax assets by considering whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. A valuation allowance has been recorded against the Company’s deferred income tax assets, as it is in the opinion of management that it is more likely than not that the net operating loss carryforwards (“NOL”) will not be utilized in the foreseeable future. The cumulative valuation allowance as of December 31, 2020 is $7.3 million, which will be reduced if and when the Company determines that the deferred income tax assets are more likely than not to be realized. As of December 31, 2020, the Company’s estimated aggregate total NOLs were $270 thousand for U.S. federal purposes with an indefinite life due to regulations set forth in the Tax Cuts and Jobs Act of 2017. The future utilization of the NOLs are limited to 80% of taxable income. The Company files its tax returns in the U.S. federal jurisdiction, as well as in various state and local jurisdictions. The Company is not currently under audit in any taxing jurisdictions. The calculation of the Company’s tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the many states in which we operate or do business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. The Company records uncertain tax positions as liabilities in accordance with ASC 740 and adjust these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December 31, 2020, the Company has not recorded any uncertain tax positions in its consolidated financial statements.

Defined Contribution Plan

Defined Contribution Plan	12 Months Ended
	Dec. 31, 2020
Defined Contribution Plan
Defined Contribution Plan	17) Defined Contribution Plan The Company has a qualified defined contribution plan under Section 401(k) of the Internal Revenue Code covering eligible employees. Eligible employees can contribute to the defined contribution plan, subject to certain limitations, on a pre-tax basis. The Company matches up to 100% of the first 6% of each employee’s contribution and is recognized as expense in general and administrative expenses on the consolidated statement of operations. Employer contributions were $116,364 and $218,361 for the year ended December 31, 2020 and 2019, respectively.

Segment Information

Segment Information	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Segment Information
Segment Information	16) Segment Information The Company manages its operations through two segments. The Company’s two segments, Prescription Medications and Medical Devices, focus on the treatment of male erectile dysfunction. The Prescription Medications segment consists primarily of operations related to Stendra®, which is sold generally in the United States, and H100™ for the treatment of Peyronie’s disease. The Medical Devices segment consists primarily of operations related to vacuum erection devices, which are sold domestically and internationally. The Company separately presents the costs associated with certain corporate functions as Corporate, primarily consisting of unallocated operating expenses including costs that were not specific to a particular segment but are general to the group, expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees, and other similar corporate expenses. Interest and other income (expense), net is also not allocated to the operating segments. The Company’s results of operations by reportable segment for the three months ended September 30, 2021 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the three months ended September 30, 2021 ​ Medications ​ Devices ​ Corporate ​ Consolidated Net sales ​ $ 1,377,291 ​ $ 767,878 ​ $ — ​ $ 2,145,169 Cost of goods sold ​ 45,254 ​ 273,904 ​ — ​ 319,158 Selling, general and administrative expenses ​ 1,318,610 ​ 722,998 ​ 1,371,615 ​ 3,413,223 Research and development expenses ​ 280,576 ​ — ​ — ​ 280,576 Depreciation and amortization expense ​ 1,398,270 ​ 330,559 ​ — ​ 1,728,829 Change in fair value of derivative liability ​ — ​ — ​ (1,970,000) ​ (1,970,000) Interest expense ​ — ​ — ​ 67,936 ​ 67,936 Income tax expense ​ — ​ (2,345) ​ — ​ (2,345) Net income (loss) ​ $ (1,665,419) ​ $ (561,928) ​ $ 530,449 ​ $ (1,696,898) ​ The Company’s results of operations by reportable segment for the three months ended September 30, 2020 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the three months ended September 30, 2020 ​ Medications Devices Corporate Consolidated Net sales ​ $ 2,590,151 ​ $ 874,544 ​ $ — ​ $ 3,464,695 Cost of goods sold ​ 749,575 ​ 232,328 ​ — ​ 981,903 Selling, general and administrative expenses ​ 1,837,864 ​ 566,666 ​ 716,493 ​ 3,121,023 Research and development expense ​ 36,828 ​ — ​ — ​ 36,828 Depreciation and amortization expense ​ 1,353,591 ​ 307,771 ​ — ​ 1,661,362 Interest expense ​ — ​ — ​ 970,085 ​ 970,085 Income tax benefit ​ — ​ 6,143 ​ — ​ 6,143 Net loss ​ $ (1,387,707) ​ $ (226,078) ​ $ (1,686,578) ​ $ (3,300,363) ​ The Company’s results of operations by reportable segment for the nine months ended September 30, 2021 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the nine months ended September 30, 2021 ​ Medications ​ Devices ​ Corporate ​ Consolidated Net sales ​ $ 6,227,753 ​ $ 2,450,671 ​ $ — ​ $ 8,678,424 Cost of goods sold ​ 607,582 ​ 748,256 ​ — ​ 1,355,838 Selling, general and administrative expenses ​ 4,985,603 ​ 2,014,424 ​ 4,411,086 ​ 11,411,113 Research and development expenses ​ 799,803 ​ — ​ — ​ 799,803 Depreciation and amortization expense ​ 4,194,809 ​ 991,677 ​ — ​ 5,186,486 Change in fair value of derivative liability ​ — ​ — ​ (9,640,000) ​ (9,640,000) Interest expense ​ — ​ — ​ 356,873 ​ 356,873 Income tax expense ​ — ​ (9,045) ​ — ​ (9,045) Net income (loss) ​ $ (4,360,044) ​ $ (1,312,731) ​ $ 4,872,041 ​ $ (800,734) ​ The Company’s results of operations by reportable segment for the nine months ended September 30, 2020 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the nine months ended September 30, 2020 ​ Medications ​ Devices ​ Corporate ​ Consolidated Net sales ​ $ 4,128,694 ​ $ 2,501,486 ​ $ — ​ $ 6,630,180 Cost of goods sold ​ 1,527,169 ​ 778,000 ​ — ​ 2,305,169 Selling, general and administrative expenses ​ 6,658,231 ​ 1,780,530 ​ 3,558,424 ​ 11,997,185 Research and development expense ​ 307,796 ​ — ​ — ​ 307,796 Depreciation and amortization expense ​ 4,060,772 ​ 923,312 ​ — ​ 4,984,084 Interest expense ​ — ​ — ​ 2,233,794 ​ 2,233,794 Income tax benefit ​ — ​ 49,895 ​ — ​ 49,895 Net loss ​ $ (8,425,274) ​ $ (930,461) ​ $ (5,792,218) ​ $ (15,147,953) ​ The following table reflects net sales by geographic region for the three and nine months ended September 30, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended ​ For the Nine Months Ended ​ ​ September 30, ​ September 30, Net sales 2021 2020 2021 2020 United States ​ $ 1,861,222 ​ $ 3,125,572 ​ $ 7,754,534 ​ $ 5,780,165 International ​ 283,947 ​ 339,123 ​ ​ 923,890 ​ ​ 850,015 ​ ​ $ 2,145,169 ​ $ 3,464,695 ​ $ 8,678,424 ​ $ 6,630,180 ​ No individual country other than the United States accounted for 10% of total sales for the three or nine months ended September 30, 2021 and 2020. The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of September 30, 2021, are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription ​ ​ ​ ​ ​ Medications Medical Devices Consolidated Intangible assets, net ​ $ 20,438,542 ​ $ 6,543,556 ​ $ 26,982,098 Total segment assets ​ $ 43,790,552 ​ $ 8,244,776 ​ $ 52,035,328 ​ The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of December 31, 2020, are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription ​ ​ ​ ​ ​ ​ ​ Medications Medical Devices Consolidated Intangible assets, net ​ $ 24,625,686 ​ $ 7,535,233 ​ $ 32,160,919 Total segment assets ​ $ 60,725,191 ​ $ 9,128,823 ​ $ 69,854,014 ​	18) Segment Information The Company manages its operations through two segments. The Company’s two segments, Prescription Medications and Medical Devices, focus on the treatment of male erectile dysfunction. The Prescription Medications segment consists primarily of operations related to Stendra®, which is sold generally in the United States, and H100™ for the treatment of Peyronie’s disease. The Medical Devices segment consists primarily of operations related to vacuum erection devices, which are sold domestically and internationally. The Company separately presents the costs associated with certain corporate functions as Corporate, primarily consisting of unallocated operating expenses including costs that were not specific to a particular segment but are general to the group, expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Interest and other income (expense), net is also not allocated to the operating segments. ​ The Company’s results of operations by reportable segment for the year ended December 31, 2020 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the year ended December 31, 2020 ​ Medications ​ Devices ​ Corporate ​ Consolidated Net sales ​ $ 6,357,498 ​ $ 3,201,971 ​ $ — ​ $ 9,559,469 Cost of goods sold ​ 3,083,417 ​ 963,049 ​ — ​ 4,046,466 Selling, general and administrative expenses ​ 8,784,716 ​ 2,024,448 ​ 4,865,804 ​ 15,674,968 Research and development expenses ​ 459,636 ​ — ​ — ​ 459,636 Depreciation and amortization expense ​ 5,424,292 ​ 1,236,146 ​ — ​ 6,660,438 Change in fair value of derivative liability ​ 1,680,000 ​ — ​ — ​ 1,680,000 Interest expense ​ — ​ — ​ 3,050,879 ​ 3,050,879 Income tax benefit ​ — ​ 1,426,993 ​ — ​ 1,426,993 Net loss ​ $ (13,074,563) ​ $ 405,321 ​ $ (7,916,683) ​ $ (20,585,925) ​ The Company’s results of operations by reportable segment for the year ended December 31, 2019 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the Year Ended December 31, 2019 ​ Medications Devices Corporate Consolidated Net sales ​ $ 11,110,660 ​ $ 4,466,506 ​ $ — ​ $ 15,577,166 Cost of goods sold ​ 6,057,977 ​ 1,369,134 ​ — ​ 7,427,111 Selling, general and administrative expenses ​ 13,873,200 ​ 2,735,390 ​ 3,118,633 ​ 19,727,223 Depreciation and amortization expense ​ 4,145,833 ​ 1,145,274 ​ — ​ 5,291,107 Impairment loss ​ 2,443,930 ​ — ​ ​ ​ 2,443,930 Interest expense ​ — ​ — ​ 13,844,961 ​ 13,844,961 Income tax expense ​ — ​ 645,866 ​ — ​ 645,866 Net loss ​ $ (15,410,280) ​ $ (137,426) ​ $ (16,963,594) ​ $ (32,511,300) ​ The following table reflects net sales by geographic region for the years ended December 31, 2020 and 2019: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended ​ ​ December 31, Net sales 2020 2019 United States ​ $ 8,555,831 ​ $ 14,236,886 International ​ 1,003,638 ​ 1,340,280 ​ ​ $ 9,559,469 ​ $ 15,577,166 ​ No individual country other than the United States accounted for 10% of total sales for the year ended December 31, 2020 and 2019. The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of December 31, 2020 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription ​ ​ ​ ​ ​ Medications Medical Devices Consolidated Intangible assets, net ​ $ 24,625,686 ​ $ 7,535,233 ​ $ 32,160,919 Total segment assets ​ $ 60,725,191 ​ $ 9,128,823 ​ $ 69,854,014 ​ The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of December 31, 2019 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription ​ ​ ​ ​ ​ ​ ​ Medications Medical Devices Consolidated Intangible assets, net ​ $ 30,039,758 ​ $ 8,771,379 ​ $ 38,811,137 Total segment assets ​ $ 47,455,382 ​ $ 10,910,911 ​ $ 58,366,293 ​

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Summary of Significant Accounting Policies
Use of Estimates	Use of Estimates The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and reported amounts of revenue and expenses during the reporting periods. Such estimates include the adequacy of accounts receivable reserves, return reserves, inventory reserves, and assessment of long-lived assets, including intangible asset impairment and the determination of the fair value of the derivative liability, among others. Actual results could differ from these estimates and changes in these estimates are recorded when known.	Use of Estimates The preparation of Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the Consolidated Financial Statements, and reported amounts of revenue and expenses during the reporting periods. Such estimates include the adequacy of accounts receivable reserves, return reserves, inventory reserves, and assessment of long-lived assets, including intangible asset impairment, and the allocation of the purchase price in acquisitions. Actual results could differ from these estimates and changes in these estimates are recorded when known.
Risks and Uncertainties		Risks and Uncertainties The Company is subject to risks common to companies in the pharmaceutical industry including, but not limited to, uncertainties related to commercialization of competitor products, regulatory approvals, dependence on key products, dependence on key customers and suppliers, and protection of intellectual property rights. In January 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. As a result of the COVID-19 pandemic, which continues to rapidly evolve, “shelter in place” orders and other public health guidance measures were implemented across much of the United States, Europe and Asia, including in the locations of the Company’s offices, key vendors and partners. The pandemic has significantly impacted the economic conditions in the U.S. and globally as federal, state and local governments react to the public health crisis, creating significant uncertainties in the economy. At this time, the future trajectory of the COVID-19 outbreak remains uncertain, both in the United States and in other markets. While the Company anticipates that currently available vaccines will be widely distributed in the future, the timing and efficacy of such vaccines are uncertain. The Company cannot reasonably estimate the length or severity of the impact that the COVID-19 outbreak will have on its financial results, and the Company may experience a material adverse impact on its sales, results of operations, and cash flows in fiscal 2021. During 2020, government regulations and the voluntary business practices of the Company and prescribing physicians have prevented in-person visits by sales representatives to physicians’ offices. The Company has taken steps to mitigate the negative impact on its businesses of such restrictions. In March 2020, the Company reduced our sales representative head count to reflect the lack of in-person visits. The Company has maintained a core sales team which continues to contact physicians via telephone and videoconference as well as continuing to have webinars provided by the Company’s key opinion leaders to other physicians and pharmacists. The Company anticipates rehiring and/or assigning representatives to cover sales territories as states reopen and physician access resumes new normal levels. In response to the spread of SARS-CoV-2 and COVID-19, in March 2020, the Company closed its administrative offices and as of December 31, 2020, they remain closed, with the Company’s employees continuing their work outside of the Company’s offices. The Company has selectively resumed in-person interactions by its customer-facing personnel in compliance with local and state restrictions. The Company also continues to engage with customers virtually as the Company seeks to continue to support healthcare professionals and patient care. However, the Company’s ability to engage in personal interactions with physicians and customers remains limited, and it is unknown when the Company’s offices will reopen, and these interactions will be fully resumed.
Concentration of Credit Risk	Risks and Uncertainties The Company is subject to risks common to companies in the pharmaceutical industry including, but not limited to, uncertainties related to commercialization of competitor products, regulatory approvals, dependence on key products, dependence on key customers and suppliers, and protection of intellectual property rights. In January 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China ( “COVID-19”) and the risks to the international community. The WHO declared COVID-19 a global pandemic on March 11, 2020, and since that time many of the previously imposed restrictions and other measures which were instituted in response have been subsequently reduced or lifted. However, the COVID-19 pandemic remains highly unpredictable and dynamic, and its duration and extent continue to be dependent on various developments, such as the emergence of variants to the virus that may cause additional strains of COVID-19, the administration and ultimate effectiveness of vaccines, and the eventual timeline to achieve a sufficient level of herd immunity among the general population. Accordingly, the COVID-19 pandemic may continue to have negative effects on the health of the U.S. economy for the foreseeable future. The Company cannot reasonably estimate the length or severity of the impact that the COVID-19 pandemic will have on its financial results, and the Company may experience a material adverse impact on its sales, results of operations, and cash flows in fiscal 2021 and thereafter. During 2020, government regulations and the voluntary business practices of the Company and prescribing physicians had prevented in-person visits by sales representatives to physicians’ offices. The Company had taken steps to mitigate the negative impact on its businesses of such restrictions. In March 2020, the Company reduced its sales representative head count to reflect the lack of in-person visits. The Company had maintained a core sales team which continued to contact physicians via telephone and videoconference as well as continuing to have webinars provided by the Company’s key opinion leaders to other physicians and pharmacists. In response to the spread of COVID-19, in March 2020, the Company closed its administrative offices and as of September 30, 2021, they remain closed, with the Company’s employees continuing their work outside of the Company’s offices. The Company has selectively resumed in-person interactions by its customer-facing personnel in compliance with local and state restrictions. The Company also continues to engage with customers virtually as the Company seeks to continue to support healthcare professionals and patient care. However, the Company’s ability to engage in personal interactions with physicians and customers remains limited, and it is unknown when the Company’s offices will reopen, and these interactions will be fully resumed.	Concentration of Credit Risk Financial instruments that subject the Company to concentrations of credit risk includes cash. The Company maintains cash on deposit at U.S.-based banks in amounts which, at times, may be in excess of insured limits.
Cash and Cash Equivalents		Cash and Cash Equivalents The Company considers all highly-liquid investments that have maturities of three months or less when acquired to be cash equivalents.
Segment Reporting		Segment Reporting Operating segments are components of a Company for which separate financial information is available and evaluated regularly by the chief operating decision maker in assessing performance and deciding how to allocate resources. The Company’s two segments, Prescription Medications and Medical Devices, focus on the treatment of male erectile dysfunction. The Prescription Medications segment consists primarily of operations related to Stendra®, which is sold generally in the United States, and H100™ for the treatment of Peyronie’s disease. The Medical Devices segment consists primarily of operations related to vacuum erection devices, which are sold domestically and internationally. See Note 18 Segment Reporting.
Revenue Recognition	Revenue Recognition Prescription Medication Sales The Company’s prescription medication sales consist of sales of Stendra® in the U.S. for the treatment of male erectile dysfunction. Under ASC Topic 606, Revenue Recognition In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers Stendra® to when the customers pay for the product is typically less than one year. The Company records prescription medication sales net of any variable consideration, including but not limited to discounts, rebates, returns, chargebacks, and distribution fees. The Company uses the expected value method when estimating its variable consideration unless terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Stendra® are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes. As of September 30, 2021, and December 31, 2020, the reserves for sales deductions were $4.2 million and $8.6 million, respectively. The most significant sales deductions included in this reserve relate to returns, contract rebates, coupon redemptions and distribution service (“DSA”) fees. The Company’s estimates are based on factors such as its direct and indirect customers’ buying patterns and the estimated resulting contractual deduction rates, historical experience, specific known market events and estimated future trends, current contractual and statutory requirements, industry data, estimated customer inventory levels, current contract sales terms with its direct and indirect customers, and other competitive factors. Significant judgment and estimation are required in developing the foregoing and other relevant assumptions. The most significant sales deductions are further described below. Product Returns Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return Stendra® and receive credit for product within six months prior to expiration date and up to one year after expiration date. The provision for returns is based upon the Company’s estimates for future Stendra® returns and historical experience. The provision of returns is part of the variable consideration recorded at the time revenue is recognized. As of September 30, 2021, and December 31, 2020, the reserves for product returns were $3.2 million and $7.1 million, respectively, and are included as a component of accrued expenses. Contract Rebates, Coupon Redemptions and DSA Fees The Company establishes contracts with wholesalers, chain stores, and indirect customers that provide for rebates, sales incentives, DSA fees and other allowances. Some customers receive rebates upon attaining established sales volumes. Direct rebates are generally rebates paid to direct purchasing customers based on a percentage applied to a direct customer’s purchases from us, including fees paid to wholesalers under our DSAs, as described below. Indirect rebates are rebates paid to indirect customers that have purchased our products from a wholesaler under a contract with us. The Company has entered into DSAs with certain of our significant wholesaler customers that obligate the wholesalers, in exchange for fees paid by us, to: (i) manage the variability of their purchases and inventory levels within specified limits based on product demand and (ii) provide us with specific services, including the provision of periodic retail demand information and current inventory levels for our pharmaceutical products held at their warehouse locations. Medical Device Sales The Company’s medical device sales consist of domestic and international sales of men’s health products for the treatment of erectile dysfunction. The men’s health products do not require a prescription and include vacuum erection devices, VenoSeal, and other related accessories. Under Topic 606, the Company recognizes revenue from medical device sales when its performance obligations with its customers have been satisfied. In the contracts with its customers, the Company has identified a single performance obligation to provide medical devices upon receipt of a customer order. The performance obligation is satisfied at a point in time when the Company’s customers obtain control of the medical device, which is typically upon shipment. The Company invoices its customers after the medical devices have been shipped and invoice payments are generally due within 30 days of invoice date for domestic customers and 90 days for international customers. In determining the transaction price, a significant financing component Product Returns Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return medical devices and receive credit for products within 90 days of the sale. The provision for returns is based upon the Company’s estimates for future product returns and historical experience. The Company has not made significant changes to the judgments made in applying Topic 606. As of September 30, 2021, and December 31, 2020, the reserves for product returns for medical devices were not significant.	Revenue Recognition Prescription Medication Sales The Company’s prescription medication sales consist of sales of Stendra® in the U.S. for the treatment of male erectile dysfunction. Under ASC Topic 606, Revenue Recognition In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers Stendra® to when the customers pay for the product is typically less than one year. The Company records prescription medication sales net of any variable consideration, including but not limited to discounts, rebates, returns, chargebacks, and distribution fees. The Company uses the expected value method when estimating its variable consideration, unless terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Stendra® are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes. As of December 31, 2020 and 2019, the reserves for sales deductions were $8.6 million and $12.0 million, respectively. The most significant sales deductions included in this reserve relate to returns, contract rebates, and distribution service (“DSA”) fees. Our estimates are based on factors such as our direct and indirect customers’ buying patterns and the estimated resulting contractual deduction rates, historical experience, specific known market events and estimated future trends, current contractual and statutory requirements, industry data, estimated customer inventory levels, current contract sales terms with our direct and indirect customers, and other competitive factors. Significant judgment and estimation is required in developing the foregoing and other relevant assumptions. The most significant sales deductions are further described below. Product Returns Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return Stendra® and receive credit for product within six months prior to expiration date and up to one year after expiration date. The provision for returns is based upon the Company’s estimates for future Stendra® returns and historical experience. The provision of returns is part of the variable consideration recorded at the time revenue is recognized. As of December 31, 2020 and 2019, the reserves for product returns were $7.1 million and $8.3 million, respectively, and are included as a component of accrued expenses. Contract Rebates, Coupon Redemptions and DSA Fees The Company establishes contracts with wholesalers, chain stores, and indirect customers that provide for rebates, sales incentives, DSA fees and other allowances. Some customers receive rebates upon attaining established sales volumes. Direct rebates are generally rebates paid to direct purchasing customers based on a percentage applied to a direct customer’s purchases from us, including fees paid to wholesalers under our DSAs, as described below. Indirect rebates are rebates paid to indirect customers that have purchased our products from a wholesaler under a contract with us. The Company has entered into DSAs with certain of our significant wholesaler customers that obligate the wholesalers, in exchange for fees paid by us, to: (i) manage the variability of their purchases and inventory levels within specified limits based on product demand and (ii) provide us with specific services, including the provision of periodic retail demand information and current inventory levels for our pharmaceutical products held at their warehouse locations. Medical Device Sales The Company’s medical device sales consist of domestic and international sales of men’s health products for the treatment of erectile dysfunction. The men’s health products do not require a prescription and include Vacuum Erection Devices, PreBoost, VenoSeal, penile injections (Rx), and urinary tract infection tests. Under Topic 606, the Company recognizes revenue from medical device sales when its performance obligations with its customers have been satisfied. In the contracts with its customers, the Company has identified a single performance obligation to provide medical devices upon receipt of a customer order. The performance obligation is satisfied at a point in time when the Company’s customers obtain control of the medical device, which is typically upon shipment. The Company invoices its customers after the medical devices have been shipped and invoice payments are generally due within 30 days of invoice date for domestic customers and 90 days for international customers. In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers the medical devices to when the customers pay for the product is typically less than one year. The Company records medical device sales net of any variable consideration, including but not limited to returns. The Company uses the expected value method when estimating its variable consideration. The identified variable consideration is recorded as a reduction of revenue at the time revenues from the medical device sales are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes. Product Returns Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return medical devices and receive credit for products within 90 days of the sale. The provision for returns is based upon the Company’s estimates for future product returns and historical experience. The Company has not made significant changes to the judgments made in applying Topic 606. As of December 31, 2020 and 2019, the reserves for product returns for medical devices were not significant. Contract Costs In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. As such, the Company did not have any contract assets at December 31, 2020 and 2019.
Accounts Receivable, net		Accounts Receivable, net The Company extends credit to its customers in the normal course of business. Accounts receivable are recorded at the invoiced amount, net of chargebacks, distribution service fees, and cash discounts. Management determines each allowance based on historical experience along with the present knowledge of potentially uncollectible accounts. See Note 3 Accounts, Receivable, net.
Inventories		Inventories Inventories consist of finished goods held for sale and raw materials. Inventories are stated at the lower of cost or net realizable value, with cost determined using the first-in, first-out method. Inventories are adjusted for excess and obsolescence. Evaluation of excess inventory includes such factors as expiry date, inventory turnover, and management’s assessment of current product demand. See Note 4 Inventories.
Intangible Assets		Intangible Assets The Company accounts for recognized intangible assets at cost. Intangible assets with finite useful lives are amortized over the useful life that the assets are expected to contribute directly or indirectly to future cash flows. Intangible assets are amortized using an accelerated method based on the pattern in which the economic benefits of the assets are consumed. The Company review the carrying value and useful lives of its intangible assets with definite lives, or whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable or the period over which they should be amortized has changed. When indicators of impairment exist, the Company determines whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The Company evaluates the remaining useful life of each intangible asset that is being amortized during each reporting period to determine whether events and circumstances warrant a revision to the remaining period of amortization. If the estimate of the intangible asset’s remaining useful life has changed, the remaining carrying amount of the intangible asset is amortized prospectively over that revised remaining useful life. Given the impact of the COVID-19 outbreak on the global economy, as well as its potential impact to the Company’s business operations and cash flows, the Company constituted the COVID-19 outbreak as a triggering event requiring an impairment test for its long-lived assets with finite useful lives. The Company’s projections included the undiscounted cash flows of the remaining estimated useful lives for the Stendra product through December 2028 and December 2030 for the medical device products. Based on the impairment assessment as of December 31, 2020, the Company determined that no intangible asset impairment occurred as the undiscounted cash flows exceeded the respective carrying values of the assets. The Company did not record any impairments of intangible assets for the years ended December 31, 2020 and 2019.
Goodwill		Goodwill Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. The Company evaluates the carrying value of goodwill annually in December of each year in connection with the annual budgeting and forecast process and also between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit to which goodwill was allocated to below its carrying amount. Such circumstances could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. When evaluating goodwill for impairment, we may first perform an assessment qualitatively whether it is more likely than not that a reporting unit’s carrying amount exceeds its fair value, referred to as a “step zero” approach. Subsequently (if necessary after step zero), an entity should perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. This quantitative impairment test uses a combination of the income method and guideline public company comparable companies. The income method is based on a discounted future cash flow approach that uses significant assumptions of projected revenue, projected operational profit, terminal growth rates and the cost of capital. Under Topic 350, goodwill impairment is measured as the excess of the carrying amount of the reporting unit over its fair value. The Company incurred a goodwill impairment loss of $2,443,930 during the year ended December 31, 2019, related to the prescription medications segment. ​ ​ ​ ​ ​ Balance, December 31, 2018 $ 2,443,930 Impairment loss ​ (2,443,930) Balance, December 31, 2019 ​ $ —
Fixed Assets		Fixed Assets Fixed assets consist of furniture and fixtures. Furniture and fixtures are recorded at cost, less accumulated depreciation, and are depreciated on a straight-line basis over its estimated useful life. The Company uses an estimated useful life of 7 years for furniture and fixtures. Depreciation expense for the years ended December 31, 2020 and 2019 was $10,220 and $1,703, respectively.
Leases		Leases The Company accounts for leases in accordance with Accounting Standards Codification (“ASC”) Topic 842. Topic 842 requires organizations to recognize leased assets and liabilities on the balance sheet. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all leases. Operating lease right-of-use (“ROU”) assets are included in other assets whereas operating lease liabilities are included in other current liabilities and other long-term liabilities on the Company’s consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The operating lease payments are recognized as lease expense on a straight-line basis over the lease term. Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Company’s consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories. Topic 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The lease term for all of the Company’s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. See Note 2 and Note 15 Commitments and Contingencies for additional information.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy: Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by an observable market. Level 3 — Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. Financial instruments recognized at historical amounts in the condensed consolidated balance sheets consist of cash, accounts receivable, other current assets, accounts payable, accrued expenses, other current liabilities, and senior debt. The Company believes that the carrying value of cash, accounts receivable, other current assets, accounts payable, accrued expenses, and other current liabilities approximates their fair values due to the short-term nature of these instruments. The carrying value of senior debt as of September 30, 2021, and December 31, 2020, approximated fair value. The fair value of the senior debt was estimated by discounting to present value the scheduled coupon payments and principal repayment, using an appropriate fair market yield and is considered Level 3 in the fair value hierarchy. In connection with the Mergers in December 2020, each security holder of Metuchen received an earnout consideration classified as a derivative liability to be paid in the form of Petros Common Stock. The Company estimated their fair value using a Monte Carlo Simulation approach. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative liability as of September 30, 2021, and December 31, 2020, was $0.3 million and $9.9 million, respectively. See Note 10 Stockholders’ Equity.	Fair Value of Financial Instruments Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy: Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market. Level 3 — Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. Financial instruments recognized at historical amounts in the consolidated balance sheets consist of cash, accounts receivable, other current assets, accounts payable, accrued expenses, other current liabilities and senior debt. The Company believes that the carrying value of cash, accounts receivable, other current assets, accounts payable, accrued expenses, other current liabilities approximates their fair values due to the short-term nature of these instruments. The carrying value of senior debt as of December 31, 2020 approximated fair value. The fair value of the senior debt was estimated by discounting to present value the scheduled coupon payments and principal repayment, using an appropriate fair market yield and is considered Level 3 in the fair value hierarchy. In connection with the Mergers in December 2020, each security holder of Metuchen received an earnout consideration classified as a derivative liability to be paid in the form of Petros Common Stock. The Company estimated their fair value using Monte Carlo Simulation approach. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative liability as of the closing of the Merger and December 31, 2020 was $8.2 million and $9.9 million, respectively. See Note 10 Stockholders’ Equity.
Deferred Financing Costs		Deferred Financing Costs Costs incurred to issue debt are deferred and presented in the consolidated balance sheets as a direct reduction from the carrying amount of the debt liability, consistent with debt discounts. Related amortization expense is recorded as a component of interest expense over the term of the related debt using the effective interest rate method.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based awards to employees and consultants in accordance with applicable accounting principles, which requires compensation expense related to stock-based transactions, including employee stock options and consultant warrants, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options or warrants. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. Employee stock option and consulting expenses are recognized over the employee’s or consultant’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the volatility and expected term. Any changes in these highly subjective assumptions can significantly impact stock-based compensation expense. See Note 11 Stock Options.	Stock-Based Compensation The Company accounts for stock-based awards to employees and consultants in accordance with applicable accounting principles, which requires compensation expense related to stock-based transactions, including employee stock options and consultant warrants, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options or warrants. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. Employee stock option and consulting expenses are recognized over the employee’s or consultant’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the volatility and expected term. Any changes in these highly subjective assumptions can significantly impact stock-based compensation expense. See Note 11 Stock Options.
Costs of Equity Transactions		Costs of Equity Transactions Incremental direct costs incurred to issue stocks of the Company’s preferred and common stocks are recorded as a reduction of the related proceeds.
Income Taxes	Income Taxes Prior to the consummation of the Mergers, Metuchen was a limited liability company (“LLC”) for federal income tax purposes and had elected to be treated as a Partnership for federal and state income tax purposes. PTV is a disregarded entity for federal income tax purposes. As such, all income tax consequences resulting from the operations were reported on the member’s income tax return. In addition, Timm Medical was included in the Company’s structure where taxes were paid at the entity level. Subsequent to the Mergers, Metuchen’s activity is included in the Company’s consolidated group. The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period the rate change is enacted. The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions in accordance with FASB ASC No. 740 Income Taxes The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statement of operations. As of September 30, 2021, and December 31, 2020, no accrued interest or penalties are recorded in the condensed consolidated balance sheets.	Income Taxes Prior to the consummation of the Mergers, Metuchen was a limited liability company (“LLCs”) for federal income tax purposes and had elected to be treated as a Partnership for federal and state income tax purposes. PTV is a disregarded entity for federal income tax purposes. As such, all income tax consequences resulting from the operations were reported on the member’s income tax return. In addition, Timm was included in the Company’s structure where taxes were paid at the entity level. Following the consummation of the Mergers, Metuchen is treated as a disregarded entity (“SMLLC”) for federal income tax purposes. As such, all income tax consequences resulting from the operations of Metuchen are reported on the members’ income tax returns through the period in which the Merger was transacted. Subsequent to the Mergers, Metuchen’s activity is included in the Company’s consolidated group. The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period the rate change is enacted. The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) it determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. As of December 31, 2020 and 2019 no accrued interest or penalties are recorded in the consolidated balance sheets. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, was enacted and signed into law, and GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act, among other things, includes changes to the tax provisions that benefits business entities and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act, including, permitting net operating losses, or NOLs, carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The CARES Act provides other reliefs and stimulus measures. We have evaluated the impact of the CARES Act, and do not expect that any provision of the CARES Act would result in a material cash benefit to us or have a material impact on our financial statements or internal controls over financial reporting.
Contingencies		Contingencies The Company may be subject to various patent challenges, product liability claims, government investigations and other legal proceedings in the ordinary course of business. Legal fees and other expenses related to litigation are expensed as incurred and included in general and administrative expenses in the consolidated statements of operations.
Shipping Costs		Shipping Costs The Company records the costs of shipping related to prescription medication sales in general and administrative expense in its consolidated statements of operations. There were no shipping costs for the years ended December 31, 2020 and 2019. Shipping costs related to medical devices are recorded as revenue and subsequently deducted as a component of cost of goods sold in the consolidated statements of operations. Shipping costs for the years ended December 31, 2020 and 2019 were $108,870 and $130,242 respectively.
Basic and Diluted Net Loss per Common Share	Basic and Diluted Net Loss per Common Share The Company computes basic net loss per common share by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period, excluding the dilutive effects of stock options and warrants to purchase common shares. The Company computes diluted net loss per common share by dividing the net loss applicable to common share by the sum of the weighted-average number of common shares outstanding during the period plus the potential dilutive effects of its convertible preferred stocks, stock options and warrants to purchase common shares, but such items are excluded if their effect is anti-dilutive. See Note 13 Basic and Diluted Net Loss per Common Share.	Basic and Diluted Net Loss per Common Share The Company computes basic net loss per common share by dividing net loss applicable to common stockholders by the weighted average number of common stocks outstanding during the period, excluding the dilutive effects of stock options and warrants to purchase common stocks. The Company computes diluted net loss per common stock by dividing the net loss applicable to common stocks by the sum of the weighted-average number of common stocks outstanding during the period plus the potential dilutive effects of its convertible preferred stocks, stock options and warrants to purchase common stocks, but such items are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between the Company’s basic and diluted net loss per stock of common stock for the years ended December 31, 2020 and 2019. See Note 13 Basic and Diluted Net Loss per Common Share.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Pending Adoption as of September 30, 2021 In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Measurement of Credit Losses on Financial Instruments	Recent Accounting Pronouncements Recently Adopted In August 2018, the FASB issued ASU 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement fair value measurements. The guidance is effective for the Company for the annual periods and interim periods within annual periods beginning after December 15, 2019 for both private and public entities. The Company adopted this guidance as of January 1, 2020 and its impact was not material. Pending Adoption as of December 31, 2020 In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Summary of Significant Accounting Policies
Schedule of goodwill	​ ​ ​ ​ ​ Balance, December 31, 2018 $ 2,443,930 Impairment loss ​ (2,443,930) Balance, December 31, 2019 ​ $ —

Accounts Receivable, net (Table

Accounts Receivable, net (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Accounts Receivable, net
Summary of accounts receivable	​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, December 31, ​ ​ 2021 ​ 2020 Gross accounts receivables ​ $ 2,929,064 ​ $ 6,560,291 Distribution service fees ​ (537,363) ​ (972,652) Chargebacks accrual ​ — ​ (121,269) Cash discount allowances ​ (135,527) ​ (84,601) Allowance for doubtful accounts ​ (303,753) ​ (228,800) Total accounts receivable, net ​ $ 1,952,421 ​ $ 5,152,969	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, December 31, ​ ​ 2020 ​ 2019 Gross accounts receivables ​ $ 6,560,291 ​ $ 4,989,260 Distribution service fees ​ (972,652) ​ (2,061,481) Chargebacks accruals ​ (121,269) ​ (60,507) Cash discount allowances ​ (84,601) ​ (235,867) Allowance for doubtful accounts ​ (228,800) ​ (26,275) Total accounts receivable, net ​ $ 5,152,969 ​ $ 2,605,130

Inventories (Tables)

Inventories (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Inventories
Schedule of Inventories	​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 December 31, 2020 Raw materials ​ $ 328,558 ​ $ 325,932 Finished goods ​ 189,923 ​ 434,598 Total inventory ​ $ 518,481 ​ $ 760,530	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 December 31, 2019 Raw materials ​ $ 325,932 ​ $ 798,161 Finished goods ​ 434,598 ​ 1,406,267 Total inventory ​ $ 760,530 ​ $ 2,204,428

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Prepaid Expenses and Other Current Assets
Schedule of Prepaid Expenses and Other Current Assets	​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 December 31, 2020 Prepaid samples ​ $ — ​ $ 58,483 Prepaid insurance ​ 172,205 ​ 149,452 Prepaid FDA fees ​ — ​ 756,972 Prepaid coupon fees ​ 71,500 ​ 71,500 API purchase commitment asset (see Note 14) ​ 1,304,541 ​ 1,304,541 Other prepaid expenses ​ 587,319 ​ 391,552 Other current assets ​ 612,673 ​ 114,784 Total prepaid expenses and other current assets ​ $ 2,748,238 ​ $ 2,847,284	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 December 31, 2019 Prepaid samples ​ $ 58,483 ​ $ 391,024 Prepaid insurance ​ 149,452 ​ 287,844 Prepaid FDA fees ​ 756,972 ​ 732,204 Prepaid coupon fees ​ 71,500 ​ 71,500 Rebates receivable ​ ​ — ​ ​ 1,243,120 API purchase commitment asset (see Note 14) ​ 1,304,541 ​ 1,409,592 Other prepaid expenses ​ 391,552 ​ 468,226 Other current assets ​ 114,784 ​ 526,310 Total prepaid expenses and other current assets ​ $ 2,847,284 ​ $ 5,129,820

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Intangible Assets
Schedule of intangible assets	​ ​ ​ ​ ​ Balance at December 31, 2019 $ 38,811,137 Amortization expense ​ (6,650,218) Balance at December 31, 2020 ​ ​ 32,160,919 Amortization expense ​ (5,178,821) Balance at September 30, 2021 ​ $ 26,982,098	​ ​ ​ ​ ​ Balance at December 31, 2018 ​ $ 44,100,542 Amortization expense ​ ​ (5,289,405) Balance at December 31, 2019 $ 38,811,137 Amortization expense ​ (6,650,218) Balance at December 31, 2020 ​ $ 32,160,919
Schedule of future annual amortization of intangible assets	​ ​ ​ ​ ​ 2021 (remaining 3 months) ​ 1,688,951 2022 ​ 6,191,740 2023 ​ 5,445,729 2024 ​ 4,650,787 Thereafter ​ 9,004,891 Total ​ $ 26,982,098	​ ​ ​ ​ ​ 2021 ​ 6,867,771 2022 ​ 6,191,740 2023 ​ 5,445,729 2024 ​ 4,650,787 Thereafter ​ 9,004,892 Total ​ $ 32,160,919

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Accrued Expenses
Summary of accrued expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 December 31, 2020 Accrued price protection ​ $ 1,853,979 ​ $ 1,853,979 Accrued product returns ​ 5,590,248 ​ 9,452,248 Accrued contract rebates ​ 341,715 ​ 412,046 Due to Vivus (see Note 14) ​ 2,267,523 ​ 2,267,523 Accrued severance ​ 25,417 ​ 519,609 Accrued professional fees ​ 31,463 ​ — Accrued marketing ​ 1,258,255 ​ — Other accrued expenses ​ 225,514 ​ 178,381 Total accrued expenses ​ $ 11,594,114 ​ $ 14,683,786	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 December 31, 2019 Accrued price protection ​ $ 1,853,979 ​ $ 1,847,639 Accrued product returns ​ 9,452,248 ​ 10,707,807 Accrued contract rebates ​ 412,046 ​ 1,368,279 Due to Vivus (see Note 14) ​ 2,267,523 ​ 2,259,769 Due to third-party logistic provider ​ — ​ 4,388,600 Accrued severance ​ 519,609 ​ — Other accrued expenses ​ 178,381 ​ 315,168 Total accrued expenses ​ $ 14,683,786 ​ $ 20,887,262

Debt (Tables)

Debt (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Debt
Summary of senior indebtedness	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 December 31, 2020 Principal balance ​ $ 1,740,752 ​ $ 6,653,292 Plus: End of term fee ​ — ​ 534,237 Less: Debt issuance costs ​ — ​ (12,500) Total senior debt ​ $ 1,740,752 ​ $ 7,175,029	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 December 31, 2019 Principal balance ​ $ 6,653,292 ​ $ 11,688,979 Plus: Paid-In-Kind interest ​ ​ — ​ ​ 1,101,575 Plus: End of term fee ​ 534,237 ​ 952,416 Less: Debt issuance costs ​ (12,500) ​ — Total senior debt ​ $ 7,175,029 ​ $ 13,742,970
Summary of interest expense on the Senior Debt	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended ​ For the Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 Interest expense for term loan ​ $ 67,936 ​ $ 287,855 ​ $ 344,373 ​ $ 1,015,898 Amortization of debt issuance costs ​ — ​ 12,500 ​ 12,500 ​ 25,000 PIK interest ​ — ​ — ​ — ​ 44,449 ​ ​ $ 67,936 ​ $ 300,355 ​ $ 356,873 ​ $ 1,085,347	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended December 31, ​ 2020 2019 Interest expense for term loan ​ $ 1,241,475 ​ $ 2,216,341 Amortization of debt issuance costs ​ 37,500 ​ — PIK interest ​ 44,449 ​ 211,923 ​ ​ $ 1,323,424 ​ $ 2,428,264
Summary of the instruments exchanged in the transaction		​ ​ ​ ​ ​ Common Units, at fair value (2,434,551.28 Units) $ 29,117,232 Preferred Units, at fair value (1,373,820.51 Units) ​ 17,500,000 Total fair value of Preferred and Common Units exchanged ​ 46,617,232 ​ ​ ​ ​ Sub Debt principal balance ​ 33,250,000 Add: PIK Interest ​ 16,544,318 Less: Debt Discount ​ 10,486,536 Total carrying value of Sub Debt exchanged ​ 39,307,782 ​ ​ ​ ​ Excess of fair value of Preferred and Common Units exchanged over the carrying value of Sub Debt ​ $ (7,309,450)

Stock Options (Tables)

Stock Options (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Stock Options
Summary of stock options	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ ​ Weighted- ​ Remaining ​ Aggregate Intrinsic ​ ​ Number of ​ Average ​ Contractual ​ Value ​ Shares Exercise Price Term (Years) ($ in thousands) Options outstanding and exercisable on December 31, 2020 574,331 ​ $ 51.43 0.9 ​ $ — Options granted 638,970 ​ 3.37 9.18 ​ — Less: options and RSU’s forfeited — ​ — — ​ — Less: options and RSU’s expired/cancelled — ​ — — ​ — Less: options and RSU’s exercised — ​ — — ​ — Options and RSU’s outstanding at September 30, 2021 1,213,301 ​ 26.57 5.08 ​ — Options and RSU’s exercisable at September 30, 2021 852,166 ​ 35.77 3.32 ​ —	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ ​ Weighted- ​ Remaining ​ Aggregate Instrinsic ​ ​ Number of ​ Average ​ Contractual ​ Value ​ Shares Exercise Price Term (Years) ($ in thousands) Options outstanding at December 1, 2020 574,331 ​ $ 51.43 0.9 ​ $ — Options granted — ​ — — ​ — Less: options forfeited — ​ — — ​ — Less: options expired/cancelled — ​ — — ​ — Less: options exercised — ​ — — ​ — Options outstanding at December 31, 2020 574,331 ​ $ 51.43 0.9 ​ $ — Options exercisable at December 31, 2020 574,331 ​ $ 51.43 0.9 ​ $ —

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Common Stock Warrants
Summary of warrants	​ ​ ​ ​ ​ Number of Shares Warrants outstanding at December 31, 2020 4,407,962 Warrants issued — Warrants exercised — Warrants outstanding at September 30, 2021 4,407,962	​ ​ ​ ​ ​ Number of Shares Warrants outstanding at December 1, 2020 4,407,962 Warrants issued — Warrants exercised — Warrants outstanding at December 31, 2020 4,407,962
Summary of warrants by expiration date	​ ​ ​ ​ ​ ​ ​ Number of Warrants Exercise Price Expiration Date 76,569 ​ $ 32.00 ​ November 17, 2021 131,344 ​ 64.00 ​ November 17, 2021 2,780 ​ 1.60 ​ August 23, 2023 18,000 ​ 35.65 ​ June 1, 2024 4,800 ​ 35.60 ​ June 5, 2024 74,864 ​ 21.85 ​ June 17, 2024 20,043 ​ 31.25 ​ June 19, 2024 22,800 ​ 26.55 ​ September 1, 2024 10,500 ​ 12.74 ​ September 16, 2024 22,800 ​ 4.30 ​ December 1, 2024 28,000 ​ 5.65 ​ March 2, 2025 28,000 ​ 7.30 ​ June 1, 2025 28,000 ​ 5.50 ​ September 1, 2025 28,000 ​ 4.71 ​ December 1, 2025 2,221,829 ​ 7.50 ​ December 1, 2025 908,498 ​ 17.50 ​ December 1, 2025 623,303 ​ 51.25 ​ December 1, 2025 157,832 ​ 125.00 ​ December 1, 2025 4,407,962 ​ ​	​ ​ ​ ​ ​ ​ ​ Number of Warrants Exercise Price Expiration Date 76,569 ​ $ 32.00 ​ November 17, 2021 131,344 ​ 64.00 ​ November 17, 2021 2,780 ​ 1.60 ​ August 23, 2023 18,000 ​ 35.65 ​ June 1, 2024 4,800 ​ 35.60 ​ June 5, 2024 74,864 ​ 21.85 ​ June 17, 2024 20,043 ​ 31.25 ​ June 19, 2024 22,800 ​ 26.55 ​ September 1, 2024 10,500 ​ 12.7382 ​ September 16, 2024 22,800 ​ 4.30 ​ December 1, 2024 28,000 ​ 5.65 ​ March 2, 2025 28,000 ​ 7.30 ​ June 1, 2025 28,000 ​ 5.50 ​ September 1, 2025 28,000 ​ 4.71 ​ December 1, 2025 2,221,829 ​ 7.50 ​ December 1, 2025 908,498 ​ 17.50 ​ December 1, 2025 623,303 ​ 51.25 ​ December 1, 2025 157,832 ​ 125.00 ​ December 1, 2025 4,407,962 ​ ​

Basic and Diluted Net Loss pe_2

Basic and Diluted Net Loss per Common Share (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Basic and Diluted Net Loss per Common Share
Summary of Computation of Basic and Diluted Net Loss per Share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended ​ For the Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 Numerator ​ ​ ​ ​ ​ Net loss ​ $ (1,696,898) ​ $ (3,300,363) ​ $ (800,734) ​ $ (15,147,953) Denominator ​ ​ ​ ​ Weighted-average common shares for basic net loss per share ​ 9,826,599 ​ 3,434,551 ​ 9,794,267 ​ 3,434,551 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic and diluted net loss per common share ​ $ (0.17) ​ $ (0.96) ​ $ (0.08) ​ $ (4.41)	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended ​ ​ December 31, ​ 2020 2019 Numerator ​ ​ Net (loss) income ​ $ (20,585,925) ​ $ (32,511,300) Denominator ​ ​ Weighted-average common shares for basic and diluted net loss per unit ​ 5,340,682 ​ 2,460,026 ​ ​ ​ ​ ​ ​ ​ Basic and diluted net loss per common share ​ $ (3.85) ​ $ (13.22)
Summary of Computation of Basic and Diluted Net Loss per Share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended ​ For the Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 Stock Options 1,213,301 — ​ 1,213,301 — Warrants 4,405,182 21,139 ​ 4,405,182 21,139 Total 5,621,263 21,139 ​ 5,621,263 21,139	​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended ​ ​ December 31, ​ 2020 2019 Stock Options 574,331 — Warrants 4,407,962 127,396 Total 4,982,293 127,396

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Commitments and Contingencies
Summary of components of lease expense		​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended ​ ​ December 31, ​ 2020 2019 Operating Lease Cost: ​ ​ Fixed lease cost ​ $ 179,246 ​ $ 88,002
Summary of supplemental balance sheet information related to leases	Supplemental balance sheet information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, 2021 As of December 31, 2020 Operating lease ROU asset: ​ ​ Other assets ​ $ 502,697 ​ $ 579,535 ​ ​ ​ ​ ​ ​ ​ Operating lease liability: ​ ​ Other current liabilities ​ $ 121,589 ​ $ 108,971 Other long-term liabilities ​ 437,749 ​ 530,597 Total operating lease liability ​ $ 559,338 ​ $ 639,568	Supplemental balance sheet information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2020 As of December 31, 2019 Operating lease ROU asset: ​ ​ Other assets ​ $ 579,535 ​ $ 672,246 ​ ​ ​ ​ ​ ​ ​ Operating lease liability: ​ ​ ​ Other current liabilities ​ $ 108,971 ​ $ 96,104 Other long-term liabilities ​ 530,597 ​ 639,568 Total operating lease liability ​ $ 639,568 ​ $ 735,672
Summary of supplemental lease term and discount rate information related to leases	Supplemental lease term and discount rate information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, 2021 ​ As of December 31, 2020 ​ Weighted-average remaining lease terms - operating leases 3.9 years 4.7 years ​ Weighted-average discount rate - operating leases 12.6 % 12.6 %	Supplemental lease term and discount rate information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2020 ​ As of December 31, 2019 ​ Weighted-average remaining lease terms - operating leases 4.7 years 5.7 years ​ Weighted-average discount rate - operating leases 12.6 % 12.6 %
Summary of supplemental cash flow information related to leases	Supplemental cash flow information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months For the Nine Months ​ ​ Ended September 30, Ended September 30, ​ 2021 2020 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: ​ ​ ​ ​ ​ Operating cash flows from operating leases ​ $ 45,942 ​ $ 45,660 ​ $ 137,826 ​ $ 136,979	Supplemental cash flow information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended ​ ​ December 31, ​ 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: ​ ​ Operating cash flows from operating leases ​ $ 182,639 ​ $ 92,068 ​ ​ ​ ​ ​ ​ ​ Right-of-use assets obtained in exchange for lease obligations: ​ ​ ​ ​ ​ ​ Operating leases ​ $ — ​ $ 698,127
Summary of future minimum lease payments under non-cancelable leases	Future minimum lease payments under non-cancelable leases as of September 30, 2021, were as follows: ​ ​ ​ ​ ​ Lease Liability Maturity Analysis Operating Leases 2021 (remaining 3 months) ​ 46,413 2022 ​ 187,739 2023 ​ 189,374 2024 ​ 155,242 2025 ​ ​ 81,107 Thereafter ​ 82,326 Total lease payments ​ 742,201 Less: Imputed Interest ​ (182,863) Total ​ $ 559,338	Future minimum lease payments under non-cancelable leases as of December 31, 2020 were as follows: ​ ​ ​ ​ ​ Lease Liability Maturity Analysis Operating Leases 2021 ​ 184,239 2022 ​ 187,739 2023 ​ 189,374 2024 ​ 155,242 Thereafter ​ 163,432 Total lease payments ​ 880,026 Less: Imputed Interest ​ (240,458) Total ​ $ 639,568

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Taxes
Summary of current and deferred income tax expense (benefit)	​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended December 31, ​ ​ 2020 ​ 2019 Current expense (benefit): ​ ​ Federal ​ $ 5,085 ​ $ — State ​ 88 ​ — Total current expense (benefit) ​ 5,173 ​ — Deferred expense (benefit): ​ ​ Federal ​ (1,378,731) ​ (165,483) State ​ (53,435) ​ (480,383) Total deferred expense (benefit) ​ (1,432,166) ​ (645,866) Total income tax expense (benefit) ​ $ (1,426,993) ​ $ (645,866)
Summary of reconciliation of the Company's statutory income tax rate to the Company's effective income tax rate	​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended December 31, ​ ​ 2020 ​ 2019 Income at US statutory rate 21.00 % 21.00 % State taxes, net of federal benefit 1.56 % 1.59 % Permanent differences (2.68) % (0.02) % Recapitalization 36.49 % 0.00 % Pass through income to members (32.71) % (21.13) % Valuation allowance (17.22) % 0.00 % Other 0.00 % 0.51 % Effective income tax rate 6.44 % 1.95 %
Summary of significant components of the Company's deferred tax assets and liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended December 31, ​ ​ 2020 ​ 2019 Accruals ​ $ 90,222 ​ $ 5,732 Intangible assets ​ (1,238,128) ​ (1,438,682) Depreciation and amortization ​ 5,661,235 ​ — Expenses no currently deductible ​ 148,708 ​ — Net operating loss carryforwards ​ 57,266 ​ 783 Interest expense limitation ​ 25,547 ​ — Stock-based compensation ​ 2,505,425 ​ — Valuation allowance ​ (7,250,275) ​ — Total deferred tax liability ​ $ — ​ $ (1,432,167)

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Segment Information
Summary of results of operations by reportable segment	The Company’s results of operations by reportable segment for the three months ended September 30, 2021 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the three months ended September 30, 2021 ​ Medications ​ Devices ​ Corporate ​ Consolidated Net sales ​ $ 1,377,291 ​ $ 767,878 ​ $ — ​ $ 2,145,169 Cost of goods sold ​ 45,254 ​ 273,904 ​ — ​ 319,158 Selling, general and administrative expenses ​ 1,318,610 ​ 722,998 ​ 1,371,615 ​ 3,413,223 Research and development expenses ​ 280,576 ​ — ​ — ​ 280,576 Depreciation and amortization expense ​ 1,398,270 ​ 330,559 ​ — ​ 1,728,829 Change in fair value of derivative liability ​ — ​ — ​ (1,970,000) ​ (1,970,000) Interest expense ​ — ​ — ​ 67,936 ​ 67,936 Income tax expense ​ — ​ (2,345) ​ — ​ (2,345) Net income (loss) ​ $ (1,665,419) ​ $ (561,928) ​ $ 530,449 ​ $ (1,696,898) ​ The Company’s results of operations by reportable segment for the three months ended September 30, 2020 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the three months ended September 30, 2020 ​ Medications Devices Corporate Consolidated Net sales ​ $ 2,590,151 ​ $ 874,544 ​ $ — ​ $ 3,464,695 Cost of goods sold ​ 749,575 ​ 232,328 ​ — ​ 981,903 Selling, general and administrative expenses ​ 1,837,864 ​ 566,666 ​ 716,493 ​ 3,121,023 Research and development expense ​ 36,828 ​ — ​ — ​ 36,828 Depreciation and amortization expense ​ 1,353,591 ​ 307,771 ​ — ​ 1,661,362 Interest expense ​ — ​ — ​ 970,085 ​ 970,085 Income tax benefit ​ — ​ 6,143 ​ — ​ 6,143 Net loss ​ $ (1,387,707) ​ $ (226,078) ​ $ (1,686,578) ​ $ (3,300,363) ​ The Company’s results of operations by reportable segment for the nine months ended September 30, 2021 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the nine months ended September 30, 2021 ​ Medications ​ Devices ​ Corporate ​ Consolidated Net sales ​ $ 6,227,753 ​ $ 2,450,671 ​ $ — ​ $ 8,678,424 Cost of goods sold ​ 607,582 ​ 748,256 ​ — ​ 1,355,838 Selling, general and administrative expenses ​ 4,985,603 ​ 2,014,424 ​ 4,411,086 ​ 11,411,113 Research and development expenses ​ 799,803 ​ — ​ — ​ 799,803 Depreciation and amortization expense ​ 4,194,809 ​ 991,677 ​ — ​ 5,186,486 Change in fair value of derivative liability ​ — ​ — ​ (9,640,000) ​ (9,640,000) Interest expense ​ — ​ — ​ 356,873 ​ 356,873 Income tax expense ​ — ​ (9,045) ​ — ​ (9,045) Net income (loss) ​ $ (4,360,044) ​ $ (1,312,731) ​ $ 4,872,041 ​ $ (800,734) ​ The Company’s results of operations by reportable segment for the nine months ended September 30, 2020 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the nine months ended September 30, 2020 ​ Medications ​ Devices ​ Corporate ​ Consolidated Net sales ​ $ 4,128,694 ​ $ 2,501,486 ​ $ — ​ $ 6,630,180 Cost of goods sold ​ 1,527,169 ​ 778,000 ​ — ​ 2,305,169 Selling, general and administrative expenses ​ 6,658,231 ​ 1,780,530 ​ 3,558,424 ​ 11,997,185 Research and development expense ​ 307,796 ​ — ​ — ​ 307,796 Depreciation and amortization expense ​ 4,060,772 ​ 923,312 ​ — ​ 4,984,084 Interest expense ​ — ​ — ​ 2,233,794 ​ 2,233,794 Income tax benefit ​ — ​ 49,895 ​ — ​ 49,895 Net loss ​ $ (8,425,274) ​ $ (930,461) ​ $ (5,792,218) ​ $ (15,147,953)	The Company’s results of operations by reportable segment for the year ended December 31, 2020 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the year ended December 31, 2020 ​ Medications ​ Devices ​ Corporate ​ Consolidated Net sales ​ $ 6,357,498 ​ $ 3,201,971 ​ $ — ​ $ 9,559,469 Cost of goods sold ​ 3,083,417 ​ 963,049 ​ — ​ 4,046,466 Selling, general and administrative expenses ​ 8,784,716 ​ 2,024,448 ​ 4,865,804 ​ 15,674,968 Research and development expenses ​ 459,636 ​ — ​ — ​ 459,636 Depreciation and amortization expense ​ 5,424,292 ​ 1,236,146 ​ — ​ 6,660,438 Change in fair value of derivative liability ​ 1,680,000 ​ — ​ — ​ 1,680,000 Interest expense ​ — ​ — ​ 3,050,879 ​ 3,050,879 Income tax benefit ​ — ​ 1,426,993 ​ — ​ 1,426,993 Net loss ​ $ (13,074,563) ​ $ 405,321 ​ $ (7,916,683) ​ $ (20,585,925) ​ The Company’s results of operations by reportable segment for the year ended December 31, 2019 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the Year Ended December 31, 2019 ​ Medications Devices Corporate Consolidated Net sales ​ $ 11,110,660 ​ $ 4,466,506 ​ $ — ​ $ 15,577,166 Cost of goods sold ​ 6,057,977 ​ 1,369,134 ​ — ​ 7,427,111 Selling, general and administrative expenses ​ 13,873,200 ​ 2,735,390 ​ 3,118,633 ​ 19,727,223 Depreciation and amortization expense ​ 4,145,833 ​ 1,145,274 ​ — ​ 5,291,107 Impairment loss ​ 2,443,930 ​ — ​ ​ ​ 2,443,930 Interest expense ​ — ​ — ​ 13,844,961 ​ 13,844,961 Income tax expense ​ — ​ 645,866 ​ — ​ 645,866 Net loss ​ $ (15,410,280) ​ $ (137,426) ​ $ (16,963,594) ​ $ (32,511,300)
Summary of net sales by geographic region	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended ​ For the Nine Months Ended ​ ​ September 30, ​ September 30, Net sales 2021 2020 2021 2020 United States ​ $ 1,861,222 ​ $ 3,125,572 ​ $ 7,754,534 ​ $ 5,780,165 International ​ 283,947 ​ 339,123 ​ ​ 923,890 ​ ​ 850,015 ​ ​ $ 2,145,169 ​ $ 3,464,695 ​ $ 8,678,424 ​ $ 6,630,180	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended ​ ​ December 31, Net sales 2020 2019 United States ​ $ 8,555,831 ​ $ 14,236,886 International ​ 1,003,638 ​ 1,340,280 ​ ​ $ 9,559,469 ​ $ 15,577,166
Summary of assets by reportable segment and reconciliation of segment assets to consolidated assets	The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of September 30, 2021, are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription ​ ​ ​ ​ ​ Medications Medical Devices Consolidated Intangible assets, net ​ $ 20,438,542 ​ $ 6,543,556 ​ $ 26,982,098 Total segment assets ​ $ 43,790,552 ​ $ 8,244,776 ​ $ 52,035,328 ​ The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of December 31, 2020, are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription ​ ​ ​ ​ ​ ​ ​ Medications Medical Devices Consolidated Intangible assets, net ​ $ 24,625,686 ​ $ 7,535,233 ​ $ 32,160,919 Total segment assets ​ $ 60,725,191 ​ $ 9,128,823 ​ $ 69,854,014	The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of December 31, 2020 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription ​ ​ ​ ​ ​ Medications Medical Devices Consolidated Intangible assets, net ​ $ 24,625,686 ​ $ 7,535,233 ​ $ 32,160,919 Total segment assets ​ $ 60,725,191 ​ $ 9,128,823 ​ $ 69,854,014 ​ The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of December 31, 2019 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription ​ ​ ​ ​ ​ ​ ​ Medications Medical Devices Consolidated Intangible assets, net ​ $ 30,039,758 ​ $ 8,771,379 ​ $ 38,811,137 Total segment assets ​ $ 47,455,382 ​ $ 10,910,911 ​ $ 58,366,293

Nature of Operations, Basis o_2

Nature of Operations, Basis of Presentation, and Liquidity (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 07, 2020
Nature of Operations, Basis of Presentation, and Liquidity [Line Items]
Cash in excess of certain limit, subject to adjustment as provided in the Merger Agreement			$ 20,000,000
Metuchen Securityholders
Nature of Operations, Basis of Presentation, and Liquidity [Line Items]
Percentage of equity securities held	51.00%	51.00%

Nature of Operations, Basis o_3

Nature of Operations, Basis of Presentation, and Liquidity - Additional information (Details) - USD ($)	Oct. 13, 2021	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Nature of Operations, Basis of Presentation, and Liquidity [Line Items]
Cash		$ 8,135,184	$ 17,139,694	$ 2,145,812
Negative working capital		20,100,000	16,000,000
Debt		1,740,752	7,175,029	13,742,970
Sustained cumulative losses attributable to common stockholders		$ (62,502,878)	$ (61,702,144)	$ (41,116,219)
Subsequent event
Nature of Operations, Basis of Presentation, and Liquidity [Line Items]
Number of shares issued	$ 3,323,616
Net proceeds	$ 5,500,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Reserves for product returns	$ 3,200,000	$ 7,100,000	$ 8,300,000
Revenue, Practical Expedient, Financing Component [true false]	true	true
Good will Roll Forward
Balance, December 31, 2018		$ 0	2,443,930
Impairment loss			(2,443,930)
Balance, December 31, 2019			0
Prescription Medication Sales
Disaggregation of Revenue [Line Items]
Reserves for sales deductions	$ 4,200,000	$ 8,600,000	$ 12,000,000
Medical Device Sales
Disaggregation of Revenue [Line Items]
Right to return and receive credit for product	90 days	90 days
Minimum | Prescription Medication Sales
Disaggregation of Revenue [Line Items]
Due period for invoice payments	30 days	30 days
Right to return and receive credit for product	6 months	6 months
Minimum | Medical Device Sales | Domestic customers
Disaggregation of Revenue [Line Items]
Due period for invoice payments	30 days	30 days
Maximum | Prescription Medication Sales
Disaggregation of Revenue [Line Items]
Due period for invoice payments	75 days	75 days
Right to return and receive credit for product	1 year	1 year
Maximum | Medical Device Sales | International Customers [Member]
Disaggregation of Revenue [Line Items]
Due period for invoice payments	90 days	90 days

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Additional information (Details)	12 Months Ended
	Dec. 31, 2020USD ($)segment	Dec. 31, 2019USD ($)	Sep. 30, 2021USD ($)	Dec. 30, 2020USD ($)
Fair Value of Financial Instruments
Fair value of the derivative liability	$ 9,900,000	$ 9,900,000	$ 300,000	$ 8,200,000
Income Taxes
Accrued interest or penalties	$ 0	0	$ 0
Number of operating segments | segment	2
Shipping costs	$ 0	0
Medical Device Sales
Income Taxes
Shipping costs	$ 108,870	130,242
Furniture and Fixtures [Member]
Income Taxes
Estimated useful life (in years)	7 years
Depreciation expense	$ 10,220	$ 1,703

Accounts Receivable, net (Detai

Accounts Receivable, net (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounts Receivable, net
Gross accounts receivables	$ 2,929,064	$ 6,560,291	$ 4,989,260
Distribution service fees	(537,363)	(972,652)	(2,061,481)
Chargebacks accrual		(121,269)	(60,507)
Cash discount allowances	(135,527)	(84,601)	(235,867)
Allowance for doubtful accounts	(303,753)	(228,800)	(26,275)
Total accounts receivable, net	$ 1,952,421	$ 5,152,969	$ 2,605,130

Accounts Receivable, net - Addi

Accounts Receivable, net - Additional information (Details) - customer	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Gross sales from customers | One customers
Concentration Risk [Line Items]
Number of customers			1	1
Gross sales from customers | Customer concentration risk | One customers
Concentration Risk [Line Items]
Concentration risk percentage		80.00%	85.00%	86.00%
Number of customers		1
Gross sales from customers | Customer concentration risk | Four customers
Concentration Risk [Line Items]
Concentration risk percentage	78.00%
Number of customers	4
Receivables from customers | One customers
Concentration Risk [Line Items]
Number of customers			1	1
Receivables from customers | Customer concentration risk | One customers
Concentration Risk [Line Items]
Concentration risk percentage			93.00%	88.00%
Receivables from customers | Credit concentration risk | Two customers
Concentration Risk [Line Items]
Concentration risk percentage	70.00%		93.00%
Number of customers	2		2

Inventories (Details)

Inventories (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Inventories
Raw materials	$ 328,558	$ 325,932	$ 798,161
Finished goods	189,923	434,598	1,406,267
Total inventory	$ 518,481	$ 760,530	$ 2,204,428

Inventories - Additional Inform

Inventories - Additional Information (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Inventories
Finished goods are net of valuation reserves	$ 435,927	$ 935,866	$ 220,254
Raw materials are net of valuation reserves	$ 2,872,977	$ 2,872,977

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Prepaid Expenses and Other Current Assets
Prepaid samples		$ 58,483	$ 391,024
Prepaid insurance	$ 172,205	149,452	287,844
Prepaid FDA fees		756,972	732,204
Prepaid coupon fees	71,500	71,500	71,500
Rebated Receivable, Current			1,243,120
API purchase commitment asset (see Note 14)	1,304,541	1,304,541	1,409,592
Other prepaid expenses	587,319	391,552	468,226
Other current assets	612,673	114,784	526,310
Total prepaid expenses and other current assets	$ 2,748,238	$ 2,847,284	$ 5,129,820

Prepaid Expenses and Other Cu_4

Prepaid Expenses and Other Current Assets - Additional Information (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Prepaid Expenses and Other Current Assets
prepaid samples reserve amount	$ 379,612	$ 351,224	$ 145,474

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Finite-lived Intangible Assets [Roll Forward]
Amortization expense	$ (5,178,821)	$ (6,650,218)	$ (5,289,405)

Intangible Assets - Future annu

Intangible Assets - Future annual amortization (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Intangible Assets
2021	$ 6,191,740	$ 6,867,771
2022	5,445,729	6,191,740
2023	4,650,787	5,445,729
2024		4,650,787
Thereafter		9,004,892
Total	$ 26,982,098	$ 32,160,919	$ 38,811,137	$ 44,100,542

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Carrying value of intangible assets	$ 26,982,098	$ 32,160,919	$ 38,811,137	$ 44,100,542
Stendra Product
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives of intangible assets	10 years	10 years
Carrying value of intangible assets	$ 20,400,000	$ 24,600,000	30,000,000
Timm Medical product
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives of intangible assets	12 years	12 years
Carrying value of intangible assets	$ 5,100,000	$ 5,900,000	6,900,000
PTV product
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives of intangible assets	12 years	12 years
Carrying value of intangible assets	$ 1,400,000	$ 1,600,000	$ 1,900,000

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Accrued Expenses
Accrued price protection	$ 1,853,979	$ 1,853,979	$ 1,847,639
Accrued product returns	5,590,248	9,452,248	10,707,807
Accrued contract rebates	341,715	412,046	1,368,279
Due to Vivus (see Note 14)	2,267,523	2,267,523	2,259,769
Due to third-party logistic provider			4,388,600
Accrued severance	25,417	519,609
Accrued professional fees	31,463
Accrued marketing	1,258,255
Other accrued expenses	225,514	178,381	315,168
Total accrued expenses	$ 11,594,114	$ 14,683,786	$ 20,887,262

Debt - Senior indebtedness (Det

Debt - Senior indebtedness (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Debt
Principal balance	$ 1,740,752	$ 6,653,292	$ 11,688,979
Plus: Paid-In-Kind interest			1,101,575
Plus: End of term fee		534,237	952,416
Less: Debt issuance costs		(12,500)
Total senior debt	$ 1,740,752	$ 7,175,029	$ 13,742,970

Debt - Senior debt (Details)

Debt - Senior debt (Details)	Apr. 13, 2020	Mar. 31, 2020	Nov. 22, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2016USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Debt Instrument [Line Items]
End of term charge						$ 534,237	$ 952,416
Senior debt
Debt Instrument [Line Items]
Face amount of debt			$ 1,068,750	$ 35,000,000	$ 35,000,000
Stated interest rate	11.50%	10.75%
Paid-In-Kind ("PIK") interest rate				1.35%	10.75%
End of term charge			1,068,750	$ 787,500	$ 787,500
Amount of principal prepaid			$ 10,000,000
Percentage added to variable rate	11.50%	10.75%
Senior debt | Minimum
Debt Instrument [Line Items]
Fixed charge coverage ratio			0.9
Senior debt | Maximum
Debt Instrument [Line Items]
Fixed charge coverage ratio			1
Senior debt | Prime rate
Debt Instrument [Line Items]
Spread on variable rate	4.25%	4.50%
Stated interest rate				7.25%	7.25%
Percentage added to variable rate				7.25%	7.25%
Debt Instrument, Basis Spread on Variable Rate	4.25%	4.50%

Debt - Financial covenant (Deta

Debt - Financial covenant (Details) - USD ($)	Feb. 01, 2021	Oct. 01, 2020	Apr. 13, 2020	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Nov. 22, 2017	Sep. 30, 2016
Debt Instrument [Line Items]
End of term charge					$ 534,237	$ 952,416
Senior debt
Debt Instrument [Line Items]
Stated interest rate			11.50%	10.75%
End of term fee paid	$ 534,375	$ 534,375
End of term charge							$ 1,068,750	$ 787,500
Senior debt | Prime rate
Debt Instrument [Line Items]
Stated interest rate								7.25%
Spread on variable rate			4.25%	4.50%

Debt - Third Amendment (Details

Debt - Third Amendment (Details) - USD ($)	Nov. 03, 2021	Sep. 30, 2020	Nov. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Repayment of senior debt	$ 1,179,651		$ 1,200,000	$ 4,912,541	$ 4,639,674	$ 6,181,711	$ 6,013,257
Senior debt
Debt Instrument [Line Items]
Required cash proceeds through an equity or debt financing or other transaction		$ 25,000,000
Escrow fund		$ 1,500,000			$ 1,500,000

Debt - Interest Expenses (Detai

Debt - Interest Expenses (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Interest expense for term loan	$ 67,936	$ 287,855	$ 344,373	$ 1,015,898	$ 1,241,475	$ 2,216,341
Amortization of debt issuance costs		12,500	12,500	25,000	37,500
PIK interest				44,449	44,449	211,923
Interest expense, senior debt	67,936	$ 300,355	356,873	$ 1,085,347	1,323,424	2,428,264
Accrued and unpaid interest	$ 16,681		$ 16,681		$ 65,885	132,006
Senior debt
Debt Instrument [Line Items]
PIK interest						$ 6,747,313

Debt - Subordinated Related Par

Debt - Subordinated Related Party Term Loans (Details) - USD ($)	Oct. 01, 2020	Aug. 31, 2020	Jul. 31, 2020	Apr. 22, 2020	Apr. 01, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Outstanding principal balance of the subordinated promissory note and accrued PIK interest						$ 0		$ 0		$ 0
Interest expense							$ 669,730		$ 1,148,447	1,727,455	$ 11,416,697
Interest expense						$ 67,936	$ 970,085	$ 356,873	2,233,794	3,050,879	13,844,961
PIK interest									$ 44,449	44,449	211,923
First Subordinated Promissory Note
Related Party Transaction [Line Items]
Principal amount of notes payable										$ 15,500,000	3,000,000
Paid-In-Kind ("PIK") interest rate										20.00%
Outstanding principal balance of the subordinated promissory note and accrued PIK interest										$ 0
Second Subordinated Promissory Note
Related Party Transaction [Line Items]
Principal amount of notes payable					$ 3,000,000
Paid-In-Kind ("PIK") interest rate					20.00%
Third Subordinated Promissory Note
Related Party Transaction [Line Items]
Principal amount of notes payable				$ 4,000,000
Paid-In-Kind ("PIK") interest rate				20.00%
Fourth Subordinated Promissory Note
Related Party Transaction [Line Items]
Principal amount of notes payable			$ 2,500,000
Paid-In-Kind ("PIK") interest rate			20.00%
Fifth Subordinated Promissory Note
Related Party Transaction [Line Items]
Principal amount of notes payable		$ 1,500,000
Paid-In-Kind ("PIK") interest rate		20.00%
Sixth Subordinated Promissory Note
Related Party Transaction [Line Items]
Principal amount of notes payable	$ 1,500,000
Paid-In-Kind ("PIK") interest rate	20.00%
Interest expense											$ 11,416,697

Debt - Subordinated Related P_2

Debt - Subordinated Related Party Term Loans Prior to 2020 (Details)	Sep. 16, 2019USD ($)item	Dec. 10, 2018USD ($)	Nov. 22, 2017USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Debt Instrument [Line Items]
Sub Debt principal balance				$ 1,740,752		$ 1,740,752		$ 6,653,292	$ 11,688,979
Add: PIK Interest									1,101,575
Interest expense on the Senior Debt				$ 67,936	$ 970,085	$ 356,873	$ 2,233,794	3,050,879	13,844,961
PIK interest							$ 44,449	$ 44,449	$ 211,923
Sub Debt
Debt Instrument [Line Items]
Principal ownership		$ 4,750,000	$ 30,579,496
Cash interest rate (in percent)			12.00%
Paid-In-Kind ("PIK") interest rate		25.00%	8.00%
Sub Debt | Common Units
Debt Instrument [Line Items]
Total fair value of Preferred and Common Units exchanged | item	2,434,551.28
Sub Debt | Preferred Units
Debt Instrument [Line Items]
Total fair value of Preferred and Common Units exchanged | item	1,373,820.51
Sub Debt | LMA
Debt Instrument [Line Items]
Percentage of amount due			20.90%
Sub Debt | KFE
Debt Instrument [Line Items]
Percentage of amount due			20.10%
Sub Debt | JCP
Debt Instrument [Line Items]
Percentage of amount due			59.00%
Metuchen Therapeutics, LLC
Debt Instrument [Line Items]
Fair value	$ 46,617,232
Sub Debt principal balance	33,250,000
Add: PIK Interest	16,544,318
Less: Debt Discount	10,486,536
Total carrying value of Sub Debt exchanged	39,307,782
Excess of fair value of Preferred and Common Units exchanged over the carrying value of Sub Debt	(7,309,450)
Interest expense on the Senior Debt	$ 39,300,000
Fair value of Preferred and Common Units	46,600,000
PIK interest	$ 7,300,000
Metuchen Therapeutics, LLC | Common Units
Debt Instrument [Line Items]
Fair value	29,117,232
Metuchen Therapeutics, LLC | Preferred Units
Debt Instrument [Line Items]
Fair value	$ 17,500,000
JCP III CI AIV, L.P | Metuchen Therapeutics, LLC
Debt Instrument [Line Items]
Ownership interest taken		55.00%
Fair value		$ 22,250,746
Debt discount		$ 15,506,463

Members' Capital (Details)

Members' Capital (Details) - USD ($)	Sep. 16, 2019	Aug. 26, 2019	Nov. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Limited Partners' Capital Account [Line Items]
Number of common units issued						3,434,551
Stock issue and sell						$ 46,617,232
Number of preferred units issued						1,619,754
Proceeds from the exercise of warrants					$ 20,551
Lead Investor Warrants
Limited Partners' Capital Account [Line Items]
Preferred unit, per share					$ 12.7382
Purchase an aggregate of shares			2,055,114.66	2,055,114.66
Preferred units , exercise price				$ 0.01
Proceeds from the exercise of warrants			$ 20,551
Percentage of public offering					125.00%
Placement Agent Warrants
Limited Partners' Capital Account [Line Items]
Warrant strike price					$ 12.7382
Risk-free rate					1.73%
Volatility					90.00%
Private Placement
Limited Partners' Capital Account [Line Items]
Dividend rate, percentage	5.00%
Preferred unit, per share	$ 15.92275
Beneficial conversion feature	$ 26,500
Proceeds received related to the issuance of the lead investor warrants	250,000
Private Placement | Lead Investor Warrants
Limited Partners' Capital Account [Line Items]
Proceeds received related to the issuance of the lead investor warrants	$ 223,500
Purchase an aggregate of shares	615,838.50
Preferred units , exercise price	$ 0.01
Estimated fair value of the lead investor warrants	$ 2,100,000
Proceeds from the exercise of warrants	250,000
Private Placement | Placement Agent Warrants
Limited Partners' Capital Account [Line Items]
Proceeds received related to the issuance of the lead investor warrants					$ 135,800
Purchase an aggregate of shares					10,500
Exercise price of warrants					$ 12.7382
Lead Investor | Private Placement
Limited Partners' Capital Account [Line Items]
Stock issue and sell	$ 3,500,000
Offering price	$ 12.7382
Number of preferred units issued	245,933
Received aggregate net proceeds	$ 2,700,000
Class A Common Units
Limited Partners' Capital Account [Line Items]
Number of common units authorized	100
Common Units
Limited Partners' Capital Account [Line Items]
Number of common units per class A unit		10,000
Class B Units
Limited Partners' Capital Account [Line Items]
Number of common units issued	0

Stockholders' Equity - Consumma

Stockholders' Equity - Consummation of the Mergers (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Common stock, par value	$ 0.0001	$ 0.0001
Preferred stock, par value	0.0001	0.0001
Common Stock | Metuchen
Class of Stock [Line Items]
Common stock, par value	0.0001	0.0001
Exchange rate per share	$ 0.4968	$ 0.4968
Number of shares of Common Stock issued to the holders in exchange	4,949,610	4,949,610
Common Stock | Neurotrope
Class of Stock [Line Items]
Common stock, par value	$ 0.0001	$ 0.0001
Number of shares issued for every share of old entity	1	1
Number of shares exchanged for every share of of new entity	5	5
Number of warrants issued for every warrants to purchase share of Common Stock of old entity	1	1
Number of warrants exchanged for every warrants to purchase share of Common Stock of new entity	5	5
Preferred Stock | Neurotrope
Class of Stock [Line Items]
Preferred stock, par value	$ 0.001	$ 0.001

Stockholders' Equity - Number o

Stockholders' Equity - Number of shares held (Details) - shares	Jan. 26, 2021	Sep. 30, 2021	Dec. 31, 2020
Neurotrope
Class of Stock [Line Items]
Ownership interest taken		51.00%	51.00%
Metuchen
Class of Stock [Line Items]
Number of shares held		4,949,610	4,949,610
Ownership interest taken		49.00%	49.00%
Common Stock
Class of Stock [Line Items]
Number of common stock issued upon conversion	60,606
Common Stock | Neurotrope
Class of Stock [Line Items]
Number of shares held		4,758,045	4,758,045
Preferred Stock
Class of Stock [Line Items]
Number of preferred stock converted	500
Preferred Stock | Neurotrope
Class of Stock [Line Items]
Number of shares held		500	500

Stockholders' Equity - Backstop

Stockholders' Equity - Backstop Agreement (Details) - Backstop Agreement - Juggernaut	9 Months Ended	12 Months Ended
	Sep. 30, 2021USD ($)D$ / shares	Dec. 31, 2020USD ($)D$ / shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Commitment Cap for working capital shortfall amount	$ 6,000,000	$ 6,000,000
Number of consecutive trading days for stock price trigger | D	10	10
Reduction in post-closing commitments (as a percent)	50.00%	50.00%
Post-closing commitments	$ 0	$ 0
Working Capital Shortfall Amount	$ 2,600,000	$ 2,600,000
Stock price equals or exceeds $2.175
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock price trigger | $ / shares	$ 2.175	$ 2.175
Stock price equals or exceeds $2.5375
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock price trigger | $ / shares	$ 2.5375	$ 2.5375

Stockholders' Equity - Continge

Stockholders' Equity - Contingent Consideration (Details) - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Stockholders' Equity
Common Stock potentially issuable upon the achievement of certain milestones	14,232,090	14,232,090
Milestones term for achievement of stock price and market capitalization	2 years	2 years

Stockholders' Equity - Mileston

Stockholders' Equity - Milestone Earnout Payments (Details) - Milestone Earnout Payments	9 Months Ended	12 Months Ended
	Sep. 30, 2021D$ / sharesshares	Dec. 31, 2020D$ / sharesshares
Maximum | Metuchen
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone earnout payments (in shares) | shares	4,000,000	4,000,000
Closing price any time prior to the one-year anniversary of the Closing
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of trading days for stock price trigger | D	20	20
Number of consecutive trading days for stock price trigger | D	30	30
Closing Price per share of $8.00
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock price trigger | $ / shares	$ 8	$ 8
Milestone earnout payments (in shares) | shares	1,000,000	1,000,000
Closing Price per share of $10.00
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock price trigger | $ / shares	$ 10	$ 10
Milestone earnout payments (in shares) | shares	1,000,000	1,000,000
Closing Price per share of $13.00
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock price trigger | $ / shares	$ 13	$ 13
Milestone earnout payments (in shares) | shares	1,000,000	1,000,000
Closing Price per share of $15.00
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock price trigger | $ / shares	$ 15	$ 15
Milestone earnout payments (in shares) | shares	1,000,000	1,000,000
Closing price any time within the twelve month period following the one-year anniversary of the Closing
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of trading days for stock price trigger | D	20	20
Number of consecutive trading days for stock price trigger | D	30	30
Closing Price Per share of $10.00
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock price trigger | $ / shares	$ 10	$ 10
Closing Price per share of $12.50
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock price trigger | $ / shares	$ 12.50	$ 12.50
Milestone earnout payments (in shares) | shares	1,000,000	1,000,000
Closing Price per share of $16.25
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock price trigger | $ / shares	$ 16.25	$ 16.25
Milestone earnout payments (in shares) | shares	1,000,000	1,000,000
Closing Price per share of $18.75
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock price trigger | $ / shares	$ 18.75	$ 18.75
Milestone earnout payments (in shares) | shares	1,000,000	1,000,000

Stockholders' Equity - Market C

Stockholders' Equity - Market Capitalization (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2021USD ($)D$ / sharesshares	Dec. 31, 2020USD ($)D$ / sharesshares	Dec. 30, 2020USD ($)	Dec. 31, 2019USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Fair value of the derivative liability	$ 300,000	$ 9,900,000	$ 8,200,000	$ 9,900,000
Market Capitalization/Gross Proceeds Earnout Payments | Metuchen
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone earnout payments (in shares) | shares	300,000	9,900,000
Market Capitalization/Gross Proceeds Earnout Payments | Maximum | Metuchen
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone earnout payments (in shares) | shares	10,232,090	10,232,090
Market Capitalization/Gross Proceeds Earnout Payments | Market Capitalization is greater than or equal to $250,000,000 | Metuchen
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone earnout payments (in shares) | shares	2,000,000	2,000,000
Market Capitalization	$ 250,000,000	$ 250,000,000
Number of trading days for stock price trigger | D	20	20
Number of consecutive trading days for stock price trigger | D	30	30
Stock price | $ / shares	$ 17.50	$ 17.50
Aggregate gross proceeds	$ 25,000,000	$ 25,000,000
Term to receive gross proceeds	60 days	60 days
Market Capitalization/Gross Proceeds Earnout Payments | Market Capitalization is greater than or equal to $300,000,000 | Metuchen
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone earnout payments (in shares) | shares	2,000,000	2,000,000
Market Capitalization	$ 300,000,000	$ 300,000,000
Number of trading days for stock price trigger | D	20	20
Number of consecutive trading days for stock price trigger | D	30	30
Stock price | $ / shares	$ 18.75	$ 18.75
Aggregate gross proceeds	$ 30,000,000	$ 30,000,000
Term to receive gross proceeds	60 days	60 days
Market Capitalization/Gross Proceeds Earnout Payments | Market Capitalization is greater than or equal to $400,000,000 | Metuchen
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone earnout payments (in shares) | shares	3,000,000	3,000,000
Market Capitalization	$ 400,000,000	$ 400,000,000
Number of trading days for stock price trigger | D	20	20
Number of consecutive trading days for stock price trigger | D	30	30
Stock price | $ / shares	$ 22.50	$ 22.50
Aggregate gross proceeds	$ 40,000,000	$ 40,000,000
Term to receive gross proceeds	60 days	60 days
Market Capitalization/Gross Proceeds Earnout Payments | Market Capitalization is greater than or equal to $500,000,000 | Metuchen
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone earnout payments (in shares) | shares	3,232,090	3,232,090
Market Capitalization	$ 500,000,000	$ 500,000,000
Number of trading days for stock price trigger | D	20	20
Number of consecutive trading days for stock price trigger | D	30	30
Stock price | $ / shares	$ 23.75	$ 23.75
Aggregate gross proceeds	$ 50,000,000	$ 50,000,000
Term to receive gross proceeds	60 days	60 days

Stock Options (Details)

Stock Options (Details) - shares	Sep. 30, 2021	Dec. 31, 2020
Stock Options
Number of shares authorized	1,213,301	1,078,346
Number of shares available for issuance	0	504,015

Stock Options - Summary of stoc

Stock Options - Summary of stock options (Details) - $ / shares	May 11, 2021	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Number of Shares
Options outstanding and exercisable on beginning		574,331	574,331
Options granted	150,000	638,970
Options and RSU's outstanding at the end		1,213,301	574,331	574,331
Options and RSU's exercisable at the end		852,166	574,331
Weighted-Average Exercise Price
Options outstanding and exercisable at the beginning (in dollars per share)		$ 51.43	$ 51.43
Options granted (in dollars per share)	$ 3.21	3.37
Options outstanding at the end (in dollars per share)		26.57	51.43	$ 51.43
Options exercisable at the end (in dollars per share)		$ 35.77	$ 51.43
Weighted-Average Remaining Contractual Term (Years) and Aggregate Intrinsic Value
Options outstanding and exercisable at the beginning (in years)		5 years 29 days	10 months 24 days	10 months 24 days
Options granted (in years)		9 years 2 months 4 days	0 years
Options outstanding at the end (in years)		5 years 29 days	10 months 24 days	10 months 24 days
Options exercisable at the end (in years)		3 years 3 months 25 days	10 months 24 days

Stock Options - Term of exercis

Stock Options - Term of exercise stock options (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Neurotrope
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term for exercise the stock options	1 year	1 year

Stock Options - Fady Boctor, th

Stock Options - Fady Boctor, the President and Chief Commercial Officer (Details) - $ / shares	May 11, 2021	Feb. 19, 2021	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted	150,000		638,970
Exercise price	$ 3.21		$ 3.37
Vesting percentage	30.00%
Fady Boctor, the President and Chief Commercial Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted		215,669
Exercise price		$ 3.74
Vesting percentage		50.00%

Common Stock Warrants - Summary

Common Stock Warrants - Summary of warrants (Details) - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Common Stock Warrants
Warrants outstanding at December 31, 2020	4,407,962	4,407,962
Warrants issued	0	0
Warrants exercised	0	0
Warrants outstanding at September 30, 2021	4,407,962	4,407,962

Common Stock Warrants - Company

Common Stock Warrants - Company's warrants by expiration date (Details) - $ / shares	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Number of Warrants	4,407,962	4,407,962	4,407,962
Expiration Date of November 17, 2021, One
Class of Warrant or Right [Line Items]
Number of Warrants	76,569	76,569
Exercise Price	$ 32	$ 32
Expiration Date of November 17, 2021, Two
Class of Warrant or Right [Line Items]
Number of Warrants	131,344	131,344
Exercise Price	$ 64	$ 64
Expiration Date of August 23, 2023
Class of Warrant or Right [Line Items]
Number of Warrants	2,780	2,780
Exercise Price	$ 1.60	$ 1.60
Expiration Date of June 1, 2024
Class of Warrant or Right [Line Items]
Number of Warrants	18,000	18,000
Exercise Price	$ 35.65	$ 35.65
Expiration Date of June 5, 2024
Class of Warrant or Right [Line Items]
Number of Warrants	4,800	4,800
Exercise Price	$ 35.60	$ 35.60
Expiration Date of June 17, 2024
Class of Warrant or Right [Line Items]
Number of Warrants	74,864	74,864
Exercise Price	$ 21.85	$ 21.85
Expiration Date of June 19, 2024
Class of Warrant or Right [Line Items]
Number of Warrants	20,043	20,043
Exercise Price	$ 31.25	$ 31.25
Expiration Date of September 1, 2024
Class of Warrant or Right [Line Items]
Number of Warrants	22,800	22,800
Exercise Price	$ 26.55	$ 26.55
Expiration Date of September 16, 2024
Class of Warrant or Right [Line Items]
Number of Warrants	10,500	10,500
Exercise Price	$ 12.74	$ 12.7382
Expiration Date of December 1, 2024
Class of Warrant or Right [Line Items]
Number of Warrants	22,800	22,800
Exercise Price	$ 4.30	$ 4.30
Expiration Date of March 2, 2025
Class of Warrant or Right [Line Items]
Number of Warrants	28,000	28,000
Exercise Price	$ 5.65	$ 5.65
Expiration Date of June 1, 2025
Class of Warrant or Right [Line Items]
Number of Warrants	28,000	28,000
Exercise Price	$ 7.30	$ 7.30
Expiration Date of September 1, 2025
Class of Warrant or Right [Line Items]
Number of Warrants	28,000	28,000
Exercise Price	$ 5.50	$ 5.50
Expiration Date of December 1, 2025, One
Class of Warrant or Right [Line Items]
Number of Warrants	28,000	28,000
Exercise Price	$ 4.71	$ 4.71
Expiration Date of December 1, 2025, Two
Class of Warrant or Right [Line Items]
Number of Warrants	2,221,829	2,221,829
Exercise Price	$ 7.50	$ 7.50
Expiration Date of December 1, 2025, Three
Class of Warrant or Right [Line Items]
Number of Warrants	908,498	908,498
Exercise Price	$ 17.50	$ 17.50
Expiration Date of December 1, 2025, Four
Class of Warrant or Right [Line Items]
Number of Warrants	623,303	623,303
Exercise Price	$ 51.25	$ 51.25
Expiration Date of December 1, 2025, Five
Class of Warrant or Right [Line Items]
Number of Warrants	157,832	157,832
Exercise Price	$ 125	$ 125

Basic and Diluted Net Loss pe_3

Basic and Diluted Net Loss per Common Share - Summary of Computation of Basic and Diluted Net Loss per Share (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Numerator
Net loss	$ (1,696,898)	$ (3,300,363)	$ (800,734)	$ (15,147,953)	$ (20,585,925)	$ (32,511,300)
Weighted average common shares outstanding
Weighted-average common shares for basic net loss per share	9,826,599	3,434,551	9,794,267	3,434,551	5,340,682	2,460,026
Weighted-average common shares for dilutive net loss per share	9,826,599	3,434,551	9,794,267	3,434,551	5,340,682	2,460,026
Basic net loss per common share	$ (0.17)	$ (0.96)	$ (0.08)	$ (4.41)	$ (3.85)	$ (13.22)
Diluted net loss per common share	$ (0.17)	$ (0.96)	$ (0.08)	$ (4.41)	$ (3.85)	$ (13.22)

Basic and Diluted Net Loss pe_4

Basic and Diluted Net Loss per Common Share - Summary of Potentially Dilutive Securities Convertible Into Common Shares Excluded from Calculation of Net Loss Per Share (Details) - shares	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	5,621,263	21,139	5,621,263	21,139	4,982,293	127,396
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,405,182	21,139	4,405,182	21,139	4,407,962	127,396
Share-based Payment Arrangement, Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,213,301		1,213,301		574,331

Marketing, Licensing and Dist_2

Marketing, Licensing and Distribution Agreements - Vivus (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2021	Jul. 07, 2020
IEH Biopharma LLC | Vivus, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Ownership interest taken									100.00%
License Agreement | Royalty on the first $500 million of net sales
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Threshold net sales				$ 500,000,000		$ 500,000,000
License Agreement | Milestone payment to be paid once $250 million in sales has been reached
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Threshold net sales				250,000,000		250,000,000
Milestone payment		$ 6,000,000		6,000,000		6,000,000
License Agreement | Milestone payment to be paid after $250 million in sales has been reached
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Threshold net sales				250,000,000		250,000,000
Milestone payment		$ 3,200,000		$ 3,200,000		3,200,000
License Agreement | Vivus, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
One-time fee to purchase and receive the license for the commercialization and exploitation of Stendra	$ 70,000,000
Additional fee to purchase and receive the license for the commercialization and exploitation of Stendra	$ 800,000
Minimum purchase obligation						$ 4,100,000
Threshold period of written purchase orders to purchase Stendra				125 days		125 days
Minimum percentage of forecasted quantities for which entity is required to submit purchase orders		90.00%		90.00%		90.00%
Maximum forecasted quantity of strenda that can be supplied (as a percent)		120.00%		120.00%		120.00%
Accrued inventory purchases						$ 14,200,000	$ 9,300,000	$ 14,200,000
Reserve						800,000	1,200,000
Royalty incurred				$ 20,700,000
License Agreement | Vivus, Inc | Other Current Assets [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accrued inventory purchases, current						1,300,000	1,400,000	1,300,000
License Agreement | Vivus, Inc | Other Noncurrent Assets [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accrued inventory purchases, non-current						$ 11,100,000	6,700,000	$ 11,100,000
License Agreement | Vivus, Inc | Royalty during the first, second, and third years following the expiration of the Royalty Period
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage				2.00%		2.00%
License Agreement | Vivus, Inc | Royalty following the fourth and fifth years following the end of the Royalty Period
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage				1.00%		1.00%
License Agreement | MTPC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty incurred		$ 68,865	$ 129,508	$ 302,346	$ 206,435	$ 317,875	550,533
Royalty payables		$ 68,865		$ 68,865		$ 8,728
Royalty receivable							$ 309,147
License Agreement | MTPC | Royalty on the first $500 million of net sales
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage				5.00%		5.00%
License Agreement | MTPC | Royalty on net sales after $500 million
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage				6.00%		6.00%

Marketing, Licensing and Dist_3

Marketing, Licensing and Distribution Agreements - Hybrid (Details) - Hybrid - USD ($)	Oct. 31, 2021	Oct. 01, 2021	Mar. 31, 2021	Sep. 24, 2020	Dec. 31, 2020	Oct. 31, 2020	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2021	Dec. 01, 2021
Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage							3.00%
Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage							6.00%
Exclusive license to H100
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Initial license fee							$ 100,000
Additional payment due upon obtainment of orphan indication for H100							900,000
Annual payments due on first anniversary of the license agreement							125,000
Annual payments due on second anniversary of the license agreement							150,000
Annual payments due on third anniversary of the license agreement							200,000
Annual payments due after third anniversary of the license agreement							250,000
Payments upon first commercial sale and a sliding scale of percentage payments on net sales							$ 1,000,000
Threshold period of notice required to terminate agreement at any time after first anniversary							90 days
Extension payment of license agreement					$ 100,000	$ 50,000	$ 100,000	$ 100,000
Extension term of license agreement			6 months	6 months
One-time, non-creditable and non-refundable payment			$ 200,000
Threshold period for payments of one-time, non-creditable and non-refundable payment			7 days
Exclusive license to H100 | Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage							3.00%
Exclusive license to H100 | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage							6.00%
Amended license agreement of H100
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of License Fees	$ 200,000	$ 150,000
Agreed Additional Payments of License Fees									$ 200,000	$ 200,000

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Employee Lease Agreement
Commitments And Contingencies [Line Items]
Percentage of payments for costs associated with employment	75.00%	75.00%
Amount of fees paid under agreement	$ 200,000	$ 200,000
Employee Lease Agreement | Maximum | Dr. Charles Ryan
Commitments And Contingencies [Line Items]
Percentage Of Working Time Performing Services	75.00%	75.00%
Separation Agreement | Mr. Keith Lavan
Commitments And Contingencies [Line Items]
Stay-on bonus	$ 50,000	$ 50,000
Percentage of base salary to be paid as an advisor	50.00%	50.00%
Percentage of fees as an advisor paid	70.00%	70.00%
Percentage of fees as an advisor to be paid in equal installments	30.00%	30.00%

Commitments and Contingencies -

Commitments and Contingencies - Operating Leases (Details)	Sep. 30, 2021	Dec. 31, 2020
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease terms	2 years 10 months 24 days	3 years 8 months 12 days
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease terms	5 years 3 months 18 days	6 years

Commitments and Contingencies_3

Commitments and Contingencies - Lease expense (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Operating Lease Cost:
Fixed lease cost	$ 44,812	$ 44,812	$ 134,435	$ 179,246	$ 179,246	$ 88,002

Commitments and Contingencies_4

Commitments and Contingencies - Supplemental balance sheet (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Supplemental balance sheet information related to leases
Operating lease ROU asset: Other assets	$ 502,697	$ 579,535	$ 672,246
Operating lease ROU asset	Other assets	Other assets	Other assets
Operating lease liability:
Operating lease liability, current	$ 121,589	$ 108,971	$ 96,104
Other current liabilities	Other current liabilities	Other current liabilities	Other current liabilities
Operating lease liability, noncurrent	$ 437,749	$ 530,597	$ 639,568
Other long-term liabilities	Other long-term liabilities	Other long-term liabilities	Other long-term liabilities
Total operating lease liability	$ 559,338	$ 639,568	$ 735,672

Commitments and Contingencies_5

Commitments and Contingencies - Lease term and discount (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Commitments and Contingencies
Weighted-average remaining lease terms - operating leases	3 years 10 months 24 days		3 years 10 months 24 days		4 years 8 months 12 days	5 years 8 months 12 days
Weighted-average discount rate - operating leases	12.60%		12.60%		12.60%	12.60%
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 45,942	$ 45,660	$ 137,826	$ 136,979	$ 182,639	$ 92,068
Right-of-use assets obtained in exchange for lease obligations: Operating leases						$ 698,127

Commitments and Contingencies_6

Commitments and Contingencies - Minimum lease payments (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Future minimum lease payments under non-cancelable leases
2021	$ 187,739	$ 184,239
2022	189,374	187,739
2023	155,242	189,374
2024	81,107	155,242
Thereafter		163,432
Total lease payments	742,201	880,026
Less: Imputed Interest	(182,863)	(240,458)
Total operating lease liability	$ 559,338	$ 639,568	$ 735,672

Commitments and Contingencies_7

Commitments and Contingencies - Additional information (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Commitments and Contingencies
Operating leases that had not yet commenced	$ 0	$ 0

Income Taxes - Current and defe

Income Taxes - Current and deferred income tax expense (benefit) (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Current expense (benefit):
Federal					$ 5,085
State					88
Total current expense (benefit)					5,173
Deferred expense (benefit):
Federal					(1,378,731)	$ (165,483)
State					(53,435)	(480,383)
Total deferred expense (benefit)				$ (196,818)	(1,432,166)	(645,866)
Income Tax Expense (Benefit), Total	$ 2,345	$ (6,143)	$ 9,045	$ (49,895)	$ (1,426,993)	$ (645,866)

Income Taxes - Reconciliation (

Income Taxes - Reconciliation (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Reconciliation of the Company's statutory income tax rate to the Company's effective income tax rate
Income at US statutory rate	21.00%	21.00%
State taxes, net of federal benefit	1.56%	1.59%
Permanent differences	(2.68%)	(0.02%)
Recapitalization	36.49%	0.00%
Pass through income to members	(32.71%)	(21.13%)
Valuation allowance	(17.22%)	0.00%
Other	0.00%	0.51%
Effective income tax rate	6.44%	1.95%

Income Taxes - Deferred tax ass

Income Taxes - Deferred tax assets and liabilities (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Significant components of the Company's deferred tax assets and liabilities
Accruals	$ 90,222	$ 5,732
Intangible assets	(1,238,128)	(1,438,682)
Depreciation and amortization	5,661,235
Expenses no currently deductible	148,708
Net operating loss carryforwards	57,266	783
Interest expense limitation	25,547
Stock-based compensation	2,505,425
Valuation allowance	$ (7,250,275)
Total deferred tax liability		$ (1,432,167)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details)	12 Months Ended
	Dec. 31, 2020USD ($)
Income Taxes
Cumulative valuation allowance	$ 7,250,275
NOLs	$ 270,000
Percentage of future utilization of the NOLs	80.00%

Defined Contribution Plan (Deta

Defined Contribution Plan (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Defined Contribution Plan
Employer matching contribution	100.00%
Employer's contribution as a percentage of employee's gross pay	6.00%
Employer contributions	$ 116,364	$ 218,361

Segment Information (Details)

Segment Information (Details)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)segment	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)segment	Dec. 31, 2019USD ($)
Segment Reporting Information [Line Items]
Number of Operating Segments | segment					2
Results of operations by reportable segment
Net sales	$ 2,145,169	$ 3,464,695	$ 8,678,424	$ 6,630,180	$ 9,559,469	$ 15,577,166
Cost of goods sold	319,158	981,903	1,355,838	2,305,169	4,046,466	7,427,111
Selling, general and administrative expenses	3,413,223	3,121,023	11,411,113	11,997,185	15,674,968	19,727,223
Research and development expenses	280,576	36,828	799,803	307,796	459,636
Depreciation and amortization expense	1,728,829	1,661,362	5,186,486	4,984,084	6,660,438	5,291,107
Change in fair value of derivative liability	(1,970,000)		(9,640,000)		1,680,000
Impairment loss						2,443,930
Interest expense	67,936	970,085	356,873	2,233,794	3,050,879	13,844,961
Income tax expense	(2,345)	6,143	(9,045)	49,895	1,426,993	645,866
Net income (loss)	(1,696,898)	(3,300,363)	$ (800,734)	(15,147,953)	$ (20,585,925)	(32,511,300)
Operating segments
Segment Reporting Information [Line Items]
Number of Operating Segments | segment			2		2
Corporate
Results of operations by reportable segment
Selling, general and administrative expenses	1,371,615	716,493	$ 4,411,086	3,558,424	$ 4,865,804	3,118,633
Change in fair value of derivative liability	(1,970,000)		(9,640,000)
Interest expense	67,936	970,085	356,873	2,233,794	3,050,879	13,844,961
Net income (loss)	530,449	(1,686,578)	4,872,041	(5,792,218)	(7,916,683)	(16,963,594)
Prescription Medication Sales
Results of operations by reportable segment
Net sales	1,377,291	2,590,151	6,227,753	4,128,694	6,357,498	11,110,660
Cost of goods sold	45,254	749,575	607,582	1,527,169	3,083,417	6,057,977
Selling, general and administrative expenses	1,318,610	1,837,864	4,985,603	6,658,231	8,784,716	13,873,200
Research and development expenses	280,576	36,828	799,803	307,796	459,636
Depreciation and amortization expense	1,398,270	1,353,591	4,194,809	4,060,772	5,424,292	4,145,833
Change in fair value of derivative liability					1,680,000
Impairment loss						2,443,930
Net income (loss)	(1,665,419)	(1,387,707)	(4,360,044)	(8,425,274)	(13,074,563)	(15,410,280)
Medical Device Sales
Results of operations by reportable segment
Net sales	767,878	874,544	2,450,671	2,501,486	3,201,971	4,466,506
Cost of goods sold	273,904	232,328	748,256	778,000	963,049	1,369,134
Selling, general and administrative expenses	722,998	566,666	2,014,424	1,780,530	2,024,448	2,735,390
Depreciation and amortization expense	330,559	307,771	991,677	923,312	1,236,146	1,145,274
Income tax expense	(2,345)	6,143	(9,045)	49,895	1,426,993	645,866
Net income (loss)	$ (561,928)	$ (226,078)	$ (1,312,731)	$ (930,461)	$ 405,321	$ (137,426)

Segment Information - Net Sales

Segment Information - Net Sales by Geographic region (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 2,145,169	$ 3,464,695	$ 8,678,424	$ 6,630,180	$ 9,559,469	$ 15,577,166
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	1,861,222	3,125,572	7,754,534	5,780,165	8,555,831	14,236,886
International
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 283,947	$ 339,123	$ 923,890	$ 850,015	$ 1,003,638	$ 1,340,280

Segment Information - Segment a

Segment Information - Segment assets (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting, Asset Reconciling Item [Line Items]
Intangible assets, net	$ 26,982,098	$ 32,160,919	$ 38,811,137
Total segment assets	52,035,328	69,854,014	58,366,293
Prescription Medication Sales
Segment Reporting, Asset Reconciling Item [Line Items]
Intangible assets, net	20,438,542	24,625,686	30,039,758
Total segment assets	43,790,552	60,725,191	47,455,382
Medical Device Sales
Segment Reporting, Asset Reconciling Item [Line Items]
Intangible assets, net	6,543,556	7,535,233	8,771,379
Total segment assets	$ 8,244,776	$ 9,128,823	$ 10,910,911

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash	$ 8,135,184	$ 17,139,694
Accounts receivable, net	1,952,421	5,152,969
Inventories	518,481	760,530
Deposits with related party		4,576
Prepaid expenses and other current assets	2,748,238	2,847,284
Total current assets	13,354,324	25,905,053
Fixed assets, net	51,952	64,250
Intangible assets, net	26,982,098	32,160,919
API purchase commitment	11,144,257	11,144,257
Other assets	502,697	579,535
Total assets	52,035,328	69,854,014
Current liabilities:
Current portion of senior debt, net	1,740,752	7,175,029
Accounts payable	5,312,344	5,609,556
Accrued expenses	11,594,114	14,683,786
Accrued inventory purchases	14,203,905	14,203,905
Other current liabilities	649,468	221,766
Total current liabilities	33,500,583	41,894,042
Derivative liability	250,000	9,890,000
Other long-term liabilities	437,749	600,920
Total liabilities	34,188,332	52,384,962
Stockholders' Equity:
Preferred stock (par value of $0.0001 per share, 50,000,000 shares authorized, 0 and 500 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively)
Common stock (par value of $0.0001 per share, 150,000,000 shares authorized, 9,826,599 and 9,707,655 shares issued and outstanding as of September 30, 2021, and December 31, 2020, respectively)	983	971
Additional paid-in capital	80,348,891	79,170,225
Accumulated deficit	(62,502,878)	(61,702,144)
Total Stockholders' Equity	17,846,996	17,469,052
Total Liabilities and Stockholders' Equity	$ 52,035,328	$ 69,854,014

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
CONDENSED CONSOLIDATED BALANCE SHEETS
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	500
Preferred stock, shares outstanding	0	500
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	9,826,599	9,707,655
Common stock, shares outstanding	9,826,599	9,707,655

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Net sales	$ 2,145,169	$ 3,464,695	$ 8,678,424	$ 6,630,180	$ 9,559,469	$ 15,577,166
Cost of goods sold	319,158	981,903	1,355,838	2,305,169	4,046,466	7,427,111
Gross profit	1,826,011	2,482,792	7,322,586	4,325,011	5,513,003	8,150,055
Operating expenses:
Selling, general and administrative	3,413,223	3,121,023	11,411,113	11,997,185	15,674,968	19,727,223
Research and development expense	280,576	36,828	799,803	307,796	459,636
Asset Impairment Charges						2,443,930
Depreciation and amortization expense	1,728,829	1,661,362	5,186,486	4,984,084	6,660,438	5,291,107
Total operating expenses	5,422,628	4,819,213	17,397,402	17,289,065	22,795,042	27,462,260
Loss from operations	(3,596,617)	(2,336,421)	(10,074,816)	(12,964,054)	(17,282,039)	(19,312,205)
Change in fair value of derivative liability	1,970,000		9,640,000		(1,680,000)
Interest expense, senior debt	(67,936)	(300,355)	(356,873)	(1,085,347)	(1,323,424)	(2,428,264)
Interest expense, subordinated related party term loans		(669,730)		(1,148,447)	(1,727,455)	(11,416,697)
Loss before income taxes	(1,694,553)	(3,306,506)	(791,689)	(15,197,848)	(22,012,918)	(33,157,166)
Income tax expense (benefit)	2,345	(6,143)	9,045	(49,895)	(1,426,993)	(645,866)
Net loss	$ (1,696,898)	$ (3,300,363)	$ (800,734)	$ (15,147,953)	$ (20,585,925)	$ (32,511,300)
Net loss per common share
Basic (in dollars per share)	$ (0.17)	$ (0.96)	$ (0.08)	$ (4.41)	$ (3.85)	$ (13.22)
Diluted (in dollars per share)	$ (0.17)	$ (0.96)	$ (0.08)	$ (4.41)	$ (3.85)	$ (13.22)
Weighted average common shares outstanding
Basic	9,826,599	3,434,551	9,794,267	3,434,551	5,340,682	2,460,026
Diluted	9,826,599	3,434,551	9,794,267	3,434,551	5,340,682	2,460,026

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY / MEMBERS' CAPITAL - USD ($)	Preferred Units	Common Units	Preferred Stock	Common Stock	Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2018						$ (1,681,269)	$ (1,681,268)
Conversion of Preferred Stock to Common Stock	$ 17,500,000	$ 29,117,232			$ (385,800)	(6,923,650)	39,307,782
Conversion of Preferred Stock to Common Stock (in shares)	1,373,821	2,434,551
Net income (loss)						(32,511,300)	(32,511,300)
Balance at Dec. 31, 2019	$ 20,018,205	$ 29,117,233				(41,116,219)	8,019,219
Balance (in shares) at Dec. 31, 2019	1,619,754	3,434,551
Net income (loss)						(15,147,953)	(15,147,953)
Balance at Sep. 30, 2020	$ 20,018,205	$ 29,117,233				(56,264,172)	(7,128,734)
Balance (in shares) at Sep. 30, 2020	1,619,754	3,434,551
Balance at Dec. 31, 2019	$ 20,018,205	$ 29,117,233				(41,116,219)	8,019,219
Balance (in shares) at Dec. 31, 2019	1,619,754	3,434,551
Conversion of Preferred Stock to Common Stock		$ 17,227,455					17,227,455
Conversion of Preferred Stock to Common Stock (in shares)		1,762,913
Net income (loss)						(20,585,925)	(20,585,925)
Balance at Dec. 31, 2020				$ 971	79,170,225	(61,702,144)	17,469,052
Balance (in shares) at Dec. 31, 2020			500	9,707,655
Balance at Jun. 30, 2020	$ 20,018,205	$ 29,117,233				(52,963,809)	(3,828,371)
Balance (in shares) at Jun. 30, 2020	1,619,754	3,434,551
Net income (loss)						(3,300,363)	(3,300,363)
Balance at Sep. 30, 2020	$ 20,018,205	$ 29,117,233				(56,264,172)	(7,128,734)
Balance (in shares) at Sep. 30, 2020	1,619,754	3,434,551
Balance at Dec. 31, 2020				$ 971	79,170,225	(61,702,144)	17,469,052
Balance (in shares) at Dec. 31, 2020			500	9,707,655
Conversion of Preferred Stock to Common Stock				$ 6	(6)
Conversion of Preferred Stock to Common Stock (in shares)			(500)	60,606
Non-employee stock-based compensation				$ 6	187,796		187,802
Non-employee stock-based compensation (in shares)				58,338
Stock-based Compensation Expense					990,876		990,876
Net income (loss)						(800,734)	(800,734)
Balance at Sep. 30, 2021				$ 983	80,348,891	(62,502,878)	17,846,996
Balance (in shares) at Sep. 30, 2021				9,826,599
Balance at Jun. 30, 2021				$ 983	80,295,724	(60,805,980)	19,490,727
Balance (in shares) at Jun. 30, 2021				9,826,599
Stock-based Compensation Expense					53,167		53,167
Net income (loss)						(1,696,898)	(1,696,898)
Balance at Sep. 30, 2021				$ 983	$ 80,348,891	$ (62,502,878)	$ 17,846,996
Balance (in shares) at Sep. 30, 2021				9,826,599

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (800,734)	$ (15,147,953)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5,186,486	4,984,084
Bad debt expense	74,953
Inventory and sample inventory reserve	(90,844)	447,761
Non-cash paid-in-kind interest		1,192,896
Amortization of deferred financing costs and debt discount	12,500	25,000
Accretion for end of term fee		116,196
Deferred tax benefit		(196,818)
Lease expense	76,838	68,538
Derivative liability	(9,640,000)
Deferred revenue	70,343
Employee stock-based compensation	990,876
Non-employee stock-based compensation	187,802
Changes in operating assets and liabilities:
Accounts receivable	3,125,595	(1,548,687)
Inventories	361,282	565,486
Deposits	4,576	2,326
Prepaid expenses and other current assets	75,289	847,593
Accounts payable	(297,212)	4,526,000
Accrued expenses	(3,089,672)	(6,464,247)
Accrued inventory purchases		(250,000)
Other current liabilities	357,361	167,794
Long-term liabilities	(163,171)	(118,399)
Net cash used in operating activities	(3,557,732)	(10,782,430)
Cash flows from investing activities:
Acquisition of fixed assets		(4,633)
Net cash used in investing activities		(4,633)
Cash flows from financing activities:
Payment of senior debt	(4,912,541)	(4,639,674)
Payment of portion of senior debt end of term fee	(534,237)
Proceeds from subordinated related party term loans		14,000,000
Debt issuance costs		(50,000)
Net cash (used in) provided by financing activities	(5,446,778)	9,310,326
Net decrease in cash	(9,004,510)	(1,476,737)
Cash, beginning of period	17,139,694	2,145,812
Cash, end of period	8,135,184	669,075
Supplemental cash flow information:
Cash paid for interest during the period	$ 393,577	953,171
Noncash Items:
Accrued Merger Transaction Costs		$ 521,395

Nature of Operations, Basis o_4

Nature of Operations, Basis of Presentation, and Liquidity	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Nature of Operations, Basis of Presentation, and Liquidity
Nature of Operations, Basis of Presentation, and Liquidity	1) Nature of Operations, Basis of Presentation, and Liquidity Nature of Operations Petros Pharmaceuticals, Inc. (“Petros” or the “Company”) was incorporated in Delaware on May 14, 2020 for the purpose of effecting the transactions contemplated by that certain Agreement and Plan of Merger, dated as of May 17, 2020 (the “Original Merger Agreement”), by and between Petros, Neurotrope, Inc., a Nevada corporation (“Neurotrope”), PM Merger Sub 1, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Petros (“Merger Sub 1”), PN Merger Sub 2, Inc., a Delaware corporation and a wholly-owned subsidiary of Petros (“Merger Sub 2”), and Metuchen Pharmaceuticals LLC, a Delaware limited liability company (“Metuchen”). On July 23, 2020, the parties to the Merger Agreement entered into the First Amendment to the Agreement and Plan of Merger and Reorganization (the “First Merger Agreement Amendment”) and on September 30, 2020, the parties to the Original Merger Agreement entered into the Second Amendment to the Agreement and Plan of Merger and Reorganization (the “Second Merger Agreement Amendment” and, together with the Original Merger Agreement and the First Merger Agreement Amendment, the “Merger Agreement”). The Merger Agreement provided for (1) the merger of Merger Sub 1, with and into Metuchen, with Metuchen surviving as a wholly owned subsidiary of Petros (the “Metuchen Merger”) and (2) the merger of Merger Sub 2 with and into Neurotrope, with Neurotrope surviving as a wholly owned subsidiary of Petros (the “Neurotrope Merger” and together with the Metuchen Merger, the “Mergers”). As a result of the Mergers, Metuchen and Neurotrope became wholly owned subsidiaries of Petros, and Petros became a publicly traded corporation on December 1, 2020. On December 7, 2020, Neurotrope completed the spin-off of certain assets, whereby (i) any cash in excess of $20,000,000, subject to adjustment as provided in the Merger Agreement, and all of the operating assets and liabilities of Neurotrope not retained by Neurotrope in connection with the Mergers were contributed to Synaptogenix, Inc. (formerly known as Neurotrope Bioscience, Inc. and a wholly owned subsidiary of Neurotrope prior to the spin-off), a Delaware corporation (“Synaptogenix”). The Mergers were accounted for as a reverse recapitalization in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Metuchen was determined to be the accounting acquirer based on an analysis of the criteria outlined in the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) No. 805, Business Combinations Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, considered necessary to present fairly our financial position, results of operations and cash flows. However, actual results could differ from those estimates. The condensed consolidated balance sheet at December 31, 2020, has been derived from audited financial statements as of that date. The unaudited interim condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the United States Securities and Exchange Commission. This Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements and notes previously distributed in our Annual Report on Form 10-K for the year ended December 31, 2020. Certain prior year amounts have been reclassified for consistency with current year presentation. These reclassifications had no effect on the reported results of operations. Principles of Consolidation The unaudited interim condensed consolidated financial statements include the accounts of TIMM Medical Technologies, Inc. (“Timm Medical”), and Pos-T-Vac, LLC (“PTV”), subsidiaries of Metuchen, as well as the accounts of Metuchen and Neurotrope, subsidiaries of Petros. All intercompany accounts and transactions are eliminated in consolidation. Liquidity The Company has experienced net losses and negative cash flows from operations since its inception. As of September 30, 2021, the Company had cash of $8.1 million, negative working capital of approximately $20.1 million, including debt of $1.7 million that matures in 2021, and sustained cumulative losses attributable to common stockholders of $62.5 million. Our plans include, or may include, utilizing our cash and cash equivalents on hand, and our liability due to Vivus as well as exploring additional ways to raise capital in addition to increasing cash flows from operations. In October 2021, the Company issued 3,323,616 shares of its common stock and received $5.5 million in net proceeds. In November 2021, the Company repaid $1.2 million in full satisfaction of its senior debt (See Note 8 Debt). While we are optimistic that we will be successful in our efforts to achieve our plan, there can be no assurances that we will be successful in doing so. As such, we obtained a continued support letter from our largest shareholder, JCP III SM AIV, L.P., (“the JCP Investor”) through November 16, 2022.	1) Nature of Operations, Basis of Presentation, and Liquidity Nature of Operations and Basis of Presentation Petros Pharmaceuticals, Inc. (“Petros” or the “Company”) was organized as a Delaware corporation on May 14, 2020 for the purpose of effecting the transactions contemplated by that certain Agreement and Plan of Merger, dated as of May 17, 2020 (the “Original Merger Agreement”), by and between Petros, Neurotrope, Inc., a Nevada corporation (“Neurotrope”), PM Merger Sub 1, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Petros (“Merger Sub 1”), PN Merger Sub 2, Inc., a Delaware corporation and a wholly-owned subsidiary of Petros (“Merger Sub 2”), and Metuchen Pharmaceuticals LLC, a Delaware limited liability company (“Metuchen”). On July 23, 2020, the parties to the Merger Agreement entered into the First Amendment to the Agreement and Plan of Merger and Reorganization (the “First Merger Agreement Amendment”) and on September 30, 2020, the parties to the Original Merger Agreement entered into the Second Amendment to the Agreement and Plan of Merger and Reorganization (the “Second Merger Agreement Amendment” and, together with the Original Merger Agreement and the First Merger Agreement Amendment, the “Merger Agreement”). The Merger Agreement provided for (1) the merger of Merger Sub 1, with and into Metuchen, with Metuchen surviving as a wholly-owned subsidiary of Petros (the “Metuchen Merger”) and (2) the merger of Merger Sub 2 with and into Neurotrope, with Neurotrope surviving as a wholly-owned subsidiary of Petros (the “Neurotrope Merger” and together with the Metuchen Merger, the “Mergers”). As a result of the Mergers, Metuchen and Neurotrope became wholly-owned subsidiaries of Petros, and Petros became a publicly traded corporation on December 1, 2020. On December 7, 2020, Neurotrope completed the spin-off of certain assets, whereby (i) any cash in excess of $20,000,000, subject to adjustment as provided in the Merger Agreement, and all of the operating assets and liabilities of Neurotrope not retained by Neurotrope in connection with the Mergers were contributed to Synaptogenix, Inc. (formerly known as Neurotrope Bioscience, Inc.), a Delaware corporation (“Synaptogenix”), and a wholly-owned subsidiary of Neurotrope. The Mergers were accounted for as a reverse recapitalization in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Metuchen was determined to be the accounting acquirer based on an analysis of the criteria outlined in the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) No. 805, Business Combinations All transactions between the consolidated entities have been eliminated in consolidation. Liquidity The Company has experienced net losses and negative cash flows from operations since its inception. As of December 31, 2020, we had cash and cash equivalents of $17.1 million, negative working capital of approximately $16.0 million, including debt of $7.2 million maturing in 2021, and sustained cumulative losses attributable to common stockholders of $61.7 million. Our plans include, or may include, utilizing our cash and cash equivalents on hand, negotiating an extension of our debt arrangement and our liability due to Vivus as well as exploring additional ways to raise capital in addition to increasing cash flows from operations. While we are optimistic that we will be successful in our efforts to achieve our plan, there can be no assurances that we will be successful in doing so. As such, we obtained a continued support letter from our largest shareholder, JCP III SM AIV, L.P., through May 17, 2022.

Summary of Significant Accoun_6

Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2) Summary of Significant Accounting Policies Use of Estimates The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and reported amounts of revenue and expenses during the reporting periods. Such estimates include the adequacy of accounts receivable reserves, return reserves, inventory reserves, and assessment of long-lived assets, including intangible asset impairment and the determination of the fair value of the derivative liability, among others. Actual results could differ from these estimates and changes in these estimates are recorded when known. Risks and Uncertainties The Company is subject to risks common to companies in the pharmaceutical industry including, but not limited to, uncertainties related to commercialization of competitor products, regulatory approvals, dependence on key products, dependence on key customers and suppliers, and protection of intellectual property rights. In January 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China ( “COVID-19”) and the risks to the international community. The WHO declared COVID-19 a global pandemic on March 11, 2020, and since that time many of the previously imposed restrictions and other measures which were instituted in response have been subsequently reduced or lifted. However, the COVID-19 pandemic remains highly unpredictable and dynamic, and its duration and extent continue to be dependent on various developments, such as the emergence of variants to the virus that may cause additional strains of COVID-19, the administration and ultimate effectiveness of vaccines, and the eventual timeline to achieve a sufficient level of herd immunity among the general population. Accordingly, the COVID-19 pandemic may continue to have negative effects on the health of the U.S. economy for the foreseeable future. The Company cannot reasonably estimate the length or severity of the impact that the COVID-19 pandemic will have on its financial results, and the Company may experience a material adverse impact on its sales, results of operations, and cash flows in fiscal 2021 and thereafter. During 2020, government regulations and the voluntary business practices of the Company and prescribing physicians had prevented in-person visits by sales representatives to physicians’ offices. The Company had taken steps to mitigate the negative impact on its businesses of such restrictions. In March 2020, the Company reduced its sales representative head count to reflect the lack of in-person visits. The Company had maintained a core sales team which continued to contact physicians via telephone and videoconference as well as continuing to have webinars provided by the Company’s key opinion leaders to other physicians and pharmacists. In response to the spread of COVID-19, in March 2020, the Company closed its administrative offices and as of September 30, 2021, they remain closed, with the Company’s employees continuing their work outside of the Company’s offices. The Company has selectively resumed in-person interactions by its customer-facing personnel in compliance with local and state restrictions. The Company also continues to engage with customers virtually as the Company seeks to continue to support healthcare professionals and patient care. However, the Company’s ability to engage in personal interactions with physicians and customers remains limited, and it is unknown when the Company’s offices will reopen, and these interactions will be fully resumed. Revenue Recognition Prescription Medication Sales The Company’s prescription medication sales consist of sales of Stendra® in the U.S. for the treatment of male erectile dysfunction. Under ASC Topic 606, Revenue Recognition In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers Stendra® to when the customers pay for the product is typically less than one year. The Company records prescription medication sales net of any variable consideration, including but not limited to discounts, rebates, returns, chargebacks, and distribution fees. The Company uses the expected value method when estimating its variable consideration unless terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Stendra® are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes. As of September 30, 2021, and December 31, 2020, the reserves for sales deductions were $4.2 million and $8.6 million, respectively. The most significant sales deductions included in this reserve relate to returns, contract rebates, coupon redemptions and distribution service (“DSA”) fees. The Company’s estimates are based on factors such as its direct and indirect customers’ buying patterns and the estimated resulting contractual deduction rates, historical experience, specific known market events and estimated future trends, current contractual and statutory requirements, industry data, estimated customer inventory levels, current contract sales terms with its direct and indirect customers, and other competitive factors. Significant judgment and estimation are required in developing the foregoing and other relevant assumptions. The most significant sales deductions are further described below. Product Returns Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return Stendra® and receive credit for product within six months prior to expiration date and up to one year after expiration date. The provision for returns is based upon the Company’s estimates for future Stendra® returns and historical experience. The provision of returns is part of the variable consideration recorded at the time revenue is recognized. As of September 30, 2021, and December 31, 2020, the reserves for product returns were $3.2 million and $7.1 million, respectively, and are included as a component of accrued expenses. Contract Rebates, Coupon Redemptions and DSA Fees The Company establishes contracts with wholesalers, chain stores, and indirect customers that provide for rebates, sales incentives, DSA fees and other allowances. Some customers receive rebates upon attaining established sales volumes. Direct rebates are generally rebates paid to direct purchasing customers based on a percentage applied to a direct customer’s purchases from us, including fees paid to wholesalers under our DSAs, as described below. Indirect rebates are rebates paid to indirect customers that have purchased our products from a wholesaler under a contract with us. The Company has entered into DSAs with certain of our significant wholesaler customers that obligate the wholesalers, in exchange for fees paid by us, to: (i) manage the variability of their purchases and inventory levels within specified limits based on product demand and (ii) provide us with specific services, including the provision of periodic retail demand information and current inventory levels for our pharmaceutical products held at their warehouse locations. Medical Device Sales The Company’s medical device sales consist of domestic and international sales of men’s health products for the treatment of erectile dysfunction. The men’s health products do not require a prescription and include vacuum erection devices, VenoSeal, and other related accessories. Under Topic 606, the Company recognizes revenue from medical device sales when its performance obligations with its customers have been satisfied. In the contracts with its customers, the Company has identified a single performance obligation to provide medical devices upon receipt of a customer order. The performance obligation is satisfied at a point in time when the Company’s customers obtain control of the medical device, which is typically upon shipment. The Company invoices its customers after the medical devices have been shipped and invoice payments are generally due within 30 days of invoice date for domestic customers and 90 days for international customers. In determining the transaction price, a significant financing component Product Returns Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return medical devices and receive credit for products within 90 days of the sale. The provision for returns is based upon the Company’s estimates for future product returns and historical experience. The Company has not made significant changes to the judgments made in applying Topic 606. As of September 30, 2021, and December 31, 2020, the reserves for product returns for medical devices were not significant. Fair Value of Financial Instruments Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy: Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by an observable market. Level 3 — Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. Financial instruments recognized at historical amounts in the condensed consolidated balance sheets consist of cash, accounts receivable, other current assets, accounts payable, accrued expenses, other current liabilities, and senior debt. The Company believes that the carrying value of cash, accounts receivable, other current assets, accounts payable, accrued expenses, and other current liabilities approximates their fair values due to the short-term nature of these instruments. The carrying value of senior debt as of September 30, 2021, and December 31, 2020, approximated fair value. The fair value of the senior debt was estimated by discounting to present value the scheduled coupon payments and principal repayment, using an appropriate fair market yield and is considered Level 3 in the fair value hierarchy. In connection with the Mergers in December 2020, each security holder of Metuchen received an earnout consideration classified as a derivative liability to be paid in the form of Petros Common Stock. The Company estimated their fair value using a Monte Carlo Simulation approach. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative liability as of September 30, 2021, and December 31, 2020, was $0.3 million and $9.9 million, respectively. See Note 10 Stockholders’ Equity. Stock-Based Compensation The Company accounts for stock-based awards to employees and consultants in accordance with applicable accounting principles, which requires compensation expense related to stock-based transactions, including employee stock options and consultant warrants, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options or warrants. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. Employee stock option and consulting expenses are recognized over the employee’s or consultant’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the volatility and expected term. Any changes in these highly subjective assumptions can significantly impact stock-based compensation expense. See Note 11 Stock Options. Income Taxes Prior to the consummation of the Mergers, Metuchen was a limited liability company (“LLC”) for federal income tax purposes and had elected to be treated as a Partnership for federal and state income tax purposes. PTV is a disregarded entity for federal income tax purposes. As such, all income tax consequences resulting from the operations were reported on the member’s income tax return. In addition, Timm Medical was included in the Company’s structure where taxes were paid at the entity level. Subsequent to the Mergers, Metuchen’s activity is included in the Company’s consolidated group. The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period the rate change is enacted. The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions in accordance with FASB ASC No. 740 Income Taxes The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statement of operations. As of September 30, 2021, and December 31, 2020, no accrued interest or penalties are recorded in the condensed consolidated balance sheets. Basic and Diluted Net Loss per Common Share The Company computes basic net loss per common share by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period, excluding the dilutive effects of stock options and warrants to purchase common shares. The Company computes diluted net loss per common share by dividing the net loss applicable to common share by the sum of the weighted-average number of common shares outstanding during the period plus the potential dilutive effects of its convertible preferred stocks, stock options and warrants to purchase common shares, but such items are excluded if their effect is anti-dilutive. See Note 13 Basic and Diluted Net Loss per Common Share. Recent Accounting Pronouncements Pending Adoption as of September 30, 2021 In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Measurement of Credit Losses on Financial Instruments	2) Summary of Significant Accounting Policies Use of Estimates The preparation of Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the Consolidated Financial Statements, and reported amounts of revenue and expenses during the reporting periods. Such estimates include the adequacy of accounts receivable reserves, return reserves, inventory reserves, and assessment of long-lived assets, including intangible asset impairment, and the allocation of the purchase price in acquisitions. Actual results could differ from these estimates and changes in these estimates are recorded when known. Risks and Uncertainties The Company is subject to risks common to companies in the pharmaceutical industry including, but not limited to, uncertainties related to commercialization of competitor products, regulatory approvals, dependence on key products, dependence on key customers and suppliers, and protection of intellectual property rights. In January 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. As a result of the COVID-19 pandemic, which continues to rapidly evolve, “shelter in place” orders and other public health guidance measures were implemented across much of the United States, Europe and Asia, including in the locations of the Company’s offices, key vendors and partners. The pandemic has significantly impacted the economic conditions in the U.S. and globally as federal, state and local governments react to the public health crisis, creating significant uncertainties in the economy. At this time, the future trajectory of the COVID-19 outbreak remains uncertain, both in the United States and in other markets. While the Company anticipates that currently available vaccines will be widely distributed in the future, the timing and efficacy of such vaccines are uncertain. The Company cannot reasonably estimate the length or severity of the impact that the COVID-19 outbreak will have on its financial results, and the Company may experience a material adverse impact on its sales, results of operations, and cash flows in fiscal 2021. During 2020, government regulations and the voluntary business practices of the Company and prescribing physicians have prevented in-person visits by sales representatives to physicians’ offices. The Company has taken steps to mitigate the negative impact on its businesses of such restrictions. In March 2020, the Company reduced our sales representative head count to reflect the lack of in-person visits. The Company has maintained a core sales team which continues to contact physicians via telephone and videoconference as well as continuing to have webinars provided by the Company’s key opinion leaders to other physicians and pharmacists. The Company anticipates rehiring and/or assigning representatives to cover sales territories as states reopen and physician access resumes new normal levels. In response to the spread of SARS-CoV-2 and COVID-19, in March 2020, the Company closed its administrative offices and as of December 31, 2020, they remain closed, with the Company’s employees continuing their work outside of the Company’s offices. The Company has selectively resumed in-person interactions by its customer-facing personnel in compliance with local and state restrictions. The Company also continues to engage with customers virtually as the Company seeks to continue to support healthcare professionals and patient care. However, the Company’s ability to engage in personal interactions with physicians and customers remains limited, and it is unknown when the Company’s offices will reopen, and these interactions will be fully resumed. Concentration of Credit Risk Financial instruments that subject the Company to concentrations of credit risk includes cash. The Company maintains cash on deposit at U.S.-based banks in amounts which, at times, may be in excess of insured limits. Cash and Cash Equivalents The Company considers all highly-liquid investments that have maturities of three months or less when acquired to be cash equivalents. Segment Reporting Operating segments are components of a Company for which separate financial information is available and evaluated regularly by the chief operating decision maker in assessing performance and deciding how to allocate resources. The Company’s two segments, Prescription Medications and Medical Devices, focus on the treatment of male erectile dysfunction. The Prescription Medications segment consists primarily of operations related to Stendra®, which is sold generally in the United States, and H100™ for the treatment of Peyronie’s disease. The Medical Devices segment consists primarily of operations related to vacuum erection devices, which are sold domestically and internationally. See Note 18 Segment Reporting. Revenue Recognition Prescription Medication Sales The Company’s prescription medication sales consist of sales of Stendra® in the U.S. for the treatment of male erectile dysfunction. Under ASC Topic 606, Revenue Recognition In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers Stendra® to when the customers pay for the product is typically less than one year. The Company records prescription medication sales net of any variable consideration, including but not limited to discounts, rebates, returns, chargebacks, and distribution fees. The Company uses the expected value method when estimating its variable consideration, unless terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Stendra® are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes. As of December 31, 2020 and 2019, the reserves for sales deductions were $8.6 million and $12.0 million, respectively. The most significant sales deductions included in this reserve relate to returns, contract rebates, and distribution service (“DSA”) fees. Our estimates are based on factors such as our direct and indirect customers’ buying patterns and the estimated resulting contractual deduction rates, historical experience, specific known market events and estimated future trends, current contractual and statutory requirements, industry data, estimated customer inventory levels, current contract sales terms with our direct and indirect customers, and other competitive factors. Significant judgment and estimation is required in developing the foregoing and other relevant assumptions. The most significant sales deductions are further described below. Product Returns Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return Stendra® and receive credit for product within six months prior to expiration date and up to one year after expiration date. The provision for returns is based upon the Company’s estimates for future Stendra® returns and historical experience. The provision of returns is part of the variable consideration recorded at the time revenue is recognized. As of December 31, 2020 and 2019, the reserves for product returns were $7.1 million and $8.3 million, respectively, and are included as a component of accrued expenses. Contract Rebates, Coupon Redemptions and DSA Fees The Company establishes contracts with wholesalers, chain stores, and indirect customers that provide for rebates, sales incentives, DSA fees and other allowances. Some customers receive rebates upon attaining established sales volumes. Direct rebates are generally rebates paid to direct purchasing customers based on a percentage applied to a direct customer’s purchases from us, including fees paid to wholesalers under our DSAs, as described below. Indirect rebates are rebates paid to indirect customers that have purchased our products from a wholesaler under a contract with us. The Company has entered into DSAs with certain of our significant wholesaler customers that obligate the wholesalers, in exchange for fees paid by us, to: (i) manage the variability of their purchases and inventory levels within specified limits based on product demand and (ii) provide us with specific services, including the provision of periodic retail demand information and current inventory levels for our pharmaceutical products held at their warehouse locations. Medical Device Sales The Company’s medical device sales consist of domestic and international sales of men’s health products for the treatment of erectile dysfunction. The men’s health products do not require a prescription and include Vacuum Erection Devices, PreBoost, VenoSeal, penile injections (Rx), and urinary tract infection tests. Under Topic 606, the Company recognizes revenue from medical device sales when its performance obligations with its customers have been satisfied. In the contracts with its customers, the Company has identified a single performance obligation to provide medical devices upon receipt of a customer order. The performance obligation is satisfied at a point in time when the Company’s customers obtain control of the medical device, which is typically upon shipment. The Company invoices its customers after the medical devices have been shipped and invoice payments are generally due within 30 days of invoice date for domestic customers and 90 days for international customers. In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers the medical devices to when the customers pay for the product is typically less than one year. The Company records medical device sales net of any variable consideration, including but not limited to returns. The Company uses the expected value method when estimating its variable consideration. The identified variable consideration is recorded as a reduction of revenue at the time revenues from the medical device sales are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes. Product Returns Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return medical devices and receive credit for products within 90 days of the sale. The provision for returns is based upon the Company’s estimates for future product returns and historical experience. The Company has not made significant changes to the judgments made in applying Topic 606. As of December 31, 2020 and 2019, the reserves for product returns for medical devices were not significant. Contract Costs In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. As such, the Company did not have any contract assets at December 31, 2020 and 2019. Accounts Receivable, net The Company extends credit to its customers in the normal course of business. Accounts receivable are recorded at the invoiced amount, net of chargebacks, distribution service fees, and cash discounts. Management determines each allowance based on historical experience along with the present knowledge of potentially uncollectible accounts. See Note 3 Accounts, Receivable, net. Inventories Inventories consist of finished goods held for sale and raw materials. Inventories are stated at the lower of cost or net realizable value, with cost determined using the first-in, first-out method. Inventories are adjusted for excess and obsolescence. Evaluation of excess inventory includes such factors as expiry date, inventory turnover, and management’s assessment of current product demand. See Note 4 Inventories. Intangible Assets The Company accounts for recognized intangible assets at cost. Intangible assets with finite useful lives are amortized over the useful life that the assets are expected to contribute directly or indirectly to future cash flows. Intangible assets are amortized using an accelerated method based on the pattern in which the economic benefits of the assets are consumed. The Company review the carrying value and useful lives of its intangible assets with definite lives, or whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable or the period over which they should be amortized has changed. When indicators of impairment exist, the Company determines whether the estimated undiscounted sum of the future cash flows of such assets is less than their carrying amounts. If less, an impairment loss is recognized in the amount, if any, by which the carrying amount of such assets exceeds their respective fair values. The Company evaluates the remaining useful life of each intangible asset that is being amortized during each reporting period to determine whether events and circumstances warrant a revision to the remaining period of amortization. If the estimate of the intangible asset’s remaining useful life has changed, the remaining carrying amount of the intangible asset is amortized prospectively over that revised remaining useful life. Given the impact of the COVID-19 outbreak on the global economy, as well as its potential impact to the Company’s business operations and cash flows, the Company constituted the COVID-19 outbreak as a triggering event requiring an impairment test for its long-lived assets with finite useful lives. The Company’s projections included the undiscounted cash flows of the remaining estimated useful lives for the Stendra product through December 2028 and December 2030 for the medical device products. Based on the impairment assessment as of December 31, 2020, the Company determined that no intangible asset impairment occurred as the undiscounted cash flows exceeded the respective carrying values of the assets. The Company did not record any impairments of intangible assets for the years ended December 31, 2020 and 2019. Goodwill Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired in a business combination. The Company evaluates the carrying value of goodwill annually in December of each year in connection with the annual budgeting and forecast process and also between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit to which goodwill was allocated to below its carrying amount. Such circumstances could include, but are not limited to: (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. When evaluating goodwill for impairment, we may first perform an assessment qualitatively whether it is more likely than not that a reporting unit’s carrying amount exceeds its fair value, referred to as a “step zero” approach. Subsequently (if necessary after step zero), an entity should perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. This quantitative impairment test uses a combination of the income method and guideline public company comparable companies. The income method is based on a discounted future cash flow approach that uses significant assumptions of projected revenue, projected operational profit, terminal growth rates and the cost of capital. Under Topic 350, goodwill impairment is measured as the excess of the carrying amount of the reporting unit over its fair value. The Company incurred a goodwill impairment loss of $2,443,930 during the year ended December 31, 2019, related to the prescription medications segment. ​ ​ ​ ​ ​ Balance, December 31, 2018 $ 2,443,930 Impairment loss ​ (2,443,930) Balance, December 31, 2019 ​ $ — ​ Fixed Assets Fixed assets consist of furniture and fixtures. Furniture and fixtures are recorded at cost, less accumulated depreciation, and are depreciated on a straight-line basis over its estimated useful life. The Company uses an estimated useful life of 7 years for furniture and fixtures. Depreciation expense for the years ended December 31, 2020 and 2019 was $10,220 and $1,703, respectively. Leases The Company accounts for leases in accordance with Accounting Standards Codification (“ASC”) Topic 842. Topic 842 requires organizations to recognize leased assets and liabilities on the balance sheet. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all leases. Operating lease right-of-use (“ROU”) assets are included in other assets whereas operating lease liabilities are included in other current liabilities and other long-term liabilities on the Company’s consolidated balance sheets. Operating lease ROU assets and operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The operating lease payments are recognized as lease expense on a straight-line basis over the lease term. Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Company’s consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories. Topic 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The lease term for all of the Company’s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. See Note 2 and Note 15 Commitments and Contingencies for additional information. Fair Value of Financial Instruments Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy: Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market. Level 3 — Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. Financial instruments recognized at historical amounts in the consolidated balance sheets consist of cash, accounts receivable, other current assets, accounts payable, accrued expenses, other current liabilities and senior debt. The Company believes that the carrying value of cash, accounts receivable, other current assets, accounts payable, accrued expenses, other current liabilities approximates their fair values due to the short-term nature of these instruments. The carrying value of senior debt as of December 31, 2020 approximated fair value. The fair value of the senior debt was estimated by discounting to present value the scheduled coupon payments and principal repayment, using an appropriate fair market yield and is considered Level 3 in the fair value hierarchy. In connection with the Mergers in December 2020, each security holder of Metuchen received an earnout consideration classified as a derivative liability to be paid in the form of Petros Common Stock. The Company estimated their fair value using Monte Carlo Simulation approach. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative liability as of the closing of the Merger and December 31, 2020 was $8.2 million and $9.9 million, respectively. See Note 10 Stockholders’ Equity. Deferred Financing Costs Costs incurred to issue debt are deferred and presented in the consolidated balance sheets as a direct reduction from the carrying amount of the debt liability, consistent with debt discounts. Related amortization expense is recorded as a component of interest expense over the term of the related debt using the effective interest rate method. Stock-Based Compensation The Company accounts for stock-based awards to employees and consultants in accordance with applicable accounting principles, which requires compensation expense related to stock-based transactions, including employee stock options and consultant warrants, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options or warrants. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. Employee stock option and consulting expenses are recognized over the employee’s or consultant’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the volatility and expected term. Any changes in these highly subjective assumptions can significantly impact stock-based compensation expense. See Note 11 Stock Options. Costs of Equity Transactions Incremental direct costs incurred to issue stocks of the Company’s preferred and common stocks are recorded as a reduction of the related proceeds. Income Taxes Prior to the consummation of the Mergers, Metuchen was a limited liability company (“LLCs”) for federal income tax purposes and had elected to be treated as a Partnership for federal and state income tax purposes. PTV is a disregarded entity for federal income tax purposes. As such, all income tax consequences resulting from the operations were reported on the member’s income tax return. In addition, Timm was included in the Company’s structure where taxes were paid at the entity level. Following the consummation of the Mergers, Metuchen is treated as a disregarded entity (“SMLLC”) for federal income tax purposes. As such, all income tax consequences resulting from the operations of Metuchen are reported on the members’ income tax returns through the period in which the Merger was transacted. Subsequent to the Mergers, Metuchen’s activity is included in the Company’s consolidated group. The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period the rate change is enacted. The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) it determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. As of December 31, 2020 and 2019 no accrued interest or penalties are recorded in the consolidated balance sheets. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, was enacted and signed into law, and GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act, among other things, includes changes to the tax provisions that benefits business entities and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act, including, permitting net operating losses, or NOLs, carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The CARES Act provides other reliefs and stimulus measures. We have evaluated the impact of the CARES Act, and do not expect that any provision of the CARES Act would result in a material cash benefit to us or have a material impact on our financial statements or internal controls over financial reporting. Contingencies The Company may be subject to various patent challenges, product liability claims, government investigations and other legal proceedings in the ordinary course of business. Legal fees and other expenses related to litigation are expensed as incurred and included in general and administrative expenses in the consolidated statements of operations. Shipping Costs The Company records the costs of shipping related to prescription medication sales in general and administrative expense in its consolidated statements of operations. There were no shipping costs for the years ended December 31, 2020 and 2019. Shipping costs related to medical devices are recorded as revenue and subsequently deducted as a component of cost of goods sold in the consolidated statements of operations. Shipping costs for the years ended December 31, 2020 and 2019 were $108,870 and $130,242 respectively. Basic and Diluted Net Loss per Common Share The Company computes basic net loss per common share by dividing net loss applicable to common stockholders by the weighted average number of common stocks outstanding during the period, excluding the dilutive effects of stock options and warrants to purchase common stocks. The Company computes diluted net loss per common stock by dividing the net loss applicable to common stocks by the sum of the weighted-average number of common stocks outstanding during the period plus the potential dilutive effects of its convertible preferred stocks, stock options and warrants to purchase common stocks, but such items are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between the Company’s basic and diluted net loss per stock of common stock for the years ended December 31, 2020 and 2019. See Note 13 Basic and Diluted Net Loss per Common Share. Recent Accounting Pronouncements Recently Adopted In August 2018, the FASB issued ASU 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement fair value measurements. The guidance is effective for the Company for the annual periods and interim periods within annual periods beginning after December 15, 2019 for both private and public entities. The Company adopted this guidance as of January 1, 2020 and its impact was not material. Pending Adoption as of December 31, 2020 In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments

Accounts Receivable, net_2

Accounts Receivable, net	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Accounts Receivable, net
Accounts Receivable, net	3) Accounts Receivable, net Accounts receivable, net is comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, December 31, ​ ​ 2021 ​ 2020 Gross accounts receivables ​ $ 2,929,064 ​ $ 6,560,291 Distribution service fees ​ (537,363) ​ (972,652) Chargebacks accrual ​ — ​ (121,269) Cash discount allowances ​ (135,527) ​ (84,601) Allowance for doubtful accounts ​ (303,753) ​ (228,800) Total accounts receivable, net ​ $ 1,952,421 ​ $ 5,152,969 ​ For the nine months ended September 30, 2021 and 2020, gross sales from customers representing 10% or more of the Company’s total gross sales included four customers and one customer, respectively, which represented approximately 78% and 80% of total gross sales, respectively. Receivables from customers representing 10% or more of the Company’s gross accounts receivable included two customers at September 30, 2021 and December 31, 2020 equal to 70% and 93%, respectively, of the Company’s total gross accounts receivables.	3) Accounts Receivable, net Accounts receivable, net is comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, December 31, ​ ​ 2020 ​ 2019 Gross accounts receivables ​ $ 6,560,291 ​ $ 4,989,260 Distribution service fees ​ (972,652) ​ (2,061,481) Chargebacks accruals ​ (121,269) ​ (60,507) Cash discount allowances ​ (84,601) ​ (235,867) Allowance for doubtful accounts ​ (228,800) ​ (26,275) Total accounts receivable, net ​ $ 5,152,969 ​ $ 2,605,130 ​ For years ended December 31, 2020 and 2019, gross sales from customers representing 10% or more of the Company’s total gross sales included one customer which represented approximately 85% and 86% of total gross sales, respectively. Receivables from customers representing 10% or more of the Company’s gross accounts receivable included one customer at December 31, 2020 and 2019 equal to 93% and 88%, respectively, of the Company’s total gross accounts receivables.

Inventories_2

Inventories	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Inventories
Inventories	4) Inventories Inventory is comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 December 31, 2020 Raw materials ​ $ 328,558 ​ $ 325,932 Finished goods ​ 189,923 ​ 434,598 Total inventory ​ $ 518,481 ​ $ 760,530 ​ Finished goods are net of valuation reserves of $435,927 and $935,866 as of September 30, 2021, and December 31, 2020, respectively. Raw materials are net of valuation reserves of $2,872,977 as of both September 30, 2021, and December 31, 2020, respectively, which is related to bulk inventory that is fully reserved.	4) Inventories Inventory is comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 December 31, 2019 Raw materials ​ $ 325,932 ​ $ 798,161 Finished goods ​ 434,598 ​ 1,406,267 Total inventory ​ $ 760,530 ​ $ 2,204,428 ​ Finished goods are net of valuation reserves of $935,866 and $220,254 as of December 31, 2020 and 2019, respectively. Raw materials are net of valuation reserves of $2,872,977 as of December 31, 2020 and 2019, which is related to bulk inventory that is fully reserved.

Prepaid Expenses and Other Cu_5

Prepaid Expenses and Other Current Assets	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Prepaid Expenses and Other Current Assets
Prepaid Expenses and Other Current Assets	5) Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets are comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 December 31, 2020 Prepaid samples ​ $ — ​ $ 58,483 Prepaid insurance ​ 172,205 ​ 149,452 Prepaid FDA fees ​ — ​ 756,972 Prepaid coupon fees ​ 71,500 ​ 71,500 API purchase commitment asset (see Note 14) ​ 1,304,541 ​ 1,304,541 Other prepaid expenses ​ 587,319 ​ 391,552 Other current assets ​ 612,673 ​ 114,784 Total prepaid expenses and other current assets ​ $ 2,748,238 ​ $ 2,847,284 ​ Prepaid samples, which are presented net of reserves, are expensed when distributed to the sales force. The prepaid samples reserve amount was $379,612 and $351,224 as of September 30, 2021, and December 31, 2020, respectively.	5) Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets are comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 December 31, 2019 Prepaid samples ​ $ 58,483 ​ $ 391,024 Prepaid insurance ​ 149,452 ​ 287,844 Prepaid FDA fees ​ 756,972 ​ 732,204 Prepaid coupon fees ​ 71,500 ​ 71,500 Rebates receivable ​ ​ — ​ ​ 1,243,120 API purchase commitment asset (see Note 14) ​ 1,304,541 ​ 1,409,592 Other prepaid expenses ​ 391,552 ​ 468,226 Other current assets ​ 114,784 ​ 526,310 Total prepaid expenses and other current assets ​ $ 2,847,284 ​ $ 5,129,820 ​ Prepaid samples, which are presented net of reserves, are expensed when distributed to the sales force. The prepaid samples reserve amount was $351,224 and $145,474 at December 31, 2020 and 2019, respectively. ​ In relation to a transition services agreement with a prior owner of the product rights to Stendra®, the prior owner had processed managed care rebates and remitted them back to the Company during the year ended December 31, 2020; therefore, the Company did not have a receivable related to rebates processed by the prior owner of the product rights to Stendra® as of December 31, 2020.

Intangible Assets_2

Intangible Assets	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Intangible Assets
Intangible Assets	6) Intangible Assets ​ ​ ​ ​ ​ Balance at December 31, 2019 $ 38,811,137 Amortization expense ​ (6,650,218) Balance at December 31, 2020 ​ ​ 32,160,919 Amortization expense ​ (5,178,821) Balance at September 30, 2021 ​ $ 26,982,098 ​ The future annual amortization related to the Company’s intangible assets is as follows as of September 30, 2021: ​ ​ ​ ​ ​ 2021 (remaining 3 months) ​ 1,688,951 2022 ​ 6,191,740 2023 ​ 5,445,729 2024 ​ 4,650,787 Thereafter ​ 9,004,891 Total ​ $ 26,982,098 ​ The intangible assets held by the Company are the Stendra® product, Timm Medical product, and PTV product and are being amortized over their estimated useful lives of 10 years , 12 years , and 12 years, respectively. The carrying value of the Stendra® product, Timm Medical product, and PTV product as of September 30, 2021, are $20.4 million, $5.1 million, and $1.4 million, respectively. The carrying value of the Stendra® product, Timm Medical product, and PTV product as of December 31, 2020, are $24.6 million, $5.9 million, and $1.6 million, respectively.	6) Intangible Assets ​ ​ ​ ​ ​ Balance at December 31, 2018 ​ $ 44,100,542 Amortization expense ​ ​ (5,289,405) Balance at December 31, 2019 $ 38,811,137 Amortization expense ​ (6,650,218) Balance at December 31, 2020 ​ $ 32,160,919 ​ The future annual amortization related to the Company’s intangible assets is as follows: ​ ​ ​ ​ ​ 2021 ​ 6,867,771 2022 ​ 6,191,740 2023 ​ 5,445,729 2024 ​ 4,650,787 Thereafter ​ 9,004,892 Total ​ $ 32,160,919 ​ The intangible assets held by the Company are the Stendra® product, Timm Medical product, and PTV product and are being amortized over their estimated useful lives of 10 years, 12 years, and 12 years, respectively. The carrying value of the Stendra® product, Timm Medical product, and PTV product as of December 31, 2020 are $24.6 million, $5.9 million and $1.6 million, respectively. The carrying value of the Stendra® product, Timm Medical product, and PTV product as of December 31, 2019 were $30.0 million, $6.9 million and $1.9 million, respectively.

Accrued Expenses_2

Accrued Expenses	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Accrued Expenses
Accrued Expenses	7) Accrued Expenses Accrued expenses are comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 December 31, 2020 Accrued price protection ​ $ 1,853,979 ​ $ 1,853,979 Accrued product returns ​ 5,590,248 ​ 9,452,248 Accrued contract rebates ​ 341,715 ​ 412,046 Due to Vivus (see Note 14) ​ 2,267,523 ​ 2,267,523 Accrued severance ​ 25,417 ​ 519,609 Accrued professional fees ​ 31,463 ​ — Accrued marketing ​ 1,258,255 ​ — Other accrued expenses ​ 225,514 ​ 178,381 Total accrued expenses ​ $ 11,594,114 ​ $ 14,683,786 ​ As part of its acquisition of Stendra®, the Company provides the previous owner with price protection for certain Stendra® product returns that are processed by the previous owner in accordance with the Company's returned goods policy. Some customer agreements require that product returns be credited at the current wholesale acquisition cost (“WAC”). If the Company subsequently raises the WAC, the Company will reimburse the previous owner for the difference between the current WAC and the original sale price for returns processed by the previous owner.	7) Accrued Expenses Accrued expenses are comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 December 31, 2019 Accrued price protection ​ $ 1,853,979 ​ $ 1,847,639 Accrued product returns ​ 9,452,248 ​ 10,707,807 Accrued contract rebates ​ 412,046 ​ 1,368,279 Due to Vivus (see Note 14) ​ 2,267,523 ​ 2,259,769 Due to third-party logistic provider ​ — ​ 4,388,600 Accrued severance ​ 519,609 ​ — Other accrued expenses ​ 178,381 ​ 315,168 Total accrued expenses ​ $ 14,683,786 ​ $ 20,887,262 ​ As part of its acquisition of Stendra®, the Company provides the previous owner with price protection for certain Stendra® product returns that are processed by the previous owner. Some customer agreements require that product returns be credited at the current wholesale acquisition cost (“WAC”). If the Company subsequently raises the WAC, the Company will reimburse the previous owner for the difference between the current WAC and the original sale price for returns processed by the previous owner.

Debt_2

Debt	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Debt
Debt	8) Debt Senior Debt The following is a summary of the Company’s senior indebtedness at September 30, 2021, and December 31, 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 December 31, 2020 Principal balance ​ $ 1,740,752 ​ $ 6,653,292 Plus: End of term fee ​ — ​ 534,237 Less: Debt issuance costs ​ — ​ (12,500) Total senior debt ​ $ 1,740,752 ​ $ 7,175,029 ​ On September 30, 2016, the Company entered into a loan and security agreement with Hercules Capital, Inc. (“Hercules”), a third party, for a $35 million term loan (the “Senior Debt”). The Senior Debt includes an additional Paid-In-Kind (“PIK”) interest that increases the outstanding principal on a monthly basis at an annual rate of 1.35% and a $787,500 end of term charge. The end of term charge is being recognized as interest expense and accreted over the term of the Senior Debt using the effective interest method. On November 22, 2017, the Company and Hercules entered into Amendment No. 1 to the Senior Debt (the “First Amendment”). A covenant was added, in which the Company may achieve a certain minimum EBITDA, as defined in the First Amendment, target for the trailing twelve-month period, ending June 30, 2018. The end of term charge was increased from $787,500 to $1,068,750. The minimum EBITDA for each of the trailing six months and the fixed charge coverage ratio were reduced from 1:1 to 0.9:1. The Company was also required to prepay $10 million in principle. On April 13, 2020, the Company and Hercules entered into Amendment No. 2 to the Senior Debt (the “Second Amendment”). The Second Amendment waived all financial covenant defaults for all periods since inception through the period ending March 31, 2020. The Second Amendment also included the following changes: ● Extended the maturity date from October 1, 2020, to April 2021, which can be further extendable to December 1, 2021, upon achieving the Financing Milestone, as defined in the agreement. ● Increased the cash interest rate from the greater of (a) 10.75% or (b) 10.75% plus the US WSJ Prime minus 4.50% to the greater of (a) 11.50% or (b) 11.50% plus the US WSJ Prime minus 4.25% . ● Removed the PIK interest rate. ● Removed the prepayment penalty. The end of term charge of $1,068,750 was partially extended with $534,375 paid on October 1, 2020, and $534,375 paid on February 1, 2021. Effective September 30, 2020, the Company and Hercules entered into the Third Amendment to the Senior Debt Loan and Security Agreement (the “Third Amendment”) to provide for interest only payments commencing on October 1, 2020, and continuing through December 22, 2020, unless the Company raised net cash proceeds of at least $25 million through an equity or debt financing or other transaction on or before December 21, 2020. The Third Amendment also amended the minimum cash, minimum net revenue, and minimum EBITDA financial covenants. On that same date, Juggernaut Capital Partners III, L.P, an affiliate of the JCP Investor., Hercules and Wells Fargo Bank, N.A. entered into an escrow agreement (the “Escrow Agreement”) to escrow funds amounting to approximately $1.5 million, an amount equal to the aggregate of certain principal payments due under the Loan Agreement, as amended. In connection with the consummation of the Mergers, the funds held in escrow were disbursed back to Juggernaut Capital Partners III, L.P. and the Escrow Agreement was terminated. The Company satisfied the maturity date extension requirement pursuant to funds retained upon the closing of the Mergers in December 2020. As a result, the Senior Debt now has a maturity date of December 1, 2021. As of September 30, 2021, the Company was in compliance with its covenants. On November 3, 2021, the Company repaid $1,179,651 towards the senior debt. This payment satisfied the remaining balance of the senior debt as of that date. Interest expense on the Senior Debt was as follows for the periods indicated: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended ​ For the Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 Interest expense for term loan ​ $ 67,936 ​ $ 287,855 ​ $ 344,373 ​ $ 1,015,898 Amortization of debt issuance costs ​ — ​ 12,500 ​ 12,500 ​ 25,000 PIK interest ​ — ​ — ​ — ​ 44,449 ​ ​ $ 67,936 ​ $ 300,355 ​ $ 356,873 ​ $ 1,085,347 ​ Included in accrued expenses in the accompanying condensed consolidated balance sheets as of September 30, 2021, and December 31, 2020, is $16,681 and $65,885, respectively, of accrued and unpaid interest. Subordinated Related Party Term Loans Subordinated Related Party Term Loans Entered into During 2020 During 2020, the Company entered into Subordinated Promissory Notes with the JCP Investor in the principal amount of $15.5 million. The maturity date of the Subordinated Promissory Notes was April 2, 2021, and they had PIK interest that increased the outstanding principal on a daily basis at an annual rate of 20%. In connection with the entry into the Merger Agreement on May 17, 2020, the JCP Investor, Neurotrope and Metuchen entered into a Note Conversion and Loan Repayment Agreement pursuant to which, the JCP Investor agreed to convert all of the above outstanding subordinated promissory notes and accrued PIK interest held by Juggernaut Capital Partners LLP and the JCP Investor, into Petros common stock in connection with the consummation of the Mergers on December 1, 2020, and the Subordinated Promissory Notes were terminated. Accordingly, the principal balance of the Subordinated Promissory Notes and accrued PIK interest was $0 as of both September 30, 2021, and December 31, 2020. Interest expense on this debt was $669,730, and $1,148,447, comprised entirely of PIK interest, for the three and nine months ended September 30, 2020, respectively.	8) Debt Senior Debt The following is a summary of the Company’s senior indebtedness at December 31, 2020 and 2019: ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 December 31, 2019 Principal balance ​ $ 6,653,292 ​ $ 11,688,979 Plus: Paid-In-Kind interest ​ ​ — ​ ​ 1,101,575 Plus: End of term fee ​ 534,237 ​ 952,416 Less: Debt issuance costs ​ (12,500) ​ — Total senior debt ​ $ 7,175,029 ​ $ 13,742,970 ​ On September 30, 2016, the Company entered into a loan agreement with Hercules, a third party, for a $35 million term loan (“Senior Debt”) with a stated interest rate of the greater of either (i) Prime plus 7.25% or (ii) 10.75%. The Senior Debt includes an additional Paid-In-Kind (“PIK”) interest that increases the outstanding principal on a monthly basis at an annual rate of 1.35% and a $787,500 end of term charge. On November 22, 2017, the Company amended its loan agreement with Hercules (“First Amendment”). A covenant was added, in which the Company must achieve a certain minimum EBITDA, as defined, target for the trailing twelve-month period, ending June 30, 2018. The end of term charge was increased from $787,500 to $1,068,750. The minimum EBITDA for each of the trailing six months and the fixed charge coverage ratio ( 1:1 0.9:1) Monthly principal payments, including interest, commenced November 1, 2018 with the outstanding balance of the Senior Debt due in full on November 1, 2020. The end of term charge is being recognized as interest expense and accreted over the term of the Senior Debt using the effective interest method. On April 13, 2020, the Company amended its loan agreement with Hercules. The amendment waived all financial covenant defaults for all periods since inception through the period ending March 31, 2020. The amendment also included the following changes: ● Removed the Adjusted EBITDA and Fixed Cost Coverage Ratio Covenants. ● Extended the maturity date from October 1, 2020 to April 2021, which can be further extendable to December 1, 2021 upon achieving the Financing Milestone, as defined in the agreement. ● Increased the cash interest rate from the greater of (a) 10.75% or (b) 10.75% plus the US WSJ Prime minus 4.50% to the greater of (a) 11.50% or (b) 11.50% plus the US WSJ Prime minus 4.25% . ● Removed the PIK interest rate. ● Removed the prepayment penalty. The end of term charge of $1,068,750 was partially extended with $534,375 paid on October 1, 2020 and $534,375 due on February 1, 2021. Effective September 30, 2020, the Company and Hercules entered into the Third Amendment to Loan and Security Agreement (“Third Amendment”) to provide for interest only payments commencing on October 1, 2020 and continuing through December 22, 2020 unless the Company raised net cash proceeds of at least $25 million through an equity or debt financing or other transaction on or before December 21, 2020. The Third Amendment also amended the minimum cash, minimum net revenue and minimum EBITDA financial covenants. On that same date, Juggernaut Capital Partners III, L.P., Hercules and Wells Fargo Bank, N.A. entered into an escrow agreement (the “Escrow Agreement”) to escrow funds amounting to approximately $1.5 million, an amount equal to the aggregate of certain principal payments due under the Loan Agreement, as amended. In connection with the consummation of the Mergers, the funds held in escrow were disbursed back to Juggernaut Capital Partners III, L.P. and the Escrow Agreement was terminated. The Company satisfied the maturity date extension requirement pursuant to funds retained upon the closing of the Mergers in December 2020. As a result, the Senior Debt now has a maturity date of December 1, 2021. As of December 31, 2020, the Company was in compliance with its covenants. Interest expense on the Senior Debt was as follows for the periods indicated: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended December 31, ​ 2020 2019 Interest expense for term loan ​ $ 1,241,475 ​ $ 2,216,341 Amortization of debt issuance costs ​ 37,500 ​ — PIK interest ​ 44,449 ​ 211,923 ​ ​ $ 1,323,424 ​ $ 2,428,264 ​ Included in accrued expenses in the accompanying consolidated balance sheets as of December 31, 2020 and 2019 is $65,885 and $132,006, respectively, of accrued and unpaid interest. Subordinated Related Party Term Loans Subordinated Related Party Term Loans Entered Into During 2020 On January 31, 2020, the Company entered into a Subordinated Promissory Note with JCP III SM AIV, L.P. (the “JCP Investor”) in the principal amount of $3.0 million (the “First Subordinated Promissory Note”). The maturity date of the First Subordinated Promissory Note was April 2, 2021 and has PIK interest that increases the outstanding principal on a daily basis at an annual rate of 20%. On April 1, 2020, the Company entered into a Subordinated Promissory Note with the JCP Investor in the principal amount of $3.0 million (the “Second Subordinated Promissory Note”). The maturity date of the Second Subordinated Promissory Note was April 2, 2021 and had PIK interest that increases the outstanding principal on a daily basis at an annual rate of 20%. On April 22, 2020, the Company entered into a Subordinated Promissory Note with the JCP Investor in the principal amount of $4.0 million (the “Third Subordinated Promissory Note”). The maturity date of the Third Subordinated Promissory Note was April 2, 2021 and had PIK interest that increases the outstanding principal on a daily basis at an annual rate of 20%. On July 31, 2020, the Company entered into a Subordinated Promissory Note with the JCP Investor in the principal amount of $2.5 million (the “Fourth Subordinated Promissory Note”). The maturity date of the Fourth Subordinated Promissory Note was April 2, 2021 and had PIK interest that increases the outstanding principal on a daily basis at an annual rate of 20%. On August 31, 2020, the Company entered into a Subordinated Promissory Note with the JCP Investor in the principal amount of $1.5 million (the “Fifth Subordinated Promissory Note”). The maturity date of the Fifth Subordinated Promissory Note was April 2, 2021 and had PIK interest that increases the outstanding principal on a daily basis at an annual rate of 20%. On October 1, 2020, the Company entered into a Subordinated Promissory Note with the JCP Investor in the principal amount of $1.5 million (the “Sixth Subordinated Promissory Note” and together with the First Subordinated Promissory Note, Second Subordinated Promissory Note, Third Subordinated Promissory Note, Fourth Subordinated Promissory Note, and Fifth Subordinated Promissory Note, the “Subordinated Promissory Notes”). The maturity date of the Sixth Subordinated Promissory Note was April 2, 2021 and had PIK interest that increases the outstanding principal on a daily basis at an annual rate of 20%. In connection with the entry into the Merger Agreement on May 17, 2020, Juggernaut Capital Partners LLP, Neurotrope and Metuchen entered into a Note Conversion and Loan Repayment Agreement pursuant to which, Juggernaut Capital Partners LLP agreed to convert all of the above outstanding subordinated promissory notes and accrued PIK interest held by Juggernaut Capital Partners LLP and the JCP Investor, into Petros common stock in connection with the consummation of the Mergers on December 1, 2020, and the Subordinated Promissory Notes were terminated. Accordingly, the principal balance of the subordinated promissory note and accrued PIK interest was $0 as of December 31, 2020. Interest expense on this debt was $1,727,455 comprised entirely of PIK interest, for the year ended December 31, 2020. ​ Subordinated Related Party Term Loans Entered Into Prior To 2020 ​ On December 10, 2018, JCP III CI AIV, L.P., an affiliate of the JCP Investor, acquired from Krivulka Family LLC (“Krivulka”) all of Krivulka’s ownership interest in Metuchen Therapeutics, LLC (“MT”), a holding company that owned 55% of Metuchen, giving the JCP Investor a controlling interest in Metuchen (such transaction, the “JCP Acquisition”). Concurrently with the JCP Acquisition, the Company executed a Subordination Agreement (“Sub Debt”) with several related parties, L. Mazur Associates, JV (“LMA”), KFE, an entity controlled by Krivulka and the JCP Investor (herein referred to collectively as “the Related Holders”). On November 22, 2107, the Company and the Related Holders entered into an Amended and Restated Subordination Agreement (“Amended Agreement”). Under the terms of the Amended Agreement, the principal balance of the Sub Debt was increased to $30,579,496. The amount due was divided 20.9%, 20.1%, and 59%, respectively, amongst LMA, KFE, and JCP. The cash interest rate of the amended sub debt was 12%. Additional PIK interest was 8% payable on the maturity date. On December 10, 2018, as part of the acquisition accounting for JCP Acquisition of a majority ownership interest in Metuchen, the outstanding Sub Debt was determined to have a fair value that was less than its carrying value. The fair value of the subordinated related party term loans was $22,250,746 at December 10, 2018. A debt discount of $15,506,463 was recognized and was being amortized to interest expense over the term of the debt using the effective interest method. On December 10, 2018, the Company signed a subordinated promissory note for an additional $4,750,000 of Sub Debt from JCP. The proceeds were used for the acquisition of the Medical Device Business. The principal, along with PIK interest at an annual rate of 25%, was due on April 2, 2021. On September 16, 2019, Metuchen entered into an Exchange Agreement (“Exchange Agreement”) with JCP and LMA to exchange Preferred Units and Common Units for the Sub Debt. Upon consummation of the exchange, the Preferred Units and Common Units issued were for the full satisfaction and termination of the subordinated related party term loan. As of each of December 31, 2020 and 2019, there was no outstanding principal balance or accrued interest for the subordinated related term loans. The following chart summarizes the instruments exchanged in the transaction as of September 16, 2019: ​ ​ ​ ​ ​ Common Units, at fair value (2,434,551.28 Units) $ 29,117,232 Preferred Units, at fair value (1,373,820.51 Units) ​ 17,500,000 Total fair value of Preferred and Common Units exchanged ​ 46,617,232 ​ ​ ​ ​ Sub Debt principal balance ​ 33,250,000 Add: PIK Interest ​ 16,544,318 Less: Debt Discount ​ 10,486,536 Total carrying value of Sub Debt exchanged ​ 39,307,782 ​ ​ ​ ​ Excess of fair value of Preferred and Common Units exchanged over the carrying value of Sub Debt ​ $ (7,309,450) ​ Based on ASC 470, the Company accounted for the exchange between related parties as a capital transaction. The carrying value of the subordinated related party term loans, including any accrued interest, on the date of the exchange was $39.3 million and the fair value of Preferred and Common Units was $46.6 million. As this is a capital transaction between related parties it is not appropriate to record an extinguishment loss; therefore, the company recorded the $7.3 million difference between the carrying value of the subordinated related party term loans and the fair value of the Preferred and Common Units to members’ capital. See Note 9 Members’ Capital for the determination of fair value of the Preferred and Common Units. The Company had subordinated related party term loans which was converted into common and preferred stocks on September 16, 2019. Interest expense on this debt was $11,416,697, including PIK interest of $6,747,313 for the year ended December 31, 2019.

Members' Capital_2

Members' Capital	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Members' Capital
Members' Capital	9) Members’ Capital (a) Capitalization Prior to September 16, 2019, the Company authorized 100 units of Class A Common Units (the “Class A Units”) to be issued and outstanding. In addition, there were Restricted Member Units (“RMU’s”) that were designated as a class of incentive units (also known as “Class B Units”). On September 16, 2019, the Company amended and restated its operating agreement creating the rights and preferences relating to the Preferred Units and Common Units mentioned in the Private Placement Offering below. The issued and outstanding Preferred Units and Common Units were exchanged for Common Stock of the Company in connection with the Mergers. (b) Preferred Units A holder of a Preferred Unit was entitled to vote on any matter requiring the approval of such units. In addition, the Preferred Unit holders were entitled to distributions, after adjustment for specific items, for each fiscal year. The following actions required the prior consent of the holders of a majority of the outstanding Preferred Units: (a) amend, alter, or repeal any provision of the amended and restated operating agreement (if such amendment would adversely affect any of the rights or preferences of the Preferred Units); (b) authorize or create membership interests that have a preference over the Preferred Units as to dividends or liquidation; (c) declare or pay any dividends or distributions; (d) dissolve or liquidate (in whole or in part), consolidate, merge, convey, lease, sell, or transfer all or substantially all of the assets of the Company; or purchase or otherwise acquire (directly or indirectly) all or substantially all of the assets or equity interest issued by another company; or file a petition for bankruptcy or receivership of the Company; (e) repurchase or redeem any Membership Interests; or (f) enter into any agreement, commitment or arrangement to do any of the foregoing. (c) Common Units (formerly known as Class A Units) A holder of a Common Unit was entitled to vote on any matter requiring the approval of such units. In addition, the Common Unit holders were entitled to distributions, after adjustment for specific items, for each fiscal year. Effective with the amended and restated operating agreement on August 26, 2019, each Class A Unit was exchanged for 10,000 Common Units. There was no change to the ownership percentages as a result of the exchange and the rights and privileges of Common Unit holders is consistent with that of the holders of Class A Units. (d) Class B Units As of September 16, 2019, none of the Class B Units had been issued. Effective with the amended and restated operating agreement on September 16, 2019, the Class B Units were no longer an authorized membership interest of the Company (e) Liquidation Upon liquidation of the Company or upon any Company sale, the Company was required to pay, hold, or distribute, or cause to be paid, held or distributed, the proceeds thereof as follows: (a) first, to the holders of Preferred Units, pro rata in proportion to the number of Preferred Units held by such holders, until the holders of such Preferred Units receive in respect of each Preferred Unit held by them, the preferred liquidation preference amount; (b) second, to the holders of Common Units, pro rata in proportion to the number of Common Units held by such holders, the remaining proceeds available for distribution.	9) Members’ Capital (a) Capitalization Prior to September 16, 2019, The Company authorized 100 units of Class A Common Units (the “Class A Units”) to be issued and outstanding. In addition, there were Restricted Member Units (“RMU’s”) that were designated as a class of incentive units (also known as “Class B Units”). On September 16, 2019, the Company amended and restated its operating agreement creating the rights and preferences relating to the Preferred Units and Common Units mentioned in the Private Placement Offering below. The issued and outstanding Preferred Units and Common Units were exchanged for Common Stock of the Company in connection with the Mergers. (b) Preferred Units A holder of a Preferred Unit was entitled to vote on any matter requiring the approval of such units. In addition, the Preferred Unit holders were entitled to distributions, after adjustment for specific items, for each fiscal year. The following actions required the prior consent of the holders of a majority of the outstanding Preferred Units: (a) amend, alter or repeal any provision of the amended and restated operating agreement (if such amendment would adversely affect any of the rights or preferences of the Preferred Units); (b) authorize or create membership interests that have a preference over the Preferred Units as to dividends or liquidation; (c) declare or pay any dividends or distributions; (d) dissolve or liquidate (in whole or in part), consolidate, merge, convey, lease, sell, or transfer all or substantially all of the assets of the Company; or purchase or otherwise acquire (directly or indirectly) all or substantially all of the assets or equity interest issued by another company; or file a petition for bankruptcy or receivership of the Company; (e) repurchase or redeem any Membership Interests; or (f) enter into any agreement, commitment or arrangement to do any of the foregoing. See also Note 12 Section (f) for further discussion of Preferred Units. (c) Common Units (formerly known as Class A Units) A holder of a Common Unit was entitled to vote on any matter requiring the approval of such units. In addition, the Common Unit holders were entitled to distributions, after adjustment for specific items, for each fiscal year. Effective with the amended and restated operating agreement on August 26, 2019, each Class A Unit was exchanged for 10,000 Common Units. There was no change to the ownership percentages as a result of the exchange and the rights and privileges of Common Unit holders is consistent with that of the Class A Unit. (d) Class B Units As of September 16, 2019, none of the Class B Units had been issued. Effective with the amended and restated operating agreement on September 16, 2019, the Class B Units were no longer an authorized membership interest of the Company. (e) Liquidation Upon liquidation of the Company or upon any Company sale, the Company was required to pay, hold, or distribute, or cause to be paid, held or distributed, the proceeds thereof as follows: (a) first, to the holders of Preferred Units, pro rata in proportion to the number of Preferred Units held by such holders, until the holders of such Preferred Units receive in respect of each Preferred Unit held by them, the preferred liquidation preference amount; (b) second, to the holders of Common Units, pro rata in proportion to the number of Common Units held by such holders, the remaining proceeds available for distribution. (f) Private Placement Offering On September 16, 2019, the Company executed a Private Placement offering (“Private Placement”) with V4 Capital Partners, LLC (“Lead Investor”) and other accredited investors (collectively “Investors”). None of the Investors had previously held an interest in the Company. Pursuant to the Private Placement, the Company agreed to issue and sell up to $3.5 million of the Company’s Preferred Units. Each Preferred Unit had an offering price of $12.7382 per unit. The Company issued 245,933 Preferred Units related to the Private Placement and received aggregate net proceeds from the Private Placement of $2.7 million. The Preferred Units maintained a 5% non-cumulative quarterly dividend, included one vote per unit on all matters to be voted upon by Common Unit holders and required a mandatory conversion upon the closing of a qualified public offering, with the conversion price being subject to adjustment if the price per share in the qualified public offering was less than $15.92275 per Preferred Unit. Subject to adjustment, each Preferred Unit could be converted into one Common Unit. The Preferred Units did not meet the criteria for liability classification and are classified within equity. In addition, the embedded conversion feature was considered clearly and closely related to the Preferred Units and did not require bifurcation. However, the embedded conversion feature represents a beneficial conversion feature with a relative fair value of $26,500 and has been recorded to additional paid-in capital, included within the $250,000 proceeds received related to the issuance of the lead investor warrants. In connection with the Private Placement, the Lead Investor received warrants (“Lead Investor Warrants”) to purchase an aggregate of 615,838.50 shares of the Company’s Preferred Units at an exercise price of $0.01 per Preferred Unit. The Lead Investor Warrants had an expiration date of September 16, 2020. The Lead Investor Warrants were only exercisable upon a qualified public offering being consummated within one year. As of the date of issuance, the fair value of the Lead Investor Warrants was estimated to be $2.1 million. To record the issuance of the Lead Investor Warrants, the Company allocated the proceeds of $250,000 received from the Lead Investor for the Preferred Units between the Lead Investor Warrants and the beneficial conversion feature for the embedded conversion option. Of the proceeds received, the relative fair value allocated to the Lead Investor Warrants was $223,500 and was included in additional paid-in capital. The Lead Investor Warrants did not meet the criteria for liability classification. In September 2020, the Company and the Lead Investor warrant holders amended the warrants to purchase an aggregate of 2,055,114.66 shares of the Company’s preferred units at an exercise price of $0.01 per preferred unit. The amendment also extended the expiration date to December 16, 2020. In November 2020, the Lead Investor warrant holders exercised their right to purchase 2,055,114.66 of the Company’s preferred units and the Company received $20,551 in proceeds. The Company estimated their fair value using Monte Carlo Simulation approach. Significant judgments used in the valuation model included the overall likelihood of a qualified public offering occurring and Management’s estimate for the aggregate equity value, including an estimate for the proceeds from a qualified public offering as well as giving consideration in the event the price per share in a qualified public offering is below 125% of the $12.7382 price per Preferred Unit. Also incorporated in the fair value of the Lead Investor Warrants was a risk-free rate, estimated volatility of equity and an incremental discount for lack of marketability. Also, in connection with the Private Placement, the placement agent received warrants (“Placement Agent Warrants”) to purchase an aggregate of 10,500 shares of the Company’s common stock at an exercise price of $12.7382 per share. The Placement Agent Warrants could be exercised any time on or after September 16, 2019. The Placement Agent Warrants contained an expiration date of September 16, 2024 and were converted into shares of common stock of the Company upon the consummation of the Mergers. As of the date of issuance, the fair value of the Placement Agent Warrants was estimated to be $135,800 and was included in additional paid-in capital. The Placement Agent Warrants did not meet the criteria for liability classification. The Company estimated their fair value using the Black-Scholes valuation model. The inputs used to value the Placement Agent Warrants included the Preferred Unit Price and the Placement Agent Warrant Strike Price (both of which are $12.7382), the expiration date of the Placement Agent Warrants of September 16, 2024, the risk-free rate to the expiration date of 1.73%, and the estimated volatility over the expected term of the Placement Agent Warrants of 90.0%. As there had been no public market for Metuchen’s Common Units, the estimated fair value of its Common Units was determined by the Board of Directors as of the Private Placement date, with input from management, considering the Company’s most recently available valuations of the aggregate equity value of the Company. In addition to considering the results of these valuations, the Company’s Board of Directors considered various objective and subjective factors to determine the fair value of its Common and Preferred Units as of the private placement date, including the progress of the Company’s products sales, external market conditions affecting and trends within the life sciences industry and the likelihood of achieving a liquidity event. The fair value of the Company’s Common Units as of the Private Placement Date was determined to be the difference between the fair value of the Company’s aggregate equity and the summation of the fair values of the Preferred Units, the Lead Investor Warrants and Placement Agent Warrants.

Stockholders' Equity_2

Stockholders' Equity	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Stockholders' Equity
Stockholders' Equity	10) Stockholders’ Equity Upon consummation of the Mergers, each outstanding Common Unit or Preferred Unit of Metuchen was exchanged for a number of shares of Petros common stock, par value $0.0001 per share (the “Petros Common Stock”), equal to 0.4968, which resulted in an aggregate of 4,949,610 shares of Petros Common Stock issued to the holders of Metuchen units in the Mergers. In addition, each holder of Neurotrope common stock, par value $0.0001 per share (the “Neurotrope Common Stock”) received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope Common Stock held, and each holder of Neurotrope preferred stock, par value $0.001 per share (the “Neurotrope Preferred Stock”) received one (1) share of Petros preferred stock (the “Petros Preferred Stock”) for every one (1) share of Neurotrope Preferred Stock held. In addition, each holder of outstanding options to purchase Neurotrope Common Stock or outstanding warrants to purchase Neurotrope Common Stock that were not previously exercised prior to the consummation of the Mergers was converted into equivalent options and warrants to purchase one (1) share of Petros Common Stock for every five (5) shares of Neurotrope Common Stock outstanding pursuant to such options or warrants. As a result of the Mergers, the former Neurotrope shareholders collectively owned approximately 4,758,045 shares of Petros Common Stock and 500 shares of Petros Preferred Stock and the former Metuchen unit holders collectively owned 4,949,610 shares of Petros Common Stock. Accordingly, the former Metuchen unit holders collectively owned approximately 51% of Petros and the former Neurotrope shareholders collectively owned approximately 49% of Petros. On January 26, 2021, 500 shares of the Company’s Preferred Stock were converted into 60,606 shares of the Company’s common stock. Effective January 1, 2021, the Company entered into a Marketing and Consulting Agreement (the “CorIRAgreement”) with CorProminence, LLC (the “Consultant”) for certain shareholder information and relation services. The term of the CorIRAgreement is for one year with automatic consecutive one-year renewal terms. As consideration for the shareholder information and relation services, the Company will pay the Consultant a monthly retainer of $7,500 and issued 30,000 restricted shares of the Company’s common stock to the Consultant on March 24, 2021 (the “CorIR Grant Date”). The restricted shares vested immediately on the CorIR Grant Date. Effective April 1, 2021, the Company entered into a Consulting and Advisory Agreement (the “King Agreement”) with Tania King, an employee of Juggernaut Capital Partners LLP, for certain services. The term of the King Agreement is indefinite but may be terminated by either party, with or without cause. As consideration for the consulting and advisory services, the Company will pay Ms. King a monthly fee of $4,000, an additional $12,000 payment included with the first monthly fee for services provided since January 1, 2021, and issue restricted stock units for shares of the Company’s common stock (“RSU’s”) with a cash value of $72,000 as of the date of the grant (the “King Grant Date”). The RSU’s shall vest and settle in full on the one-year anniversary of the King Grant Date. Effective June 4, 2021, the Company entered into a Service Agreement (the “IRTH Agreement”) with IRTH Communications, LLC (“ITRH”) for certain investor relations services. The term of the IRTH is for one year with an optional one-year renewal term. As consideration for the services, the Company will pay IRTH a fixed fee of $6,750 per month for the term of the IRTH Agreement and issued 28,338 restricted shares of the Company’s common stock with a value of $90,002 as of the date of the grant (the “IRTH Grand Date”). The restricted shares vest immediately on the IRTH Grant Date. Backstop Agreement In connection with the entry into the Merger Agreement, Neurotrope and an affiliated entity of the JCP Investor entered into a Backstop Agreement pursuant to which Juggernaut agreed to contribute to Metuchen at the closing of the Mergers an amount equal to the Working Capital Shortfall Amount (as defined in the Merger Agreement), if any, as determined in accordance with the Merger Agreement, up to an aggregate amount not to exceed $6,000,000 (the “Commitment Cap”). Following the closing of the Mergers and until the one-year anniversary of the closing of the Mergers (the “Anniversary Date”), Juggernaut agreed to contribute, or cause an affiliate to contribute, to Petros an amount equal to the Commitment Cap less the Working Capital Shortfall Amount (the “Post-Closing Commitment”) on the Anniversary Date; provided, however, that, (a) in the event that, at any time between the closing of the Mergers and the Anniversary Date, the closing price per share of Petros’s Common Stock on The Nasdaq Capital Market or any other securities exchanges on which the Petros Common Stock is then traded equals or exceeds $2.175 for a period of ten consecutive trading days, then the Post-Closing Commitment shall be reduced by fifty percent (50%) and (b) in the event that, at any time between the closing of the Mergers and the Anniversary Date, the closing price per share of Petros’s Common Stock on The Nasdaq Capital Market or any other securities exchanges on which the Petros Common Stock is then traded equals or exceeds $2.5375 for a period of ten (10) consecutive trading days, then the Post-Closing Commitment shall be $0. Pursuant to the Backstop Agreement and upon closing of the Mergers, Juggernaut paid the Company $2.6 million for the Working Capital Shortfall Amount, which was recorded in equity in relation to the net proceeds received from the reverse capitalization. Contingent Consideration Pursuant to the Merger Agreement, each security holder of Metuchen received a right to receive such security holder’s pro rata stock of an aggregate of 14,232,090 stocks of Petros Common Stock potentially issuable upon the achievement of certain milestones set forth in the Merger Agreement. The milestones are for the achievement of stock price and market capitalization, as defined over a two-year period. Milestone Earnout Payments In connection with the Mergers, each security holder of Metuchen received an equity classified earnout consideration to be paid in the form of Petros Common Stock if the Closing Price (as defined in the Merger Agreement) per share of stock of Petros’ Common Stock equals or exceeds certain milestones set forth in the Merger Agreement, as discussed below. Each milestone earnout payment is only achievable and payable one time and upon attainment of such milestone earnout payment. In no event will the sum of the milestone earnout payments be greater than 4,000,000 shares of Petros Common Stock. As of September 30, 2021, the milestones have not been achieved. If at any time following the Closing (as defined in the Merger Agreement) and prior to the one-year anniversary of the Closing, the Closing Price per share of Petros Common Stock is, for a period of twenty (20) trading days during any thirty (30) consecutive trading day period, greater than or equal to: ● $ 8.00 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 10.00 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 13.00 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 15.00 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. If at any time within the twelve (12) month period following the one-year anniversary of the Closing, the Closing Price per share of Petros Common Stock is, for a period of twenty (20) trading days during any thirty (30) consecutive trading day period, greater than or equal to: ● $ 10.00 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 12.50 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 16.25 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 18.75 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. Market Capitalization/Gross Proceeds Earnout Payments In connection with the Mergers, each security holder of Metuchen received the right to receive earnout consideration, which is liability classified, to be paid in the form of Petros Common Stock if either Petros’ Market Capitalization (as defined in the Merger Agreement) or Petros receives aggregate gross proceeds that equals or exceeds certain milestones set forth in the Merger Agreement, as discussed below. Each milestone earnout payment is only achievable and payable one time and upon attainment of such milestone. In no event will the sum of the milestone earnout payments be greater than 10,232,090 shares of Petros Common Stock. As of September 30, 2021, the milestones have not been achieved. The fair value of the derivative liability was $0.3 million and $9.9 million as of September 30, 2021, and December 31, 2020, respectively. Metuchen equity holders will have the opportunity to receive the following during the period ending on the second anniversary of the Closing: a. The Earnout Payment shall be equal to 2,000,000 shares of Petros Common Stock if: i. Petros’ Market Capitalization (as defined in the Merger Agreement) is greater than or equal to $250,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $17.50 on each such trading day; or ii. Petros receives aggregate gross proceeds of at least $25,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $17.50 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $250,000,000 . b. The Earnout Payment shall be equal to 2,000,000 shares of Petros Common Stock if: i. Petros’ Market Capitalization is greater than or equal to $300,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $18.75 on each such trading day; or ii. Petros receives aggregate gross proceeds of at least $30,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $18.75 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $300,000,000 . c. The Earnout Payment shall be equal to 3,000,000 shares of Petros Common Stock if: i. Petros’ Market Capitalization is greater than or equal to $400,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $22.50 on each such trading day; or ii. Petros receives aggregate gross proceeds of at least $40,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $22.50 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $400,000,000 . d. The Earnout Payment shall be equal to 3,232,090 shares of Petros Common Stock if: i. Petros’ Market Capitalization is greater than or equal to $500,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $23.75 on each such trading day; or ii. Petros receives aggregate gross proceeds of at least $50,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $23.75 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $500,000,000 . ​	10) Stockholders’ Equity Upon consummation of the Mergers, each outstanding Common Unit or Preferred Unit of Metuchen was exchanged for a number of shares of Petros common stock, par value $0.0001 per share (the “Petros Common Stock”), equal to 0.4968, which resulted in an aggregate of 4,949,610 shares of Petros Common Stock issued to the holders of Metuchen units in the Mergers. In addition, each holder of Neurotrope common stock, par value $0.0001 per share (the “Neurotrope Common Stock”) received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope Common Stock held, and each holder of Neurotrope preferred stock, par value $0.001 per share (the “Neurotrope Preferred Stock”) received one (1) share of Petros preferred stock (the “Petros Preferred Stock”) for every one (1) share of Neurotrope Preferred Stock held. In addition, each holder of outstanding options to purchase Neurotrope Common Stock or outstanding warrants to purchase Neurotrope Common Stock that were not previously exercised prior to the consummation of the Mergers was converted into equivalent options and warrants to purchase one (1) share of Petros Common Stock for every five (5) shares of Neurotrope Common Stock outstanding pursuant to such options or warrants. As a result of the Mergers, the former Neurotrope shareholders collectively own approximately 4,758,045 shares of Petros Common Stock and 500 shares of Petros Preferred Stock and the former Metuchen unit holders collectively own 4,949,610 shares of Petros Common Stock. Accordingly, the former Metuchen unit holders collectively own approximately 51% of Petros and the former Neurotrope shareholders collectively own approximately 49% of Petros. On January 26, 2021, 500 shares of the Company’s Preferred Stock were converted into 60,606 shares of the Company’s common stock. Backstop Agreement In connection with the entry into the Merger Agreement, Neurotrope and an affiliated entity of Juggernaut Capital Partners (“Juggernaut”) entered into a Backstop Agreement pursuant to which Juggernaut agreed to contribute to Metuchen at the closing of the Mergers an amount equal to the Working Capital Shortfall Amount (as defined in the Merger Agreement), if any, as determined in accordance with the Merger Agreement, up to an aggregate amount not to exceed $6,000,000 (the “Commitment Cap”). Following the closing of the Mergers and until the one-year anniversary of the closing of the Mergers (the “Anniversary Date”), Juggernaut agreed to contribute, or cause an affiliate to contribute, to Petros an amount equal to the Commitment Cap less the Working Capital Shortfall Amount (the “Post-Closing Commitment”) on the Anniversary Date; provided, however, that, (a) in the event that, at any time between the closing of the Mergers and the Anniversary Date, the closing price per share of Petros’s Common Stock on The Nasdaq Capital Market or any other securities exchanges on which the Petros Common Stock is then traded equals or exceeds $2.175 for a period of ten consecutive trading days, then the Post-Closing Commitment shall be reduced by fifty percent (50%) and (b) in the event that, at any time between the closing of the Mergers and the Anniversary Date, the closing price per share of Petros’s Common Stock on The Nasdaq Capital Market or any other securities exchanges on which the Petros Common Stock is then traded equals or exceeds $2.5375 for a period of ten (10) consecutive trading days, then the Post-Closing Commitment shall be $0. Pursuant to the Backstop Agreement and upon closing of the Mergers, Juggernaut paid the Company $2.6 million for the Working Capital Shortfall Amount, which was recorded in equity in relation to the net proceeds received from the reverse capitalization. Contingent Consideration Pursuant to the Merger Agreement, each security holder of Metuchen received a right to receive such security holder’s pro rata stock of an aggregate of 14,232,090 stocks of Petros Common Stock potentially issuable upon the achievement of certain milestones set forth in the Merger Agreement. The milestones are for the achievement of stock price and market capitalization, as defined over a two-year period. Milestone Earnout Payments In connection with the Mergers, each security holder of Metuchen received an equity classified earnout consideration to be paid in the form of Petros Common Stock if the Closing Price (as defined in the Merger Agreement) per share of stock of Petros’ Common Stock equals or exceeds certain milestones set forth in the Merger Agreement, as discussed below. Each milestone earnout payment is only achievable and payable one time and upon attainment of such milestone earnout payment. In no event will the sum of the milestone earnout payments be greater than 4,000,000 shares of Petros Common Stock. As of December 31, 2020, the milestones have not been achieved. If at any time following the Closing (as defined in the Merger Agreement) and prior to the one-year anniversary of the Closing, the Closing Price per share of Petros Common Stock is, for a period of twenty (20) trading days during any thirty (30) consecutive trading day period, greater than or equal to: ● $ 8.00 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 10.00 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 13.00 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 15.00 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. If at any time within the twelve (12) month period following the one-year anniversary of the Closing, the Closing Price per share of Petros Common Stock is, for a period of twenty (20) trading days during any thirty (30) consecutive trading day period, greater than or equal to: ● $ 10.00 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 12.50 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 16.25 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. ● $ 18.75 - then the earnout payment will be equal to 1,000,000 shares of Petros Common Stock. Market Capitalization/Gross Proceeds Earnout Payments In connection with the Mergers, each security holder of Metuchen received the right to receive earnout consideration, which is liability classified, to be paid in the form of Petros Common Stock if either Petros’ Market Capitalization (as defined in the Merger Agreement) or Petros receives aggregate gross proceeds that equals or exceeds certain milestones set forth in the Merger Agreement, as discussed below. Each milestone earnout payment is only achievable and payable one time and upon attainment of such milestone. In no event will the sum of the milestone earnout payments be greater than 10,232,090 shares of Petros Common Stock. As of December 31, 2020, the milestones have not been achieved. The fair value of the derivative liability was $9.9 million as of December 31, 2020. Metuchen equity holders will have the opportunity to receive the following during the period ending on the second anniversary of the Closing: a. The Earnout Payment shall be equal to 2,000,000 shares of Petros Common Stock if: i. Petros’ Market Capitalization (as defined in the Merger Agreement) is greater than or equal to $250,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $17.50 on each such trading day; or ii. Petros receives aggregate gross proceeds of at least $25,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $17.50 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $250,000,000 . b. The Earnout Payment shall be equal to 2,000,000 shares of Petros Common Stock if: i. Petros’ Market Capitalization is greater than or equal to $300,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $18.75 on each such trading day; or ii. Petros receives aggregate gross proceeds of at least $30,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $18.75 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $300,000,000 . c. The Earnout Payment shall be equal to 3,000,000 shares of Petros Common Stock if: i. Petros’ Market Capitalization is greater than or equal to $400,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $22.50 on each such trading day; or ii. Petros receives aggregate gross proceeds of at least $40,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $22.50 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $400,000,000 . d. The Earnout Payment shall be equal to 3,232,090 shares of Petros Common Stock if: i. Petros’ Market Capitalization is greater than or equal to $500,000,000 for a period of twenty (20) trading days during any thirty (30) consecutive trading day period with a Closing Price of no less than $23.75 on each such trading day; or ii. Petros receives aggregate gross proceeds of at least $50,000,000 in an offering (or series of offerings within a sixty (60) calendar day period) of Petros Common Stock with a price per share of Petros Common Stock sold equal to no less than $23.75 in each offering (or series of offerings) and where Petros has a Market Capitalization immediately prior to each such offering (or series of offerings) equal to at least $500,000,000 .

Stock Options and Restricted St

Stock Options and Restricted Stock Units ("RSU's")	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Stock Options
Stock Options and Restricted Stock Units ("RSU's")	11) Stock Options and Restricted Stock Units (“RSU’s”) The Company established the 2020 Omnibus Incentive Compensation plan (the “2020 Plan”) which provides for the grants of awards to our directors, officers, employees, and consultants. The 2020 Plan authorizes the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, restricted stock units and other stock-based awards and cash-based awards. As of September 30, 2021, there were 1,213,301 shares authorized, and 0 shares available for issuance, under the 2020 Plan. Upon the consummation of the Mergers as disclosed in Note 1, Neurotrope options issued and outstanding as of December 1, 2020, were converted into equivalent options to purchase stocks of Petros common stock and restricted stock units were adjusted to give effect to the Exchange Ratio set forth in the Merger Agreement. The following is a summary of stock options for the nine months ended September 30, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ ​ Weighted- ​ Remaining ​ Aggregate Intrinsic ​ ​ Number of ​ Average ​ Contractual ​ Value ​ Shares Exercise Price Term (Years) ($ in thousands) Options outstanding and exercisable on December 31, 2020 574,331 ​ $ 51.43 0.9 ​ $ — Options granted 638,970 ​ 3.37 9.18 ​ — Less: options and RSU’s forfeited — ​ — — ​ — Less: options and RSU’s expired/cancelled — ​ — — ​ — Less: options and RSU’s exercised — ​ — — ​ — Options and RSU’s outstanding at September 30, 2021 1,213,301 ​ 26.57 5.08 ​ — Options and RSU’s exercisable at September 30, 2021 852,166 ​ 35.77 3.32 ​ — ​ Upon the consummation of the Mergers as disclosed in Note 1, the vesting of former Neurotrope stock options in accordance with their terms was accelerated due to a change in control pursuant to the terms of the Neurotrope, Inc. 2013 Equity Incentive Plan and the Neurotrope, Inc. 2017 Equity Incentive Plan. Pursuant to the change in control, Neurotrope extended the period to exercise the stock options to be one-year from the closing of the Mergers. Accordingly, the Company did not record any stock-based compensation expense in connection with these stock options during the period from December 1, 2020, through December 31, 2020. On February 19, 2021, Fady Boctor, the President and Chief Commercial Officer of the Company, was granted an option to purchase 215,669 shares of the Company’s common stock at an exercise price of $3.74 per share. The option vested 50% as of February 19, 2021, the date of grant, and the remainder shall vest in equal installments on the first and second anniversary thereof. On April 8, 2021, in connection with the Directors’ appointment to the Board upon the Company becoming an independent publicly traded company on December 1, 2020, the Company awarded each of the five Directors an initial grant of options (the “Initial Grant”) to purchase 50,000 shares of common stock of the Company at an exercise price of $3.18 per share. The shares of common stock underlying the options vested 25% on the date of grant, 25% shall vest upon the six-month anniversary of the date of grant and the remainder shall vest in equal installments over the following four On May 11, 2021, the Company granted to certain officers of the Company options to purchase 150,000 shares of common stock of the Company at an exercise price or $3.21 per share. The shares of common stock underlying the options vested 30% on the date of grant, 30% shall vest upon the one year anniversary of the date of the grant, and the remainder shall vest upon the two year anniversary of the date of the grant. As of September 30, 2021, the plan is short of shares to cover all the May 11, 2021, option grants by 134,955 shares, and the grantees have agreed to not exercise such options until the Company notifies them there are shares available to cover such option exercises.	11) Stock Options The Company established the 2020 Omnibus Incentive Compensation plan (the “2020 Plan”) which provides for the grants of awards to our directors, officers, employees, and consultants. The 2020 Plan authorizes the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, stock units and other stock-based awards and cash-based awards. As of December 31, 2020, there were 1,078,346 shares authorized and 504,015 shares available for issuance under the 2020 Plan. Upon the consummation of the Mergers as disclosed in Note 1, Neurotrope options issued and outstanding as of December 1, 2020 were converted into equivalent options to purchase stocks of Petros common stock and were adjusted to give effect to the Exchange Ratio set forth in the Merger Agreement. The following is a summary of stock options for the period from December 1, 2020 through December 31, 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ ​ Weighted- ​ Remaining ​ Aggregate Instrinsic ​ ​ Number of ​ Average ​ Contractual ​ Value ​ Shares Exercise Price Term (Years) ($ in thousands) Options outstanding at December 1, 2020 574,331 ​ $ 51.43 0.9 ​ $ — Options granted — ​ — — ​ — Less: options forfeited — ​ — — ​ — Less: options expired/cancelled — ​ — — ​ — Less: options exercised — ​ — — ​ — Options outstanding at December 31, 2020 574,331 ​ $ 51.43 0.9 ​ $ — Options exercisable at December 31, 2020 574,331 ​ $ 51.43 0.9 ​ $ — ​ Upon the consummation of the Mergers as disclosed in Note 1, the vesting of former Neurotrope stock options in accordance with their terms was accelerated due to a change in control pursuant to the terms of the Neurotrope, Inc. 2013 Equity Incentive Plan and the Neurotrope, Inc. 2017 Equity Incentive Plan. Pursuant to the change in control, Neurotrope extended the period to exercise the stock options to be one-year from the closing of the Mergers. Accordingly, the Company did not record any stock-based compensation expense in connection with these stock options. On February 19, 2021, Fady Boctor, the President and Chief Commercial Officer of the Company, was granted an option to purchase 215,669 shares of the Company’s common stock at an exercise price of $3.74 per share. The option vested 50% as of February 19, 2021, the date of grant, and the remainder shall vest in equal installments on the first and second anniversary thereof.

Common Stock Warrants_2

Common Stock Warrants	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Common Stock Warrants
Common Stock Warrants	12) Common Stock Warrants Upon the consummation of the Merger as disclosed in Note 1, Neurotrope warrants issued and outstanding as of December 1, 2020, were converted into equivalent warrants to purchase common stock of Petros and were adjusted to give effect to the Exchange Ratio set forth in the Merger Agreement. The following is a summary of warrants for the three months ended September 30, 2021: ​ ​ ​ ​ ​ Number of Shares Warrants outstanding at December 31, 2020 4,407,962 Warrants issued — Warrants exercised — Warrants outstanding at September 30, 2021 4,407,962 ​ As of September 30, 2021, the Company’s warrants by expiration date were as follows: ​ ​ ​ ​ ​ ​ ​ Number of Warrants Exercise Price Expiration Date 76,569 ​ $ 32.00 ​ November 17, 2021 131,344 ​ 64.00 ​ November 17, 2021 2,780 ​ 1.60 ​ August 23, 2023 18,000 ​ 35.65 ​ June 1, 2024 4,800 ​ 35.60 ​ June 5, 2024 74,864 ​ 21.85 ​ June 17, 2024 20,043 ​ 31.25 ​ June 19, 2024 22,800 ​ 26.55 ​ September 1, 2024 10,500 ​ 12.74 ​ September 16, 2024 22,800 ​ 4.30 ​ December 1, 2024 28,000 ​ 5.65 ​ March 2, 2025 28,000 ​ 7.30 ​ June 1, 2025 28,000 ​ 5.50 ​ September 1, 2025 28,000 ​ 4.71 ​ December 1, 2025 2,221,829 ​ 7.50 ​ December 1, 2025 908,498 ​ 17.50 ​ December 1, 2025 623,303 ​ 51.25 ​ December 1, 2025 157,832 ​ 125.00 ​ December 1, 2025 4,407,962 ​ ​ ​	12) Common Stock Warrants Upon the consummation of the Merger as disclosed in Note 1, Neurotrope warrants issued and outstanding as of December 1, 2020 were converted into equivalent warrants to purchase common stock of Petros and were adjusted to give effect to the Exchange Ratio set forth in the Merger Agreement. The following is a summary of warrants for the period from December 1, 2020 through December 31, 2020: ​ ​ ​ ​ ​ Number of Shares Warrants outstanding at December 1, 2020 4,407,962 Warrants issued — Warrants exercised — Warrants outstanding at December 31, 2020 4,407,962 ​ As of December 31, 2020, the Company’s warrants by expiration date were as follows: ​ ​ ​ ​ ​ ​ ​ Number of Warrants Exercise Price Expiration Date 76,569 ​ $ 32.00 ​ November 17, 2021 131,344 ​ 64.00 ​ November 17, 2021 2,780 ​ 1.60 ​ August 23, 2023 18,000 ​ 35.65 ​ June 1, 2024 4,800 ​ 35.60 ​ June 5, 2024 74,864 ​ 21.85 ​ June 17, 2024 20,043 ​ 31.25 ​ June 19, 2024 22,800 ​ 26.55 ​ September 1, 2024 10,500 ​ 12.7382 ​ September 16, 2024 22,800 ​ 4.30 ​ December 1, 2024 28,000 ​ 5.65 ​ March 2, 2025 28,000 ​ 7.30 ​ June 1, 2025 28,000 ​ 5.50 ​ September 1, 2025 28,000 ​ 4.71 ​ December 1, 2025 2,221,829 ​ 7.50 ​ December 1, 2025 908,498 ​ 17.50 ​ December 1, 2025 623,303 ​ 51.25 ​ December 1, 2025 157,832 ​ 125.00 ​ December 1, 2025 4,407,962 ​ ​ ​

Basic and Diluted Net Loss pe_5

Basic and Diluted Net Loss per Common Share	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Basic and Diluted Net Loss per Common Share
Basic and Diluted Net Loss per Common Share	13) Basic and Diluted Net Loss per Common Share Upon the consummation of the Mergers on December 1, 2020, the basic weighted average number of common shares outstanding for the three and nine months ended September 30, 2020, has been calculated using the number of common units outstanding of Metuchen from January 1, 2020, through September 30, 2020, multiplied by the exchange ratio used in the transaction. The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended ​ For the Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 Numerator ​ ​ ​ ​ ​ Net loss ​ $ (1,696,898) ​ $ (3,300,363) ​ $ (800,734) ​ $ (15,147,953) Denominator ​ ​ ​ ​ Weighted-average common shares for basic net loss per share ​ 9,826,599 ​ 3,434,551 ​ 9,794,267 ​ 3,434,551 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic and diluted net loss per common share ​ $ (0.17) ​ $ (0.96) ​ $ (0.08) ​ $ (4.41) ​ The following table summarizes the potentially dilutive securities convertible into common shares that were excluded from the calculation of diluted net loss per share because their inclusion would have been antidilutive: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended ​ For the Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 Stock Options 1,213,301 — ​ 1,213,301 — Warrants 4,405,182 21,139 ​ 4,405,182 21,139 Total 5,621,263 21,139 ​ 5,621,263 21,139 ​	13) Basic and Diluted Net Loss per Common Share Upon the consummation of the Mergers on December 1, 2020, the basic weighted average number of common shares outstanding for the year ended December 31, 2019 have been calculated on a pro forma basis using Metuchen’s historical weighted average number of common units outstanding multiplied by the exchange ratio used in the reverse recapitalization. For the year ended December 31, 2020, the basic weighted average shares outstanding has been calculated using the number of common units outstanding of Metuchen from January 1, 2020 through the December 1, 2020 acquisition date multiplied by the exchange ratio used in the transaction and the number of common shares outstanding of the Company from December 1, 2020 through December 31, 2020. The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended ​ ​ December 31, ​ 2020 2019 Numerator ​ ​ Net (loss) income ​ $ (20,585,925) ​ $ (32,511,300) Denominator ​ ​ Weighted-average common shares for basic and diluted net loss per unit ​ 5,340,682 ​ 2,460,026 ​ ​ ​ ​ ​ ​ ​ Basic and diluted net loss per common share ​ $ (3.85) ​ $ (13.22) ​ The following table summarizes the potentially dilutive securities convertible into common shares that were excluded from the calculation of diluted net loss per share because their inclusion would have been antidilutive: ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended ​ ​ December 31, ​ 2020 2019 Stock Options 574,331 — Warrants 4,407,962 127,396 Total 4,982,293 127,396 ​

Marketing, Licensing and Dist_4

Marketing, Licensing and Distribution Agreements	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Marketing, Licensing and Distribution Agreements
Marketing, Licensing and Distribution Agreements	14) Marketing, Licensing and Distribution Agreements (a) Vivus On September 30, 2016, the Company entered into a License and Commercialization Agreement (the “License Agreement”) with Vivus, Inc (“Vivus”) to purchase and receive the license for the commercialization and exploitation of Stendra® for a one-time fee of $70 million, and for an additional $0.8 million, the Company also acquired the current Stendra® product and sample inventories as of September 30, 2016, that were owned by Vivus. The License Agreement gives the Company the right to sell Stendra® in the U.S and its territories, Canada, South America, and India. In December 2000, Vivus originally was granted the license from Mitsubishi Tanabe Pharma Corporation (“MTPC”) to develop, market, and manufacture Stendra®. Stendra® was approved by the Food and Drug Administration (“FDA”) in April 2012 to treat male erectile dysfunction. The Company will pay MTPC a royalty of 5% on the first $500 million of net sales and 6% of net sales thereafter. In consideration for the trademark assignment and the use of the trademarks associated with the product and the Vivus technology, the Company shall (a) during the first, second, and third years following the expiration of the Royalty Period in a particular country in the Company’s territory, pay to Vivus a royalty equal to 2% of the net sales of products in such territory; and (b) following the fourth and fifth years following the end of the Royalty Period in such territory, pay to Vivus a royalty equal to 1% of the net sales of products in such territory. Thereafter, no further royalties shall be owed with respect to net sales of Stendra® in such territory. In addition, the Company will be responsible for a pro-rata portion of a $6 million milestone payment to be paid once $250 million in sales has been reached on the separate revenue stream of Stendra®. Should the $250 million of sales threshold be reached, the Company will be responsible for $3.2 million of the milestone payment. In connection with the License Agreement, the Company and Vivus also entered into a Supply Agreement on the effective date of the License Agreement, which has since been terminated, effective as of September 30, 2021. The Supply Agreement stated that Vivus would initially manufacture, test, and supply the product to the Company or its designee, directly or through one or more third parties. In connection with the Supply Agreement , we and Vivus have been in negotiations to determine the amounts ultimately owed to Vivus, but we may be responsible for payments of approximately $20.7 million. The Company provided Vivus with notice of termination of the Supply Agreement on September 30, 2019, which became effective on September 30, 2021. The Company is currently negotiating with multiple contract manufacturers to manufacture and supply Stendra® and serve as potential replacements for Vivus. The Company intends to enter into a new supply agreement with one or more of these candidates in the near future and hopes to have an agreement in place by the end of the year. However, these negotiations are ongoing and there is no assurance that we will be able to enter into any new supply agreement with such potential vendors or that we will be able to do so at terms favorable to us in a timely manner. As of November 15, 2021, we believe that we have sufficient supplies of Stendra® to meet demand for the next 10 months. Stendra Stendra As of both September 30, 2021, and December 31, 2020, the Company had $14.2 million of accrued inventory purchases related to the Company’s minimum purchase obligations with Vivus for raw material or API inventory. As API inventory is not a finished good, the Company does not have title to the product and classifies API Inventory in either other current assets or other assets, depending on whether the Company expects to take title to the product within one year from the date of the financial statements. As of both September 30, 2021, and December 31, 2020, there was $1.3 million included in other current assets (see Note 5 Prepaid and Other Current Assets). As of both September 30, 2021, and December 31, 2020, $11.1 million is included in other assets on the accompanying condensed consolidated balance sheets. The Company reviews its inventory levels and purchase commitments for excess amounts that it is required to purchase but projects it will not be able to sell prior to product expiry. During the three and nine months ended September 30, 2021, and 2020, the Company has not recorded any additional reserve to reduce the cost of API inventory. During the nine months ended September 30, 2021 and 2020, the Company incurred royalties to MTPC for Stendra® of $302,346 and $206,435, respectively. During the three months ended September 30, 2021 and 2020, the Company incurred royalties to MTPC for Stendra® of $68,865 and $129,508, respectively. Royalties incurred were included in cost of goods sold in the condensed consolidated statements of operations. As of September 30, 2021, and December 31, 2020, the Company had a payable for royalties of $68,865 and $8,728, respectively, which is included in accrued expenses in the accompanying condensed consolidated balance sheets. The license agreement between MTPC and Vivus (“MTPC License”) contains certain termination rights that would allow MTPC to terminate the agreement if Vivus were to breach any of the terms of the MTPC License or become insolvent or bankrupt. In the event that MTPC terminates the MTPC License with Vivus because of any contractual breach the Company has step-in rights with MTPC, which would allow the Company to continue to sell Stendra (b) Hybrid In March 2020, the Company acquired the exclusive license to H100™ from Hybrid (the “Hybrid License”). H100™ is a topical candidate with at least one active ingredient and potentially a combination of ingredients responsible for the improvement of penile curvature during the acute phase of Peyronie’s disease. We paid an initial license fee of $100,000, with an additional $900,000 payment due upon obtainment of orphan indication for H100™ and termination of Hybrid’s existing agreement with a compounding pharmacy, and additional annual payments of $125,000, $150,000, and $200,000 due on each of the first, second and third anniversaries of the Hybrid License and $250,000 annual payments due thereafter. The Company is also required to make a $1,000,000 payment upon first commercial sale and a sliding scale of percentage payments on net sales in the low single digits. Annual anniversary payments will not be required after commercialization. The Company is also obligated to make royalty payments between 3-6% of any net sales. In addition, the Company may terminate at any time after first anniversary, without cause, upon ninety The initial license fee of $100,000 and an extension payment of $100,000 has been recorded in research and development during the year ended December 31, 2020. The Company has treated the acquisition as an asset acquisition and has concluded that the asset acquired, and the upfront payment should be expensed as it was considered an IPR&D asset with no alternative future uses. On September 24, 2020, the Company and Hybrid entered into a letter agreement, pursuant to which the term of the license agreement was extended for an additional six months six seven	14) Marketing, Licensing and Distribution Agreements (a) Vivus On September 30, 2016, the Company entered into a License and Commercialization Agreement (the “License Agreement”) with Vivus, Inc (“Vivus”) to purchase and receive the license for the commercialization and exploitation of Stendra® for a one-time fee of $70 million, and for an additional $0.8 million, the Company also acquired the current Stendra® product and sample inventories as of September 30, 2016 that were owned by Vivus. The License Agreement gives the Company the right to sell Stendra® in the U.S and its territories, Canada, South America, and India. In December 2000, Vivus originally was granted the license from Mitsubishi Tanabe Pharma Corporation (“MTPC”) to develop, market, and manufacture Stendra®. Stendra® was approved by the Food and Drug Administration (“FDA”) in April 2012 to treat male erectile dysfunction. The Company will pay MTPC a royalty of 5% on the first $500 million of net sales and 6% of net sales thereafter. In consideration for the trademark assignment and the use of the trademarks associated with the product and the Vivus technology, the Company shall (a) during the first, second, and third years following the expiration of the Royalty Period in a particular country in the Company’s territory, pay to Vivus a royalty equal to 2% of the net sales of products in such territory; and (b) following the fourth and fifth years following the end of the Royalty Period in such territory, pay to Vivus a royalty equal to 1% of the net sales of products in such territory. Thereafter, no further royalties shall be owed with respect to net sales of Stendra® in such territory. In addition, the Company will be responsible for a pro-rata portion of a $6 million milestone payment to be paid once $250 million in sales has been reached on the separate revenue stream of Stendra®. Should the $250 million of sales threshold be reached, the Company will be responsible for $3.2 million of the milestone payment. In connection with the License Agreement, the Company and Vivus also entered into a Supply Agreement on the effective date of the License Agreement. The Supply Agreement states that Vivus will initially manufacture, test, and supply the product to the Company or its designee, directly or through one or more third parties. The agreement is effective through December 31, 2021. The Company provided Vivus with notice of termination of the supply agreement on September 30, 2019, effective on September 30. 2021. The Company is required to make future minimum annual purchases of Stendra® under the Supply Agreement as follows (based on current prices, however, subject to annual price increases). As of December 31, 2020, the minimum purchase obligation is $4.1 million in 2021. Stendra® can be purchased by written purchase orders submitted to Vivus at least 125 days in advance of the desired shipment date. For each quarter, the Company is required to submit purchase orders for at least 90% of the quantities in the forecast above. Vivus will have no obligation to supply Stendra® in excess of 120% of the quantity specified above but will use reasonable efforts. As of December 31, 2020 and 2019, the Company has $14.2 million and $9.3 million, respectively, of accrued inventory purchases related to the Company’s minimum purchase obligations with Vivus for raw material or API inventory. As API inventory is not a finished good, the Company does not have title to the product and classifies API Inventory in either other current assets or other assets, depending on whether the Company expects to take title to the product within one year from the date of the financial statements. As of December 31, 2020 and 2019, there was $1.3 million and $1.4 million, respectively, included in other current assets (see Note 5 Prepaid and Other Current Assets). As of December 31, 2020 and 2019, there was $11.1 million and $6.7 million included on the accompanying consolidated balance sheets, respectively. The Company reviews its inventory levels and purchase commitments for excess amounts that it is required to purchase but projects it will not be able to sell prior to product expiry. During the years ended December 31, 2020 and 2019, the Company recorded a reserve of $0.8 million and $1.2 million, respectively, which is included in cost of goods sold, to reduce the cost of API inventory to its net realizable value. During the years ended December 31, 2020 and 2019, the Company incurred royalties to MTPC for Stendra of $317,875 and $550,533. Royalties incurred were included in cost of goods sold in the consolidated statements of operations. As of December 31, 2020, the Company had a payable for royalties of $8,728, which is included in accrued expenses in the accompanying consolidated balance sheet. As of December 31, 2019, the Company had a receivable for royalties of $309,147, which is included in other current assets in prepaid expenses and other current assets (see Note 5 Prepaid and Other Current Assets). On July 7, 2020, Vivus announced that it has completed the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma LLC will take 100% ownership of Vivus. Vivus is a specialty pharmaceutical company and the Company has a License Agreement with Vivus for commercialization and exploitation of Stendra® as well as the Company and Vivus are parties to a Supply Agreement for which Vivus will manufacture, test and supply Stendra® to the Company. The License Agreement is a sublicense under Vivus’ license agreement with the owner of the Stendra® patent, MTPC. The license agreement between MTPC and Vivus (“MTPC License”) contains certain termination rights that would allow MTPC to terminate the agreement if Vivus were to breach any of the terms of the MTPC License or become insolvent or bankrupt. In the event that MTPC terminates the MTPC License with Vivus because of any contractual breach the Company has step-in rights with MTPC, which would allow the Company to continue to sell Stendra®. (b) Hybrid In March 2020, the Company acquired the exclusive license to H100™ from Hybrid. H100™ is a topical candidate with at least one active ingredient and potentially a combination of ingredients responsible for the improvement of penile curvature during the acute phase of Peyronie’s disease. We paid an initial license fee of $100,000, with an additional $900,000 payment due upon obtainment of orphan indication for H100™ and termination of Hybrid’s existing agreement with a compounding pharmacy, and additional annual payments of $125,000, $150,000 and $200,000 due on each of the first, second and third anniversaries of the license agreement and $250,000 annual payments due thereafter. The Company is also required to make a $1,000,000 payment upon first commercial sale and a sliding scale of percentage payments on net sales in the low single digits. Annual anniversary payments will not be required after commercialization. The Company is also obligated to make royalty payments between 3-6% of any net sales. In addition, the Company may terminate at any time after first anniversary, without cause, upon ninety The initial license fee of $100,000 and an extension payment of $100,000 has been recorded in research and development during the year ended December 31, 2020. The Company has treated the acquisition as an asset acquisition and has concluded that the asset acquired and the upfront payment should be expensed as it was considered an IPR&D asset with no alternative future uses. On September 24, 2020, the Company and Hybrid amended the license agreement for H100™ to extend the term of the license agreement for an additional six months to March 24, 2021. In consideration for the amendment, the Company paid Hybrid $50,000 in October 2020 and an additional $100,000 in December 2020.

Commitments and Contingencies_8

Commitments and Contingencies	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Commitments and Contingencies
Commitments and Contingencies	15) Commitments and Contingencies (a) Employment Agreements The Company has employment agreements with certain executive officers and key employees that provide for, among other things, salary, and performance bonuses. In connection with entry into the First Merger Agreement Amendment, Neurotrope, Neurotrope Bioscience, Inc. (a wholly owned subsidiary of Neurotrope) and Metuchen entered into an Employee Lease Agreement pursuant to which Neurotrope and Neurotrope Bioscience, Inc. agreed to lease the services of Dr. Charles Ryan to Metuchen prior to the Closing. Dr. Ryan was required to devote no more than 75% of his working time performing services to Metuchen under the Employee Lease Agreement and Metuchen paid 75% of the costs associated with Dr. Ryan’s employment from the period beginning on June 1, 2020, through the Closing, including but not limited to, the costs for all compensation and benefits paid to, for or on behalf of Dr. Ryan (the “Fees”). Upon consummation of the Mergers, Metuchen paid approximately $0.2 million for the Fees pursuant to the Employee Lease Agreement, which reduced the amount of cash that Petros retained following the Closing. In connection with the consummation of the Mergers, on December 24, 2020, the Company and Mr. Keith Lavan entered into a Separation Agreement (the “Separation Agreement”), pursuant to which Mr. Lavan resigned as Senior Vice President and Chief Financial Officer of the Company and agreed to serve as an advisor to the Company through December 31, 2020 (the “Separation Date”). Pursuant to the Separation Agreement, in addition to other benefits, Mr. Lavan received a stay-on bonus of $50,000 for continuing to remain employed by the Company through the Separation Date. For his services as an advisor, the Company agreed to pay Mr. Lavan an amount equal to 50% of his base salary as of immediately prior to the Separation Date. The Company paid 70% of such amount on January 15, 2021, and 30% of such amount in equal installments from the Separation Date through June 30, 2021. In addition, Mr. Lavan executed a general release of liabilities in favor of the Company. (b) Legal Proceedings On July 14, 2020, Greg Ford, the Chief Executive Officer of the Company, was terminated. On July 14, 2020, Mr. Ford, through his attorney, claimed that he was entitled to severance pay pursuant to an employment agreement following the termination of his employment on that same date. This claim is currently at an early stage where the Company is unable to determine the likelihood of any unfavorable outcome. The Company is not currently involved in any other significant claims or legal actions that, in the opinion of management, will have a material adverse impact on the Company’s operations, financial position or cash flows. (c) Operating Leases The Company has commitments under operating leases for office and warehouse space used in its operations. The Company’s leases have remaining lease terms ranging from 2.9, years to 5.3 years. The components of lease expense were consisted entirely of fixed lease costs related to operating leases. These costs were $44,812 for the three months ended September 30, 2021, and 2020, and $134,435, and $179,246, for the nine months ended September 30, 2021, and 2020, respectively. ​ Supplemental balance sheet information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, 2021 As of December 31, 2020 Operating lease ROU asset: ​ ​ Other assets ​ $ 502,697 ​ $ 579,535 ​ ​ ​ ​ ​ ​ ​ Operating lease liability: ​ ​ Other current liabilities ​ $ 121,589 ​ $ 108,971 Other long-term liabilities ​ 437,749 ​ 530,597 Total operating lease liability ​ $ 559,338 ​ $ 639,568 ​ Supplemental lease term and discount rate information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, 2021 ​ As of December 31, 2020 ​ Weighted-average remaining lease terms - operating leases 3.9 years 4.7 years ​ Weighted-average discount rate - operating leases 12.6 % 12.6 % ​ Supplemental cash flow information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months For the Nine Months ​ ​ Ended September 30, Ended September 30, ​ 2021 2020 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: ​ ​ ​ ​ ​ Operating cash flows from operating leases ​ $ 45,942 ​ $ 45,660 ​ $ 137,826 ​ $ 136,979 ​ Future minimum lease payments under non-cancelable leases as of September 30, 2021, were as follows: ​ ​ ​ ​ ​ Lease Liability Maturity Analysis Operating Leases 2021 (remaining 3 months) ​ 46,413 2022 ​ 187,739 2023 ​ 189,374 2024 ​ 155,242 2025 ​ ​ 81,107 Thereafter ​ 82,326 Total lease payments ​ 742,201 Less: Imputed Interest ​ (182,863) Total ​ $ 559,338 ​ As of September 30, 2021, the Company had no operating leases that had not yet commenced.	15) Commitments and Contingencies (a) Employment Agreements The Company has employment agreements with certain executive officers and key employees that provide for, among other things, salary and performance bonuses. In connection with entry into the Merger Agreement Amendment, Neurotrope, Neurotrope Bioscience, Inc. (a wholly-owned subsidiary of Neurotrope) and Metuchen entered into an Employee Lease Agreement pursuant to which Neurotrope and Neurotrope Bioscience, Inc. agreed to lease the services of Dr. Charles Ryan to Metuchen prior to the Closing. Dr. Ryan was required to devote no more than 75% of his working time performing services to Metuchen under the Employee Lease Agreement and Metuchen paid 75% of the costs associated with Dr. Ryan’s employment from the period beginning on June 1, 2020 through the Closing, including but not limited to, the costs for all compensation and benefits paid to, for or on behalf Dr. Ryan (the “Fees”). Upon consummation of the Mergers, Metuchen paid approximately $0.2 million for the Fees pursuant to the Employee Lease Agreement, which reduced the amount of cash that Petros retained following the Closing. In connection with the consummation of the Mergers, on December 24, 2020, the Company and Mr. Keith Lavan entered into a Separation Agreement (the “Separation Agreement”), pursuant to which Mr. Lavan resigned as Senior Vice President and Chief Financial Officer of the Company and agreed to serve as an advisor to the Company through December 31, 2020 (the “Separation Date”). Pursuant to the Separation Agreement, in addition to other benefits, Mr. Lavan received a stay-on bonus of $50,000 for continuing to remain employed by the Company through the Separation Date. For his services as an advisor, the Company agreed to pay Mr. Lavan an amount equal to 50% of his base salary as of immediately prior to the Separation Date. The Company paid 70% of such amount on January 15, 2021 and 30% of such amount in equal installments from the Separation Date through June 30, 2021. In addition, Mr. Lavan executed a general release of liabilities in favor of the Company. (b) Legal Proceedings On July 14, 2020, Greg Ford, the Chief Executive Officer of the Company, was terminated. On July 14, 2020, Mr. Ford, through his attorney, claimed that he was entitled to severance pay pursuant to an employment agreement following the termination of his employment on that same date. This claim is currently at an early stage where the Company is unable to determine the likelihood of any unfavorable outcome. The Company is not currently involved in any other significant claims or legal actions that, in the opinion of management, will have a material adverse impact on the Company’s operations, financial position or cash flows. (c) Operating Leases The Company has commitments under operating leases for office and warehouse space used in its operations. The Company’s leases have remaining lease terms ranging from 3.7 years to 6.0 years. The components of lease expense were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended ​ ​ December 31, ​ 2020 2019 Operating Lease Cost: ​ ​ Fixed lease cost ​ $ 179,246 ​ $ 88,002 ​ Supplemental balance sheet information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2020 As of December 31, 2019 Operating lease ROU asset: ​ ​ Other assets ​ $ 579,535 ​ $ 672,246 ​ ​ ​ ​ ​ ​ ​ Operating lease liability: ​ ​ ​ Other current liabilities ​ $ 108,971 ​ $ 96,104 Other long-term liabilities ​ 530,597 ​ 639,568 Total operating lease liability ​ $ 639,568 ​ $ 735,672 ​ Supplemental lease term and discount rate information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2020 ​ As of December 31, 2019 ​ Weighted-average remaining lease terms - operating leases 4.7 years 5.7 years ​ Weighted-average discount rate - operating leases 12.6 % 12.6 % ​ Supplemental cash flow information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended ​ ​ December 31, ​ 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: ​ ​ Operating cash flows from operating leases ​ $ 182,639 ​ $ 92,068 ​ ​ ​ ​ ​ ​ ​ Right-of-use assets obtained in exchange for lease obligations: ​ ​ ​ ​ ​ ​ Operating leases ​ $ — ​ $ 698,127 ​ Future minimum lease payments under non-cancelable leases as of December 31, 2020 were as follows: ​ ​ ​ ​ ​ Lease Liability Maturity Analysis Operating Leases 2021 ​ 184,239 2022 ​ 187,739 2023 ​ 189,374 2024 ​ 155,242 Thereafter ​ 163,432 Total lease payments ​ 880,026 Less: Imputed Interest ​ (240,458) Total ​ $ 639,568 ​ As of December 31, 2020, the Company had no operating leases that had not yet commenced.

Segment Information_2

Segment Information	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Segment Information
Segment Information	16) Segment Information The Company manages its operations through two segments. The Company’s two segments, Prescription Medications and Medical Devices, focus on the treatment of male erectile dysfunction. The Prescription Medications segment consists primarily of operations related to Stendra®, which is sold generally in the United States, and H100™ for the treatment of Peyronie’s disease. The Medical Devices segment consists primarily of operations related to vacuum erection devices, which are sold domestically and internationally. The Company separately presents the costs associated with certain corporate functions as Corporate, primarily consisting of unallocated operating expenses including costs that were not specific to a particular segment but are general to the group, expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees, and other similar corporate expenses. Interest and other income (expense), net is also not allocated to the operating segments. The Company’s results of operations by reportable segment for the three months ended September 30, 2021 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the three months ended September 30, 2021 ​ Medications ​ Devices ​ Corporate ​ Consolidated Net sales ​ $ 1,377,291 ​ $ 767,878 ​ $ — ​ $ 2,145,169 Cost of goods sold ​ 45,254 ​ 273,904 ​ — ​ 319,158 Selling, general and administrative expenses ​ 1,318,610 ​ 722,998 ​ 1,371,615 ​ 3,413,223 Research and development expenses ​ 280,576 ​ — ​ — ​ 280,576 Depreciation and amortization expense ​ 1,398,270 ​ 330,559 ​ — ​ 1,728,829 Change in fair value of derivative liability ​ — ​ — ​ (1,970,000) ​ (1,970,000) Interest expense ​ — ​ — ​ 67,936 ​ 67,936 Income tax expense ​ — ​ (2,345) ​ — ​ (2,345) Net income (loss) ​ $ (1,665,419) ​ $ (561,928) ​ $ 530,449 ​ $ (1,696,898) ​ The Company’s results of operations by reportable segment for the three months ended September 30, 2020 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the three months ended September 30, 2020 ​ Medications Devices Corporate Consolidated Net sales ​ $ 2,590,151 ​ $ 874,544 ​ $ — ​ $ 3,464,695 Cost of goods sold ​ 749,575 ​ 232,328 ​ — ​ 981,903 Selling, general and administrative expenses ​ 1,837,864 ​ 566,666 ​ 716,493 ​ 3,121,023 Research and development expense ​ 36,828 ​ — ​ — ​ 36,828 Depreciation and amortization expense ​ 1,353,591 ​ 307,771 ​ — ​ 1,661,362 Interest expense ​ — ​ — ​ 970,085 ​ 970,085 Income tax benefit ​ — ​ 6,143 ​ — ​ 6,143 Net loss ​ $ (1,387,707) ​ $ (226,078) ​ $ (1,686,578) ​ $ (3,300,363) ​ The Company’s results of operations by reportable segment for the nine months ended September 30, 2021 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the nine months ended September 30, 2021 ​ Medications ​ Devices ​ Corporate ​ Consolidated Net sales ​ $ 6,227,753 ​ $ 2,450,671 ​ $ — ​ $ 8,678,424 Cost of goods sold ​ 607,582 ​ 748,256 ​ — ​ 1,355,838 Selling, general and administrative expenses ​ 4,985,603 ​ 2,014,424 ​ 4,411,086 ​ 11,411,113 Research and development expenses ​ 799,803 ​ — ​ — ​ 799,803 Depreciation and amortization expense ​ 4,194,809 ​ 991,677 ​ — ​ 5,186,486 Change in fair value of derivative liability ​ — ​ — ​ (9,640,000) ​ (9,640,000) Interest expense ​ — ​ — ​ 356,873 ​ 356,873 Income tax expense ​ — ​ (9,045) ​ — ​ (9,045) Net income (loss) ​ $ (4,360,044) ​ $ (1,312,731) ​ $ 4,872,041 ​ $ (800,734) ​ The Company’s results of operations by reportable segment for the nine months ended September 30, 2020 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the nine months ended September 30, 2020 ​ Medications ​ Devices ​ Corporate ​ Consolidated Net sales ​ $ 4,128,694 ​ $ 2,501,486 ​ $ — ​ $ 6,630,180 Cost of goods sold ​ 1,527,169 ​ 778,000 ​ — ​ 2,305,169 Selling, general and administrative expenses ​ 6,658,231 ​ 1,780,530 ​ 3,558,424 ​ 11,997,185 Research and development expense ​ 307,796 ​ — ​ — ​ 307,796 Depreciation and amortization expense ​ 4,060,772 ​ 923,312 ​ — ​ 4,984,084 Interest expense ​ — ​ — ​ 2,233,794 ​ 2,233,794 Income tax benefit ​ — ​ 49,895 ​ — ​ 49,895 Net loss ​ $ (8,425,274) ​ $ (930,461) ​ $ (5,792,218) ​ $ (15,147,953) ​ The following table reflects net sales by geographic region for the three and nine months ended September 30, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended ​ For the Nine Months Ended ​ ​ September 30, ​ September 30, Net sales 2021 2020 2021 2020 United States ​ $ 1,861,222 ​ $ 3,125,572 ​ $ 7,754,534 ​ $ 5,780,165 International ​ 283,947 ​ 339,123 ​ ​ 923,890 ​ ​ 850,015 ​ ​ $ 2,145,169 ​ $ 3,464,695 ​ $ 8,678,424 ​ $ 6,630,180 ​ No individual country other than the United States accounted for 10% of total sales for the three or nine months ended September 30, 2021 and 2020. The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of September 30, 2021, are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription ​ ​ ​ ​ ​ Medications Medical Devices Consolidated Intangible assets, net ​ $ 20,438,542 ​ $ 6,543,556 ​ $ 26,982,098 Total segment assets ​ $ 43,790,552 ​ $ 8,244,776 ​ $ 52,035,328 ​ The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of December 31, 2020, are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription ​ ​ ​ ​ ​ ​ ​ Medications Medical Devices Consolidated Intangible assets, net ​ $ 24,625,686 ​ $ 7,535,233 ​ $ 32,160,919 Total segment assets ​ $ 60,725,191 ​ $ 9,128,823 ​ $ 69,854,014 ​	18) Segment Information The Company manages its operations through two segments. The Company’s two segments, Prescription Medications and Medical Devices, focus on the treatment of male erectile dysfunction. The Prescription Medications segment consists primarily of operations related to Stendra®, which is sold generally in the United States, and H100™ for the treatment of Peyronie’s disease. The Medical Devices segment consists primarily of operations related to vacuum erection devices, which are sold domestically and internationally. The Company separately presents the costs associated with certain corporate functions as Corporate, primarily consisting of unallocated operating expenses including costs that were not specific to a particular segment but are general to the group, expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Interest and other income (expense), net is also not allocated to the operating segments. ​ The Company’s results of operations by reportable segment for the year ended December 31, 2020 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the year ended December 31, 2020 ​ Medications ​ Devices ​ Corporate ​ Consolidated Net sales ​ $ 6,357,498 ​ $ 3,201,971 ​ $ — ​ $ 9,559,469 Cost of goods sold ​ 3,083,417 ​ 963,049 ​ — ​ 4,046,466 Selling, general and administrative expenses ​ 8,784,716 ​ 2,024,448 ​ 4,865,804 ​ 15,674,968 Research and development expenses ​ 459,636 ​ — ​ — ​ 459,636 Depreciation and amortization expense ​ 5,424,292 ​ 1,236,146 ​ — ​ 6,660,438 Change in fair value of derivative liability ​ 1,680,000 ​ — ​ — ​ 1,680,000 Interest expense ​ — ​ — ​ 3,050,879 ​ 3,050,879 Income tax benefit ​ — ​ 1,426,993 ​ — ​ 1,426,993 Net loss ​ $ (13,074,563) ​ $ 405,321 ​ $ (7,916,683) ​ $ (20,585,925) ​ The Company’s results of operations by reportable segment for the year ended December 31, 2019 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the Year Ended December 31, 2019 ​ Medications Devices Corporate Consolidated Net sales ​ $ 11,110,660 ​ $ 4,466,506 ​ $ — ​ $ 15,577,166 Cost of goods sold ​ 6,057,977 ​ 1,369,134 ​ — ​ 7,427,111 Selling, general and administrative expenses ​ 13,873,200 ​ 2,735,390 ​ 3,118,633 ​ 19,727,223 Depreciation and amortization expense ​ 4,145,833 ​ 1,145,274 ​ — ​ 5,291,107 Impairment loss ​ 2,443,930 ​ — ​ ​ ​ 2,443,930 Interest expense ​ — ​ — ​ 13,844,961 ​ 13,844,961 Income tax expense ​ — ​ 645,866 ​ — ​ 645,866 Net loss ​ $ (15,410,280) ​ $ (137,426) ​ $ (16,963,594) ​ $ (32,511,300) ​ The following table reflects net sales by geographic region for the years ended December 31, 2020 and 2019: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended ​ ​ December 31, Net sales 2020 2019 United States ​ $ 8,555,831 ​ $ 14,236,886 International ​ 1,003,638 ​ 1,340,280 ​ ​ $ 9,559,469 ​ $ 15,577,166 ​ No individual country other than the United States accounted for 10% of total sales for the year ended December 31, 2020 and 2019. The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of December 31, 2020 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription ​ ​ ​ ​ ​ Medications Medical Devices Consolidated Intangible assets, net ​ $ 24,625,686 ​ $ 7,535,233 ​ $ 32,160,919 Total segment assets ​ $ 60,725,191 ​ $ 9,128,823 ​ $ 69,854,014 ​ The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of December 31, 2019 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription ​ ​ ​ ​ ​ ​ ​ Medications Medical Devices Consolidated Intangible assets, net ​ $ 30,039,758 ​ $ 8,771,379 ​ $ 38,811,137 Total segment assets ​ $ 47,455,382 ​ $ 10,910,911 ​ $ 58,366,293 ​

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events
Subsequent Event	17) Subsequent Events On October 13, 2021, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited and institutional investors (the “Purchasers”). Pursuant to the Purchase Agreement, the Company sold in a registered direct offering (the “Registered Direct Offering”) 3,323,616 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), to the Purchasers at an offering price of $1.715 per share and associated Investor Warrant (as defined herein). Pursuant to the Purchase Agreement, in a concurrent private placement (together with the Registered Direct Offering, the “Offerings”), the Company also agreed to sell to the Purchasers unregistered warrants (the “Investor Warrants”) to purchase up to an aggregate of 3,323,616 shares of Common Stock, representing 100% of the shares of Common Stock to be purchased in the Registered Direct Offering (the “Warrant Shares”). The Investor Warrants are exercisable at an exercise price of $1.715 per share, are exercisable immediately upon issuance and have a term of exercise equal to five years from the date of issuance. The Company received net proceeds from the sale of the Shares, after deducting fees and other offering expenses payable by the Company, of approximately $5.5 million. The Company intends to use the net proceeds for expansion of its men’s health platform and for working capital and general corporate purposes. The Offerings closed on October 18, 2021. Katalyst Securities LLC (“Katalyst”) served as a financial advisor to the company pursuant to an advisory consulting agreement (the “Katalyst Agreement”) entered into by the Company and Katalyst on October 13, 2021. Pursuant to the Katalyst Agreement, the Company paid Katalyst an advisory fee and legal expenses totaling $0.2 million for its services as a financial advisor in connection with this offering. Additionally, the Company issued to Katalyst’s representatives or designees warrants to purchase up to an aggregate of 130,000 shares of Common Stock (the “Katalyst Warrants”) with the same terms as the Investor Warrants.

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Summary of Significant Accounting Policies
Use of Estimates	Use of Estimates The preparation of Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and reported amounts of revenue and expenses during the reporting periods. Such estimates include the adequacy of accounts receivable reserves, return reserves, inventory reserves, and assessment of long-lived assets, including intangible asset impairment and the determination of the fair value of the derivative liability, among others. Actual results could differ from these estimates and changes in these estimates are recorded when known.	Use of Estimates The preparation of Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the Consolidated Financial Statements, and reported amounts of revenue and expenses during the reporting periods. Such estimates include the adequacy of accounts receivable reserves, return reserves, inventory reserves, and assessment of long-lived assets, including intangible asset impairment, and the allocation of the purchase price in acquisitions. Actual results could differ from these estimates and changes in these estimates are recorded when known.
Risks and Uncertainties	Risks and Uncertainties The Company is subject to risks common to companies in the pharmaceutical industry including, but not limited to, uncertainties related to commercialization of competitor products, regulatory approvals, dependence on key products, dependence on key customers and suppliers, and protection of intellectual property rights. In January 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China ( “COVID-19”) and the risks to the international community. The WHO declared COVID-19 a global pandemic on March 11, 2020, and since that time many of the previously imposed restrictions and other measures which were instituted in response have been subsequently reduced or lifted. However, the COVID-19 pandemic remains highly unpredictable and dynamic, and its duration and extent continue to be dependent on various developments, such as the emergence of variants to the virus that may cause additional strains of COVID-19, the administration and ultimate effectiveness of vaccines, and the eventual timeline to achieve a sufficient level of herd immunity among the general population. Accordingly, the COVID-19 pandemic may continue to have negative effects on the health of the U.S. economy for the foreseeable future. The Company cannot reasonably estimate the length or severity of the impact that the COVID-19 pandemic will have on its financial results, and the Company may experience a material adverse impact on its sales, results of operations, and cash flows in fiscal 2021 and thereafter. During 2020, government regulations and the voluntary business practices of the Company and prescribing physicians had prevented in-person visits by sales representatives to physicians’ offices. The Company had taken steps to mitigate the negative impact on its businesses of such restrictions. In March 2020, the Company reduced its sales representative head count to reflect the lack of in-person visits. The Company had maintained a core sales team which continued to contact physicians via telephone and videoconference as well as continuing to have webinars provided by the Company’s key opinion leaders to other physicians and pharmacists. In response to the spread of COVID-19, in March 2020, the Company closed its administrative offices and as of September 30, 2021, they remain closed, with the Company’s employees continuing their work outside of the Company’s offices. The Company has selectively resumed in-person interactions by its customer-facing personnel in compliance with local and state restrictions. The Company also continues to engage with customers virtually as the Company seeks to continue to support healthcare professionals and patient care. However, the Company’s ability to engage in personal interactions with physicians and customers remains limited, and it is unknown when the Company’s offices will reopen, and these interactions will be fully resumed.	Concentration of Credit Risk Financial instruments that subject the Company to concentrations of credit risk includes cash. The Company maintains cash on deposit at U.S.-based banks in amounts which, at times, may be in excess of insured limits.
Revenue Recognition	Revenue Recognition Prescription Medication Sales The Company’s prescription medication sales consist of sales of Stendra® in the U.S. for the treatment of male erectile dysfunction. Under ASC Topic 606, Revenue Recognition In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers Stendra® to when the customers pay for the product is typically less than one year. The Company records prescription medication sales net of any variable consideration, including but not limited to discounts, rebates, returns, chargebacks, and distribution fees. The Company uses the expected value method when estimating its variable consideration unless terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Stendra® are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes. As of September 30, 2021, and December 31, 2020, the reserves for sales deductions were $4.2 million and $8.6 million, respectively. The most significant sales deductions included in this reserve relate to returns, contract rebates, coupon redemptions and distribution service (“DSA”) fees. The Company’s estimates are based on factors such as its direct and indirect customers’ buying patterns and the estimated resulting contractual deduction rates, historical experience, specific known market events and estimated future trends, current contractual and statutory requirements, industry data, estimated customer inventory levels, current contract sales terms with its direct and indirect customers, and other competitive factors. Significant judgment and estimation are required in developing the foregoing and other relevant assumptions. The most significant sales deductions are further described below. Product Returns Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return Stendra® and receive credit for product within six months prior to expiration date and up to one year after expiration date. The provision for returns is based upon the Company’s estimates for future Stendra® returns and historical experience. The provision of returns is part of the variable consideration recorded at the time revenue is recognized. As of September 30, 2021, and December 31, 2020, the reserves for product returns were $3.2 million and $7.1 million, respectively, and are included as a component of accrued expenses. Contract Rebates, Coupon Redemptions and DSA Fees The Company establishes contracts with wholesalers, chain stores, and indirect customers that provide for rebates, sales incentives, DSA fees and other allowances. Some customers receive rebates upon attaining established sales volumes. Direct rebates are generally rebates paid to direct purchasing customers based on a percentage applied to a direct customer’s purchases from us, including fees paid to wholesalers under our DSAs, as described below. Indirect rebates are rebates paid to indirect customers that have purchased our products from a wholesaler under a contract with us. The Company has entered into DSAs with certain of our significant wholesaler customers that obligate the wholesalers, in exchange for fees paid by us, to: (i) manage the variability of their purchases and inventory levels within specified limits based on product demand and (ii) provide us with specific services, including the provision of periodic retail demand information and current inventory levels for our pharmaceutical products held at their warehouse locations. Medical Device Sales The Company’s medical device sales consist of domestic and international sales of men’s health products for the treatment of erectile dysfunction. The men’s health products do not require a prescription and include vacuum erection devices, VenoSeal, and other related accessories. Under Topic 606, the Company recognizes revenue from medical device sales when its performance obligations with its customers have been satisfied. In the contracts with its customers, the Company has identified a single performance obligation to provide medical devices upon receipt of a customer order. The performance obligation is satisfied at a point in time when the Company’s customers obtain control of the medical device, which is typically upon shipment. The Company invoices its customers after the medical devices have been shipped and invoice payments are generally due within 30 days of invoice date for domestic customers and 90 days for international customers. In determining the transaction price, a significant financing component Product Returns Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return medical devices and receive credit for products within 90 days of the sale. The provision for returns is based upon the Company’s estimates for future product returns and historical experience. The Company has not made significant changes to the judgments made in applying Topic 606. As of September 30, 2021, and December 31, 2020, the reserves for product returns for medical devices were not significant.	Revenue Recognition Prescription Medication Sales The Company’s prescription medication sales consist of sales of Stendra® in the U.S. for the treatment of male erectile dysfunction. Under ASC Topic 606, Revenue Recognition In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers Stendra® to when the customers pay for the product is typically less than one year. The Company records prescription medication sales net of any variable consideration, including but not limited to discounts, rebates, returns, chargebacks, and distribution fees. The Company uses the expected value method when estimating its variable consideration, unless terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from sales of Stendra® are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes. As of December 31, 2020 and 2019, the reserves for sales deductions were $8.6 million and $12.0 million, respectively. The most significant sales deductions included in this reserve relate to returns, contract rebates, and distribution service (“DSA”) fees. Our estimates are based on factors such as our direct and indirect customers’ buying patterns and the estimated resulting contractual deduction rates, historical experience, specific known market events and estimated future trends, current contractual and statutory requirements, industry data, estimated customer inventory levels, current contract sales terms with our direct and indirect customers, and other competitive factors. Significant judgment and estimation is required in developing the foregoing and other relevant assumptions. The most significant sales deductions are further described below. Product Returns Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return Stendra® and receive credit for product within six months prior to expiration date and up to one year after expiration date. The provision for returns is based upon the Company’s estimates for future Stendra® returns and historical experience. The provision of returns is part of the variable consideration recorded at the time revenue is recognized. As of December 31, 2020 and 2019, the reserves for product returns were $7.1 million and $8.3 million, respectively, and are included as a component of accrued expenses. Contract Rebates, Coupon Redemptions and DSA Fees The Company establishes contracts with wholesalers, chain stores, and indirect customers that provide for rebates, sales incentives, DSA fees and other allowances. Some customers receive rebates upon attaining established sales volumes. Direct rebates are generally rebates paid to direct purchasing customers based on a percentage applied to a direct customer’s purchases from us, including fees paid to wholesalers under our DSAs, as described below. Indirect rebates are rebates paid to indirect customers that have purchased our products from a wholesaler under a contract with us. The Company has entered into DSAs with certain of our significant wholesaler customers that obligate the wholesalers, in exchange for fees paid by us, to: (i) manage the variability of their purchases and inventory levels within specified limits based on product demand and (ii) provide us with specific services, including the provision of periodic retail demand information and current inventory levels for our pharmaceutical products held at their warehouse locations. Medical Device Sales The Company’s medical device sales consist of domestic and international sales of men’s health products for the treatment of erectile dysfunction. The men’s health products do not require a prescription and include Vacuum Erection Devices, PreBoost, VenoSeal, penile injections (Rx), and urinary tract infection tests. Under Topic 606, the Company recognizes revenue from medical device sales when its performance obligations with its customers have been satisfied. In the contracts with its customers, the Company has identified a single performance obligation to provide medical devices upon receipt of a customer order. The performance obligation is satisfied at a point in time when the Company’s customers obtain control of the medical device, which is typically upon shipment. The Company invoices its customers after the medical devices have been shipped and invoice payments are generally due within 30 days of invoice date for domestic customers and 90 days for international customers. In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers the medical devices to when the customers pay for the product is typically less than one year. The Company records medical device sales net of any variable consideration, including but not limited to returns. The Company uses the expected value method when estimating its variable consideration. The identified variable consideration is recorded as a reduction of revenue at the time revenues from the medical device sales are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes. Product Returns Consistent with industry practice, the Company maintains a return policy that generally allows its customers to return medical devices and receive credit for products within 90 days of the sale. The provision for returns is based upon the Company’s estimates for future product returns and historical experience. The Company has not made significant changes to the judgments made in applying Topic 606. As of December 31, 2020 and 2019, the reserves for product returns for medical devices were not significant. Contract Costs In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. As such, the Company did not have any contract assets at December 31, 2020 and 2019.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy: Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by an observable market. Level 3 — Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. Financial instruments recognized at historical amounts in the condensed consolidated balance sheets consist of cash, accounts receivable, other current assets, accounts payable, accrued expenses, other current liabilities, and senior debt. The Company believes that the carrying value of cash, accounts receivable, other current assets, accounts payable, accrued expenses, and other current liabilities approximates their fair values due to the short-term nature of these instruments. The carrying value of senior debt as of September 30, 2021, and December 31, 2020, approximated fair value. The fair value of the senior debt was estimated by discounting to present value the scheduled coupon payments and principal repayment, using an appropriate fair market yield and is considered Level 3 in the fair value hierarchy. In connection with the Mergers in December 2020, each security holder of Metuchen received an earnout consideration classified as a derivative liability to be paid in the form of Petros Common Stock. The Company estimated their fair value using a Monte Carlo Simulation approach. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative liability as of September 30, 2021, and December 31, 2020, was $0.3 million and $9.9 million, respectively. See Note 10 Stockholders’ Equity.	Fair Value of Financial Instruments Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy: Level 1 — Quoted prices in active markets for identical assets or liabilities. Level 2 — Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market. Level 3 — Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. Financial instruments recognized at historical amounts in the consolidated balance sheets consist of cash, accounts receivable, other current assets, accounts payable, accrued expenses, other current liabilities and senior debt. The Company believes that the carrying value of cash, accounts receivable, other current assets, accounts payable, accrued expenses, other current liabilities approximates their fair values due to the short-term nature of these instruments. The carrying value of senior debt as of December 31, 2020 approximated fair value. The fair value of the senior debt was estimated by discounting to present value the scheduled coupon payments and principal repayment, using an appropriate fair market yield and is considered Level 3 in the fair value hierarchy. In connection with the Mergers in December 2020, each security holder of Metuchen received an earnout consideration classified as a derivative liability to be paid in the form of Petros Common Stock. The Company estimated their fair value using Monte Carlo Simulation approach. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the derivative liability as of the closing of the Merger and December 31, 2020 was $8.2 million and $9.9 million, respectively. See Note 10 Stockholders’ Equity.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based awards to employees and consultants in accordance with applicable accounting principles, which requires compensation expense related to stock-based transactions, including employee stock options and consultant warrants, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options or warrants. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. Employee stock option and consulting expenses are recognized over the employee’s or consultant’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the volatility and expected term. Any changes in these highly subjective assumptions can significantly impact stock-based compensation expense. See Note 11 Stock Options.	Stock-Based Compensation The Company accounts for stock-based awards to employees and consultants in accordance with applicable accounting principles, which requires compensation expense related to stock-based transactions, including employee stock options and consultant warrants, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options or warrants. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. Employee stock option and consulting expenses are recognized over the employee’s or consultant’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the volatility and expected term. Any changes in these highly subjective assumptions can significantly impact stock-based compensation expense. See Note 11 Stock Options.
Income Taxes	Income Taxes Prior to the consummation of the Mergers, Metuchen was a limited liability company (“LLC”) for federal income tax purposes and had elected to be treated as a Partnership for federal and state income tax purposes. PTV is a disregarded entity for federal income tax purposes. As such, all income tax consequences resulting from the operations were reported on the member’s income tax return. In addition, Timm Medical was included in the Company’s structure where taxes were paid at the entity level. Subsequent to the Mergers, Metuchen’s activity is included in the Company’s consolidated group. The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period the rate change is enacted. The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions in accordance with FASB ASC No. 740 Income Taxes The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statement of operations. As of September 30, 2021, and December 31, 2020, no accrued interest or penalties are recorded in the condensed consolidated balance sheets.	Income Taxes Prior to the consummation of the Mergers, Metuchen was a limited liability company (“LLCs”) for federal income tax purposes and had elected to be treated as a Partnership for federal and state income tax purposes. PTV is a disregarded entity for federal income tax purposes. As such, all income tax consequences resulting from the operations were reported on the member’s income tax return. In addition, Timm was included in the Company’s structure where taxes were paid at the entity level. Following the consummation of the Mergers, Metuchen is treated as a disregarded entity (“SMLLC”) for federal income tax purposes. As such, all income tax consequences resulting from the operations of Metuchen are reported on the members’ income tax returns through the period in which the Merger was transacted. Subsequent to the Mergers, Metuchen’s activity is included in the Company’s consolidated group. The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period the rate change is enacted. The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) it determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. As of December 31, 2020 and 2019 no accrued interest or penalties are recorded in the consolidated balance sheets. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, was enacted and signed into law, and GAAP requires recognition of the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act, among other things, includes changes to the tax provisions that benefits business entities and makes certain technical corrections to the 2017 Tax Cuts and Jobs Act, including, permitting net operating losses, or NOLs, carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The CARES Act provides other reliefs and stimulus measures. We have evaluated the impact of the CARES Act, and do not expect that any provision of the CARES Act would result in a material cash benefit to us or have a material impact on our financial statements or internal controls over financial reporting.
Basic and Diluted Net Loss per Common Share	Basic and Diluted Net Loss per Common Share The Company computes basic net loss per common share by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period, excluding the dilutive effects of stock options and warrants to purchase common shares. The Company computes diluted net loss per common share by dividing the net loss applicable to common share by the sum of the weighted-average number of common shares outstanding during the period plus the potential dilutive effects of its convertible preferred stocks, stock options and warrants to purchase common shares, but such items are excluded if their effect is anti-dilutive. See Note 13 Basic and Diluted Net Loss per Common Share.	Basic and Diluted Net Loss per Common Share The Company computes basic net loss per common share by dividing net loss applicable to common stockholders by the weighted average number of common stocks outstanding during the period, excluding the dilutive effects of stock options and warrants to purchase common stocks. The Company computes diluted net loss per common stock by dividing the net loss applicable to common stocks by the sum of the weighted-average number of common stocks outstanding during the period plus the potential dilutive effects of its convertible preferred stocks, stock options and warrants to purchase common stocks, but such items are excluded if their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between the Company’s basic and diluted net loss per stock of common stock for the years ended December 31, 2020 and 2019. See Note 13 Basic and Diluted Net Loss per Common Share.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Pending Adoption as of September 30, 2021 In June 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-13, Measurement of Credit Losses on Financial Instruments	Recent Accounting Pronouncements Recently Adopted In August 2018, the FASB issued ASU 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement fair value measurements. The guidance is effective for the Company for the annual periods and interim periods within annual periods beginning after December 15, 2019 for both private and public entities. The Company adopted this guidance as of January 1, 2020 and its impact was not material. Pending Adoption as of December 31, 2020 In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments

Accounts Receivable, net (Tab_2

Accounts Receivable, net (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Accounts Receivable, net
Summary of accounts receivable	​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, December 31, ​ ​ 2021 ​ 2020 Gross accounts receivables ​ $ 2,929,064 ​ $ 6,560,291 Distribution service fees ​ (537,363) ​ (972,652) Chargebacks accrual ​ — ​ (121,269) Cash discount allowances ​ (135,527) ​ (84,601) Allowance for doubtful accounts ​ (303,753) ​ (228,800) Total accounts receivable, net ​ $ 1,952,421 ​ $ 5,152,969	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, December 31, ​ ​ 2020 ​ 2019 Gross accounts receivables ​ $ 6,560,291 ​ $ 4,989,260 Distribution service fees ​ (972,652) ​ (2,061,481) Chargebacks accruals ​ (121,269) ​ (60,507) Cash discount allowances ​ (84,601) ​ (235,867) Allowance for doubtful accounts ​ (228,800) ​ (26,275) Total accounts receivable, net ​ $ 5,152,969 ​ $ 2,605,130

Inventories (Tables)_2

Inventories (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Inventories
Schedule of Inventories	​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 December 31, 2020 Raw materials ​ $ 328,558 ​ $ 325,932 Finished goods ​ 189,923 ​ 434,598 Total inventory ​ $ 518,481 ​ $ 760,530	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 December 31, 2019 Raw materials ​ $ 325,932 ​ $ 798,161 Finished goods ​ 434,598 ​ 1,406,267 Total inventory ​ $ 760,530 ​ $ 2,204,428

Prepaid Expenses and Other Cu_6

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Prepaid Expenses and Other Current Assets
Schedule of Prepaid Expenses and Other Current Assets	​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 December 31, 2020 Prepaid samples ​ $ — ​ $ 58,483 Prepaid insurance ​ 172,205 ​ 149,452 Prepaid FDA fees ​ — ​ 756,972 Prepaid coupon fees ​ 71,500 ​ 71,500 API purchase commitment asset (see Note 14) ​ 1,304,541 ​ 1,304,541 Other prepaid expenses ​ 587,319 ​ 391,552 Other current assets ​ 612,673 ​ 114,784 Total prepaid expenses and other current assets ​ $ 2,748,238 ​ $ 2,847,284	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 December 31, 2019 Prepaid samples ​ $ 58,483 ​ $ 391,024 Prepaid insurance ​ 149,452 ​ 287,844 Prepaid FDA fees ​ 756,972 ​ 732,204 Prepaid coupon fees ​ 71,500 ​ 71,500 Rebates receivable ​ ​ — ​ ​ 1,243,120 API purchase commitment asset (see Note 14) ​ 1,304,541 ​ 1,409,592 Other prepaid expenses ​ 391,552 ​ 468,226 Other current assets ​ 114,784 ​ 526,310 Total prepaid expenses and other current assets ​ $ 2,847,284 ​ $ 5,129,820

Intangible Assets (Tables)_2

Intangible Assets (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Intangible Assets
Schedule of intangible assets	​ ​ ​ ​ ​ Balance at December 31, 2019 $ 38,811,137 Amortization expense ​ (6,650,218) Balance at December 31, 2020 ​ ​ 32,160,919 Amortization expense ​ (5,178,821) Balance at September 30, 2021 ​ $ 26,982,098	​ ​ ​ ​ ​ Balance at December 31, 2018 ​ $ 44,100,542 Amortization expense ​ ​ (5,289,405) Balance at December 31, 2019 $ 38,811,137 Amortization expense ​ (6,650,218) Balance at December 31, 2020 ​ $ 32,160,919
Schedule of future annual amortization of intangible assets	​ ​ ​ ​ ​ 2021 (remaining 3 months) ​ 1,688,951 2022 ​ 6,191,740 2023 ​ 5,445,729 2024 ​ 4,650,787 Thereafter ​ 9,004,891 Total ​ $ 26,982,098	​ ​ ​ ​ ​ 2021 ​ 6,867,771 2022 ​ 6,191,740 2023 ​ 5,445,729 2024 ​ 4,650,787 Thereafter ​ 9,004,892 Total ​ $ 32,160,919

Accrued Expenses (Tables)_2

Accrued Expenses (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Accrued Expenses
Summary of accrued expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 December 31, 2020 Accrued price protection ​ $ 1,853,979 ​ $ 1,853,979 Accrued product returns ​ 5,590,248 ​ 9,452,248 Accrued contract rebates ​ 341,715 ​ 412,046 Due to Vivus (see Note 14) ​ 2,267,523 ​ 2,267,523 Accrued severance ​ 25,417 ​ 519,609 Accrued professional fees ​ 31,463 ​ — Accrued marketing ​ 1,258,255 ​ — Other accrued expenses ​ 225,514 ​ 178,381 Total accrued expenses ​ $ 11,594,114 ​ $ 14,683,786	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 December 31, 2019 Accrued price protection ​ $ 1,853,979 ​ $ 1,847,639 Accrued product returns ​ 9,452,248 ​ 10,707,807 Accrued contract rebates ​ 412,046 ​ 1,368,279 Due to Vivus (see Note 14) ​ 2,267,523 ​ 2,259,769 Due to third-party logistic provider ​ — ​ 4,388,600 Accrued severance ​ 519,609 ​ — Other accrued expenses ​ 178,381 ​ 315,168 Total accrued expenses ​ $ 14,683,786 ​ $ 20,887,262

Debt (Tables)_2

Debt (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Debt
Summary of senior indebtedness	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2021 December 31, 2020 Principal balance ​ $ 1,740,752 ​ $ 6,653,292 Plus: End of term fee ​ — ​ 534,237 Less: Debt issuance costs ​ — ​ (12,500) Total senior debt ​ $ 1,740,752 ​ $ 7,175,029	​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 December 31, 2019 Principal balance ​ $ 6,653,292 ​ $ 11,688,979 Plus: Paid-In-Kind interest ​ ​ — ​ ​ 1,101,575 Plus: End of term fee ​ 534,237 ​ 952,416 Less: Debt issuance costs ​ (12,500) ​ — Total senior debt ​ $ 7,175,029 ​ $ 13,742,970
Summary of interest expense on the Senior Debt	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended ​ For the Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 Interest expense for term loan ​ $ 67,936 ​ $ 287,855 ​ $ 344,373 ​ $ 1,015,898 Amortization of debt issuance costs ​ — ​ 12,500 ​ 12,500 ​ 25,000 PIK interest ​ — ​ — ​ — ​ 44,449 ​ ​ $ 67,936 ​ $ 300,355 ​ $ 356,873 ​ $ 1,085,347	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended December 31, ​ 2020 2019 Interest expense for term loan ​ $ 1,241,475 ​ $ 2,216,341 Amortization of debt issuance costs ​ 37,500 ​ — PIK interest ​ 44,449 ​ 211,923 ​ ​ $ 1,323,424 ​ $ 2,428,264

Stock Options and Restricted _2

Stock Options and Restricted Stock Units ("RSU's") (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Stock Options
Summary of stock options	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ ​ Weighted- ​ Remaining ​ Aggregate Intrinsic ​ ​ Number of ​ Average ​ Contractual ​ Value ​ Shares Exercise Price Term (Years) ($ in thousands) Options outstanding and exercisable on December 31, 2020 574,331 ​ $ 51.43 0.9 ​ $ — Options granted 638,970 ​ 3.37 9.18 ​ — Less: options and RSU’s forfeited — ​ — — ​ — Less: options and RSU’s expired/cancelled — ​ — — ​ — Less: options and RSU’s exercised — ​ — — ​ — Options and RSU’s outstanding at September 30, 2021 1,213,301 ​ 26.57 5.08 ​ — Options and RSU’s exercisable at September 30, 2021 852,166 ​ 35.77 3.32 ​ —	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ ​ ​ ​ ​ Weighted- ​ Remaining ​ Aggregate Instrinsic ​ ​ Number of ​ Average ​ Contractual ​ Value ​ Shares Exercise Price Term (Years) ($ in thousands) Options outstanding at December 1, 2020 574,331 ​ $ 51.43 0.9 ​ $ — Options granted — ​ — — ​ — Less: options forfeited — ​ — — ​ — Less: options expired/cancelled — ​ — — ​ — Less: options exercised — ​ — — ​ — Options outstanding at December 31, 2020 574,331 ​ $ 51.43 0.9 ​ $ — Options exercisable at December 31, 2020 574,331 ​ $ 51.43 0.9 ​ $ —

Common Stock Warrants (Tables_2

Common Stock Warrants (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Common Stock Warrants
Summary of warrants	​ ​ ​ ​ ​ Number of Shares Warrants outstanding at December 31, 2020 4,407,962 Warrants issued — Warrants exercised — Warrants outstanding at September 30, 2021 4,407,962	​ ​ ​ ​ ​ Number of Shares Warrants outstanding at December 1, 2020 4,407,962 Warrants issued — Warrants exercised — Warrants outstanding at December 31, 2020 4,407,962
Summary of warrants by expiration date	​ ​ ​ ​ ​ ​ ​ Number of Warrants Exercise Price Expiration Date 76,569 ​ $ 32.00 ​ November 17, 2021 131,344 ​ 64.00 ​ November 17, 2021 2,780 ​ 1.60 ​ August 23, 2023 18,000 ​ 35.65 ​ June 1, 2024 4,800 ​ 35.60 ​ June 5, 2024 74,864 ​ 21.85 ​ June 17, 2024 20,043 ​ 31.25 ​ June 19, 2024 22,800 ​ 26.55 ​ September 1, 2024 10,500 ​ 12.74 ​ September 16, 2024 22,800 ​ 4.30 ​ December 1, 2024 28,000 ​ 5.65 ​ March 2, 2025 28,000 ​ 7.30 ​ June 1, 2025 28,000 ​ 5.50 ​ September 1, 2025 28,000 ​ 4.71 ​ December 1, 2025 2,221,829 ​ 7.50 ​ December 1, 2025 908,498 ​ 17.50 ​ December 1, 2025 623,303 ​ 51.25 ​ December 1, 2025 157,832 ​ 125.00 ​ December 1, 2025 4,407,962 ​ ​	​ ​ ​ ​ ​ ​ ​ Number of Warrants Exercise Price Expiration Date 76,569 ​ $ 32.00 ​ November 17, 2021 131,344 ​ 64.00 ​ November 17, 2021 2,780 ​ 1.60 ​ August 23, 2023 18,000 ​ 35.65 ​ June 1, 2024 4,800 ​ 35.60 ​ June 5, 2024 74,864 ​ 21.85 ​ June 17, 2024 20,043 ​ 31.25 ​ June 19, 2024 22,800 ​ 26.55 ​ September 1, 2024 10,500 ​ 12.7382 ​ September 16, 2024 22,800 ​ 4.30 ​ December 1, 2024 28,000 ​ 5.65 ​ March 2, 2025 28,000 ​ 7.30 ​ June 1, 2025 28,000 ​ 5.50 ​ September 1, 2025 28,000 ​ 4.71 ​ December 1, 2025 2,221,829 ​ 7.50 ​ December 1, 2025 908,498 ​ 17.50 ​ December 1, 2025 623,303 ​ 51.25 ​ December 1, 2025 157,832 ​ 125.00 ​ December 1, 2025 4,407,962 ​ ​

Basic and Diluted Net Loss pe_6

Basic and Diluted Net Loss per Common Share (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Basic and Diluted Net Loss per Common Share
Summary of Computation of Basic and Diluted Net Loss per Share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended ​ For the Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 Numerator ​ ​ ​ ​ ​ Net loss ​ $ (1,696,898) ​ $ (3,300,363) ​ $ (800,734) ​ $ (15,147,953) Denominator ​ ​ ​ ​ Weighted-average common shares for basic net loss per share ​ 9,826,599 ​ 3,434,551 ​ 9,794,267 ​ 3,434,551 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic and diluted net loss per common share ​ $ (0.17) ​ $ (0.96) ​ $ (0.08) ​ $ (4.41)	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended ​ ​ December 31, ​ 2020 2019 Numerator ​ ​ Net (loss) income ​ $ (20,585,925) ​ $ (32,511,300) Denominator ​ ​ Weighted-average common shares for basic and diluted net loss per unit ​ 5,340,682 ​ 2,460,026 ​ ​ ​ ​ ​ ​ ​ Basic and diluted net loss per common share ​ $ (3.85) ​ $ (13.22)
Summary of Computation of Basic and Diluted Net Loss per Share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended ​ For the Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 Stock Options 1,213,301 — ​ 1,213,301 — Warrants 4,405,182 21,139 ​ 4,405,182 21,139 Total 5,621,263 21,139 ​ 5,621,263 21,139	​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended ​ ​ December 31, ​ 2020 2019 Stock Options 574,331 — Warrants 4,407,962 127,396 Total 4,982,293 127,396

Commitments and Contingencies_9

Commitments and Contingencies (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Commitments and Contingencies
Summary of supplemental balance sheet information related to leases	Supplemental balance sheet information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, 2021 As of December 31, 2020 Operating lease ROU asset: ​ ​ Other assets ​ $ 502,697 ​ $ 579,535 ​ ​ ​ ​ ​ ​ ​ Operating lease liability: ​ ​ Other current liabilities ​ $ 121,589 ​ $ 108,971 Other long-term liabilities ​ 437,749 ​ 530,597 Total operating lease liability ​ $ 559,338 ​ $ 639,568	Supplemental balance sheet information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2020 As of December 31, 2019 Operating lease ROU asset: ​ ​ Other assets ​ $ 579,535 ​ $ 672,246 ​ ​ ​ ​ ​ ​ ​ Operating lease liability: ​ ​ ​ Other current liabilities ​ $ 108,971 ​ $ 96,104 Other long-term liabilities ​ 530,597 ​ 639,568 Total operating lease liability ​ $ 639,568 ​ $ 735,672
Summary of supplemental lease term and discount rate information related to leases	Supplemental lease term and discount rate information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ As of September 30, 2021 ​ As of December 31, 2020 ​ Weighted-average remaining lease terms - operating leases 3.9 years 4.7 years ​ Weighted-average discount rate - operating leases 12.6 % 12.6 %	Supplemental lease term and discount rate information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, 2020 ​ As of December 31, 2019 ​ Weighted-average remaining lease terms - operating leases 4.7 years 5.7 years ​ Weighted-average discount rate - operating leases 12.6 % 12.6 %
Summary of supplemental cash flow information related to leases	Supplemental cash flow information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months For the Nine Months ​ ​ Ended September 30, Ended September 30, ​ 2021 2020 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: ​ ​ ​ ​ ​ Operating cash flows from operating leases ​ $ 45,942 ​ $ 45,660 ​ $ 137,826 ​ $ 136,979	Supplemental cash flow information related to leases was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended ​ ​ December 31, ​ 2020 2019 Cash paid for amounts included in the measurement of lease liabilities: ​ ​ Operating cash flows from operating leases ​ $ 182,639 ​ $ 92,068 ​ ​ ​ ​ ​ ​ ​ Right-of-use assets obtained in exchange for lease obligations: ​ ​ ​ ​ ​ ​ Operating leases ​ $ — ​ $ 698,127
Summary of future minimum lease payments under non-cancelable leases	Future minimum lease payments under non-cancelable leases as of September 30, 2021, were as follows: ​ ​ ​ ​ ​ Lease Liability Maturity Analysis Operating Leases 2021 (remaining 3 months) ​ 46,413 2022 ​ 187,739 2023 ​ 189,374 2024 ​ 155,242 2025 ​ ​ 81,107 Thereafter ​ 82,326 Total lease payments ​ 742,201 Less: Imputed Interest ​ (182,863) Total ​ $ 559,338	Future minimum lease payments under non-cancelable leases as of December 31, 2020 were as follows: ​ ​ ​ ​ ​ Lease Liability Maturity Analysis Operating Leases 2021 ​ 184,239 2022 ​ 187,739 2023 ​ 189,374 2024 ​ 155,242 Thereafter ​ 163,432 Total lease payments ​ 880,026 Less: Imputed Interest ​ (240,458) Total ​ $ 639,568

Segment Information (Tables)_2

Segment Information (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Segment Information
Summary of results of operations by reportable segment	The Company’s results of operations by reportable segment for the three months ended September 30, 2021 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the three months ended September 30, 2021 ​ Medications ​ Devices ​ Corporate ​ Consolidated Net sales ​ $ 1,377,291 ​ $ 767,878 ​ $ — ​ $ 2,145,169 Cost of goods sold ​ 45,254 ​ 273,904 ​ — ​ 319,158 Selling, general and administrative expenses ​ 1,318,610 ​ 722,998 ​ 1,371,615 ​ 3,413,223 Research and development expenses ​ 280,576 ​ — ​ — ​ 280,576 Depreciation and amortization expense ​ 1,398,270 ​ 330,559 ​ — ​ 1,728,829 Change in fair value of derivative liability ​ — ​ — ​ (1,970,000) ​ (1,970,000) Interest expense ​ — ​ — ​ 67,936 ​ 67,936 Income tax expense ​ — ​ (2,345) ​ — ​ (2,345) Net income (loss) ​ $ (1,665,419) ​ $ (561,928) ​ $ 530,449 ​ $ (1,696,898) ​ The Company’s results of operations by reportable segment for the three months ended September 30, 2020 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the three months ended September 30, 2020 ​ Medications Devices Corporate Consolidated Net sales ​ $ 2,590,151 ​ $ 874,544 ​ $ — ​ $ 3,464,695 Cost of goods sold ​ 749,575 ​ 232,328 ​ — ​ 981,903 Selling, general and administrative expenses ​ 1,837,864 ​ 566,666 ​ 716,493 ​ 3,121,023 Research and development expense ​ 36,828 ​ — ​ — ​ 36,828 Depreciation and amortization expense ​ 1,353,591 ​ 307,771 ​ — ​ 1,661,362 Interest expense ​ — ​ — ​ 970,085 ​ 970,085 Income tax benefit ​ — ​ 6,143 ​ — ​ 6,143 Net loss ​ $ (1,387,707) ​ $ (226,078) ​ $ (1,686,578) ​ $ (3,300,363) ​ The Company’s results of operations by reportable segment for the nine months ended September 30, 2021 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the nine months ended September 30, 2021 ​ Medications ​ Devices ​ Corporate ​ Consolidated Net sales ​ $ 6,227,753 ​ $ 2,450,671 ​ $ — ​ $ 8,678,424 Cost of goods sold ​ 607,582 ​ 748,256 ​ — ​ 1,355,838 Selling, general and administrative expenses ​ 4,985,603 ​ 2,014,424 ​ 4,411,086 ​ 11,411,113 Research and development expenses ​ 799,803 ​ — ​ — ​ 799,803 Depreciation and amortization expense ​ 4,194,809 ​ 991,677 ​ — ​ 5,186,486 Change in fair value of derivative liability ​ — ​ — ​ (9,640,000) ​ (9,640,000) Interest expense ​ — ​ — ​ 356,873 ​ 356,873 Income tax expense ​ — ​ (9,045) ​ — ​ (9,045) Net income (loss) ​ $ (4,360,044) ​ $ (1,312,731) ​ $ 4,872,041 ​ $ (800,734) ​ The Company’s results of operations by reportable segment for the nine months ended September 30, 2020 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the nine months ended September 30, 2020 ​ Medications ​ Devices ​ Corporate ​ Consolidated Net sales ​ $ 4,128,694 ​ $ 2,501,486 ​ $ — ​ $ 6,630,180 Cost of goods sold ​ 1,527,169 ​ 778,000 ​ — ​ 2,305,169 Selling, general and administrative expenses ​ 6,658,231 ​ 1,780,530 ​ 3,558,424 ​ 11,997,185 Research and development expense ​ 307,796 ​ — ​ — ​ 307,796 Depreciation and amortization expense ​ 4,060,772 ​ 923,312 ​ — ​ 4,984,084 Interest expense ​ — ​ — ​ 2,233,794 ​ 2,233,794 Income tax benefit ​ — ​ 49,895 ​ — ​ 49,895 Net loss ​ $ (8,425,274) ​ $ (930,461) ​ $ (5,792,218) ​ $ (15,147,953)	The Company’s results of operations by reportable segment for the year ended December 31, 2020 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the year ended December 31, 2020 ​ Medications ​ Devices ​ Corporate ​ Consolidated Net sales ​ $ 6,357,498 ​ $ 3,201,971 ​ $ — ​ $ 9,559,469 Cost of goods sold ​ 3,083,417 ​ 963,049 ​ — ​ 4,046,466 Selling, general and administrative expenses ​ 8,784,716 ​ 2,024,448 ​ 4,865,804 ​ 15,674,968 Research and development expenses ​ 459,636 ​ — ​ — ​ 459,636 Depreciation and amortization expense ​ 5,424,292 ​ 1,236,146 ​ — ​ 6,660,438 Change in fair value of derivative liability ​ 1,680,000 ​ — ​ — ​ 1,680,000 Interest expense ​ — ​ — ​ 3,050,879 ​ 3,050,879 Income tax benefit ​ — ​ 1,426,993 ​ — ​ 1,426,993 Net loss ​ $ (13,074,563) ​ $ 405,321 ​ $ (7,916,683) ​ $ (20,585,925) ​ The Company’s results of operations by reportable segment for the year ended December 31, 2019 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription Medical ​ ​ ​ ​ For the Year Ended December 31, 2019 ​ Medications Devices Corporate Consolidated Net sales ​ $ 11,110,660 ​ $ 4,466,506 ​ $ — ​ $ 15,577,166 Cost of goods sold ​ 6,057,977 ​ 1,369,134 ​ — ​ 7,427,111 Selling, general and administrative expenses ​ 13,873,200 ​ 2,735,390 ​ 3,118,633 ​ 19,727,223 Depreciation and amortization expense ​ 4,145,833 ​ 1,145,274 ​ — ​ 5,291,107 Impairment loss ​ 2,443,930 ​ — ​ ​ ​ 2,443,930 Interest expense ​ — ​ — ​ 13,844,961 ​ 13,844,961 Income tax expense ​ — ​ 645,866 ​ — ​ 645,866 Net loss ​ $ (15,410,280) ​ $ (137,426) ​ $ (16,963,594) ​ $ (32,511,300)
Summary of net sales by geographic region	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended ​ For the Nine Months Ended ​ ​ September 30, ​ September 30, Net sales 2021 2020 2021 2020 United States ​ $ 1,861,222 ​ $ 3,125,572 ​ $ 7,754,534 ​ $ 5,780,165 International ​ 283,947 ​ 339,123 ​ ​ 923,890 ​ ​ 850,015 ​ ​ $ 2,145,169 ​ $ 3,464,695 ​ $ 8,678,424 ​ $ 6,630,180	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Years Ended ​ ​ December 31, Net sales 2020 2019 United States ​ $ 8,555,831 ​ $ 14,236,886 International ​ 1,003,638 ​ 1,340,280 ​ ​ $ 9,559,469 ​ $ 15,577,166
Summary of assets by reportable segment and reconciliation of segment assets to consolidated assets	The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of September 30, 2021, are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription ​ ​ ​ ​ ​ Medications Medical Devices Consolidated Intangible assets, net ​ $ 20,438,542 ​ $ 6,543,556 ​ $ 26,982,098 Total segment assets ​ $ 43,790,552 ​ $ 8,244,776 ​ $ 52,035,328 ​ The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of December 31, 2020, are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription ​ ​ ​ ​ ​ ​ ​ Medications Medical Devices Consolidated Intangible assets, net ​ $ 24,625,686 ​ $ 7,535,233 ​ $ 32,160,919 Total segment assets ​ $ 60,725,191 ​ $ 9,128,823 ​ $ 69,854,014	The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of December 31, 2020 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription ​ ​ ​ ​ ​ Medications Medical Devices Consolidated Intangible assets, net ​ $ 24,625,686 ​ $ 7,535,233 ​ $ 32,160,919 Total segment assets ​ $ 60,725,191 ​ $ 9,128,823 ​ $ 69,854,014 ​ The Company’s assets by reportable segment and reconciliation of segment assets to consolidated assets as of December 31, 2019 are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Prescription ​ ​ ​ ​ ​ ​ ​ Medications Medical Devices Consolidated Intangible assets, net ​ $ 30,039,758 ​ $ 8,771,379 ​ $ 38,811,137 Total segment assets ​ $ 47,455,382 ​ $ 10,910,911 ​ $ 58,366,293

Nature of Operations, Basis o_5

Nature of Operations, Basis of Presentation, and Liquidity (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 07, 2020
Nature of Operations, Basis of Presentation, and Liquidity [Line Items]
Cash in excess of certain limit, subject to adjustment as provided in the Merger Agreement			$ 20,000,000
Metuchen Securityholders
Nature of Operations, Basis of Presentation, and Liquidity [Line Items]
Percentage of equity securities held	51.00%	51.00%

Nature of Operations, Basis o_6

Nature of Operations, Basis of Presentation, and Liquidity - Additional information (Details) - USD ($)	Nov. 03, 2021	Oct. 13, 2021	Nov. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Nature of Operations, Basis of Presentation, and Liquidity [Line Items]
Cash				$ 8,135,184		$ 17,139,694	$ 2,145,812
Negative working capital				20,100,000		16,000,000
Debt				1,740,752		7,175,029	13,742,970
Sustained cumulative losses attributable to common stockholders				(62,502,878)		(61,702,144)	(41,116,219)
Repayment of senior debt	$ 1,179,651		$ 1,200,000	$ 4,912,541	$ 4,639,674	$ 6,181,711	$ 6,013,257
Subsequent event
Nature of Operations, Basis of Presentation, and Liquidity [Line Items]
Number of shares issued		$ 3,323,616
Net proceeds		$ 5,500,000

Summary of Significant Accoun_8

Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Reserves for product returns	$ 3.2	$ 7.1	$ 8.3
Revenue, Practical Expedient, Financing Component [true false]	true	true
Prescription Medication Sales
Disaggregation of Revenue [Line Items]
Reserves for sales deductions	$ 4.2	$ 8.6	$ 12
Medical Device Sales
Disaggregation of Revenue [Line Items]
Right to return and receive credit for product	90 days	90 days
Minimum | Prescription Medication Sales
Disaggregation of Revenue [Line Items]
Due period for invoice payments	30 days	30 days
Right to return and receive credit for product	6 months	6 months
Minimum | Medical Device Sales | Domestic customers
Disaggregation of Revenue [Line Items]
Due period for invoice payments	30 days	30 days
Maximum | Prescription Medication Sales
Disaggregation of Revenue [Line Items]
Due period for invoice payments	75 days	75 days
Right to return and receive credit for product	1 year	1 year
Maximum | Medical Device Sales | International Customers [Member]
Disaggregation of Revenue [Line Items]
Due period for invoice payments	90 days	90 days

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Additional information (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 30, 2020	Dec. 31, 2019
Fair Value of Financial Instruments
Fair value of the derivative liability	$ 300,000	$ 9,900,000	$ 8,200,000	$ 9,900,000
Income Taxes
Accrued interest or penalties	$ 0	$ 0		$ 0

Accounts Receivable, net (Det_2

Accounts Receivable, net (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounts Receivable, net
Gross accounts receivables	$ 2,929,064	$ 6,560,291	$ 4,989,260
Distribution service fees	(537,363)	(972,652)	(2,061,481)
Chargebacks accrual		(121,269)	(60,507)
Cash discount allowances	(135,527)	(84,601)	(235,867)
Allowance for doubtful accounts	(303,753)	(228,800)	(26,275)
Total accounts receivable, net	$ 1,952,421	$ 5,152,969	$ 2,605,130

Accounts Receivable, net - Ad_2

Accounts Receivable, net - Additional information (Details) - customer	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Gross sales from customers | One customers
Concentration Risk [Line Items]
Number of customers			1	1
Gross sales from customers | Customer concentration risk | One customers
Concentration Risk [Line Items]
Concentration risk percentage		80.00%	85.00%	86.00%
Number of customers		1
Gross sales from customers | Customer concentration risk | Four customers
Concentration Risk [Line Items]
Concentration risk percentage	78.00%
Number of customers	4
Receivables from customers | One customers
Concentration Risk [Line Items]
Number of customers			1	1
Receivables from customers | Customer concentration risk | One customers
Concentration Risk [Line Items]
Concentration risk percentage			93.00%	88.00%
Receivables from customers | Credit concentration risk | Two customers
Concentration Risk [Line Items]
Concentration risk percentage	70.00%		93.00%
Number of customers	2		2

Inventories (Details)_2

Inventories (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Inventories
Raw materials	$ 328,558	$ 325,932	$ 798,161
Finished goods	189,923	434,598	1,406,267
Total inventory	$ 518,481	$ 760,530	$ 2,204,428

Inventories - Additional Info_2

Inventories - Additional Information (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Inventories
Finished goods are net of valuation reserves	$ 435,927	$ 935,866	$ 220,254
Raw materials are net of valuation reserves	$ 2,872,977	$ 2,872,977

Prepaid Expenses and Other Cu_7

Prepaid Expenses and Other Current Assets (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Prepaid Expenses and Other Current Assets
Prepaid samples		$ 58,483	$ 391,024
Prepaid insurance	$ 172,205	149,452	287,844
Prepaid FDA fees		756,972	732,204
Prepaid coupon fees	71,500	71,500	71,500
API purchase commitment asset (see Note 14)	1,304,541	1,304,541	1,409,592
Other prepaid expenses	587,319	391,552	468,226
Other current assets	612,673	114,784	526,310
Total prepaid expenses and other current assets	$ 2,748,238	$ 2,847,284	$ 5,129,820

Prepaid Expenses and Other Cu_8

Prepaid Expenses and Other Current Assets - Additional Information (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Prepaid Expenses and Other Current Assets
prepaid samples reserve amount	$ 379,612	$ 351,224	$ 145,474

Intangible Assets (Details)_2

Intangible Assets (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Finite-lived Intangible Assets [Roll Forward]
Amortization expense	$ (5,178,821)	$ (6,650,218)	$ (5,289,405)

Intangible Assets - Future an_2

Intangible Assets - Future annual amortization (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Intangible Assets
2021 (remaining 3 months)	$ 1,688,951
2022	6,191,740	$ 6,867,771
2023	5,445,729	6,191,740
2024	4,650,787	5,445,729
Thereafter	9,004,891
Total	$ 26,982,098	$ 32,160,919	$ 38,811,137	$ 44,100,542

Intangible Assets - Additiona_2

Intangible Assets - Additional Information (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Carrying value of intangible assets	$ 26,982,098	$ 32,160,919	$ 38,811,137	$ 44,100,542
Stendra Product
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives of intangible assets	10 years	10 years
Carrying value of intangible assets	$ 20,400,000	$ 24,600,000	30,000,000
Timm Medical product
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives of intangible assets	12 years	12 years
Carrying value of intangible assets	$ 5,100,000	$ 5,900,000	6,900,000
PTV product
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives of intangible assets	12 years	12 years
Carrying value of intangible assets	$ 1,400,000	$ 1,600,000	$ 1,900,000

Accrued Expenses (Details)_2

Accrued Expenses (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Accrued Expenses
Accrued price protection	$ 1,853,979	$ 1,853,979	$ 1,847,639
Accrued product returns	5,590,248	9,452,248	10,707,807
Accrued contract rebates	341,715	412,046	1,368,279
Due to Vivus (see Note 14)	2,267,523	2,267,523	2,259,769
Accrued severance	25,417	519,609
Accrued professional fees	31,463
Accrued marketing	1,258,255
Other accrued expenses	225,514	178,381	315,168
Total accrued expenses	$ 11,594,114	$ 14,683,786	$ 20,887,262

Debt - Senior indebtedness (D_2

Debt - Senior indebtedness (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Debt
Principal balance	$ 1,740,752	$ 6,653,292	$ 11,688,979
Plus: End of term fee		534,237	952,416
Less: Debt issuance costs		(12,500)
Total senior debt	$ 1,740,752	$ 7,175,029	$ 13,742,970

Debt - Senior debt (Details)_2

Debt - Senior debt (Details)	Apr. 13, 2020	Mar. 31, 2020	Nov. 22, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2016USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Debt Instrument [Line Items]
End of term charge						$ 534,237	$ 952,416
Senior debt
Debt Instrument [Line Items]
Face amount of debt			$ 1,068,750	$ 35,000,000	$ 35,000,000
Stated interest rate	11.50%	10.75%
Paid-In-Kind ("PIK") interest rate				1.35%	10.75%
End of term charge			1,068,750	$ 787,500	$ 787,500
Amount of principal prepaid			$ 10,000,000
Senior debt | Minimum
Debt Instrument [Line Items]
Fixed charge coverage ratio			0.9
Senior debt | Maximum
Debt Instrument [Line Items]
Fixed charge coverage ratio			1
Senior debt | Prime rate
Debt Instrument [Line Items]
Spread on variable rate	4.25%	4.50%
Stated interest rate				7.25%	7.25%

Debt - Financial covenant (De_2

Debt - Financial covenant (Details) - USD ($)	Feb. 01, 2021	Oct. 01, 2020	Apr. 13, 2020	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Nov. 22, 2017	Sep. 30, 2016
Debt Instrument [Line Items]
End of term charge					$ 534,237	$ 952,416
Senior debt
Debt Instrument [Line Items]
Stated interest rate			11.50%	10.75%
End of term fee paid	$ 534,375	$ 534,375
End of term charge							$ 1,068,750	$ 787,500
Senior debt | Prime rate
Debt Instrument [Line Items]
Stated interest rate								7.25%
Spread on variable rate			4.25%	4.50%

Debt - Third Amendment (Detai_2

Debt - Third Amendment (Details) - USD ($)	Nov. 03, 2021	Sep. 30, 2020	Nov. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Repayment of senior debt	$ 1,179,651		$ 1,200,000	$ 4,912,541	$ 4,639,674	$ 6,181,711	$ 6,013,257
Senior debt
Debt Instrument [Line Items]
Required cash proceeds through an equity or debt financing or other transaction		$ 25,000,000
Escrow fund		$ 1,500,000			$ 1,500,000

Debt - Interest Expenses (Det_2

Debt - Interest Expenses (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Debt
Interest expense for term loan	$ 67,936	$ 287,855	$ 344,373	$ 1,015,898	$ 1,241,475	$ 2,216,341
Amortization of debt issuance costs		12,500	12,500	25,000	37,500
PIK interest				44,449	44,449	211,923
Interest expense, senior debt	67,936	$ 300,355	356,873	$ 1,085,347	1,323,424	2,428,264
Accrued and unpaid interest	$ 16,681		$ 16,681		$ 65,885	$ 132,006

Debt - Subordinated Related P_3

Debt - Subordinated Related Party Term Loans (Details) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2021
Related Party Transaction [Line Items]
Outstanding principal balance of the subordinated promissory note and accrued PIK interest			$ 0		$ 0
Interest expense	$ 669,730	$ 1,148,447	1,727,455	$ 11,416,697
First Subordinated Promissory Note
Related Party Transaction [Line Items]
Principal amount of notes payable			$ 15,500,000	$ 3,000,000
Paid-In-Kind ("PIK") interest rate			20.00%
Outstanding principal balance of the subordinated promissory note and accrued PIK interest			$ 0

Members' Capital (Details)_2

Members' Capital (Details) - shares	Aug. 26, 2019	Dec. 31, 2019	Sep. 16, 2019
Limited Partners' Capital Account [Line Items]
Number of common units issued		3,434,551
Class A Common Units
Limited Partners' Capital Account [Line Items]
Number of common units authorized			100
Common Units
Limited Partners' Capital Account [Line Items]
Number of common units per class A unit	10,000
Class B Units
Limited Partners' Capital Account [Line Items]
Number of common units issued			0

Stockholders' Equity - Consum_2

Stockholders' Equity - Consummation of the Mergers (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Common stock, par value	$ 0.0001	$ 0.0001
Preferred stock, par value	0.0001	0.0001
Common Stock | Metuchen
Class of Stock [Line Items]
Common stock, par value	0.0001	0.0001
Exchange rate per share	$ 0.4968	$ 0.4968
Number of shares of Common Stock issued to the holders in exchange	4,949,610	4,949,610
Common Stock | Neurotrope
Class of Stock [Line Items]
Common stock, par value	$ 0.0001	$ 0.0001
Number of shares issued for every share of old entity	1	1
Number of shares exchanged for every share of of new entity	5	5
Number of warrants issued for every warrants to purchase share of Common Stock of old entity	1	1
Number of warrants exchanged for every warrants to purchase share of Common Stock of new entity	5	5
Preferred Stock | Neurotrope
Class of Stock [Line Items]
Preferred stock, par value	$ 0.001	$ 0.001

Stockholders' Equity - Number_2

Stockholders' Equity - Number of shares held (Details) - shares	Jan. 26, 2021	Sep. 30, 2021	Dec. 31, 2020
Neurotrope
Class of Stock [Line Items]
Ownership interest taken		51.00%	51.00%
Metuchen
Class of Stock [Line Items]
Number of shares held		4,949,610	4,949,610
Ownership interest taken		49.00%	49.00%
Common Stock
Class of Stock [Line Items]
Number of common stock issued upon conversion	60,606
Common Stock | Neurotrope
Class of Stock [Line Items]
Number of shares held		4,758,045	4,758,045
Preferred Stock
Class of Stock [Line Items]
Number of preferred stock converted	500
Preferred Stock | Neurotrope
Class of Stock [Line Items]
Number of shares held		500	500

Stockholders' Equity - Marketin

Stockholders' Equity - Marketing and Consulting Agreement (Details) - USD ($)	Jun. 04, 2021	May 11, 2021	Apr. 01, 2021	Jan. 01, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Vesting period		2 years
Marketing and Consulting Agreement | CorProminence, LLC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Term of agreement				1 year
Renewal term of agreement				1 year
Monthly retainer amount				$ 7,500,000
Number of restricted shares issued				30,000
Consulting and Advisory Agreement | Tania King
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Monthly retainer amount			$ 4,000,000
Additional payment included with the first monthly fee			12,000,000
Restricted share cash value			$ 72,000,000
Vesting period			1 year
Service Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Term of agreement	1 year
Renewal term of agreement	1 year
Monthly retainer amount	$ 6,750
Number of restricted shares issued	28,338
Restricted share cash value	$ 90,002

Stockholders' Equity - Backst_2

Stockholders' Equity - Backstop Agreement (Details) - Backstop Agreement - Juggernaut	9 Months Ended	12 Months Ended
	Sep. 30, 2021USD ($)D$ / shares	Dec. 31, 2020USD ($)D$ / shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Commitment Cap for working capital shortfall amount	$ 6,000,000	$ 6,000,000
Number of consecutive trading days for stock price trigger | D	10	10
Reduction in post-closing commitments (as a percent)	50.00%	50.00%
Post-closing commitments	$ 0	$ 0
Working Capital Shortfall Amount	$ 2,600,000	$ 2,600,000
Stock price equals or exceeds $2.175
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock price trigger | $ / shares	$ 2.175	$ 2.175
Stock price equals or exceeds $2.5375
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock price trigger | $ / shares	$ 2.5375	$ 2.5375

Stockholders' Equity - Contin_2

Stockholders' Equity - Contingent Consideration (Details) - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Stockholders' Equity
Common Stock potentially issuable upon the achievement of certain milestones	14,232,090	14,232,090
Milestones term for achievement of stock price and market capitalization	2 years	2 years

Stockholders' Equity - Milest_2

Stockholders' Equity - Milestone Earnout Payments (Details) - Milestone Earnout Payments	9 Months Ended	12 Months Ended
	Sep. 30, 2021D$ / sharesshares	Dec. 31, 2020D$ / sharesshares
Maximum | Metuchen
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone earnout payments (in shares) | shares	4,000,000	4,000,000
Closing price any time prior to the one-year anniversary of the Closing
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of trading days for stock price trigger | D	20	20
Number of consecutive trading days for stock price trigger | D	30	30
Closing Price per share of $8.00
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock price trigger | $ / shares	$ 8	$ 8
Milestone earnout payments (in shares) | shares	1,000,000	1,000,000
Closing Price per share of $10.00
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock price trigger | $ / shares	$ 10	$ 10
Milestone earnout payments (in shares) | shares	1,000,000	1,000,000
Closing Price per share of $13.00
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock price trigger | $ / shares	$ 13	$ 13
Milestone earnout payments (in shares) | shares	1,000,000	1,000,000
Closing Price per share of $15.00
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock price trigger | $ / shares	$ 15	$ 15
Milestone earnout payments (in shares) | shares	1,000,000	1,000,000
Closing price any time within the twelve month period following the one-year anniversary of the Closing
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of trading days for stock price trigger | D	20	20
Number of consecutive trading days for stock price trigger | D	30	30
Closing Price Per share of $10.00
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock price trigger | $ / shares	$ 10	$ 10
Closing Price per share of $12.50
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock price trigger | $ / shares	$ 12.50	$ 12.50
Milestone earnout payments (in shares) | shares	1,000,000	1,000,000
Closing Price per share of $16.25
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock price trigger | $ / shares	$ 16.25	$ 16.25
Milestone earnout payments (in shares) | shares	1,000,000	1,000,000
Closing Price per share of $18.75
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock price trigger | $ / shares	$ 18.75	$ 18.75
Milestone earnout payments (in shares) | shares	1,000,000	1,000,000

Stockholders' Equity - Market_2

Stockholders' Equity - Market Capitalization (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2021USD ($)D$ / sharesshares	Dec. 31, 2020USD ($)D$ / sharesshares	Dec. 30, 2020USD ($)	Dec. 31, 2019USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Fair value of the derivative liability	$ 300,000	$ 9,900,000	$ 8,200,000	$ 9,900,000
Market Capitalization/Gross Proceeds Earnout Payments | Metuchen
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone earnout payments (in shares) | shares	300,000	9,900,000
Market Capitalization/Gross Proceeds Earnout Payments | Maximum | Metuchen
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone earnout payments (in shares) | shares	10,232,090	10,232,090
Market Capitalization/Gross Proceeds Earnout Payments | Market Capitalization is greater than or equal to $250,000,000 | Metuchen
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone earnout payments (in shares) | shares	2,000,000	2,000,000
Market Capitalization	$ 250,000,000	$ 250,000,000
Number of trading days for stock price trigger | D	20	20
Number of consecutive trading days for stock price trigger | D	30	30
Stock price | $ / shares	$ 17.50	$ 17.50
Aggregate gross proceeds	$ 25,000,000	$ 25,000,000
Term to receive gross proceeds	60 days	60 days
Market Capitalization/Gross Proceeds Earnout Payments | Market Capitalization is greater than or equal to $300,000,000 | Metuchen
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone earnout payments (in shares) | shares	2,000,000	2,000,000
Market Capitalization	$ 300,000,000	$ 300,000,000
Number of trading days for stock price trigger | D	20	20
Number of consecutive trading days for stock price trigger | D	30	30
Stock price | $ / shares	$ 18.75	$ 18.75
Aggregate gross proceeds	$ 30,000,000	$ 30,000,000
Term to receive gross proceeds	60 days	60 days
Market Capitalization/Gross Proceeds Earnout Payments | Market Capitalization is greater than or equal to $400,000,000 | Metuchen
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone earnout payments (in shares) | shares	3,000,000	3,000,000
Market Capitalization	$ 400,000,000	$ 400,000,000
Number of trading days for stock price trigger | D	20	20
Number of consecutive trading days for stock price trigger | D	30	30
Stock price | $ / shares	$ 22.50	$ 22.50
Aggregate gross proceeds	$ 40,000,000	$ 40,000,000
Term to receive gross proceeds	60 days	60 days
Market Capitalization/Gross Proceeds Earnout Payments | Market Capitalization is greater than or equal to $500,000,000 | Metuchen
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone earnout payments (in shares) | shares	3,232,090	3,232,090
Market Capitalization	$ 500,000,000	$ 500,000,000
Number of trading days for stock price trigger | D	20	20
Number of consecutive trading days for stock price trigger | D	30	30
Stock price | $ / shares	$ 23.75	$ 23.75
Aggregate gross proceeds	$ 50,000,000	$ 50,000,000
Term to receive gross proceeds	60 days	60 days

Stock Options and Restricted _3

Stock Options and Restricted Stock Units ("RSU's") (Details) - shares	Sep. 30, 2021	Dec. 31, 2020
Stock Options
Number of shares authorized	1,213,301	1,078,346
Number of shares available for issuance	0	504,015

Stock Options and Restricted _4

Stock Options and Restricted Stock Units ("RSU's") - Summary of stock options (Details) - $ / shares	May 11, 2021	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Number of Shares
Options outstanding and exercisable on beginning		574,331	574,331
Options granted	150,000	638,970
Options and RSU's outstanding at the end		1,213,301	574,331	574,331
Options and RSU's exercisable at the end		852,166	574,331
Weighted-Average Exercise Price
Options outstanding and exercisable at the beginning (in dollars per share)		$ 51.43	$ 51.43
Options granted (in dollars per share)	$ 3.21	3.37
Options outstanding at the end (in dollars per share)		26.57	51.43	$ 51.43
Options exercisable at the end (in dollars per share)		$ 35.77	$ 51.43
Weighted-Average Remaining Contractual Term (Years) and Aggregate Intrinsic Value
Options outstanding and exercisable at the beginning (in years)		5 years 29 days	10 months 24 days	10 months 24 days
Options granted (in years)		9 years 2 months 4 days	0 years
Options outstanding at the end (in years)		5 years 29 days	10 months 24 days	10 months 24 days
Options exercisable at the end (in years)		3 years 3 months 25 days	10 months 24 days

Stock Options and Restricted _5

Stock Options and Restricted Stock Units ("RSU's") - Term of exercise stock options (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Neurotrope
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term for exercise the stock options	1 year	1 year

Stock Options and Restricted _6

Stock Options and Restricted Stock Units ("RSU's") - Fady Boctor, the President and Chief Commercial Officer (Details) - $ / shares	May 11, 2021	Feb. 19, 2021	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted	150,000		638,970
Exercise price	$ 3.21		$ 3.37
Vesting percentage	30.00%
Fady Boctor, the President and Chief Commercial Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted		215,669
Exercise price		$ 3.74
Vesting percentage		50.00%

Stock Options and Restricted _7

Stock Options and Restricted Stock Units ("RSU's") - Additional Information (Details)	May 11, 2021$ / sharesshares	Apr. 23, 2021USD ($)$ / sharesshares	Apr. 08, 2021USD ($)director$ / sharesshares	Sep. 30, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted	150,000			638,970
Exercise price | $ / shares	$ 3.21			$ 3.37
Vesting percentage	30.00%
Vesting period	2 years
Option grants	134,955
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted		23,301	93,802
Stock issued During period, Value gross | $		$ 72,000	$ 296,000
Exercise price | $ / shares		$ 3.09
Vesting percentage		100.00%
Vesting period		1 year
Vesting upon six-month anniversary of the date of grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	30.00%
Vesting period	1 year
Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of directors to whom option is granted | director			5
Number of options granted			50,000
Exercise price | $ / shares			$ 3.18
Directors | Vesting on the date of grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage			25.00%
Directors | Vesting upon six-month anniversary of the date of grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage			25.00%
Vesting period			6 months
Directors | Vesting in equal installments over the following four fiscal quarters
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			12 months

Common Stock Warrants - Summa_2

Common Stock Warrants - Summary of warrants (Details) - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Common Stock Warrants
Warrants outstanding at December 31, 2020	4,407,962	4,407,962
Warrants issued	0	0
Warrants exercised	0	0
Warrants outstanding at September 30, 2021	4,407,962	4,407,962

Common Stock Warrants - Compa_2

Common Stock Warrants - Company's warrants by expiration date (Details) - $ / shares	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Number of Warrants	4,407,962	4,407,962	4,407,962
Expiration Date of November 17, 2021, One
Class of Warrant or Right [Line Items]
Number of Warrants	76,569	76,569
Exercise Price	$ 32	$ 32
Expiration Date of November 17, 2021, Two
Class of Warrant or Right [Line Items]
Number of Warrants	131,344	131,344
Exercise Price	$ 64	$ 64
Expiration Date of August 23, 2023
Class of Warrant or Right [Line Items]
Number of Warrants	2,780	2,780
Exercise Price	$ 1.60	$ 1.60
Expiration Date of June 1, 2024
Class of Warrant or Right [Line Items]
Number of Warrants	18,000	18,000
Exercise Price	$ 35.65	$ 35.65
Expiration Date of June 5, 2024
Class of Warrant or Right [Line Items]
Number of Warrants	4,800	4,800
Exercise Price	$ 35.60	$ 35.60
Expiration Date of June 17, 2024
Class of Warrant or Right [Line Items]
Number of Warrants	74,864	74,864
Exercise Price	$ 21.85	$ 21.85
Expiration Date of June 19, 2024
Class of Warrant or Right [Line Items]
Number of Warrants	20,043	20,043
Exercise Price	$ 31.25	$ 31.25
Expiration Date of September 1, 2024
Class of Warrant or Right [Line Items]
Number of Warrants	22,800	22,800
Exercise Price	$ 26.55	$ 26.55
Expiration Date of September 16, 2024
Class of Warrant or Right [Line Items]
Number of Warrants	10,500	10,500
Exercise Price	$ 12.74	$ 12.7382
Expiration Date of December 1, 2024
Class of Warrant or Right [Line Items]
Number of Warrants	22,800	22,800
Exercise Price	$ 4.30	$ 4.30
Expiration Date of March 2, 2025
Class of Warrant or Right [Line Items]
Number of Warrants	28,000	28,000
Exercise Price	$ 5.65	$ 5.65
Expiration Date of June 1, 2025
Class of Warrant or Right [Line Items]
Number of Warrants	28,000	28,000
Exercise Price	$ 7.30	$ 7.30
Expiration Date of September 1, 2025
Class of Warrant or Right [Line Items]
Number of Warrants	28,000	28,000
Exercise Price	$ 5.50	$ 5.50
Expiration Date of December 1, 2025, One
Class of Warrant or Right [Line Items]
Number of Warrants	28,000	28,000
Exercise Price	$ 4.71	$ 4.71
Expiration Date of December 1, 2025, Two
Class of Warrant or Right [Line Items]
Number of Warrants	2,221,829	2,221,829
Exercise Price	$ 7.50	$ 7.50
Expiration Date of December 1, 2025, Three
Class of Warrant or Right [Line Items]
Number of Warrants	908,498	908,498
Exercise Price	$ 17.50	$ 17.50
Expiration Date of December 1, 2025, Four
Class of Warrant or Right [Line Items]
Number of Warrants	623,303	623,303
Exercise Price	$ 51.25	$ 51.25
Expiration Date of December 1, 2025, Five
Class of Warrant or Right [Line Items]
Number of Warrants	157,832	157,832
Exercise Price	$ 125	$ 125

Basic and Diluted Net Loss pe_7

Basic and Diluted Net Loss per Common Share - Summary of Computation of Basic and Diluted Net Loss per Share (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Numerator
Net loss	$ (1,696,898)	$ (3,300,363)	$ (800,734)	$ (15,147,953)	$ (20,585,925)	$ (32,511,300)
Weighted average common shares outstanding
Weighted-average common shares for basic net loss per share	9,826,599	3,434,551	9,794,267	3,434,551	5,340,682	2,460,026
Weighted-average common shares for dilutive net loss per share	9,826,599	3,434,551	9,794,267	3,434,551	5,340,682	2,460,026
Basic net loss per common share	$ (0.17)	$ (0.96)	$ (0.08)	$ (4.41)	$ (3.85)	$ (13.22)
Diluted net loss per common share	$ (0.17)	$ (0.96)	$ (0.08)	$ (4.41)	$ (3.85)	$ (13.22)

Basic and Diluted Net Loss pe_8

Basic and Diluted Net Loss per Common Share - Summary of Potentially Dilutive Securities Convertible Into Common Shares Excluded from Calculation of Net Loss Per Share (Details) - shares	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	5,621,263	21,139	5,621,263	21,139	4,982,293	127,396
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,405,182	21,139	4,405,182	21,139	4,407,962	127,396
Share-based Payment Arrangement, Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,213,301		1,213,301		574,331

Marketing, Licensing and Dist_5

Marketing, Licensing and Distribution Agreements - Vivus (Details) - License Agreement - USD ($)	Sep. 30, 2016	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Mar. 31, 2021
Royalty on the first $500 million of net sales
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Threshold net sales				$ 500,000,000		$ 500,000,000
Milestone payment to be paid once $250 million in sales has been reached
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Threshold net sales				250,000,000		250,000,000
Milestone payment		$ 6,000,000		6,000,000		6,000,000
Milestone payment to be paid after $250 million in sales has been reached
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Threshold net sales				250,000,000		250,000,000
Milestone payment		$ 3,200,000		$ 3,200,000		$ 3,200,000
Vivus, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
One-time fee to purchase and receive the license for the commercialization and exploitation of Stendra	$ 70,000,000
Additional fee to purchase and receive the license for the commercialization and exploitation of Stendra	$ 800,000
Threshold period of written purchase orders to purchase Stendra				125 days		125 days
Minimum percentage of forecasted quantities for which entity is required to submit purchase orders		90.00%		90.00%		90.00%
Maximum forecasted quantity of strenda that can be supplied (as a percent)		120.00%		120.00%		120.00%
Accrued inventory purchases						$ 14,200,000	$ 9,300,000	$ 14,200,000
Royalty incurred				$ 20,700,000
Vivus, Inc | Other Current Assets [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accrued inventory purchases, current						1,300,000	1,400,000	1,300,000
Vivus, Inc | Other Noncurrent Assets [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accrued inventory purchases, non-current						$ 11,100,000	6,700,000	$ 11,100,000
Vivus, Inc | Royalty during the first, second, and third years following the expiration of the Royalty Period
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage				2.00%		2.00%
Vivus, Inc | Royalty following the fourth and fifth years following the end of the Royalty Period
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage				1.00%		1.00%
MTPC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty incurred		$ 68,865	$ 129,508	$ 302,346	$ 206,435	$ 317,875	$ 550,533
Royalty payables		$ 68,865		$ 68,865		$ 8,728
MTPC | Royalty on the first $500 million of net sales
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage				5.00%		5.00%
MTPC | Royalty on net sales after $500 million
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage				6.00%		6.00%

Marketing, Licensing and Dist_6

Marketing, Licensing and Distribution Agreements - Hybrid (Details) - Hybrid - USD ($)	Oct. 31, 2021	Oct. 01, 2021	Mar. 31, 2021	Sep. 24, 2020	Dec. 31, 2020	Oct. 31, 2020	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2021	Dec. 01, 2021
Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage							3.00%
Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage							6.00%
Exclusive license to H100
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Initial license fee							$ 100,000
Additional payment due upon obtainment of orphan indication for H100							900,000
Annual payments due on first anniversary of the license agreement							125,000
Annual payments due on second anniversary of the license agreement							150,000
Annual payments due on third anniversary of the license agreement							200,000
Annual payments due after third anniversary of the license agreement							250,000
Payments upon first commercial sale and a sliding scale of percentage payments on net sales							$ 1,000,000
Threshold period of notice required to terminate agreement at any time after first anniversary							90 days
Extension payment of license agreement					$ 100,000	$ 50,000	$ 100,000	$ 100,000
Extension term of license agreement			6 months	6 months
One-time, non-creditable and non-refundable payment			$ 200,000
Threshold period for payments of one-time, non-creditable and non-refundable payment			7 days
Exclusive license to H100 | Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage							3.00%
Exclusive license to H100 | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty percentage							6.00%
Amended license agreement of H100
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of License Fees	$ 200,000	$ 150,000
Agreed Additional Payments of License Fees									$ 200,000	$ 200,000

Commitments and Contingencie_10

Commitments and Contingencies (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Employee Lease Agreement
Commitments And Contingencies [Line Items]
Percentage of payments for costs associated with employment	75.00%	75.00%
Amount of fees paid under agreement	$ 200,000	$ 200,000
Employee Lease Agreement | Maximum | Dr. Charles Ryan
Commitments And Contingencies [Line Items]
Percentage Of Working Time Performing Services	75.00%	75.00%
Separation Agreement | Mr. Keith Lavan
Commitments And Contingencies [Line Items]
Stay-on bonus	$ 50,000	$ 50,000
Percentage of base salary to be paid as an advisor	50.00%	50.00%
Percentage of fees as an advisor paid	70.00%	70.00%
Percentage of fees as an advisor to be paid in equal installments	30.00%	30.00%

Commitments and Contingencie_11

Commitments and Contingencies - Operating Leases (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Lessee, Lease, Description [Line Items]
Fixed lease cost	$ 44,812	$ 44,812	$ 134,435	$ 179,246	$ 179,246	$ 88,002
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease terms	2 years 10 months 24 days		2 years 10 months 24 days		3 years 8 months 12 days
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease terms	5 years 3 months 18 days		5 years 3 months 18 days		6 years

Commitments and Contingencie_12

Commitments and Contingencies - Supplemental balance sheet (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Supplemental balance sheet information related to leases
Operating lease ROU asset: Other assets	$ 502,697	$ 579,535	$ 672,246
Operating lease ROU asset	Other assets	Other assets	Other assets
Operating lease liability:
Operating lease liability, current	$ 121,589	$ 108,971	$ 96,104
Other current liabilities	Other current liabilities	Other current liabilities	Other current liabilities
Operating lease liability, noncurrent	$ 437,749	$ 530,597	$ 639,568
Other long-term liabilities	Other long-term liabilities	Other long-term liabilities	Other long-term liabilities
Total operating lease liability	$ 559,338	$ 639,568	$ 735,672

Commitments and Contingencie_13

Commitments and Contingencies - Lease term and discount (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Commitments and Contingencies
Weighted-average remaining lease terms - operating leases	3 years 10 months 24 days		3 years 10 months 24 days		4 years 8 months 12 days	5 years 8 months 12 days
Weighted-average discount rate - operating leases	12.60%		12.60%		12.60%	12.60%
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 45,942	$ 45,660	$ 137,826	$ 136,979	$ 182,639	$ 92,068

Commitments and Contingencie_14

Commitments and Contingencies - Minimum lease payments (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Future minimum lease payments under non-cancelable leases
2021 (remaining 3 months)	$ 46,413
2022	187,739	$ 184,239
2023	189,374	187,739
2024	155,242	189,374
2025	81,107	155,242
Thereafter	82,326
Total lease payments	742,201	880,026
Less: Imputed Interest	(182,863)	(240,458)
Total operating lease liability	$ 559,338	$ 639,568	$ 735,672

Commitments and Contingencie_15

Commitments and Contingencies - Additional information (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Commitments and Contingencies
Operating leases that had not yet commenced	$ 0	$ 0

Segment Information (Details)_2

Segment Information (Details)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)segment	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)segment	Dec. 31, 2019USD ($)
Segment Reporting Information [Line Items]
Number of Operating Segments | segment					2
Results of operations by reportable segment
Net sales	$ 2,145,169	$ 3,464,695	$ 8,678,424	$ 6,630,180	$ 9,559,469	$ 15,577,166
Cost of goods sold	319,158	981,903	1,355,838	2,305,169	4,046,466	7,427,111
Selling, general and administrative	3,413,223	3,121,023	11,411,113	11,997,185	15,674,968	19,727,223
Research and development expense	280,576	36,828	799,803	307,796	459,636
Depreciation and amortization expense	1,728,829	1,661,362	5,186,486	4,984,084	6,660,438	5,291,107
Change in fair value of derivative liability	(1,970,000)		(9,640,000)		1,680,000
Interest expense	67,936	970,085	356,873	2,233,794	3,050,879	13,844,961
Income tax expense	(2,345)	6,143	(9,045)	49,895	1,426,993	645,866
Net loss	(1,696,898)	(3,300,363)	(800,734)	(15,147,953)	(20,585,925)	(32,511,300)
Prescription Medication Sales
Results of operations by reportable segment
Net sales	1,377,291	2,590,151	6,227,753	4,128,694	6,357,498	11,110,660
Cost of goods sold	45,254	749,575	607,582	1,527,169	3,083,417	6,057,977
Selling, general and administrative	1,318,610	1,837,864	4,985,603	6,658,231	8,784,716	13,873,200
Research and development expense	280,576	36,828	799,803	307,796	459,636
Depreciation and amortization expense	1,398,270	1,353,591	4,194,809	4,060,772	5,424,292	4,145,833
Change in fair value of derivative liability					1,680,000
Net loss	(1,665,419)	(1,387,707)	(4,360,044)	(8,425,274)	(13,074,563)	(15,410,280)
Medical Device Sales
Results of operations by reportable segment
Net sales	767,878	874,544	2,450,671	2,501,486	3,201,971	4,466,506
Cost of goods sold	273,904	232,328	748,256	778,000	963,049	1,369,134
Selling, general and administrative	722,998	566,666	2,014,424	1,780,530	2,024,448	2,735,390
Depreciation and amortization expense	330,559	307,771	991,677	923,312	1,236,146	1,145,274
Income tax expense	(2,345)	6,143	(9,045)	49,895	1,426,993	645,866
Net loss	(561,928)	(226,078)	$ (1,312,731)	(930,461)	$ 405,321	(137,426)
Operating segments
Segment Reporting Information [Line Items]
Number of Operating Segments | segment			2		2
Corporate
Results of operations by reportable segment
Selling, general and administrative	1,371,615	716,493	$ 4,411,086	3,558,424	$ 4,865,804	3,118,633
Change in fair value of derivative liability	(1,970,000)		(9,640,000)
Interest expense	67,936	970,085	356,873	2,233,794	3,050,879	13,844,961
Net loss	$ 530,449	$ (1,686,578)	$ 4,872,041	$ (5,792,218)	$ (7,916,683)	$ (16,963,594)

Segment Information - Net Sal_2

Segment Information - Net Sales by Geographic region (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 2,145,169	$ 3,464,695	$ 8,678,424	$ 6,630,180	$ 9,559,469	$ 15,577,166
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	1,861,222	3,125,572	7,754,534	5,780,165	8,555,831	14,236,886
International
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 283,947	$ 339,123	$ 923,890	$ 850,015	$ 1,003,638	$ 1,340,280

Segment Information - Segment_2

Segment Information - Segment assets (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting, Asset Reconciling Item [Line Items]
Intangible assets, net	$ 26,982,098	$ 32,160,919	$ 38,811,137
Total segment assets	52,035,328	69,854,014	58,366,293
Prescription Medication Sales
Segment Reporting, Asset Reconciling Item [Line Items]
Intangible assets, net	20,438,542	24,625,686	30,039,758
Total segment assets	43,790,552	60,725,191	47,455,382
Medical Device Sales
Segment Reporting, Asset Reconciling Item [Line Items]
Intangible assets, net	6,543,556	7,535,233	8,771,379
Total segment assets	$ 8,244,776	$ 9,128,823	$ 10,910,911

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Oct. 13, 2021	Sep. 30, 2021	Dec. 31, 2020
Subsequent Event [Line Items]
Common stock, par value		$ 0.0001	$ 0.0001
Subsequent event
Subsequent Event [Line Items]
Number of shares issued	$ 3,323,616
Proceeds from sale of shares	5,500,000
Subsequent event | Securities purchase agreement | Registered Direct Offering
Subsequent Event [Line Items]
Number of shares issued	$ 3,323,616
Common stock, par value	$ 0.0001
Offering price per share	$ 1.715
Warrants to purchase shares of common stock	3,323,616
Percentage of common stock to be purchased	100.00%
Exercise price of warrants	$ 1.715
Warrants term	5 years
Proceeds from sale of shares	$ 5,500,000
Subsequent event | Katalyst Agreement
Subsequent Event [Line Items]
Warrants to purchase shares of common stock	130,000
Advisory fee and legal expenses	$ 200,000